<SEC-DOCUMENT>0000950170-23-061544.txt : 20231109
<SEC-HEADER>0000950170-23-061544.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109075523
ACCESSION NUMBER:		0000950170-23-061544
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		231390119

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>wve-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-11-08T20:21:35.1707+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:wve="http://www.wavelifesciences.com/20230930" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8beb7387-5c79-44d8-9b5b-f7bd6eee8e48" name="dei:AmendmentFlag" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac">false</ix:nonNumeric><ix:nonNumeric id="F_20c50bbd-0950-4405-a41c-46113e32956a" name="dei:EntityCentralIndexKey" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac">0001631574</ix:nonNumeric><ix:nonNumeric id="F_852bd4e7-289f-4cfe-856d-d2b7add5b5fe" name="dei:DocumentFiscalPeriodFocus" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac">Q3</ix:nonNumeric><ix:nonNumeric id="F_f88d25c5-cb9d-4ddf-8e17-5b60ded6d0c5" name="dei:CurrentFiscalYearEndDate" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac">--12-31</ix:nonNumeric><ix:nonNumeric id="F_59cf8e65-320f-4b29-af97-3896ca1e1d01" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_55d600e9-4b00-4f6b-9908-ad3bd243a1bd" format="ixt-sec:durwordsen">one year</ix:nonNumeric><ix:nonNumeric id="F_540eabce-9c76-47de-9406-1bc8ab641938" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_55d600e9-4b00-4f6b-9908-ad3bd243a1bd" format="ixt-sec:durwordsen">five years</ix:nonNumeric><ix:nonNumeric id="F_f5411f6a-e73e-4d8f-a9d0-7e8d4a09dbbe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_9c7c3c88-24e4-486a-88b6-f2916fcfb70c" format="ixt-sec:durwordsen">one year</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="wve-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_b0103dac-17ed-4d3e-b978-10b5e0f32584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3f6c33e-1898-4179-94ee-85f8a300f503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59ab39c1-8765-403a-8d50-7defda76d4c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_031576dd-6bf3-4f90-aea3-59700962dfb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec9ca9b5-ccad-4c2b-9ec4-b7bea741597b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:C9AlsFtdProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a97c8ae9-b044-4820-96e5-a71d47eaadf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6729cef-6185-408f-8064-d6b87f459534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60b075bf-4787-4dda-9217-73cdf8491478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_201df0c5-2f9f-47b0-8746-12e41626744b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8020a29b-f7f7-45cc-88f8-6951be62c024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76f837ad-ce37-4a72-b121-93223dc95d69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a8994db-d61b-431c-a197-e1e739d2ccf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a04b64a0-15b9-4cd7-a1a3-3e35f0aae6c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d76d5b9d-2f04-4715-8806-517e6f2315cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_373691fb-08ed-497e-9cf8-b3671c52971a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f906dd5-bc79-446d-adfc-71bac06784f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f8ac8dc-ad38-47bb-bee3-820517d4de91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc35d10c-0d48-4c9e-abb1-dc91feb594a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:GSKEquityInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_570400f0-19c4-42b7-ba7f-514509f5a992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:EmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f8ea7fd-3044-4c36-9304-529ddf0e84c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3abbdbcd-9d9e-40d7-bd45-c1f8652ed620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_604ade02-22f4-4b35-9117-540972b59c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ScientificAdvisorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">wve:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd2a4a95-ce73-44cb-9465-c2c5da963d29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec472920-af11-4b8e-ab46-31b361f6eeb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_833bb004-b15e-4e44-9c08-c7223704a04a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ee08ac2-8a9a-4c40-92e9-b73ab7051fa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:OptionsToEmployeesAndNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ceac785-d0e4-4aac-b036-774e9a55619b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43e449a1-c4a0-4f65-a9bf-139d62938bee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d5aa44f-3484-4f2c-b16b-289c55dc6ac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50ef92aa-d66d-4705-8a6c-621cfb4e0838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea2de7e1-ba02-4ca3-bc26-5a09679f28d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:C9AlsFtdProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e637694-fa20-42ed-887e-0196d4053e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b444e81-468e-4a28-afad-15b895940ca5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feb4d052-987c-4678-af34-398b68e10a90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53b91417-a246-4bc6-83db-9e8a41010b3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77f5b6ef-f560-4092-beba-520c88cb4208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_883042b4-2458-4bfa-b9a2-8b427c1b5850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_840fd055-64a1-4ec7-a0cc-cb9b2c7fb2fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac1fc334-0f8b-4953-924e-cff0d0ea9a58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0053e917-12df-482b-a1b1-4cf6b49da388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_057199ca-f556-4877-bcce-76b3e2df83a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8257ee6a-7c25-48ed-80dd-852b2a1ee5f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3191a85c-f3b2-48d6-8581-322638c1e7a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_069c6b44-6229-411e-bbb8-49186918c1be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8adc395c-a848-43c3-81d7-7bf7b1af08f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ccbca11-eac3-41df-97e1-6373fedbb104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca05b972-3868-479c-9caa-f39e6f757273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b49a495-e20c-4db7-93d9-124b08adfa81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcce8355-0cd7-4000-b527-e0b8174914e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5140a810-8f0d-4fdc-a8ea-09de8f50f3ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_527f6f22-23ca-4707-bf9b-bef67aa616a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a43e788a-cf11-428f-8ee5-ea64fab1594f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed60e8fb-2b52-4f3b-bd07-879599965982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18bc13d9-5690-4a43-97b0-b95ab8bdc359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_560af56f-fc78-4a72-851b-af2add5880d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb7a3370-5e9c-4bba-9912-d41ddf5d3118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a37111d-91fa-4fde-b91f-100be35676a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bd1bce8-1ec5-4990-b178-f06fa824bbff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a17689c5-8054-49b6-8e0c-c74a6d530b3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57950620-43a2-4507-aaea-bddaf12233fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ShinNipponBiomedicalLaboratoriesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33aa57c2-493d-4ba2-a29e-f3b3aff746a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_181f3afe-396d-4ffd-a95b-40aadae0a1b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5335805a-7dbf-45b8-95e4-abf4ef8a5bc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_073c80a2-e6c4-48a5-8c06-850081b3c583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5297058f-1335-4562-8740-d05d615ccae7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94bdf4a5-d105-4b29-bf1b-6287987ba4ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3237fbdb-d95d-4cfe-b9f1-61899a543f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6824cde-b172-405b-bbd6-fc57065305e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9be0c66-eeb0-4d40-b8a8-bef5175660c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ShinNipponBiomedicalLaboratoriesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10087a5f-b7dd-4e5a-b0de-5322b540ff23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e8e072b-2447-4085-9e05-53042061b71e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">wve:USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c2ffaa3-8a8f-48ce-9822-3cfeaeb473c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c12b888-5c51-44db-8ef5-cea86938cf76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44ca1475-425a-4297-bd8a-940ba67acc8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:GSKEquityInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_718175b2-0b3b-4964-aae7-ad8959e6fab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fd28c55-542d-4350-976c-ab012247df20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00b8ed9d-656c-4ce6-a17b-1713a99a3935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:ServicePeriodOfOctober12022ThroughDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ScientificAdvisorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">wve:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2219b93b-3833-4eb7-8a14-84b6377f1837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1cc32b4-5c83-4f9e-9124-5240a39712b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f388230d-6596-4497-8c1d-93584b70794e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_984b526b-31b9-492a-a2fd-be71e501c555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ed5c27e-cc4c-49b1-84c5-c1e7b5ece75b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0423170f-46b0-46fd-9d6a-f9ddcaa37597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f9d681a-3066-4ee8-9ecd-b527dd2f4e9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fda8411-f581-4b47-ab60-7fcc4a2e2534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_929ba747-8e45-447c-88e7-e51ab1e75ceb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5faabcb-be56-4b08-bc24-70fe0b903474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88f078e5-7f55-4c1c-a31f-bbef6752eb47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3db33f7-84dd-4c09-bd63-ab26c7341876"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c7c3c88-24e4-486a-88b6-f2916fcfb70c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf4df239-e091-4dea-a22c-442719bad5aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ac4d4e1-f240-4794-bcf4-e1187c6640aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d8668ee-4d05-4c91-8b3d-392dfe7aafc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f171fb21-e8be-445f-a99b-bee1ca07227d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7648e40-cd9d-4899-a7d2-538b38a342e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d27d437-20db-40a7-8a31-79dc5b79363e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21febb15-521e-425b-9fd0-a8ee30908050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3160b90d-92fd-4f20-8899-bd69ca3f321d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d17bd9b-fc3b-4ebf-a913-cc842346df8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_031a13b4-1502-40ec-87b3-130a5d96f105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5edc625-147f-4242-abcb-34c2ad06e65c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbf83c0e-e95e-428b-ab66-63c3c348927d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad580d82-9ef7-4699-b3e9-1f9292c5d61b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e102754-2c0a-4b97-a8a7-084bee04df37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60168293-95c2-4194-a4bf-2c7a29d5b380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba4f1a9d-c900-4002-8f99-c4ecdde3a741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c39743c8-fdc8-49a0-ab6b-18dcad1a2377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48607354-e4f1-4154-a753-18ac7e90279b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55d600e9-4b00-4f6b-9908-ad3bd243a1bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a3a2265-ad67-4510-96a2-aae424a5f323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fe920df-49d4-4e5f-a9a3-7bb9c0f95914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-27</xbrli:startDate><xbrli:endDate>2023-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6400cc97-e4a5-49ec-8444-d2e2844fe3ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b385b66-69ef-4b47-a1f9-aaee7fd51b80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e729bf0c-f0b3-47e5-a084-8d1595c64779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fe29c86-e07c-4543-8cde-57f6ad77b97d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d16ff73c-b9ec-427d-b56c-2031a5ccc0f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f99c07b-5657-4e59-9506-e7a0651e9e56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb5251fa-7c39-49df-b15b-5c68f20d47c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fda03e0b-63d3-4280-b99e-297c22e0b692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">wve:USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_deb104c1-49f6-405f-aa32-79ca3de0a224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc3001b7-e63c-414e-93fa-1a04b0fba6dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3135871c-4f8d-45bd-ac2a-b5c1f0447408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_878fd094-b224-474e-b2c6-88e67084090b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ed14954-a596-4947-9acd-47caf500b6f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bc05ff7-8cc5-4878-970b-926a4d26e663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffc4f0bd-1ed1-49eb-882b-b9fd1a18891e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ShinNipponBiomedicalLaboratoriesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92b7c4c9-c8c0-4b4a-8126-4f88d02330de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dca3ae87-1bee-4d72-a16c-3f7596e1d46d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaeb1ca3-95e6-48fb-8268-9d462b4bf5df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b5223d2-51e2-46ce-b962-d9b615c02b42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d950313-80c4-4f92-b61d-13e608cecd5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Target"><xbrli:measure>wve:Target</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b457ccaf-189d-41a6-840e-703789ce31af" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:12pt;">
    <td style="text-indent:24.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b72ff4c2-4b59-48b6-b4e3-4a78bb0c718e" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bd37342-34c8-4372-9b14-ea6995759809" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41ad8ee9-e7fb-4c9b-be33-eb1fc0d10c2e" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:12pt;">
    <td style="text-indent:24.5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68053579-28c2-421f-872a-eac4e27b1085" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ______ to ______</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee797c8e-b2e7-4c3d-a99a-faa29af8eb04" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-37627</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c41072ab-797e-491e-b325-df109f37b662" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.5%;"></td>
    <td style="width:22.5%;"></td>
    <td style="width:35%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89cdbb8d-f40d-4d23-a25e-1d9a6c014622" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Singapore</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f0b5efa-634b-4e8a-a7f8-4cbccecb43ce" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98-1356880</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f47ca9e5-f762-4174-be94-e662b9410854" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7 Straits View #12-00</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_398a1857-1a31-4bd7-8455-40d4e38bdece" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marina One</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_028f8256-e9fa-4553-99e4-bb19eb797350" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">East Tower</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecffe5e1-e04b-46ac-a90d-e27081b632b7" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Singapore</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdab9d2e-a36d-4181-9026-9423ad9f7036" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">018936</span></ix:nonNumeric></span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05bd1b37-a1e7-416e-b597-75a3d5952895" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+65</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d89cca2-7725-40cd-80ca-706c6bce3470" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6236 3388</span></ix:nonNumeric></span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34.56%;"></td>
    <td style="width:32.68%;"></td>
    <td style="width:32.76%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Trading symbol</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29f97c98-8867-4d01-8167-470cc08a02fc" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">$0 Par Value Ordinary Shares</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fbfc50f-4944-4f3f-a5b6-d55a1d83ccfa" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">WVE</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83217c28-40de-4389-8793-724d651bdd51" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9930f141-b2f5-43c7-9adf-92d1307f4083" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70abb957-5c94-47a3-8f22-3a5995f40125" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x2018;&#x2018;large accelerated filer,&#x2019;&#x2019; &#x2018;&#x2018;accelerated filer,&#x2019;&#x2019; &#x2018;&#x2018;smaller reporting company,&#x2019;&#x2019; and &#x2018;&#x2018;emerging growth company&#x2019;&#x2019; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.84%;"></td>
    <td style="width:4.16%;"></td>
    <td style="width:41.66%;"></td>
    <td style="width:29.2%;"></td>
    <td style="width:4.14%;"></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49c57d31-88d0-42ac-bd01-12618cb5c02f" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57514f7a-648e-4778-aa68-d21c50383e9f" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9pt;">
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38390a94-c608-4895-8eca-2dc137ac8029" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9fe96d1-7b8e-47d6-810c-7b659b2b3cd9" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">    No  &#9746;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The number of outstanding ordinary shares of the registrant as of November 1, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fef5da68-e179-4a1c-a1ea-a4d2941d5f55" contextRef="C_c39743c8-fdc8-49a0-ab6b-18dcad1a2377" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,053,902</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">.<br /></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">QUARTERLY REPORT ON FORM 10-Q</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90.56%;"></td>
    <td style="width:1%;"></td>
    <td style="width:8.44%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i_financial_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I - FINANCIAL INFORMATION</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financial Statements</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Balance Sheets</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unaudited_consolidated_statements_series"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_unaudited_condensed_consolidate"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Consolidated Financial Statements</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls and Procedures</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii_or_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTHER INFORMATION</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Legal Proceedings</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults Upon Senior Securities</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety Disclosures</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_or_information"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. Exhibits</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, references to &#x201c;Wave,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or similar terms refer to Wave Life Sciences Ltd. and our wholly-owned subsidiaries.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. In some cases, forward-looking statements are identified by the words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;future,&#x201d; &#x201c;goals,&#x201d; &#x201c;intend,&#x201d; &#x201c;likely,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;strategy,&#x201d; &#x201c;target,&#x201d; &#x201c;will&#x201d; and &#x201c;would&#x201d; or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements, other than statements of historical fact, about, among other things: </span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and development activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing; the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates; the potential benefits that may be derived from any of our product candidates; our strategies, prospects, plans, goals, expectations, forecasts or objectives; the success of our collaborations with third parties; any payment that our collaboration partners may make to us; our ability to identify and develop new product candidates; our intellectual property position; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding future expenses and needs for additional financing; our ability to develop sales and marketing capabilities; our ability to identify, recruit and retain key personnel; our financial performance; developments and projections relating to our competitors in the industry; our liquidity and working capital requirements; the expected impact of new accounting standards;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and our expectations regarding the impact of the coronavirus (&#x201c;COVID-19&#x201d;) and variants thereof on our business, including on our research and development activities, preclinical studies and clinical trials, supply of drug product, and workforce.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance or achievements expressed or implied by any forward-looking statement to differ. These risks, uncertainties and other factors include, among other things, our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> any impacts on our business as a result of or related to the COVID-19 pandemic, the conflict involving Russia and Ukraine, the conflict in the Middle East, global economic uncertainty, rising inflation, rising interest rates or market disruptions, </span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as well as other risks and uncertainties under the caption &#x201c;Risk Factors&#x201d; contained in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each forward-looking statement contained in this report is based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or warranties by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We caution you not to place undue reliance on any forward-looking statement.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any forward-looking statement in this report represents our views only as of the date of this report and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. and Wave Life Sciences Pte. Ltd. names, the Wave Life Sciences mark, PRISM and the other registered and pending trademarks, trade names and service marks of Wave Life Sciences Ltd. appearing in this Quarterly Report on Form 10-Q are the property of Wave Life Sciences Ltd. This Quarterly Report on Form 10-Q also contains additional trade names, trademarks and service marks belonging to Wave Life Sciences Ltd. and to other companies. We do not intend our use or display of other parties&#x2019; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q are referred to without the &#174; and &#153; symbols, but such reference should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_i_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I - FINANCI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AL INFORMATION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">al Statements</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TED BALANCE SHEETS</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.122%;"></td>
    <td style="width:1.682%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.257000000000001%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.682%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.257000000000001%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b15ced6c-2b0e-4249-b8cc-0605a74c8ede" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,942</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_99ed6dfc-c247-49c5-a45e-6819d6956059" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,497</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1dce024e-20d8-40ce-9529-d4780e64262d" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_24962636-9f68-4e4a-9497-b8144025a1d7" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,514</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5521839c-fbb6-4f24-b5c8-094a8b3b9a08" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,932</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2de03b90-7963-4fa5-a5cd-758a83820cf9" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,116</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_adfe3a5b-2ed1-448f-87e5-df26f363a2af" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,108</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a8dffef2-a7f6-4d22-83ae-c77a7a231ad6" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158,572</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2616aac3-d69a-4e50-a51a-de2be45f2931" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,537</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term assets:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net of accumulated depreciation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fae316f6-b095-4179-a5e1-dd128dda567d" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,596</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5587cf49-35d1-4a88-bc10-ca1e57794900" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,846</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;<br />&#160;&#160;&#160;as of September 30, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_377635b0-02a0-43aa-a9ac-9378892b1114" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,770</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1813a412-b522-476a-aef4-ad650396eaab" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,284</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f341b771-157c-4a84-b3a3-b8c8df13b677" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,738</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e9b26805-dbe7-49cc-8235-81cdb4483096" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,843</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_49ba01a4-492b-42c0-9124-824a1fe01806" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,683</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c4e6948a-dd3f-4911-98d1-0912bc1736df" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,660</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8374c218-1e5d-4ead-8830-9ba70824de1f" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8bcf6ec8-0a7d-4759-8fd9-1db0e3af5645" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total long-term assets</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03d5f2e1-7916-4f9d-86a0-465f154aa732" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,346</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d5f7c389-85e7-4881-bc9b-d8dcbdd75344" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,849</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b811521e-ccad-4cf2-a68b-271edc7f27f1" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,918</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5aeefb22-8e2d-478a-92a1-54817f878a88" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,386</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liabilities, Series A preferred shares and shareholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_905f174a-1e1d-429f-bc0f-4b605b0fc967" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,608</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_48a8e820-924b-4a3c-be9d-f5ac4e8e23c8" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,915</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2f3dd5b8-1c42-4135-9e44-e08f97bb9ce2" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,624</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1901132b-8714-42a7-9be8-f06f7fbd58d7" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,552</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current portion of deferred revenue</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8877b8ee-d46b-46bd-b0a4-9a84669718fc" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,251</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a8f133d-fabc-4a7e-be89-4eddda344012" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,558</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d129644e-9a1a-4807-ab7b-3dc4a4eb801c" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,497</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aa4cd2ce-502e-4c7d-82d9-ca71054d735c" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,496</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e701ad2-ee07-4d3d-83b9-5daaf8c82090" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,980</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_613ab02a-0a00-48b4-add5-c0157446c8af" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,521</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term liabilities:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb0b2d49-c645-4100-aaf3-e462e950884a" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,380</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cf4a99bb-579b-42b2-87a3-c5dd6ae94ce1" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,774</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6444d933-d453-423a-abb1-09f3eb0480c8" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,170</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_758bdabe-5e4b-4f45-b5b8-0f046d109018" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,118</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d190652-f34e-4470-aa6e-b8a3044585cf" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total long-term liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f8a72ec-afcb-4b11-b615-53549bfacc03" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,550</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c6a49589-b656-440f-8a54-234a8ce69355" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,082</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c141377-628b-4522-80f0-a533a035e901" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232,530</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6190d0f5-1321-43cd-b3eb-faf81bf98c76" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,603</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Series A preferred shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a147626c-1bc1-43ca-9870-35dd1a52ff4c" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_43a3a73b-87da-4c5d-b7b8-b41d2cc19eae" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9b547dbe-c519-4aeb-ab53-79a182ddcfe0" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_07cd0f9a-7175-483d-9ecb-37a73adafa7b" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_475448fc-dff8-4621-84b1-ba0c04ebbc9c" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5d760e63-24b6-463e-a506-b4d3bd997956" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding at September 30, 2023 and December 31, 2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_74290b93-4132-452c-9f35-8bbaa8e506f0" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_65738fce-ec62-40a8-ba1c-6c93ed72da10" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shareholders&#x2019; equity (deficit):</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ordinary shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a33064ad-19c1-424a-b407-be2d2b89285d" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_46e0cc51-2dba-48de-b68f-67da97030226" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_458d8d76-3941-4af9-a3b6-3ef999685287" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0ded6d67-d539-4a07-88bb-c9d891326a89" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,011,901</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bc2102f4-cb80-4010-bad8-8fa54f970e6b" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_20897ae3-5ab9-4d84-91ee-a81802e324b5" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,924,643</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding at September 30, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2643e669-0581-4ea5-b3e3-8e6974b85bd3" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841,405</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_24907302-02c0-4624-b280-d93438dd2d26" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802,833</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4477c510-af63-41fd-9d88-7d2b59c333a7" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,885</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c73b375b-8165-403c-9deb-657ed95baf6b" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,442</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ba40856-909c-42d9-a9f4-9a7773c6bca6" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cb9ff337-043e-4740-a326-50ec0371c41b" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6150f40c-1d0e-4a65-befb-eabe4a504093" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,008,594</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b788f0b9-837a-4d8a-a828-2af2b21df2bd" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">967,337</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total shareholders&#x2019; deficit</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ec21da53-509c-4939-b318-8a3d7411dd4c" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,486</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f95c2a8-2b6e-4b52-aa35-5dee1ee250e2" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,091</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities, Series A preferred shares and shareholders&#x2019; deficit</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b6edca20-414b-43f2-bd2d-acce3fcefa50" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">199,918</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5304eead-60d1-4fc2-a25f-634a904cac45" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,386</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.56%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.736%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.736%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.736%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.624%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.736%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00429002-dac2-4570-82da-8b14f3e31fd1" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,214</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_93d4a342-3e46-43a4-b916-0630d7efda77" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9cc5786e-1591-402a-9a4e-4b1cc0c1d628" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,249</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_85687675-a163-496a-af17-cded196e6196" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,410</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f5964c29-3a3a-43e4-9f2f-e027ab47fce8" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,642</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_17493a6f-3680-4d15-89f8-e40b975f34ee" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,575</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b7354a19-5c4d-4b01-9f76-953b68fe2df0" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,935</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d4c4557-b471-4a04-9f9c-23428cd40668" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,778</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60f6f84c-b74d-4008-b04e-8091db71af28" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,128</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f4d64782-4886-4a49-af22-2066c491b5a6" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,609</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a46f5640-5beb-4fc8-9fa3-d90a19a87362" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,628</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_80528a2b-7880-469e-927e-7f997d89798d" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,789</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0bd6e3c2-4e58-435c-aa6a-508fce22428b" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,770</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d47c019-cf87-413d-b86a-256bae7e078c" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,184</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_561fe215-096d-4cff-a823-2cf6704ac50d" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,563</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5a8038ea-115c-4e5f-92e3-cf51d73e0117" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,567</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8c8e25df-9526-42ba-9b8f-e02aac2417f1" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,444</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0d4f6b8a-5d22-4053-a315-99382be5dda5" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38,899</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c29d445e-0900-4109-8a77-763d6962fb52" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,314</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_21a809aa-cbb2-43ee-a49e-1c5eeb7cc27b" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,157</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend income and interest income, net</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_97707880-9252-49f0-b959-8ef4708f3373" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,960</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3b3b0920-9bab-4314-8c64-e0a7cd97bc19" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc3c7fd8-e1de-4a1e-899c-24f64e45130c" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,084</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_21158d4b-40d2-4350-bfd9-6b363c24afd1" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">746</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_700032e7-18ce-4491-bf63-ec6b5c6f08ab" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a7b519b-eeaa-4506-86a0-257cbdaf7198" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">701</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_95bfec7a-1d9d-4619-ac0e-da0f16212198" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,296</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_558ca743-642f-433d-9a59-0270f94b2953" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">297</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf1bc1be-58dc-4251-96a3-5aed94a439d6" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,131</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c5957e1e-5892-4053-bddf-3e2c2a72db7b" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_de884102-d85c-4366-a919-6852a9d42804" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,380</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6655ffaf-1ad5-4292-b4f5-bdfde3fa74af" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,043</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_20f99965-394f-4c9e-9ec7-3dea6321e1d0" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,575</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_698b8e21-376b-480d-8434-f0e06458d28b" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b30e371c-26f0-4f57-a2f3-4d1733187d10" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,934</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6808731f-61ab-477f-a19f-ae1ce0ad024b" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax benefit (provision)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34d6587e-5715-4d59-b983-966ea332a8f7" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_85a46b16-2c8a-40c0-a9a5-bf976680a90a" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0fd47f3-7c08-4f4a-87f9-a8ea943766b2" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,252</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_213dc01f-497b-4941-a792-f13580b09135" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_12a894a1-ebea-47a5-b004-2d9a15a8b13d" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,257</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2923c51-d1b9-401f-9a38-81f9396c8294" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Less: net income attributable to <br />&#160;&#160;&#160;&#160;&#160;&#160;participating securities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0322cb7-6620-4090-b31f-ab90170356a7" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) attributable to ordinary <br />&#160;&#160;&#160;shareholders, basic and diluted</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_458d6c5e-a402-42b5-8cee-1a1f09deb0e5" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,995</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_50a85584-ff95-4e89-b20a-02d79601c8b6" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_10dfbea4-0a56-4222-ba18-3ebf87ab4a12" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,257</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9604ac9a-fed4-4009-aaa2-cc4b9cd09deb" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br />&#160;&#160;ordinary shareholders&#x2014;basic</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fbfe3b78-6afd-4e67-a426-57c6d498d85c" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a43c5f3-6e3e-43a3-9a7f-d2c52dd5eeed" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f107b48a-89af-4064-84b5-eed6ce2a8798" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d7c7ba0f-9e6b-47d6-846b-c0a98bf31192" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.60</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br />&#160;&#160;&#160;computing net income (loss) per share <br />&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;basic</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_718a030c-a3ba-4d65-8674-874d40b98f33" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,025,063</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4313f334-9aac-4a8f-be5c-070defa1b135" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">93,900,484</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d63d686-e1a0-43db-ae0c-962ad866f43e" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">104,529,266</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1f15b056-6ad4-4357-b80f-972ad40ec768" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,754,417</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br />&#160;&#160;&#160;ordinary shareholders&#x2014;diluted</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c103bc38-27fb-4b0c-9452-22961285c328" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0813fb1d-8deb-4bce-a827-e9c08947df86" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d28e3fdd-d717-433e-9c46-a54c6493e0dc" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d167e66d-6d99-485c-b0ac-aa230b8d4942" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.60</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br />&#160;&#160;&#160;computing net income (loss) per share <br />&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;diluted</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_03dd9a9b-d45d-4098-88ee-65076c0ae05a" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,975,231</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_48dfa3a9-9093-4927-b919-99c6a748fa35" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">93,900,484</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_26c4f817-e3eb-44f2-96f3-1b2683da3ead" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">104,529,266</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09f0b8a8-d8a4-4f18-a299-c3d95f2128c0" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,754,417</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00598778-0c96-413d-afd7-cdefc1d04308" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,252</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_76a2925a-b954-4272-90eb-22deb14dd5ca" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d37fcb40-7cbb-4374-828a-52392a09505f" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,257</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4f673569-1331-442d-8169-d38a52767359" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign currency translation</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dcb81694-087f-47e6-8a2a-9ff348855e69" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e640d40-487e-4d17-a246-33725410ded9" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ce277d1b-9cc7-412a-886b-b39b64e3a31d" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bbef14a6-7682-4a75-a63e-f9dcd929a056" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">304</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive income (loss)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3198c93d-cac1-4d8d-83cd-ff44d647ad11" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,220</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6f3ade78-b333-4fec-b0cd-bfd035f2cc59" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,080</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5c6a0a49-434f-4e25-91ef-ce557ac60a82" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,410</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78fc45ca-d1f6-414e-9700-3cbde2e33dd9" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,418</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="unaudited_consolidated_statements_series"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED STATEMENTS OF SERIES </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A PREFERRED SHARES AND SHAREHOLDERS&#x2019; EQUITY (DEFICIT)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.177%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.175%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:5.951%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.175%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Series A<br />Preferred Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Ordinary Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-In-</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Total<br />Shareholders&#x2019;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Equity (Deficit)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d69b9d54-d7b7-408d-aa4a-4c6d119c3860" contextRef="C_76f837ad-ce37-4a72-b121-93223dc95d69" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_042abf6b-d28d-4a37-9126-985e4cfdf327" contextRef="C_76f837ad-ce37-4a72-b121-93223dc95d69" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b7c6d58f-c346-448d-ba8d-346b9e2411ee" contextRef="C_dbf83c0e-e95e-428b-ab66-63c3c348927d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,841,116</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_535dff10-3000-4208-a8ac-aadfb06bdfff" contextRef="C_dbf83c0e-e95e-428b-ab66-63c3c348927d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">749,851</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_145ea3f9-9727-4039-8bb3-1f53b815f61e" contextRef="C_10087a5f-b7dd-4e5a-b0de-5322b540ff23" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,980</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6a53068-63f5-4582-b3d2-abbc1382b595" contextRef="C_0423170f-46b0-46fd-9d6a-f9ddcaa37597" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3349bf2a-3c5a-4849-a6df-43fd6c32a005" contextRef="C_8020a29b-f7f7-45cc-88f8-6951be62c024" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">805,514</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dcd596ef-cfba-41d7-8fb3-cea61f79c4de" contextRef="C_0053e917-12df-482b-a1b1-4cf6b49da388" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,498</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;pursuant to the at-the-market <br />&#160;&#160;&#160;equity program, net</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_36170ef2-c88e-441d-92e5-71c0a0bfecb9" contextRef="C_a17689c5-8054-49b6-8e0c-c74a6d530b3e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">458,092</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e5e43989-af81-4e00-a97a-4f504df5d883" contextRef="C_a17689c5-8054-49b6-8e0c-c74a6d530b3e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,167</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d14f5088-2241-4964-8f90-d06b28aa7915" contextRef="C_073c80a2-e6c4-48a5-8c06-850081b3c583" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,167</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be82eb22-5840-4c5a-b04e-799b993e856f" contextRef="C_88f078e5-7f55-4c1c-a31f-bbef6752eb47" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,971</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c021445c-92d2-40e6-a062-59b474540e92" contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,971</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_70d93e1c-a20c-4189-8844-fa5153e38d3a" contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">468,226</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_51b98b81-f08a-4423-959f-a5c84d72c228" contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_daa5e290-139e-4afe-95bd-30117101bf63" contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a2bb1a4d-816f-41a1-95ab-d73121e351ac" contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;under the ESPP</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b4c19ce-079d-4d3f-8287-1ee02755e193" contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,534</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_382a8b63-e88b-4be7-9a62-7fabc8707626" contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_58381bbe-486f-4c8c-a753-38ba7b4560fe" contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f2cc6c2f-6599-45a2-8718-c90a4eda6629" contextRef="C_18bc13d9-5690-4a43-97b0-b95ab8bdc359" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_433bf3a9-664d-44cd-9891-a9fcfaf1a82c" contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_378c4bfa-6135-40c5-b2d4-e91e0451e521" contextRef="C_7c2ffaa3-8a8f-48ce-9822-3cfeaeb473c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,814</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf8255d9-fac7-4ed1-8ea3-8b2e26095855" contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,814</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_957d12fa-b45b-4e8d-aa55-8647de766d2a" contextRef="C_3191a85c-f3b2-48d6-8581-322638c1e7a9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_33201577-6ac4-421f-9c9c-022423ac3992" contextRef="C_3191a85c-f3b2-48d6-8581-322638c1e7a9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f828d421-3765-4267-a049-37f9e41faef1" contextRef="C_3ac4d4e1-f240-4794-bcf4-e1187c6640aa" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,859,968</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6e29c05e-10de-4180-bb83-13fa90f61541" contextRef="C_3ac4d4e1-f240-4794-bcf4-e1187c6640aa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">751,229</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b5e1ce05-9299-47ce-bab3-60d52c6b176f" contextRef="C_50ef92aa-d66d-4705-8a6c-621cfb4e0838" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,951</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_25886973-08e8-4ac9-a630-1b93c6d7cec7" contextRef="C_94bdf4a5-d105-4b29-bf1b-6287987ba4ff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e1bebe8b-a897-42c6-a796-2ec3f1d7d9a8" contextRef="C_9bd1bce8-1ec5-4990-b178-f06fa824bbff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">843,328</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d875fe0f-a37c-48f7-bed4-493b8eb50e01" contextRef="C_2f99c07b-5657-4e59-9506-e7a0651e9e56" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares, <br />&#160;&#160;&#160;net of offering costs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_22785eb1-c07e-40c4-a7e2-c44715cab69a" contextRef="C_e729bf0c-f0b3-47e5-a084-8d1595c64779" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,464,483</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5ad0ff87-06ca-41ab-af34-2bdf00e0b483" contextRef="C_e729bf0c-f0b3-47e5-a084-8d1595c64779" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,220</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d981d10f-8452-40fc-923c-ca3d216a6938" contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,220</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of pre-funded warrants, <br />&#160;&#160;&#160;net of offering costs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2b0867f3-e134-4d05-a1cc-da14670f2099" contextRef="C_984b526b-31b9-492a-a2fd-be71e501c555" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,268</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_75dbdf7d-e687-4cec-aa3e-b513fb0a6820" contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,268</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7803a6ae-43e1-40f2-a58b-0e0af412b1c2" contextRef="C_984b526b-31b9-492a-a2fd-be71e501c555" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,950</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dd78aaca-b5ee-4cdf-a033-68bfc8db47c7" contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,950</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0922b64f-8c76-4b52-90fd-824eff351fd5" contextRef="C_e729bf0c-f0b3-47e5-a084-8d1595c64779" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,207</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e1e83025-e1f1-42f7-8d55-1311f17767f7" contextRef="C_ba4f1a9d-c900-4002-8f99-c4ecdde3a741" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_50ab1b7c-ac79-4455-8b09-c8839bf918df" contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3547e4d4-54fe-4c7f-a1d1-63c6406619f1" contextRef="C_cf4df239-e091-4dea-a22c-442719bad5aa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_343f81a9-13ed-4dd8-9573-6e6506131e9e" contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c42f7a9a-4cc1-4116-9a5f-1c6fbdd8b90b" contextRef="C_2b385b66-69ef-4b47-a1f9-aaee7fd51b80" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1772f88a-abff-4f16-b121-d03d520e4ba1" contextRef="C_2b385b66-69ef-4b47-a1f9-aaee7fd51b80" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e71b208-597f-4914-873a-876b85bce9be" contextRef="C_eb7a3370-5e9c-4bba-9912-d41ddf5d3118" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,724,658</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb886070-23f9-44cf-8f42-8b74bebfedbc" contextRef="C_eb7a3370-5e9c-4bba-9912-d41ddf5d3118" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802,449</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_33b67a30-9921-4f4a-83c1-c3982c8c7e70" contextRef="C_069c6b44-6229-411e-bbb8-49186918c1be" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,169</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1589c54e-e896-467c-a9db-9bcd66802a21" contextRef="C_7ed5c27e-cc4c-49b1-84c5-c1e7b5ece75b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c45ac23-db89-465b-975e-2271e47fc115" contextRef="C_7f9d681a-3066-4ee8-9ecd-b527dd2f4e9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">884,624</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fef0b8c7-dec3-4701-a641-59357357e3c3" contextRef="C_6400cc97-e4a5-49ec-8444-d2e2844fe3ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,947</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4486afe6-c61f-48b7-8a07-9e2a04b2ef0e" contextRef="C_4d8668ee-4d05-4c91-8b3d-392dfe7aafc5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,366</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_89b21a97-6f4f-4b4e-9095-0c65f00dbcb2" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,366</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fd348d35-077f-4e41-b144-7f888079e70a" contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,338</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27b14ef7-dfc9-4cf1-9490-3d658d9abcbc" contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af2d7b04-c4cf-421a-bdaa-a69283249535" contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dad6c615-bd40-481e-a1ca-b7326946ef54" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;under the ESPP</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c820051-ff51-4ef7-82ec-18a560242037" contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">88,527</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9556adac-d12b-490c-b1c0-b4ca7b5cae0b" contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_213cad4d-a243-49ec-9601-94da408263cf" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f14ad416-25fc-42f7-94e7-3301033f24e1" contextRef="C_cd2a4a95-ce73-44cb-9465-c2c5da963d29" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_514feb99-b76d-4983-a2a9-8a16968704c1" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ced1d56a-de3c-49ea-b551-cf572ac60e68" contextRef="C_aaeb1ca3-95e6-48fb-8268-9d462b4bf5df" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_21b5cec1-8245-48ab-a6cc-390326cd082a" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at September 30, 2022</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9b8d6703-fbe7-41ef-a3ec-07f01b79b0c8" contextRef="C_e6729cef-6185-408f-8064-d6b87f459534" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef34d80b-525a-4635-93a5-0f79b655b5bc" contextRef="C_e6729cef-6185-408f-8064-d6b87f459534" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_887a866b-e8d4-45eb-bd87-b1c0ba5848a4" contextRef="C_5335805a-7dbf-45b8-95e4-abf4ef8a5bc2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,841,523</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a85d4211-06f8-43b5-aac6-7499d8b87fd1" contextRef="C_5335805a-7dbf-45b8-95e4-abf4ef8a5bc2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802,697</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8fe9696f-7f9d-4289-87e7-67044fcdddf5" contextRef="C_48607354-e4f1-4154-a753-18ac7e90279b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,535</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_05013560-b062-4073-a745-8bcca82c86dc" contextRef="C_f3db33f7-84dd-4c09-bd63-ab26c7341876" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5a7171cf-8fe9-4e07-96d7-86637c30e729" contextRef="C_2ed14954-a596-4947-9acd-47caf500b6f6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">923,628</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2779beab-e08e-4425-ae74-1b4b1f4c5e74" contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,519</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED STATEMENTS OF SERIES A PREFERRED SHARES AND SHAREHOLDERS&#x2019; EQUITY (DEFICIT) CONTINUED</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.177%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.175%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:5.951%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7.175%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.225%;"></td>
    <td style="width:1%;"></td>
    <td style="width:6.633%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Series A<br />Preferred Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Ordinary Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-In-</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Total<br />Shareholders&#x2019;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Equity (Deficit)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_91218ec9-5604-44ef-848f-eaaf60e1ca6c" contextRef="C_21febb15-521e-425b-9fd0-a8ee30908050" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4176e850-69de-452b-90b1-f95e74510311" contextRef="C_21febb15-521e-425b-9fd0-a8ee30908050" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d3a272dc-f9c7-4e7f-a20d-4cc5ca110a06" contextRef="C_ad580d82-9ef7-4699-b3e9-1f9292c5d61b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">86,924,643</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8fde7db-6225-4327-aa7a-efdb49e68ed7" contextRef="C_ad580d82-9ef7-4699-b3e9-1f9292c5d61b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802,833</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a968a5b-f8b0-41a9-8038-6cff617ca375" contextRef="C_3d27d437-20db-40a7-8a31-79dc5b79363e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,442</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_001e1df0-fdd8-46ad-817e-17ffe42aa7e9" contextRef="C_718175b2-0b3b-4964-aae7-ad8959e6fab2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a5e90c4-f7a7-4264-840a-1c4cc7d5012a" contextRef="C_ac1fc334-0f8b-4953-924e-cff0d0ea9a58" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">967,337</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b13fbe3-bf6c-4e27-8a5f-fe66dadc7717" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,091</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_786ebb5e-abe7-4a68-b1a3-105dbfa826fb" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,683,761</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eb5aa9ad-4e47-4b90-a0f8-e3f845191869" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,623</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_64515d90-7c70-4e63-adb8-4656415158ac" contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,623</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bc5cc3a7-9416-43b9-8ce2-7952b72362de" contextRef="C_1f8ea7fd-3044-4c36-9304-529ddf0e84c8" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,750</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cbb5f812-d049-49cb-9f6d-03538c0f68bd" contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,750</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b87b0a57-7bae-42a9-8242-3b0bad1f2255" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">363,161</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dfae9b8e-a790-4281-94e8-657ab44bde2f" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0fbff281-bf1a-4bea-8669-8c14e61ecab6" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_76904d28-73a2-45cb-ab45-80ba6e9d5151" contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;under the ESPP</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_43f27622-7b8c-41c2-afa5-7272102af520" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">133,098</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1174b2d1-02e7-4bde-a650-878f294713ce" contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e6d772a0-fd2c-45d8-aafb-d2105b546ad6" contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6ee2cbc-0fcb-4cbb-bd5b-b5c3a9d3fa37" contextRef="C_929ba747-8e45-447c-88e7-e51ab1e75ceb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fd38c35b-7121-4548-8fc6-2b460c1a830f" contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_983818d7-dc19-4b85-a16d-b6ceb1ea4147" contextRef="C_604ade02-22f4-4b35-9117-540972b59c0a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,405</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ddcb039f-a4f2-41e1-a683-57d331049016" contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,405</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7ece15bc-b3df-45dd-a7b3-64d51f5c4003" contextRef="C_560af56f-fc78-4a72-851b-af2add5880d5" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6b787309-5b1a-4c77-b405-09ca9e0b9778" contextRef="C_560af56f-fc78-4a72-851b-af2add5880d5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d8503a2-126d-494c-88f4-f13d90fda6ba" contextRef="C_3237fbdb-d95d-4cfe-b9f1-61899a543f68" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,104,844</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d07167f9-f95c-4a83-94ae-876b5ae1c2c7" contextRef="C_3237fbdb-d95d-4cfe-b9f1-61899a543f68" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837,886</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d5c518a-0f34-462a-9c13-85640f897462" contextRef="C_7e102754-2c0a-4b97-a8a7-084bee04df37" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,192</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0676443-1a1a-4f6c-827f-3592e3fdc3cf" contextRef="C_9d5aa44f-3484-4f2c-b16b-289c55dc6ac4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32a98b48-c210-481a-b609-4844a4ac9431" contextRef="C_ed60e8fb-2b52-4f3b-bd07-879599965982" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">994,742</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_927856b2-624e-417e-9a77-6bef68e4a93d" contextRef="C_0fda8411-f581-4b47-ab60-7fcc4a2e2534" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">34,714</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;pursuant to the at-the-market <br />&#160;&#160;&#160;equity program, net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4174599-4d39-4b71-afb6-7263d8be9d41" contextRef="C_833bb004-b15e-4e44-9c08-c7223704a04a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">429,051</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1177ae8f-f32c-471a-a7c6-d1442c482123" contextRef="C_833bb004-b15e-4e44-9c08-c7223704a04a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,704</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b5d4b08-1caf-426d-9cea-1d8e776b0769" contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,704</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b5c234d6-1d26-4161-9240-5f5e1b2d7594" contextRef="C_fcce8355-0cd7-4000-b527-e0b8174914e9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_16b01a09-5f5b-45dc-a972-0093d93ccb4a" contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9ad0c548-3033-4dab-9197-90c0b15d7a5b" contextRef="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,234</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_469b131e-1ffc-4816-bcaf-4e67943e3626" contextRef="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,687</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dbecfe6d-9516-4768-95e9-63f6630c2675" contextRef="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a08f2b4b-baef-4817-bab7-875ee52d7937" contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a24c8e86-f439-4f52-abf8-b52ab77b7756" contextRef="C_3fd28c55-542d-4350-976c-ab012247df20" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f7dce58e-ee9e-4f92-9505-9939bf91ce8f" contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4e4c2aba-cbb0-4a82-baa3-bce9c1a15d1e" contextRef="C_c3f6c33e-1898-4179-94ee-85f8a300f503" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,104</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ac3521ee-d9c0-4aeb-9f60-7db2d09d36af" contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,104</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2023</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_246fd9da-3097-42a2-bfa0-756880b44ef3" contextRef="C_d16ff73c-b9ec-427d-b56c-2031a5ccc0f1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84dab08a-13ef-4858-b851-53fb8bec0d92" contextRef="C_d16ff73c-b9ec-427d-b56c-2031a5ccc0f1" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4e2ffb74-8410-4073-8ac1-b7f9e613e686" contextRef="C_031576dd-6bf3-4f90-aea3-59700962dfb0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">98,566,816</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc689bc1-f217-433f-849a-9cb83f8b0016" contextRef="C_031576dd-6bf3-4f90-aea3-59700962dfb0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">839,675</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_623f86e8-72cd-46c6-8a77-4cb6febba031" contextRef="C_33aa57c2-493d-4ba2-a29e-f3b3aff746a1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,601</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8c2a523f-a9b9-482c-b211-b05bfde0ce28" contextRef="C_43e449a1-c4a0-4f65-a9bf-139d62938bee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6a172297-272a-41ce-a5b5-0a261906aefe" contextRef="C_c5edc625-147f-4242-abcb-34c2ad06e65c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,015,846</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ce6eb56f-0994-45e7-a86e-170edbd9631d" contextRef="C_b1cc32b4-5c83-4f9e-9124-5240a39712b1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">51,720</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;pursuant to the at-the-market <br />&#160;&#160;&#160;equity program, net</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_764cb045-ac29-4465-858e-27cc9f269e62" contextRef="C_fc3001b7-e63c-414e-93fa-1a04b0fba6dd" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">322,637</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_04e81059-967c-45fc-bbc8-e3e71ccd0c44" contextRef="C_fc3001b7-e63c-414e-93fa-1a04b0fba6dd" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,376</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_90db9d3a-060b-48a7-8cf7-a38b98430e93" contextRef="C_6b5223d2-51e2-46ce-b962-d9b615c02b42" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,376</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1435d60d-3d2c-4028-8e16-b31f6d8a4156" contextRef="C_2fe29c86-e07c-4543-8cde-57f6ad77b97d" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,284</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_114e52f1-4a0f-47e7-b4ae-d1aed54a332f" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,284</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1345ba21-a58f-447e-ba24-30baafeee373" contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,657</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cb77eb62-f228-4b02-bed9-40530a01126b" contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,976</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e03ecdb4-a23b-4d2b-86eb-666c5c4c374d" contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32fc96c3-0b6b-4c2f-8a67-8953356dac6d" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;under the ESPP</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0a50607c-f457-44c0-8cc9-fb813c37d434" contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">92,815</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_73819bfb-6f00-4999-a225-8533f617f57b" contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a571f774-4c74-41f8-b64d-4aa29dedc70b" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45948983-fdab-4959-86a8-26ace539a6d5" contextRef="C_fb5251fa-7c39-49df-b15b-5c68f20d47c3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1207c103-1869-49b0-bc8c-553930c468fd" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_985e24ae-34c8-4db4-811d-d62d2b2a029c" contextRef="C_f171fb21-e8be-445f-a99b-bee1ca07227d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,252</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c90c397f-20af-46c3-83b7-9be1fe301d6b" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,252</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance at September 30, 2023</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7bbe48ec-0ae7-4ded-b285-bfacffbb5bf7" contextRef="C_7a8994db-d61b-431c-a197-e1e739d2ccf8" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4b286e4e-617d-4d74-a836-961aa3988923" contextRef="C_7a8994db-d61b-431c-a197-e1e739d2ccf8" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;border-right:0.5pt solid #000000;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2acc9cce-4ac7-4c6d-9336-3cfe7b0d1262" contextRef="C_60168293-95c2-4194-a4bf-2c7a29d5b380" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,011,901</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0ef0000e-4dd0-4bd6-9c3f-1f1ea3ef0d6c" contextRef="C_60168293-95c2-4194-a4bf-2c7a29d5b380" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841,405</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df996865-41ab-4317-9852-5442eb51e9a0" contextRef="C_d76d5b9d-2f04-4715-8806-517e6f2315cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,885</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cb825cb4-540c-4266-bc05-1b88d1fbe5aa" contextRef="C_7e637694-fa20-42ed-887e-0196d4053e95" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b742e8d4-a2b5-4b75-8719-fce1b68daae3" contextRef="C_3b49a495-e20c-4db7-93d9-124b08adfa81" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,008,594</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4ced5282-8931-4619-963a-babc54668388" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,486</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TATEMENTS OF CASH FLOWS</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.722%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.995999999999999%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1%;"></td>
    <td style="width:11.995999999999999%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e64ae20-926f-4d7a-97a6-f5328d617db4" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,257</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b54d502-4e89-4827-be09-3d1ac01b8401" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td colspan="8" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9bc72875-c575-4575-9be2-1af3b9f1b45d" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="wve:AmortizationOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,105</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_db546b93-aa5f-4f4a-8bae-899cb1cb19b5" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="wve:AmortizationOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,557</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation of property and equipment</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_088337f7-145a-469d-95fe-acaf88c175b7" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,919</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_14268336-f275-4efc-a871-4a6ad90c5514" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,062</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78b08d25-812f-41dc-99fd-954c9c8181b4" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,443</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_47dcc47a-3810-4914-ad65-85d84642d885" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,287</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_35bb6ff2-d9a9-44bc-8e8e-00929d62b182" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,000</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e852c66-017c-4744-a97d-1a1397d3aa4e" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">418</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c962a0ab-eeee-494c-8b3d-f4e42d19a713" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">835</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_16fef326-2ebe-41fc-984e-209a50a9542c" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,101</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b3727452-6284-4c57-bce5-63ec3556ec41" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,503</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0bd96524-0432-4820-b2c6-3feebd0874df" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,953</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6da6de1c-ab8a-4c5d-8fde-353f173390dc" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,337</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f0326b2b-103b-4358-9d26-0784ed3cd692" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,928</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9969538f-010e-470d-b1ef-cb0fe733d442" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,805</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8dc9feb5-4c85-4ef1-9871-aaad86a249b5" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,299</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_072783b5-9dcb-44b0-ad1a-a371df8c5c23" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,006</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_71bbf674-033e-4dc8-88fb-167cbca1af0e" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="wve:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,947</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_74124e9b-955e-4eae-a3d1-8bcda39e8c29" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="wve:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,327</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:20pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3f99306d-62b5-4904-a198-f1673fefb216" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_94898331-2cc7-482d-90a8-a5c7926c0047" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,808</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_751ec360-67fa-48b9-a9c6-ddcff811b934" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,341</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_637ffce0-75ff-4418-8509-c4bcef179107" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b127885-cd86-49d1-b075-3d0900985e8e" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the sale property and equipment</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf630855-36c5-4e10-a841-62ba2d68d1d3" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchase of short-term investments</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dcb646bf-91d5-44da-aaa4-cb6c1c623271" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,044</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from maturity of short-term investments</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_061c262b-e90f-4792-b45d-70c3bc055647" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2aa43c46-6c36-458b-a396-5aed4d1baae1" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">759</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_48472130-5673-4761-9a81-785db6ac7054" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26,095</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of ordinary shares, net of offering costs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c74b97b6-9098-424c-9fd7-41dbfd3b3901" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,623</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_86b5740d-e69a-4571-8fc0-965e4ab085a1" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,235</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of pre-funded warrants, net of offering costs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7f667fd0-b265-4fa2-ac36-c5dedbb7a993" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,272</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of ordinary shares pursuant to the <br />&#160;&#160;&#160;at-the-market equity program, net of offering costs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_49d56834-9658-4c89-9a4e-dc5ac49b4e57" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="wve:ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,080</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_019dcfd6-d75e-4ed4-b19f-6594aa95479a" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="wve:ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,167</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the exercise of share options</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_02dd0842-c907-46e8-936f-2ae76570552c" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a09360cd-a924-4b8c-9deb-f2a65dd3d896" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the ESPP</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a63acf95-d790-4928-a2ec-e5bcb1b59a27" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3">748</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f208d06-8f4e-4bb6-a800-44a388e7be6e" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3">372</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_94c97f29-ea8d-43a9-b6c5-324265ca393a" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,572</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_891e0255-41e0-466a-b7aa-6da796db324f" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,133</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_186803d0-807b-4645-b1e7-9811208f5932" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-">153</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc1f5ffa-efa1-4e74-93c1-cf0e7360524e" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-">304</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f99ccaa-551b-484b-9d09-653745ebfa33" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,468</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3a007d9b-fa75-486f-8c54-e2845d99fbe0" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,607</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_96b03a15-b237-4d90-8220-0fdba4d01ee7" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,157</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a9d86029-fed4-4d12-bead-177a986a542e" contextRef="C_0053e917-12df-482b-a1b1-4cf6b49da388" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,215</ix:nonFraction></span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_889549ff-3768-48fa-9e58-38895dc24c7a" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,625</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5f746185-fbaf-42f6-8c4b-b71b2b28c7f8" contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,608</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increase in operating lease right-of-use assets and<br />&#160;&#160;&#160;lease liabilities related to lease extension</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dab20169-a08c-4002-ba2d-04f8433e9031" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,006</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_unaudited_condensed_consolidate"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Con</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">solidated Financial Statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4f652e9-7417-4167-a549-c72b71cb9bf7" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. THE COMPANY</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd. (together with its subsidiaries, &#x201c;Wave&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, Wave&#x2019;s proprietary discovery and drug development platform that enables the precise design, optimization, and production of novel stereopure oligonucleotides, Wave is working to develop first- or best-in-class medicines that target the transcriptome (the full set of ribonucleic acid (&#x201c;RNA&#x201d;) molecules produced from the human genome) to treat diseases with a high degree of unmet need.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#x201c;Wave USA&#x201d;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#x201c;Wave Japan&#x201d;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (&#x201c;Wave Ireland&#x201d;) was formed as a wholly</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (&#x201c;Wave UK&#x201d;) was formed as a wholly</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company&#x2019;s differentiated portfolio, building the Company&#x2019;s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#x2019;s intellectual property, and assuring adequate capital to support these activities.</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has not generated any product revenue and has incurred recurring operating losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include upfront and milestone payments from collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategy.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9908687b-5298-4379-b186-9a3e88519593" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">139.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects that its existing cash and cash equivalents will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company&#x2019;s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#x2019;s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#x2019;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development efforts will be successful, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and in U.S. dollars.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56070c82-e391-4251-918a-4710d4028e31" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies described in the Company&#x2019;s audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 23, 2023, as amended (the &#x201c;2022 Annual Report on Form 10-K&#x201d;), have had no material changes during the nine months ended September 30, 2023, except as described below.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eba3d1be-487c-4fef-b49e-87eac612ea7a" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company&#x2019;s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company&#x2019;s analysis of contracts with contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions and conditions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ec842bd-28d6-422f-af7a-85e7a3e0fbbe" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Data</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim consolidated balance sheet as of September 30, 2023, the related interim consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of Series A preferred shares and shareholders&#x2019; equity (deficit) for the three months ended March 31, June 30, and September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2023 and 2022 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or any other interim period or future year or period.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da0673c8-c2e4-43d7-afb1-98ea77a6f408" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40a2cda4-4678-4700-8dea-21e51dc4c129" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.304%;"></td>
        <td style="width:2.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.145%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.145%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b3d33126-ca34-493b-91cf-95414367d023" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,457</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_382f8790-01f4-4ec2-a166-32aab62b1911" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,287</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses related to CROs and CMOs</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dba85cb5-bc35-4396-86ea-e04ea1dba75e" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,080</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09f18e79-f3e9-47d8-a846-accce3153f55" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,516</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3dcfb71e-2945-459b-9aa7-a0333eaa90af" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="wve:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,087</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2f351b03-c1d8-4b0a-b210-d28d5465376a" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="wve:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,749</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b54e4dc-5662-4765-aea6-5aa9d113cd7c" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,624</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0519e76-d454-444d-8824-8a8243b456af" contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,552</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c24eac7d-9201-4ddf-9ab0-9bb26b922576" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. SHARE-BASED COMPENSATION</span></p><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2021 Equity Incentive Plan was approved by the Company&#x2019;s shareholders and went into effect on August 10, 2021 and was amended effective as of August 9, 2022 and August 1, 2023 (as amended, the &#x201c;2021 Plan&#x201d;). The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#x201c;2014 Plan&#x201d;), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan was originally </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9507548c-b882-4f3e-bf38-b17ed8e2c32d" contextRef="C_3135871c-4f8d-45bd-ac2a-b5c1f0447408" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,450,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, and was subsequently increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dcaba3b6-6473-4a71-b851-77720ea52b95" contextRef="C_77f5b6ef-f560-4092-beba-520c88cb4208" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,450,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ab0e4541-f8df-488c-8ba6-5dfb16c4789b" contextRef="C_2c12b888-5c51-44db-8ef5-cea86938cf76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,950,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in August 2022 and August 2023, respectively, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2021 Plan authorizes (and the 2014 Plan previously authorized) the board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (&#x201c;RSUs&#x201d;), and performance awards to eligible employees and directors of the Company. The Company accounts for grants to its non-employee directors as grants to employees.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options generally vest over periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_59cf8e65-320f-4b29-af97-3896ca1e1d01;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90442e40-efc1-49ce-9569-db0a277ea329" contextRef="C_feb4d052-987c-4678-af34-398b68e10a90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_540eabce-9c76-47de-9406-1bc8ab641938;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_707964e4-1302-41f0-a608-4f23bfc011c2" contextRef="C_feb4d052-987c-4678-af34-398b68e10a90" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f5411f6a-e73e-4d8f-a9d0-7e8d4a09dbbe;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_225e2f8b-6836-433a-8f90-dcc264b927c4" contextRef="C_8257ee6a-7c25-48ed-80dd-852b2a1ee5f9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, the Company granted an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_723ce041-e00f-46e4-8588-75d99a28e253" contextRef="C_5ee08ac2-8a9a-4c40-92e9-b73ab7051fa6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,646,300</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to employees and non-employee directors and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3cd5fd26-bf3f-4c1c-9fd6-4b312b02c7c3" contextRef="C_f6824cde-b172-405b-bbd6-fc57065305e3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">152,475</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> time-based RSUs to employees.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_80d4253d-b772-48c7-a8cb-1112e76cdcbb" contextRef="C_60b075bf-4787-4dda-9217-73cdf8491478" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,124,732</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ordinary shares remained available for future grant under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0e56a46-b93a-4530-8612-3abe96e85a29" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below shows the options and RSUs outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.56%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.8%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c273dcd-92a6-443b-9954-70c081cd28bd" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,238,590</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_42bc8857-109f-4d3a-a7dd-bf3ebfc101b1" contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,732,711</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_905ecbad-ddbb-4260-896a-465e2bef68bf" contextRef="C_5297058f-1335-4562-8740-d05d615ccae7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">633,283</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_57f12720-60d3-401b-ae2a-3ab28c52e8ac" contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">999,771</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan, as amended (the &#x201c;ESPP&#x201d;) allows full-time and certain part-time employees to purchase the Company&#x2019;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning every January 15th and July 15th. Ordinary shares are purchased at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1e6ba1c-63cb-4e39-afc2-f439e88ef7ae" contextRef="C_570400f0-19c4-42b7-ba7f-514509f5a992" name="wve:SharePurchasePriceAtEqualToFairMarketValuePercentage" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the Company&#x2019;s ordinary shares on the first business day or the last business day of an offering period. The aggregate number of ordinary shares authorized for issuance under the ESPP was originally </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc8824c5-5a0c-48bc-84b4-ecc022437ac1" contextRef="C_b0103dac-17ed-4d3e-b978-10b5e0f32584" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and was subsequently increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_584b8ab0-7022-4c10-93c1-21d22414c714" contextRef="C_201df0c5-2f9f-47b0-8746-12e41626744b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in August 2023. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_51e7ed96-6c47-4f30-b06a-d1a613fecfae" contextRef="C_570400f0-19c4-42b7-ba7f-514509f5a992" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">225,913</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares were issued under the ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_31f8d245-8868-40c3-8edf-165ae0ebe003" contextRef="C_b0103dac-17ed-4d3e-b978-10b5e0f32584" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,490,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares available for issuance under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a99d99f-b275-4e10-bc24-df1f0b3be203" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. COLLABORATION AGREEMENTS</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GSK Collaboration and Equity Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 13, 2022, Wave USA and Wave UK entered into a Collaboration and License Agreement (the &#x201c;GSK Collaboration Agreement&#x201d;) with GlaxoSmithKline Intellectual Property (No. 3) (&#x201c;GSK&#x201d;). Pursuant to the GSK Collaboration Agreement, Wave and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including an exclusive global license to WVE-006. The discovery collaboration component has an initial four-year research term and combines Wave&#x2019;s proprietary discovery and drug development platform, PRISM, with GSK&#x2019;s unique insights from human genetics and its global development and commercial capabilities. On January 27, 2023, the GSK Collaboration Agreement became effective, and GSK paid Wave an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_582f2252-b00c-40e2-a19a-a5088aaa5c8f" contextRef="C_5fe920df-49d4-4e5f-a9a3-7bb9c0f95914" name="wve:CollaborationAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Simultaneously with the execution of the GSK Collaboration Agreement, Wave entered into a Share Purchase Agreement (the &#x201c;SPA&#x201d;) on December 13, 2022, with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, pursuant to which Wave agreed to sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b600da16-7016-41b6-9c5d-40368cc24918" contextRef="C_44ca1475-425a-4297-bd8a-940ba67acc8a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,683,761</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of its ordinary shares to GGL at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0915414d-7f6f-47a9-8302-4811f5a2392f" contextRef="C_fc35d10c-0d48-4c9e-abb1-dc91feb594a7" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.68</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the &#x201c;GSK Equity Investment&#x201d;). The GSK Equity Investment closed on January 26, 2023, following the completion of customary closing conditions. The ordinary shares purchased by GGL are subject to lock-up and standstill restrictions and carry certain registration rights, customary for transactions of this kind. The Company did not incur any material costs in connection with the issuance of the ordinary shares under the SPA.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Collaboration Agreement has three components:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An exclusive global license for GSK to WVE-006, the Company&#x2019;s preclinical, first-in-class A-to-I(G) RNA editing candidate for alpha-1 antitrypsin deficiency, with development and commercialization responsibilities transferring to GSK </span></div></div><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after the Company completes the first-in-patient study (the &#x201c;AATD Collaboration&#x201d;). The Company will be responsible for preclinical, regulatory, manufacturing, and clinical activities for WVE-006 through the initial Phase 1/2 study, at the Company&#x2019;s sole cost. Thereafter, GSK will be responsible for advancing WVE-006 through pivotal studies, registration, and global commercialization at GSK&#x2019;s sole cost;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discovery research collaboration which enables GSK to advance up to eight programs leveraging PRISM and the Company&#x2019;s oligonucleotide expertise and discovery capabilities (the &#x201c;Discovery Research Collaboration&#x201d;); and </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discovery collaboration which enables the Company to advance up to three programs leveraging targets informed by GSK&#x2019;s novel insights (&#x201c;Wave&#x2019;s Collaboration Programs&#x201d;). </span></div></div><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the GSK Collaboration Agreement, each party grants to the other party certain licenses to the collaboration products to enable the other party to perform its obligations and exercise its rights under the GSK Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the GSK Collaboration Agreement. The parties&#x2019; exclusivity obligations to each other are limited on a target-by-target basis with regard to targets in the collaboration. GSK may terminate the GSK Collaboration Agreement for convenience, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the GSK Collaboration Agreement on a target-by-target basis if the other party, or a related party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product that is subject to the GSK Collaboration Agreement. In the event of any material breach of the GSK Collaboration Agreement by a party, subject to cure rights, the other party may terminate the GSK Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that GSK and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the GSK Collaboration Agreement and directed to a particular target, the Company may terminate the GSK Collaboration Agreement with respect to such target. Either party may terminate the GSK Collaboration Agreement for the other party&#x2019;s insolvency. In certain termination circumstances, the Company would receive a license from GSK to continue researching, developing and manufacturing certain products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Collaboration Agreement, unless terminated earlier, will continue until the date on which: (i) with respect to a validation target, the date on which such validation target is not advanced into a collaboration program; or (ii) with respect to a collaboration target, the royalty term has expired for all collaboration products directed to the applicable collaboration target. The GSK Collaboration Agreement includes options to extend the research term for up to three additional years, which would increase the number of programs available to both parties. The Company will lead all preclinical research for GSK and the Company&#x2019;s collaboration programs up to investigational new drug (&#x201c;IND&#x201d;)-enabling studies. The Company will lead IND-enabling studies, clinical development and commercialization for the Company&#x2019;s collaboration programs. GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Collaboration Agreement is managed by a joint steering committee in which both parties are represented equally. In addition, the AATD Collaboration is overseen by a joint development committee, a joint patent committee advises on intellectual property activities, and the Discovery Research Collaboration is overseen by a joint research committee. Both parties are represented equally for these committees and report to the joint steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;) and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term. The Company identified the following material promises under the arrangement: (1) the exclusive global license for WVE-006; (2) the research and development services for WVE-006 through the Phase 1/2 study; (3) the discovery research services under the Discovery Research Collaboration to perform target validation programs; (4) research and development license for the Discovery Research Collaboration; and (5) the research and development services for the GSK collaboration programs through completion of a candidate selection. The research and development services for WVE-006 were determined to not be distinct from the exclusive global license and should therefore be combined into a single performance obligation for the AATD Collaboration. The research and development services for the Discovery Research Collaboration were determined to not be distinct from the research and development license for the Discovery Research Collaboration and should therefore be combined into a single performance obligation. In addition, the Company determined that the option to advance up to eight programs from the Discovery Research Collaboration was priced at fair value and did not provide a material right to GSK.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on these assessments, the Company identified two performance obligations in the GSK Collaboration Agreement: (1) AATD Collaboration consisting of the research and development services through completion of the Phase 1/2 study and research and development license for WVE-006 and (2) Discovery Research Collaboration which consists of research and development services for validating the targets and license for research and development license for targets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the outset of the arrangement, the transaction price included fixed consideration of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_98e06675-dde5-4bba-b0b7-1a379c03eb54" contextRef="C_840fd055-64a1-4ec7-a0cc-cb9b2c7fb2fa" name="wve:CollaborationAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_acd93661-73ff-43a7-a38c-50c69c17021c" contextRef="C_840fd055-64a1-4ec7-a0cc-cb9b2c7fb2fa" name="wve:CollaborationAgreementInPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in premium related to the GSK Equity Investment and the estimated variable consideration related to the additional target validation research funding. The Company allocated the estimated variable consideration to the Discovery Research Collaboration programs and</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">then </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocated the fixed consideration to the performance obligations on a relative standalone selling price basis. The Company determined that the GSK Collaboration Agreement did not contain a significant financing component. The program initiation fees to research and preclinically develop the GSK collaboration programs and the additional potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the GSK Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period, and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company developed the estimated standalone selling price for the global license for WVE-006, under the AATD Collaboration, using a discounted cash flow model. For the performance obligation associated with the research and development services under the Discovery Research Collaboration and the research and development services for WVE-006 under the AATD Collaboration, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with the AATD Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The revenue associated with the Discovery Research Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet. Additional funding related to the Company&#x2019;s research activities related to Discovery Research Collaboration will be recorded as accounts receivable when contractually enforceable and recorded as deferred revenue, or as revenue as the services are provided.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023, the Company recognized revenue of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf662f65-a339-4ca6-94c3-d951640418b7" contextRef="C_6a37111d-91fa-4fde-b91f-100be35676a6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_30924a4b-179f-4b30-86bb-23e826cf5e3f" contextRef="C_a43e788a-cf11-428f-8ee5-ea64fab1594f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, under the GSK Collaboration Agreement using the input method described above.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue on September 30, 2023 is approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b183433c-1c9b-40f1-bc7f-bb7df7b69a54" contextRef="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">92.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b173c683-d6ae-4afe-aa39-c89c6837947a" contextRef="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">65.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in current liabilities </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_845c1af9-a3b4-486b-af44-d3bef0d48cbb" contextRef="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in long-term liabilities.</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Collaboration and Equity Agreements</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2fc86c32-ee41-4f8d-9572-49101cbfb7ad" contextRef="C_92b7c4c9-c8c0-4b4a-8126-4f88d02330de" name="wve:CollaborationAndLicenseAgreementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA and Wave UK entered into a global strategic collaboration (the &#x201c;Takeda Collaboration&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#x201c;CNS&#x201d;). The Takeda Collaboration provides the Company with at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b693b26f-c9e8-4d60-8134-bc1fbd32b319" contextRef="C_6a3a2265-ad67-4510-96a2-aae424a5f323" name="wve:CollaborationAgreementCommittedCash" unitRef="U_USD" scale="6" decimals="-5">230.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in committed cash and Takeda with the option to co-develop and co-commercialize the Company&#x2019;s CNS development programs in (1) Huntington&#x2019;s disease (&#x201c;HD&#x201d;); (2) amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal dementia (&#x201c;FTD&#x201d;); and (3) the Company&#x2019;s discovery-stage program targeting </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATXN3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of spinocerebellar ataxia 3 (&#x201c;SCA3&#x201d;) (collectively, &#x201c;Category 1 Programs&#x201d;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease (collectively, &#x201c;Category 2 Programs&#x201d;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_494e3a99-1db3-4e6a-ac0b-b8c886e3d499" contextRef="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02" name="wve:CollaborationAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5">110.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as an upfront payment. Takeda also agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f1637540-993e-4be2-928f-4b3aa4dc7bd6" contextRef="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02" name="wve:FundReceivableForResearchAndPreclinicalActivities" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2883d5c0-268f-4cb8-9d70-2dd4f7eb2998" contextRef="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02" name="wve:CollaborationAndLicenseAgreementResearchTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by Wave that exceed that amount.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Simultaneously with Wave USA and Wave UK&#x2019;s entry into the collaboration and license agreement with Takeda (the &#x201c;Takeda Collaboration Agreement&#x201d;), the Company entered into a share purchase agreement with Takeda (the &#x201c;Takeda Equity Agreement,&#x201d; and together with the Takeda Collaboration Agreement, the &#x201c;Takeda Agreements&#x201d;) pursuant to which it agreed to sell to Takeda </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_68f6a281-f9be-4ef2-81b3-1a5e5c8c2378" contextRef="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,096,892</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of its ordinary shares at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4dab16e-5be2-495e-8f03-16a3be5f2fd9" contextRef="C_ca05b972-3868-479c-9caa-f39e6f757273" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">54.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. In </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1b63084-ec9d-4d68-a612-8a502d1627ba" contextRef="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc" name="wve:EquityInvestmentAgreementOfficialClosureDateMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_527ef5be-ce6a-454f-aae7-f6dcc5bccf07" contextRef="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company did not incur any material costs in connection with the issuance of the shares.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_401a5f1d-9fee-415b-9aa5-28ff1f1788f5" contextRef="C_181f3afe-396d-4ffd-a95b-40aadae0a1b4" name="wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e35a3a73-efe5-4e31-89b3-da5afbc2c76e" contextRef="C_f388230d-6596-4497-8c1d-93584b70794e" name="wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61f4c0d1-0389-44f5-8297-27c16a3b591b" contextRef="C_5d950313-80c4-4f92-b61d-13e608cecd5c" name="wve:CollaborationAndLicenseAgreementResearchTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#x201c;Category 2 Research Term&#x201d;). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_28cdf3d5-e1c0-4dce-baec-e2d6e6c61769" contextRef="C_5d950313-80c4-4f92-b61d-13e608cecd5c" name="wve:MaximumTargetsForPreclinicalPrograms" unitRef="U_Target" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> targets at </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_329f88bb-5953-4abe-80ec-4a810e1c78f7" contextRef="C_dca3ae87-1bee-4d72-a16c-3f7596e1d46d" name="wve:OptionToReachMaximumTargetsForPreclinicalPrograms"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any one time</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (&#x201c;IND&#x201d;)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company&#x2019;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_50d547c6-1568-4519-9631-a3224a84e565" contextRef="C_5d950313-80c4-4f92-b61d-13e608cecd5c" name="wve:FundReceivableForResearchAndPreclinicalActivities" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda&#x2019;s global commercial sales of products from each Category 2 Program.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Takeda Collaboration Agreement commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21ba0585-de74-4e2f-929f-ee87a33bd8a6" contextRef="C_c7648e40-cd9d-4899-a7d2-538b38a342e1" name="wve:CollaborationAgreementCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2, 2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Takeda may terminate the Takeda Collaboration Agreement for convenience on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0921f111-491b-4edf-9357-5d742867eefb" contextRef="C_c7648e40-cd9d-4899-a7d2-538b38a342e1" name="wve:MaximumTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#x2019; notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#x2019;s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Takeda Collaboration is managed by a joint steering committee in which both parties are represented equally. The joint steering committee is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and therefore were combined into a single performance obligation.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the outset of the arrangement, the transaction price included the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6e7b8d6b-0045-4477-a0d8-decaf6f3a46a" contextRef="C_a04b64a0-15b9-4cd7-a1a3-3e35f0aae6c4" name="wve:UpFrontConsiderationReceived" unitRef="U_USD" scale="6" decimals="-5">110.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront consideration received and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2cd6b1cd-b20f-4159-b495-7a590aea167c" contextRef="C_a04b64a0-15b9-4cd7-a1a3-3e35f0aae6c4" name="wve:FundReceivableForResearchAndPreclinicalActivities" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. Prior to the Amendment (as defined below), revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation was recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95347802-8b98-472b-88c0-98f103f82a95" contextRef="C_878fd094-b224-474e-b2c6-88e67084090b" name="wve:CollaborationAndLicenseAgreementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 15, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the &#x201c;Amendment&#x201d;), which discontinued the Category 2 component of the Takeda Collaboration. The Category 1 Programs under the Collaboration Agreement remain in effect and are unchanged by the Amendment. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_35ebc3ac-7d56-4c2d-9c9e-9a2a9cb78b52" contextRef="C_ec472920-af11-4b8e-ab46-31b361f6eeb4" name="wve:CollaborationBudgetedResearchAndPreclinicalExpenses" unitRef="U_USD" scale="6" decimals="-5">22.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as full payment for reimbursable Category 2 Programs collaboration-budgeted research and preclinical expenses. The Company received this payment from Takeda related to the Category 2 component and recognized the full amount as collaboration revenue in the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company announced its decision to discontinue clinical development of WVE-004 for C9orf72-associated ALS and FTD (&#x201c;C9 for ALS/FTD&#x201d;), one of the Category 1 Programs. In July 2023, the joint steering committee that manages the Takeda Collaboration terminated C9 for ALS/FTD as a target under the collaboration (the &#x201c;C9 Target&#x201d;) and consequently Takeda and the Company&#x2019;s rights and obligations under the Takeda Collaboration were terminated with respect to the C9 Target. As a result of the termination of the C9 for ALS/FTD Category 1 Program, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1711fc04-cab6-4072-86ec-f8cae9c143b6" contextRef="C_ec9ca9b5-ccad-4c2b-9ec4-b7bea741597b" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue during the three months ended September 30, 2023, which represented the remainder of the deferred revenue for the C9 for ALS/FTD Category 1 Program as of June 30, 2023.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company achieved a developmental milestone related to the HD Category 1 Program, which pertained to the positive results from a non-clinical study of WVE-003 in non-human primates (&#x201c;NHPs&#x201d;). As a result of achieving the milestone, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_989175dd-5e57-4e69-9137-803c9a56aa62" contextRef="C_057199ca-f556-4877-bcce-76b3e2df83a1" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue during the three months ended September 30, 2023, which was not previously recorded in deferred revenue, as it was fully constrained at the inception of the Takeda Collaboration. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9e5f5b39-95f1-459d-91cf-b1111408677b" contextRef="C_ea2de7e1-ba02-4ca3-bc26-5a09679f28d4" name="wve:AcheivementOfMilestoneIncludedInCurrentPortionReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the achievement of the milestone is included in the current portion of accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has recognized revenue of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1e92a5bf-a648-418e-8afe-47dab0b46f78" contextRef="C_5bc05ff7-8cc5-4878-970b-926a4d26e663" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">118.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collaboration revenue under the Takeda Collaboration Agreement in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss). During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_10bc5e89-3a52-476d-b4be-b6806b7f8f91" contextRef="C_527f6f22-23ca-4707-bf9b-bef67aa616a8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">34.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_553c348e-bf02-4a86-b8c0-2408782757fe" contextRef="C_8ceac785-d0e4-4aac-b036-774e9a55619b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement, respectively. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized revenue of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13613545-953e-4441-9e65-c7d116eddd7f" contextRef="C_5140a810-8f0d-4fdc-a8ea-09de8f50f3ee" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_99aeb193-2f6b-4482-8559-b03fee6ba824" contextRef="C_0f8ac8dc-ad38-47bb-bee3-820517d4de91" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement, respectively.</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_95075990-b022-4ab3-ab2d-0a738ed2d06e" contextRef="C_59ab39c1-8765-403a-8d50-7defda76d4c8" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">111.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_957c9596-8396-485e-939d-f1d803cadccc" contextRef="C_59ab39c1-8765-403a-8d50-7defda76d4c8" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included in current liabilities and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_876bd480-b2db-4381-98b7-5bbcda637667" contextRef="C_59ab39c1-8765-403a-8d50-7defda76d4c8" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included in long-term liabilities. The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_643bf861-4e3c-40ae-b4f7-6998ed8e39b1" contextRef="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">81.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c10d4a39-adc3-4a78-8de7-5208d1e74340" contextRef="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in current liabilities and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_619d6fd9-e158-488a-9835-b38c78686f41" contextRef="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in long-term liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each remaining Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each remaining Category 1 Program option upon Takeda&#x2019;s exercise or termination of such option, or immediately as each option expires unexercised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_911ea568-ed6a-439b-bfb0-8b234984afd0" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. NET INCOME (LOSS) PER ORDINARY SHARE</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the two-class method to calculate its basic and diluted net income (loss) per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_67b6e5d8-b313-4c42-8c0e-de964d21717b" contextRef="C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,093,656</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vested and exercisable pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) outstanding to purchase ordinary shares for the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f7367751-2741-417a-9f18-e24897e3df26" contextRef="C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, provided that, unless and until the Company obtains shareholder approval for the issuance of the shares underlying the Pre-Funded Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of our ordinary shares beneficially owned by the holder (together with its affiliates) to exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ba5bef29-ea6e-4864-aa11-fff500d64070" contextRef="C_031a13b4-1502-40ec-87b3-130a5d96f105" name="wve:PercentageOfOwnershipInterestInOrdinarySharesOutstanding" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of our ordinary shares outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net income (loss) per share as the exercise price is negligible and the warrants are fully vested and exercisable.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic loss per share is computed by dividing net income (loss) attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net income (loss) per share when their effect is dilutive.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of as of September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_032f85d7-c5eb-4677-aec7-5b09fefaef5b" contextRef="C_7a8994db-d61b-431c-a197-e1e739d2ccf8" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3079027d-54e6-4410-ad3f-04552264ca35" contextRef="C_e6729cef-6185-408f-8064-d6b87f459534" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,901,348</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series A preferred shares outstanding; the Series A preferred shares are participating securities under the two-class method. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the nine months ended September 30, 2023 and the three and nine months ended September 30, 2022, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods and holders of Series A preferred shares do not participate in losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0d53aac-e36e-453e-957b-886c078df7ee" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below sets forth the computation of the Company&#x2019;s basic and diluted net income (loss) attributable to ordinary shareholders:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.663%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Numerator</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c69f0213-c1d9-43ba-8416-39bf075aaca9" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,252</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60ed7fe0-9409-490c-9554-73599b7ad8f3" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d9c64cb-3c16-416e-9be5-d26b82596dda" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,257</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00674efe-6e54-455d-b278-29a45f076f9a" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Less: net income attributable to <br />&#160;&#160;&#160;&#160;&#160;&#160;participating securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7eb3d8c4-d3e2-4ae1-aa60-e4fd3ebaeb61" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) attributable to ordinary <br />&#160;&#160;&#160;shareholders, basic and diluted</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ec1a5e0b-f406-4af2-b6b5-c01736fbfd9b" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,995</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_239cd6ee-b7d9-4a84-a008-52bdb40c1764" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,004</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_27569a5f-abbd-440c-99ab-f6499feee621" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,257</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_60cbd849-7e0f-4881-ba13-67dff7c3d39b" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="wve:NetIncomeLossAvailableToCommonStockholders" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118,114</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Denominator</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br />&#160;&#160;&#160;computing net income (loss) per share <br />&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;basic</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1931bbfb-6b8a-481c-82c6-0df09c82bcea" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,025,063</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15f42d10-735a-47c1-9b37-d3d2fb7d38e8" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">93,900,484</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_37c29f07-d216-4a6b-971c-0091a5e345e2" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">104,529,266</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4cb73cd2-38b6-488a-b4c3-ca9e46618c5e" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,754,417</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of employee share plans</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9bdf9e08-1231-4434-a4f0-e20f3a5680d7" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">950,168</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br />&#160;&#160;&#160;computing net income (loss) per share <br />&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;diluted</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9f899093-9538-4697-a0a6-f4b62c15c3e0" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">106,975,231</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_191e1dd3-2fc3-4560-8f52-0a132bbf245f" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">93,900,484</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ed7273a8-e9de-47e1-aa53-4ddbbfbb3062" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">104,529,266</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e13390d-b58e-45c3-a2fc-a465b8ed80a5" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">73,754,417</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br />&#160;&#160;ordinary shareholders&#x2014;basic</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_388d7700-ecf4-4c89-be82-1a54d2495d02" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e6ffe73e-fdf9-4266-a844-36a448ae7d1f" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_878a959d-6e73-4fee-986a-ec183ba2bae4" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dafaa54c-5464-41a4-b5f3-81028f4cd3f8" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.60</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br />&#160;&#160;&#160;ordinary shareholders&#x2014;diluted</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_99f5b96f-67f4-459e-9e96-8ab15b27fc3e" contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_95cd0744-08b7-41b3-b69c-af89fadc70e1" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f1a7c3ee-6d76-41f8-b580-a822751a777f" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.39</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2c84e9da-89df-4d0a-90cb-c1df73a89a52" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.60</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16f0377b-22a2-43ee-8684-91657a586a17" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes awards that were excluded from the computation of diluted earnings as their inclusion would have been anti-dilutive.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.58%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_581da5fc-837f-40ed-a7d6-e3e42a166105" contextRef="C_5b444e81-468e-4a28-afad-15b895940ca5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,470,166</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2dee1b04-0575-424a-b232-cdc076db1fda" contextRef="C_8d17bd9b-fc3b-4ebf-a913-cc842346df8b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,332,977</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_40e42138-b622-4f0d-8563-da34bf106f2f" contextRef="C_883042b4-2458-4bfa-b9a2-8b427c1b5850" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,303,670</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e3e24b15-a3db-4708-bb52-d5faeec6c659" contextRef="C_c5faabcb-be56-4b08-bc24-70fe0b903474" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,907,290</ix:nonFraction></span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8ae3cfb-5d9e-41ef-9266-3f1861ee8843" contextRef="C_3160b90d-92fd-4f20-8899-bd69ca3f321d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">62,899</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f684bccf-2e51-4d36-8ec4-ab6dab98c92d" contextRef="C_a97c8ae9-b044-4820-96e5-a71d47eaadf7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">521,146</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f62a7f4d-5bfc-437c-a3e4-599a34ac9f94" contextRef="C_8adc395c-a848-43c3-81d7-7bf7b1af08f5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,648</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_30d64865-43d8-4372-b75d-df9ea90648ea" contextRef="C_3abbdbcd-9d9e-40d7-bd45-c1f8652ed620" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">802,355</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_107d6194-71a2-411d-9e0b-c14708db4b15" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. INCOME TAXES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company recorded an income tax benefit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_397a2a00-b5de-4526-a87f-f856928e9b5a" contextRef="C_0e8e072b-2447-4085-9e05-53042061b71e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_734c5ab7-909a-49c1-85f1-de033a0a88f6" contextRef="C_fda03e0b-63d3-4280-b99e-297c22e0b692" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million due to a provision to return adjustment in connection with the recent U.S. tax guidance relating to the capitalization of research and development expenditures. During the three and nine months ended September 30</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1ff3fb4-34c6-4447-b00e-ecf6e0071fd7" contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0e0b31e4-a190-4e13-9106-75804acaeabe" contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> income tax benefit or provision.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintained a full valuation allowance for the three and nine months ended September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in all jurisdictions due to uncertainty regarding future taxable income.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_555e4c0d-d913-49c0-94a2-5031e15dfd35" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="wve:GeographicDataDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. GEOGRAPHIC DATA</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#x2019;s long-lived assets were located in the United States as of September 30, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9473b5b-0312-4022-9303-5338b6d63009" contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following related party transactions:</span></p><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company&#x2019;s founders and a member of the Company&#x2019;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_367d8f8d-1a66-4d5f-9941-75e6fcc89885" contextRef="C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6" name="wve:AgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#x2019; prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d636404-0514-4ff0-ac90-72143e70d1a3" contextRef="C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="U_USD" scale="3" decimals="-3">13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand per month, plus reimbursement for certain expenses. In October 2022, the compensation committee of the Company&#x2019;s board of directors granted Dr. Verdine a non-qualified share option for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5abe5884-81fc-4a5f-857a-2e8964ff0764" contextRef="C_00b8ed9d-656c-4ce6-a17b-1713a99a3935" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">163,467</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares in lieu of cash as payment under this consulting agreement for the service period of October 1, 2022 through December 31, 2024, the monthly vesting of which is subject to Dr. Verdine&#x2019;s continued service under the consulting agreement. </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, the Company engaged Shin Nippon Biomedical Laboratories Ltd. (&#x201c;SNBL&#x201d;), one of the Company&#x2019;s shareholders, to provide approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df4ea494-c629-478e-8a9c-68ded1495493" contextRef="C_e9be0c66-eeb0-4d40-b8a8-bef5175660c7" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain NHP contract research services to the Company. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company paid SNBL $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_59565b06-b947-4482-abad-ddbbde971fe2" contextRef="C_ffc4f0bd-1ed1-49eb-882b-b9fd1a18891e" name="wve:PaymentsRelatedToContractResearchServices" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the aforementioned contract research services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During the three months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_076bc99b-03c7-4921-af6f-73a78eba82d2" contextRef="C_57950620-43a2-4507-aaea-bddaf12233fc" name="wve:PaymentsRelatedToContractResearchServices" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t make any payments to SNBL.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div></ix:nonNumeric></div>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Financial Condition and Results of Operations</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 23, 2023, as amended (the &#x201c;2022 Annual Report on Form 10-K&#x201d;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Quarterly Report on Form 10-Q</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and the &#x201c;Risk Factor&#x201d; section of our 2022 Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, our proprietary discovery and drug development platform that enables the precise design, optimization, and production of novel stereopure oligonucleotides, we are working to develop first- or best-in-class medicines that target the transcriptome (the full set of ribonucleic acid (&#x201c;RNA&#x201d;) molecules produced from the human genome) to treat diseases with a high degree of unmet need.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our RNA-targeting oligonucleotides are designed to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins or reduce the expression of disease-promoting RNAs or proteins. Data from our ongoing clinical and preclinical studies has demonstrated significant improvements in potency, durability, and distribution for our oligonucleotides designed through PRISM, compared with competitor chemistries. These data support our platform as best-in-class for designing and optimizing RNA-targeting medicines.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have seen the value of developing RNA-targeting medicines compared to other nucleic acid therapeutics, including gene therapy and DNA editing. By intervening at the RNA level, we can modulate the transcriptome to impact RNA, including expression levels and splicing. We also have the potential to address diseases that have historically been difficult to treat with small molecules or biologics, while retaining the ability to titrate dose, modulate duration of effect, and avoid risk of permanent off-target genetic changes and other challenges associated with DNA editing or gene therapy approaches. Oligonucleotides have additional advantages as a therapeutic class, including the ability to access multiple tissue types and the ability to modulate the frequency of dosing to ensure broad distribution within tissues over time. Oligonucleotides also have well-established manufacturing processes and validated test methods based on decades of improvements, as well as established regulatory, access, and reimbursement pathways.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our approach is based on the scientific insight that the biological machinery necessary to address human diseases already exists in human cells and can be harnessed for therapeutic purposes with the right tools. We believe we have built the most versatile RNA medicines platform in the industry as it is comprised of multiple therapeutic modalities, which provides flexibility to design built-for-purpose molecules that enable us to access novel areas of disease biology. These modalities are RNA editing, splicing, RNA interference (&#x201c;RNAi&#x201d;) and antisense silencing, all of which incorporate proprietary and novel chemistries to optimize the pharmacological properties of our therapeutic oligonucleotides.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img56423468_0.jpg" alt="img56423468_0.jpg" style="width:411px;height:298px;" />&#160;</p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a robust and diverse pipeline of potential first- or best-in-class programs. Our clinical programs are designed to treat high-impact genetic diseases, including those in muscle, liver; and the central nervous system (&#x201c;CNS&#x201d;). These programs include:</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WVE-N531 (splicing), our exon 53 molecule for the treatment of Duchenne muscular dystrophy (&#x201c;DMD&#x201d;); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WVE-006 (editing), our SERPINA1 molecule for the treatment of alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;); and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WVE-003 (silencing), our mHTT SNP3 molecule for the treatment of Huntington&#x2019;s disease (&#x201c;HD&#x201d;).</span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also advancing a preclinical, wholly-owned </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-acetylgalactosamine (&#x201c;GalNAc&#x201d;) -conjugated RNAi program targeting inhibin &#x3b2;E (&#x201c;INHBE&#x201d;) for metabolic disorders, including obesity, as well as building a pipeline of novel RNA editing oligonucleotides.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Over the last several years, we have built a leading RNA editing capability. Our A-to-I RNA editing oligonucleotides (&#x201c;AIMers&#x201d;) enable access to areas of disease biology that are not viable for other therapeutic modalities. Our editing capability affords us the dexterity to address both rare diseases, as well as those diseases impacting large patient populations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AIMers are designed to target single bases on an RNA transcript and recruit proteins that exist in the body, called ADAR (adenosine deaminases acting on RNA) enzymes, which naturally possess the ability to change an adenine (A) to an inosine (I), which cells read as guanine (G). This approach enables both the correction of G-to-A point mutations, as well as the modulation of RNA to upregulate protein expression, modify protein-protein interactions, or alter RNA folding and processing. AIMers enable simplified delivery and avoid the risk of permanent changes to the genome and irreversible off-target effects with DNA-targeting approaches. AIMers are short in length, fully chemically modified, and use novel chemistry, including proprietary PN backbone modifications and chiral control, which make them distinct from other ADAR-mediated editing approaches.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our PRISM platform was built on the recognition that a significant opportunity exists to tune the pharmacological properties of oligonucleotide therapeutics by leveraging three key features of these molecules: sequence, chemistry, and stereochemistry. Our unique ability to control stereochemistry provides the resolution necessary to optimize pharmacological profiles and develop and manufacture stereopure oligonucleotides. Stereopure oligonucleotides are comprised of molecules with atoms precisely and purposefully arranged in three-dimensional orientations at each linkage. These differ from the mixture-based oligonucleotides currently on the market or in development by others. Additionally, to mitigate pharmacological risks and potential manufacturing challenges, our approach focuses on designing short, chemically modified oligonucleotides without the need for complex delivery vehicles. We have also established and continue to enhance our internal current good manufacturing practices (&#x201c;cGMP&#x201d;) manufacturing capabilities to increase control and visibility of our drug substance supply chain, while continuing to innovate oligonucleotide manufacturing.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRISM also incorporates our novel, proprietary PN backbone chemistry modifications, which have been shown preclinically and clinically to increase potency, distribution, and durability of effect across our various modalities. PN chemistry is incorporated in all of our current clinical, preclinical and discovery-stage programs.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, we announced a strategic collaboration with GlaxoSmithKline Intellectual Property (No. 3) (&#x201c;GSK&#x201d;) to advance transformative oligonucleotide therapeutics, including WVE-006. The collaboration combines GSK&#x2019;s unique insights in human genetics, as well as its global development and commercial capabilities, with our PRISM platform and oligonucleotide expertise. The collaboration will enable us to continue building a pipeline of first-in-class oligonucleotide-based therapeutics and unlock new areas of disease biology, as well as realize the full value of WVE-006 as a potential best-in-class treatment for AATD that has the potential to simultaneously address both liver and lung manifestations of the disease.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK collaboration has three components:</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discovery collaboration which enables us to advance up to three programs leveraging targets informed by GSK&#x2019;s novel insights, the first of which will target INHBE for metabolic disorders, including obesity;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discovery collaboration which enables GSK to advance up to eight programs leveraging PRISM and our oligonucleotide expertise and discovery capabilities; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An exclusive global license for GSK to WVE-006, our clinical program for AATD that uses our proprietary AIMer technology. We will maintain development responsibilities for WVE-006 through completion of the first clinical study, at which point development and commercial responsibilities will transition to GSK.</span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 23, 2023, we announced topline results from the Phase 1b/2a FOCUS-C9 study and our decision to discontinue clinical development of WVE-004 for C9orf72-associated amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal dementia (&#x201c;FTD&#x201d;) (&#x201c;C9-ALS/FTD&#x201d;). Results from the study indicated that WVE-004 was generally safe and well-tolerated across doses of WVE-004, with most adverse events presenting as mild in intensity. Importantly, robust, sustained reductions in poly(GP) dipeptide proteins from baseline were observed in the cerebrospinal fluid (&#x201c;CSF&#x201d;), with a maximal mean reduction of 48% (p&lt;0.0001) in the Q12W dose and 50% (p=0.0001) in the Q4W dose of WVE-004, successfully translating preclinical model pharmacodynamic effects to clinical</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">biomarker effects. However, no trends in clinical benefit were observed at 24 weeks, and reductions in poly(GP) were not correlated with stabilization or improvement in functional outcomes. Based on these data, and in the absence of biomarkers reasonably likely to predict clinical outcomes, we discontinued development of WVE-004. In July 2023 C9 for ALS/FTD was terminated as a target under the collaboration (the &#x201c;C9 Target&#x201d;) and consequently Takeda and our rights and obligations under the Takeda Collaboration were terminated with respect to the C9 Target.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Current Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img56423468_1.jpg" alt="img56423468_1.jpg" style="width:720px;height:351px;" />&#160;</p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional details regarding our lead therapeutic programs are set forth below.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Duchenne muscular dystrophy (&#x201c;DMD&#x201d;)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In DMD, we are advancing WVE-N531, which is designed to skip exon 53 within the dystrophin gene &#x2013; a therapeutic approach that would address approximately 8-10% of DMD cases. WVE-N531 is designed to cause the cellular splicing machinery to skip over this exon during pre-mRNA processing, which restores the dystrophin mRNA reading frame and enables production of truncated, but functional, dystrophin protein. Exon skipping produces dystrophin from the endogenous dystrophin gene (not micro or mini dystrophin expressed from a vector), under the control of native gene-regulatory elements, resulting in normal expression. WVE-N531 is both our first splicing candidate and our first systemically administered candidate incorporating PN chemistry to be assessed in the clinic.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022 (data cut-off: December 6, 2022), we announced a positive update from Part A of the Phase 1b/2a proof-of-concept trial of WVE-N531 in three boys with DMD amenable to exon 53 skipping. High muscle concentrations of WVE-N531 and exon skipping were observed six weeks after initiating biweekly multi-dosing at 10 mg/kg, achieving proof-of-concept in the trial. WVE-N531 also appeared safe and well-tolerated.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To evaluate dystrophin protein restoration, we are investigating WVE-N531 in FORWARD-53, the Phase 2 portion of the open-label trial (&#x201c;Part B&#x201d;). We expect to initiate dosing in 2023 and plan to enroll up to ten boys. Boys will be dosed at 10 mg/kg biweekly, and we plan to assess dystrophin protein after 24 and 48 weeks of dosing. The primary endpoint will be dystrophin protein levels, and the trial will also evaluate pharmacokinetics, digital and functional endpoints, and safety and tolerability. We expect to deliver data from FORWARD-53 in 2024. Pending positive results from this trial, we are planning to advance a broader DMD pipeline with PN-modified splicing oligonucleotides for skipping other exons, with the goal of providing new treatment options for a larger population of boys with DMD.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our AATD program is the first to leverage our novel RNA editing capability and uses clinically proven GalNAc-conjugated AIMers with subcutaneous dosing. By correcting the single RNA base mutation that causes a majority of AATD cases with the Pi*ZZ</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">phenotype (approximately 200,000 in the United States and Europe), RNA editing may provide an ideal approach for increasing circulating levels of wild-type Alpha-1 antitrypsin (&#x201c;AAT&#x201d;) protein and reducing mutant protein aggregation in the liver, thus simultaneously addressing both the lung and liver manifestations of the disease.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the third quarter of 2022, we announced WVE-006 as our development candidate for AATD. WVE-006 is first-in-class in AATD and is the most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for RNA editing. In the fourth quarter of 2023, we announced the initiation of our RestorAATion clinical program investigating WVE-006 as a treatment for alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;) and approval of our multiple clinical trial applications (&#x201c;CTAs&#x201d;) for WVE-006. The RestorAATion clinical program will include both healthy volunteers (RestorAATion-1), as well as individuals with AATD who have the homozygous PiZZ mutation (RestorAATion-2) and is designed to provide an efficient path to proof-of-mechanism as measured by restoration of wild-type alpha-1 antitrypsin (&#x201c;M-AAT&#x201d;) protein in serum. We expect to initiate dosing with WVE-006 in healthy volunteers in the fourth quarter of 2023 and deliver proof-of-mechanism data in individuals with AATD in 2024.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the GSK collaboration, GSK received the exclusive global license for WVE-006, with clinical development and commercial responsibilities transitioning to GSK after we complete the first clinical trial. Under the terms of the collaboration, we are eligible to receive up to $525 million in development, launch and sales-related milestones, as well as double-digit tiered royalties as a percentage of net sales up to the high teens, for WVE-006.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical data show that treatment with WVE-006 resulted in approximately 50% RNA editing of SERPINA1 transcript and approximately 7-fold greater AAT protein levels (well above the predicted protective threshold of 11uM) at 13 weeks in an established AATD mouse model (NSG-PiZ). WVE-006 also led to restoration of approximately 50% wild-type M-AAT protein in serum and a 3-fold increase in neutrophil elastase inhibition activity, indicating that the restored M-AAT protein was functional. Wave&#x2019;s AATD AIMers are highly specific to SERPINA1 RNA </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on transcriptome-wide analyses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are successful in the clinic with WVE-006, we will both validate our clinical approach to AATD, as well as validate the feasibility of RNA editing in humans.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Huntington&#x2019;s disease (&#x201c;HD&#x201d;)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In HD, we are currently advancing WVE-003, a stereopure antisense oligonucleotide designed to selectively target an undisclosed single nucleotide polymorphism (&#x201c;SNP&#x201d;), &#x201c;mHTT SNP3&#x201d;, associated with the disease-causing mutant huntingtin (&#x201c;mHTT&#x201d;) mRNA transcript within the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Huntingtin</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(&#x201c;HTT&#x201d;) </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gene. Approximately 40% of the HD population carries SNP3 according to published literature (Carroll et al., Molecular Therapy, 2011).</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WVE-003 incorporates our novel PN chemistry, as well as learnings from our first-generation HD programs. Targeting mRNA with SNP3 allows us to lower expression of transcript from the mutant allele, while leaving the healthy transcript relatively intact, thereby preserving wild-type (healthy) huntingtin (&#x201c;wtHTT&#x201d;) protein, which is important for neuronal function. Our allele-selective approach may also enable us to address the pre-manifest, or asymptomatic, HD patient population in the future. In preclinical studies, WVE-003 showed dose-dependent and selective reduction of mHTT mRNA </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as well as potent and durable knockdown of mHTT mRNA and protein </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in mouse models.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SELECT-HD trial is a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of intrathecally administered WVE-003 for patients with early manifest HD. Additional objectives include measurement of mHTT and wtHTT protein and exploratory pharmacokinetic, pharmacodynamic, clinical and magnetic resonance imaging (&#x201c;MRI&#x201d;) endpoints. The SELECT-HD trial is designed to be adaptive, with dose level and dosing frequency being guided by an independent committee.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022 (data cut-off: August 29, 2022), we announced a positive update from SELECT-HD driven by the observation of reductions in mHTT protein in cerebrospinal fluid (&#x201c;CSF&#x201d;) after trial participants received either a single 30 or 60 mg dose of WVE-003. Additionally, wtHTT protein levels appeared consistent with allele-selectivity. Single doses (30 mg, 60 mg, and 90 mg) of WVE-003 appeared generally safe and well-tolerated. Based on the SELECT-HD data, we adapted the trial to expand the single-dose cohorts and the multi-dose portion is underway.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed enrollment in the 30 mg multi-dose cohort, which is evaluating doses of WVE-003 administered every eight weeks. Having rolled over patients from the single-dose cohort and fully enrolled the 30 mg multi-dose cohort, we will now evaluate the completed single-dose and multi-dose cohorts simultaneously. We expect to report data from the 30 mg multi-dose cohort with extended follow-up, along with all single-dose data, in the second quarter of 2024. These data are expected to enable decision making on the program and support our opt-in package for Takeda.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the third quarter of 2023, we achieved a milestone in our collaboration with Takeda, which pertained to the positive results from a non-clinical study of WVE-003 in non-human primates (&#x201c;NHPs&#x201d;) and resulted in a payment of $7.0 million to Wave in the fourth quarter of 2023. This study showed significant tissue exposure levels of WVE-003 in the deep brain regions, including striatum and bolstered our existing datasets that confirm the ability of our oligonucleotides to distribute to the areas of the CNS important for HD.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Metabolic disorders, including obesity</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, in connection with our Research and Development (&#x201c;R&amp;D&#x201d;) Day, we announced our first wholly owned program emerging from our collaboration with GSK, a GalNAc-conjugated siRNA silencing program targeting INHBE for metabolic disorders, including obesity. There are approximately 47 million people in the United States and Europe with metabolic disorders, including obesity, and therapeutic options beyond GLP-1 receptor agonists are needed. GLP-1 receptor agonists lead to weight loss at the expense of muscle, suppress general reward system, and are associated with poor tolerability profile, with 68% drop-off after 1 year. INHBE loss-of-function heterozygous human carriers exhibit a healthy metabolic profile, including reduced waist-to-hip ratio and reduced odds of type 2 diabetes and coronary artery disease, and INHBE reduction of 50% or greater is expected to restore a healthy metabolic profile. In connection with R&amp;D Day, we shared </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in-vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> proof of concept data achieving INHBE silencing well beyond the 50% therapeutic threshold, which led to substantially lower body weight and reduction of visceral fat in diet-induced obesity mice as compared to control. These are the first data to demonstrate INHBE silencing </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is consistent with the phenotypes of heterozygous loss-of-function carrier. We have identified potent and highly specific leads and expect to select an INHBE clinical candidate in the fourth quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Discovery pipeline</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing new targets across multiple disease areas, in light of compelling preclinical data indicating our oligonucleotides can distribute to various tissues and cells without complex delivery vehicles. With AATD, we have demonstrated that we can edit to correct monogenic diseases by restoring or correcting protein function. In September 2023, in connection with our R&amp;D Day, we demonstrated that we can build on our work on AATD to address larger diseases by editing RNA to upregulate or increase the stability of the mRNA transcript, thereby increasing endogenous protein production. We announced that we are utilizing a proprietary &#x201c;edit-verse,&#x201d; which is powered by genetic datasets and deep learning models, to identify new RNA editing targets and edit sites. These targets leverage easily accessible biomarkers, offer efficient paths to proof-of-concept in humans, and represent meaningful commercial opportunities. We demonstrated preclinical proof-of-concept data on several of these new targets, achieving at least 2-fold mRNA upregulation in liver and kidney targets and more than 60% mRNA correction in liver and lung targets. Also at R&amp;D Day, we announced that we expect to select five new clinical candidates by the end of 2025, including INHBE.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, we announced the publication of preclinical data for our novel small interfering RNA (&#x201c;siRNA&#x201d;) formats in the journal of Nucleic Acids Research. The preclinical data demonstrated unprecedented Argonaute2 (&#x201c;Ago2&#x201d;) loading following administration of single subcutaneous GalNAc-siRNA dose, leading to improved potency and durability </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> versus comparator siRNA formats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also demonstrated the potential of our siRNA to silence targets in extra-hepatic tissues. In the first quarter of 2023, we announced data from our first </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> siRNA study in the central nervous system (&#x201c;CNS&#x201d;), where our unconjugated siRNA constructs demonstrated 70-90% App silencing across six brain regions in mouse CNS at eight weeks, following a single intracerebroventricular (ICV) dose. In September 2023, in connection with our R&amp;D Day, we announced updated data demonstrating sustained App silencing in CNS of at least 75% through a 16-week </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> study following a single dose of our unconjugated siRNA.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through our collaboration with GSK, we are gaining access to proprietary genetic insights to expand our wholly-owned pipeline. In addition, we and GSK are actively working on multiple target validation programs for our GSK-partnered programs, for which all of our costs and expenses are prepaid by GSK.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never been profitable, and since our inception, we have incurred significant operating losses. Our net income for the three months ended September 30, 2023 was $7.3 million and our net loss for the three months ended September 30, 2022 was $39.0 million. Our net loss for the nine months ended September 30, 2023 and 2022 was $41.3 million and $118.1 million, respectively. As of September 30, 2023 and December 31, 2022, we had an accumulated deficit of $1,008.6 million and $967.3 million, respectively. We expect to continue to incur significant expenses and operating losses for the foreseeable future.</span><span style="color:#333333;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize collaboration revenue under the GSK Collaboration Agreement, which became effective in January 2023, and the Takeda Collaboration Agreement (as defined in Note 5 - Collaboration Agreements to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q), which became effective in April 2018. We have not generated any product revenue since our inception and do not expect to generate any revenue from the sale of products for the foreseeable future.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative expenses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, which include:</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compensation-related expenses, including employee salaries, bonuses, share-based compensation expense and other related benefits expenses for personnel in our research and development organization;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with third parties, including contract research organizations (&#x201c;CROs&#x201d;) that conduct research, preclinical and clinical activities on our behalf, as well as contract manufacturing organizations (&#x201c;CMOs&#x201d;) that manufacture drug product for use in our preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred related to our internal manufacturing of drug substance for use in our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses related to compliance with regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses related to third-party consultants;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development supplies and services expenses; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facility-related expenses, including rent, maintenance and other general operating expenses.</span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued expenses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our primary research and development focus since inception has been the development of our proprietary discovery and drug development platform, PRISM. We are using PRISM, which includes our novel PN backbone chemistry modifications, to design, develop and commercialize a broad pipeline of nucleic acid therapeutic candidates that target RNA using RNA editing, splicing, and silencing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses consist primarily of expenses related to our CROs, CMOs, consultants, other external vendors and fees paid to global regulatory agencies to conduct our clinical trials, in addition to compensation-related expenses, internal manufacturing expenses, facility-related expenses and other general operating expenses. These expenses are incurred in connection with research and development efforts and our preclinical studies and clinical trials. We track certain external expenses on a program-by-program basis. However, we do not allocate compensation-related expenses, internal manufacturing expenses, equipment repairs and maintenance expense, facility-related expenses or other operating expenses to specific programs. These expenses, which are not allocated on a program-by-program basis, are included in the &#x201c;PRISM and other research and development expenses&#x201d; category along with other external expenses related to our discovery and development programs, as well as platform development and identification of potential drug discovery candidates.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to continue to incur significant research and development expenses in the foreseeable future as we continue to manage our existing clinical trials, initiate additional clinical trials for certain product candidates, pursue later stages of clinical development for certain product candidates, maintain our manufacturing capabilities and continue to discover and develop additional product candidates in multiple therapeutic areas.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of compensation-related expenses, including salaries, bonuses, share-based compensation and other related benefits costs for personnel in our executive, finance, corporate, legal and administrative functions, as well as compensation-related expenses for our board of directors. General and administrative expenses also include legal fees; expenses associated with being a public company; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; other operating costs; and facility-related expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net is comprised primarily of dividend income and refundable tax credits from tax authorities. We recognize refundable tax credits when there is reasonable assurance that we will comply with the requirements of the refundable tax credit and that the refundable tax credit will be received.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a Singapore multi-national company subject to taxation in the United States and various other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. We believe that our revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in our analysis of contracts with CROs and CMOs to estimate the contract expense, involve a greater degree of judgment, and therefore we consider them to be our critical accounting policies. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the three months ended September 30, 2023 and 2022</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.017%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.743%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49,214</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">285</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48,929</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31,642</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27,575</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,067</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13,128</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,609</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,519</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44,770</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39,184</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,586</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,444</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(38,899</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43,343</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,131</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(105</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,236</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,575</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(39,004</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,579</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax benefit (provision)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">677</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">677</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,252</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(39,004</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46,256</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the three months ended September 30, 2023 was $49.2 million and was earned under the GSK Collaboration Agreement and the Takeda Collaboration Agreement. Revenue for the three months ended September 30, 2022 was $0.3 million and was earned primarily under the Takeda Collaboration Agreement, as the GSK Collaboration Agreement became effective in January 2023. The year-over-year increase in revenue is driven by the $28.0 million of revenue related to the termination of the C9 program and the $7.0 million of revenue related to the achievement of a development milestone under the Takeda Collaboration Agreement, as well as the revenue that was earned under the GSK Collaboration Agreement, which became effective in January 2023.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.017%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.743%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALS and FTD program</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,564</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,153</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(589</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HD programs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,873</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,732</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,141</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DMD programs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,528</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">796</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">732</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AATD program</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,204</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">281</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,923</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRISM and other research and development expenses (1)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22,473</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21,613</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">860</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31,642</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27,575</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,067</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes expenses related to discovery and development programs, identification of potential drug discovery candidates, compensation, internal manufacturing, equipment repairs and maintenance, facilities and other operating expenses, which are not allocated to specific programs. </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $31.6 million for the three months ended September 30, 2023, compared to $27.6 million for the three months ended September 30, 2022. The increase of approximately $4.1 million was due to the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $0.6 million in external expenses related to our ALS and FTD program, WVE-004 (PN-modified silencing oligonucleotide), which we discontinued in May 2023; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $1.1 million in external expenses related to our HD programs, including WVE-003 (PN-modified silencing oligonucleotide); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $0.7 million in external expenses related to our DMD programs, including WVE-N531 (PN-modified splicing oligonucleotide); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $1.9 million in external expenses related to our AATD program, WVE-006 (PN-modified RNA editing oligonucleotide); and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $0.9 million in internal and external research and development expenses that are not allocated on a program-by-program basis and are related to other discovery and development programs, including PRISM and the identification of potential drug discovery candidates, mainly due to increases in compensation-related expenses. </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $13.1 million for the three months ended September 30, 2023, as compared to $11.6 million for the three months ended September 30, 2022. The increase is primarily driven by increases in external general and administrative expenses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net for the three months ended September 30, 2023 was $2.1 million and consisted primarily of dividend income. Other expense, net for the three months ended September 30, 2022 was $0.1 million and was comprised of foreign exchange losses and other expenses, partially offset by dividend income and estimated refundable tax credits. The increase in other income year-over-year was primarily driven by an increase in dividend income and a decrease in foreign exchange losses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Benefit (Provision)</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023, we recorded an income tax benefit of $0.7 million due to a provision to return adjustment in connection with the recent U.S. tax guidance relating to the capitalization of research and development expenditures. During the three months ended September 30, 2022, we did not record an income tax benefit or provision.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintained a full valuation allowance for the three months ended September 30, 2023 and 2022 in all jurisdictions due to uncertainty regarding future taxable income.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the nine months ended September 30, 2023 and 2022</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.017%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.743%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84,249</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,410</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81,839</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95,935</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84,778</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,157</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;text-indent:5pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37,628</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36,789</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">839</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133,563</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121,567</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,996</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(49,314</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(119,157</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69,843</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,380</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,043</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,337</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(41,934</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(118,114</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76,180</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax benefit (provision)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">677</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">677</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(41,257</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(118,114</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76,857</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the nine months ended September 30, 2023 was $84.2 million and was earned under the GSK Collaboration Agreement and the Takeda Collaboration Agreement. Revenue for the nine months ended September 30, 2022 was $2.4 million and was primarily earned under the Takeda Collaboration Agreement, as the GSK Collaboration Agreement became effective in January 2023. The year-over-year increase in revenue is driven by the $47.4 million in revenue that was earned under the GSK Collaboration Agreement, which became effective in January 2023, as well as the $28.0 million of revenue recognized related to the termination of the C9 program and the $7.0 million related to the achievement of a development milestone under the Takeda Collaboration Agreement.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.017%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.366%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.743%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALS and FTD program</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,614</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,240</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">374</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HD programs</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,290</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,178</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,112</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DMD programs</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,097</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,613</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,484</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AATD program</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,930</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,133</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,797</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRISM and other research and development expenses (1)</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67,004</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67,614</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(610</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95,935</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84,778</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,157</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes expenses related to discovery and development programs, identification of potential drug discovery candidates, compensation, internal manufacturing, equipment repairs and maintenance, facilities and other operating expenses, which are not allocated to specific programs. </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $95.9 million for the nine months ended September 30, 2023, compared to $84.8 million for the nine months ended September 30, 2022. The increase of approximately $11.2 million was due to the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $0.4 million in external expenses related to our ALS and FTD program, WVE-004 (PN-modified silencing oligonucleotide), which we discontinued in May 2023; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $5.1 million in external expenses related to our HD programs, including WVE-003 (PN-modified silencing oligonucleotide); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $2.5 million in external expenses related to our DMD programs, including WVE-N531 (PN-modified splicing oligonucleotide); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an increase of $3.8 million in external expenses related to our AATD program, WVE-006 (PN-modified RNA editing oligonucleotide); and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $0.6 million in internal and external research and development expenses that are not allocated on a program-by-program basis and are related to other discovery and development programs, including PRISM and the identification of potential drug discovery candidates, primarily due to decreases in external research and development expenses and depreciation expenses, partially offset by increased facilities-related expenses and compensation-related expenses. </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $37.6 million for the nine months ended September 30, 2023, as compared to approximately $36.8 million for the nine months ended September 30, 2022. The increase of $0.8 million was primarily due to increases in external general and administrative expenses.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net for the nine months ended September 30, 2023 was $7.4 million and consisted primarily of dividend income, as well as estimated refundable tax credits. Other income, net for the nine months ended September 30, 2022 was $1.0 million and primarily related to estimated refundable tax credits. The increase year-over-year was primarily driven by an increase in dividend income.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Benefit (Provision)</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, we recorded an income tax benefit of $0.7 million due to a provision to return adjustment in connection with the recent U.S. tax guidance relating to the capitalization of research and development expenditures. During the nine months ended September 30, 2022, we did not record an income tax benefit or provision.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintained a full valuation allowance for the nine months ended September 30, 2023 and 2022 in all jurisdictions due to uncertainty regarding future taxable income.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any product revenue and have incurred recurring operating losses. To date, we have primarily funded our operations through public and other registered offerings of our ordinary shares, collaborations with third parties and private placements of debt and equity securities. Through September 30, 2023, we have received an aggregate of approximately $1,194.3 million in net proceeds from these transactions, consisting of $634.0 million in net proceeds from public and other registered offerings of our ordinary shares, $471.0 million from our collaborations and $89.3 million in net proceeds from private placements of our debt and equity securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, we had cash and cash equivalents totaling $139.9 million, restricted cash of $3.7 million and an accumulated deficit of $1,008.6 million.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months. We have based this expectation on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we currently expect. In addition, we may elect to raise additional funds before we need them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if we expect we have sufficient funds for our current or future operating plans.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating lease commitments as of September 30, 2023 total approximately $39.9 million, of which $1.5 million is related to payments in 2023 and $38.4 million is related to payments beyond 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until we can generate significant revenue from product sales, if ever, we expect to continue to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. In May 2019, we filed a shelf registration statement on Form S-3ASR with the SEC pursuant to which we registered for sale an indeterminate amount of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine. Our shelf registration statement on Form S-3ASR also included a prospectus covering up to an aggregate of $250.0 million in ordinary shares that we may issue and sell from time to time, through Jefferies LLC (&#x201c;Jefferies&#x201d;) acting as our sales agent, pursuant to the open market sales agreement that we entered into with Jefferies in May 2019, as amended in March 2020 and March 2022 (as amended, the &#x201c;Sales Agreement&#x201d;), for our &#x201c;at-the-market&#x201d; equity program. Since we no longer qualified as a &#x201c;well-known seasoned issuer&#x201d; at the time of the filing of our Annual Report on Form 10-K for the year ended December 31, 2019, we previously amended the shelf registration statement to register for sale up to $500.0 million of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, including the $250.0 million in ordinary shares that we may issue and sell from time to time pursuant to our &#x201c;at-the-market&#x201d; equity program. This registration statement, which we refer to as the &#x201c;2019 Form S-3,&#x201d; remained effective until our 2022 Form S-3 (as defined below) was declared effective on May 4, 2022, after which time we may no longer offer or sell any securities under the 2019 Form S-3.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 3, 2022, we filed a new universal shelf registration on Form S-3 with the SEC, which was declared effective by the SEC on May 4, 2022, pursuant to which we registered for sale up to $500.0 million of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, which we refer to as the &#x201c;2022 Form S-3.&#x201d; The 2022 Form S-3 includes a prospectus covering up to approximately $132.0 million in ordinary shares that had not yet been issued or sold under our Sales Agreement with Jefferies. During the nine months ended September 30, 2023, we sold 751,688 ordinary shares under our at-the-market equity program for aggregate gross proceeds of $3.3 million. As of September 30, 2023, we have $426.7 million in securities available for issuance under the 2022 Form S-3, including approximately $128.7 million in ordinary shares available for issuance under our at-the-market equity program.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flow activity:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.439%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1%;"></td>
    <td style="width:13.637999999999998%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1%;"></td>
    <td style="width:13.637999999999998%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13,808</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(94,341</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(759</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(26,095</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38,572</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67,133</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(153</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(304</span></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51,468</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(53,607</span></p></td>
    <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, operating activities provided $13.8 million of cash, due to our net loss of $41.3 million, offset by non-cash charges of $14.5 million and changes in operating assets and liabilities of $40.6 million. The largest non-cash charge was the $7.4 million of share-based compensation. The largest change in operating assets and liabilities was a $62.3 million increase in deferred revenue, mainly driven by our GSK Collaboration Agreement, which became effective in January 2023, which was offset by the second largest change in operating assets and liabilities, the $7.0 million increase in accounts receivable related to the achievement of a milestone under the Takeda Collaboration Agreement.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2022, operating activities used $94.3 million of cash, primarily due to our net loss of $118.1 million, partially offset by non-cash charges of $21.9 million which mainly consisted of share-based compensation expense and depreciation expense.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, investing activities used $0.8 million of cash, related to purchases of property and equipment.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2022, investing activities used $26.1 million of cash, of which $75.0 million related to purchases of short-term investments, $50.0 million of which subsequently matured, and $1.1 million related to purchases and sales of property and equipment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, net cash provided by financing activities was $38.6 million, which was primarily due to the GSK Equity Investment (as defined in Note 5 - Collaboration Agreements to our consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q).</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2022, net cash provided by financing activities was $67.1 million, which was primarily due to the net proceeds from our previously disclosed June 2022 underwritten offering, which was comprised of sales of ordinary shares and Pre-Funded Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant expenses in connection with our ongoing research and development activities and our internal cGMP manufacturing activities. Furthermore, we anticipate that our expenses will continue to vary if and as we:</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to conduct our clinical trials evaluating our product candidates in patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct research and preclinical development of discovery targets and advance additional programs into clinical development; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">file clinical trial applications with global regulatory agencies and conduct clinical trials for our programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">make strategic investments in continuing to innovate our research and development platform, PRISM, and in optimizing our manufacturing processes and formulations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain our manufacturing capabilities through our internal facility and our CMOs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain our intellectual property portfolio and consider the acquisition of complementary intellectual property;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek and obtain regulatory approvals for our product candidates; </span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respond to the impacts of the COVID-19 global pandemic, the conflict involving Russia and Ukraine, the conflict in the Middle East, global economic uncertainty, rising inflation, rising interest rates or market disruptions on our business; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish and build capabilities to market, distribute and sell our product candidates.</span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with the development of drug candidates and because the extent to which we may enter into collaborations with third parties for development of product candidates is unknown, we are unable to estimate the amounts of future capital outlays and operating expenses associated with completing the research and development for our therapeutic programs. Our future capital requirements for our therapeutic programs will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, results and costs of conducting research and continued preclinical and clinical development for our therapeutic programs and future potential pipeline candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and characteristics of product candidates and programs that we pursue;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of manufacturing clinical supplies of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and to what extent milestone events are achieved under our collaborations with Takeda and GSK or any potential future licensee or collaborator;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain marketing approval for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impacts of the COVID-19 global pandemic, the conflict involving Russia and Ukraine, the conflict in the Middle East, global economic uncertainty, rising inflation, rising interest rates or market disruptions on our business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market acceptance of our product candidates, to the extent any are approved for commercial sale, and the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.</span></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adequate additional funds may not be available to us on acceptable terms when we need them, or at all. We do not currently have any committed external source of funds, except for possible future payments from Takeda or GSK under our collaborations with them. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our shareholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our shareholders&#x2019; ownership interests.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign exchange rates, as well as, to a lesser extent, inflation and capital market risk.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to interest rate risk in the ordinary course of our business. Our cash and cash equivalents are comprised of funds held in checking accounts and money market accounts.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Historically, we have not hedged our foreign currency exposure. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, our financial conditions, our results of operations or our cash flows. For the three and nine months ended September 30, 2023 and 2022, changes in foreign currency exchange rates did not have a material impact on our historical financial position, our business, our financial condition, our results of operations or our cash flows.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inflation Risk</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not believe that inflation had a material effect on our business, financial condition, results of operations or cash flows in the last two years. If global inflation trends continue, we expect appreciable increases in clinical trial, labor, and other operating costs.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capital Market Risk</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no product revenues and depend on funds raised through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our share price, including impacts of global economic uncertainty on the capital markets.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Procedures</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023. The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_ii_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II &#x2013; OTHE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proceedings</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ri</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sk Factors</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed under the caption &#x201c;Risk Factors&#x201d; that appear in Item 1A of our 2022 Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sales of Equit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent  Unregistered Sales of Equity Securities</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not repurchase any of our equity securities during the three months ended September 30, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults Upon</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Senior Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. E</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">xhibits</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.88%;"></td>
    <td style="width:1%;"></td>
    <td style="width:47.74%;"></td>
    <td style="width:1%;"></td>
    <td style="width:7%;"></td>
    <td style="width:1.4%;"></td>
    <td style="width:13.04%;"></td>
    <td style="width:1%;"></td>
    <td style="width:9.04%;"></td>
    <td style="width:1%;"></td>
    <td style="width:9.9%;"></td>
   </tr>
   <tr style="height:8pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Number</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Filed</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">with this</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Report</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Incorporated by</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Reference herein</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">from Form or</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Schedule</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Filing</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Date</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">SEC</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">File/Reg.</span></p><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.1+</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="wve-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-Employee Director Compensation Policy, effective as of August 7, 2023</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.2+</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/d539015dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Form 8-K</span></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exhibit 10.1)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">08/07/2023</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">001-37627</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.3+</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1631574/000119312523205066/d539015dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan, as amended</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Form 8-K</span></p><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exhibit 10.2)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">08/07/2023</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">001-37627</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31.1</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="wve-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31.2</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="wve-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32*</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="wve-ex32.htm"><span style="color:#0000ff;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1350 Certifications of Principal Executive Officer and Principal Financial Officer</span></a></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101.INS</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Instance Document &#x2013; The instance document does not appear in the interactive data file because its Inline XBRL tags are embedded within the Inline XBRL document</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101.SCH</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101.CAL</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101.DEF</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101.LAB</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101.PRE</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(*) The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Wave Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:3%;"></td>
    <td style="width:1%;"></td>
    <td style="width:46%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: November 9, 2023</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Paul B. Bolno, M.D., MBA</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Paul B. Bolno, M.D., MBA</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: November 9, 2023</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</span></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>wve-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Effective: Upon the date of receipt of final voting results (August 7, 2023) evidencing requisite shareholder approval of non-employee director compensation proposal at 2023 Annual General Meeting through 2024 Annual General Meeting</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:7.705pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">WAVE Life Sciences Ltd.</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">2023 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	The Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Wave Life Sciences Ltd. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has approved the following 2023 Non-Employee Director Compensation Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which establishes compensation to be paid to non-employee directors of the Company to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Board. Except as otherwise indicated herein, this Policy shall be effective as of the date of receipt of the final voting results evidencing requisite shareholder approval of the non-employee director compensation proposal at the 2023 annual general meeting (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) through the date of the Company&#x2019;s 2024 annual general meeting, at which time the shareholders of the Company will be asked to approve the key parameters of a new or extended non-employee director compensation policy for the following year. Subject to receipt of shareholder approval, such new or extended policy shall take effect and that cycle will continue from annual general meeting to annual general meeting.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Applicable Persons</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	This Policy shall apply to each director of the Company who is not an employee of the Company or any Affiliate (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Outside Director</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). &#x201c;Affiliate&#x201d; shall mean a corporation which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Equity Compensation - Share Option Grants </font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	All share amounts set forth herein shall be subject to automatic adjustment in the event of any share split or other recapitalization affecting the Company&#x2019;s ordinary shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Ordinary Shares</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) following the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Initial Share Option Grants for Newly Appointed or Elected Directors</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	Each new Outside Director appointed or elected on or after the Effective Date shall be granted a non-qualified share option to purchase 90,000 Ordinary Shares under the Company&#x2019;s then-effective equity incentive plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Equity Incentive Plan</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), on the date of their initial appointment or election to the Board (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Initial Share Option Grant</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Initial Share Option Grants shall (i) vest as to 12.5% of the shares on a quarterly basis during the two-year period following the grant date, subject to the Outside Director&#x2019;s continued service on the Board; </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> that such options shall become exercisable in full immediately prior to and contingent upon the closing of a Change of Control of the Company (as defined in the applicable award agreement); (ii) have an exercise price equal to the fair market value of the Ordinary Shares on the grant date; (iii) expire and no longer be exercisable after the five-year anniversary of the grant date; and (iv) contain such other terms and conditions as the Board or the Compensation Committee shall determine.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Refresh Share Option Grants for Long-Term Service</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	Section 77 of the Companies Act (Cap. 50 of Singapore) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Companies Act&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">) imposes a five-year maximum term for share options granted to non-employee directors of public companies (as defined in the Companies Act). Due to this limitation, on the Effective Date, subject to receiving shareholder approval at the 2023 annual general meeting, each Outside Director who holds an initial share option that was granted in connection with their initial</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">appointment or election to the Board and which has an expiration date within twelve months following the 2023 annual general meeting shall be granted a non-qualified share option to purchase 90,000 Ordinary Shares under the Equity Incentive Plan (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Refresh Share Option Grant</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Refresh Share Option Grants shall (i) vest as to 12.5% of the shares on a quarterly basis during the two-year period following the grant date, subject to the Outside Director&#x2019;s continued service on the Board; </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> that such options shall become exercisable in full immediately prior to and contingent upon the closing of a Change of Control of the Company (as defined in the applicable award agreement); (ii) have an exercise price equal to the fair market value of the Ordinary Shares on the grant date; (iii) expire and no longer be exercisable after the five-year anniversary of the grant date; and (iv) contain such other terms and conditions as the Board or the Compensation Committee shall determine.</font></p>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Annual Share Option Grants</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">On the Effective Date, subject to receiving shareholder approval at the 2023 annual general meeting, each Outside Director (other than an Outside Director receiving an Initial Share Option Grant or a Refresh Share Option Grant) shall be granted a non-qualified share option to purchase 45,000 Ordinary Shares under the Equity Incentive Plan (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Annual Share Option Grant</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Annual Share Option Grants shall (i) vest as to 100% of the shares on the earlier of the 2024 annual general meeting or the first anniversary of the grant date, subject to the Outside Director&#x2019;s continued service on the Board during that period; </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> that such options shall become exercisable in full immediately prior to and contingent upon the closing of a Change of Control of the Company (as defined in the applicable award agreement); (ii) have an exercise price equal to the fair market value of the Ordinary Shares on the grant date; (iii) expire and no longer be exercisable after the five-year anniversary of the grant date; and (iv) contain such other terms and conditions as the Board or the Compensation Committee shall determine.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">For the avoidance of doubt, an Outside Director shall be eligible to receive only one type of option grant on the Effective Date, which shall be an Initial Share Option Grant, a Refresh Share Option Grant or an Annual Share Option Grant.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Cash Compensation </font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Annual Cash Fees</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">The following annual cash fees shall be paid to the Outside Directors serving on the Board and the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Research and Development Committee, as applicable.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.04%;"></td>
    <td style="width:24.64%;"></td>
    <td style="width:24.32%;"></td>
   </tr>
   <tr style="height:11pt;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Board or Committee of Board</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Annual Amount for Chair</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Annual Amount for Member</font></p></td>
   </tr>
   <tr style="height:11pt;">
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Board</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$75,000</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$40,000</font></p></td>
   </tr>
   <tr style="height:11pt;">
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Audit Committee</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$18,000</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$9,000</font></p></td>
   </tr>
   <tr style="height:11pt;">
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Compensation Committee</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$15,000</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$7,500</font></p></td>
   </tr>
   <tr style="height:11pt;">
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Nominating and Corporate Governance Committee</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$15,000</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$7,500</font></p></td>
   </tr>
   <tr style="height:11pt;">
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Committee</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$15,000</font></p></td>
    <td style="border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">$7,500</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Payment Terms for All Cash Fees</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	Except as otherwise indicated herein, cash fees payable to Outside Directors shall be paid quarterly in arrears as of the last day of each fiscal quarter commencing on the later of the Effective Date or an Outside Director&#x2019;s first election or appointment to the Board, prorated from the Effective Date or such Outside Director&#x2019;s election or appointment date, as applicable. If an Outside Director dies, resigns or is removed during any quarter, he or she shall be entitled to a cash fee on a prorated basis through their last day of Board service.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font></div></div>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Upon presentation of documented expenses, reasonably satisfactory to the Company, each Outside Director shall be reimbursed for their reasonable, documented out-of-pocket business expenses incurred in connection with attending meetings of the Board and Committees thereof, or general meetings of shareholders, or in connection with other business related to their Board service.</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-25%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Amendments</font></div></div>
  <p style="margin-left:6.667%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee or the Board, as appropriate, shall review this Policy from time to time to assess whether any changes in the type or amount of compensation provided herein should be adjusted in order to fulfill the objectives of this Policy, </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">, that changes to this Policy which require shareholder approval under applicable law shall require such shareholder approval to be obtained before taking effect.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>wve-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Paul B. Bolno, M.D., MBA, certify that:</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Wave Life Sciences Ltd.;</font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:    November 9, 2023</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.5%;"></td>
    <td style="width:2.5%;"></td>
    <td style="width:90%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>wve-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Kyle Moran, certify that:</font></p>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Wave Life Sciences Ltd.;</font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div></div>
  <div style="text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:    November 9, 2023</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.5%;"></td>
    <td style="width:2.5%;"></td>
    <td style="width:90%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>wve-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 906</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Wave Life Sciences Ltd. (the &#x201c;Company&#x201d;), does hereby certify, to such officer&#x2019;s knowledge, that:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Quarterly Report for the quarter ended September 30, 2023 (the &#x201c;Form 10-Q&#x201d;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.84%;"></td>
    <td style="width:1%;"></td>
    <td style="width:39.16%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:   November 9, 2023</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.84%;"></td>
    <td style="width:1%;"></td>
    <td style="width:39.16%;"></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:   November 9, 2023</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;">
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img56423468_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img56423468_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '2 H(# 2(  A$! Q$!_\0
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MA.B_\\Y_^_S5T5%'MZO\S#ZAA?\ GVON.=_X0G1?^><__?YJ/^$)T7_GG/\
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MZ+_SSG_[_-1_PA.B_P#/.?\ [_-7144>WJ_S,/J&%_Y]K[CG?^$)T7_GG/\
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M%% &#XQMA<>&KE@</!B9&'8J?\,UJZ?<?:]-M;@]98E?\QFJOB/_ )%O4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K.UZT6^T*]MV'WHB1]1R/U K1J*Y_X])O]QOY547:2:(JQ4H.+V:.!
ML_&KPV-O$Q4LD:J23U(%%>?T5[3PE-N]CXB.<8E*USU_P+_R+$7_ %T?^==)
M7-^!?^18B_ZZ/_.NDKR<1_%EZGU^ _W6GZ+\@HHHK$ZPHHHH **** "BBB@
MHHHH **** "B@$$9%-=@L;,2  "<GM0!B>*]6&F>'KZ2&8+="%O+ /(..M<!
MX7\2ZS;07"IIM[J*173JLHG& ,#Y>?S_ !K=U2#[38QF;YE=2CGN<]ZXOPY?
M:M:ZG<Z58/8[Y,RLETS AEPK ;<]< UT4+3IR5EIKJ<U=N,XN^_8]?T35+K5
M;9YKG2YK##85975MX]1BM2N*T?4]5M8Y!J,UB&S\BV[DKCWW=_I71+K4/V3S
M2"9!_ O?\?2N>4ES'1!/E1=DNK>*58I)HUD;D*6 )J0.I. P)],UP.L2S22R
MW?F8,F%90.@Z<4\,4"["1@<$5FZA?*=/J.N)8W!A$1=@,DYP*L:7J::E"S!-
MCH<%<Y_&N.N9Y+B0R2L6;&,FHX+N>SD+P2,C'@X[U'M'<?+H>AT5F:1JT6H6
MZJS@7('S+TS[BM.MD[JZ(:L%%%%, HHHH **** "BBB@ HHHH **** ,SQ%_
MR+>I?]>[_P J7P__ ,BYIO\ UZQ_^@BD\1?\BWJ7_7N_\J7P_P#\BYIO_7K'
M_P"@BMO^77S_ $.3_F+_ .W?U-*N;\)?ZW6_^PC)725S?A+_ %NM_P#81DHA
M_#E\@K?QZ7S_ ".DHHHK$ZPKDOB+_P BTG_7PO\ Z"U=;7(_$7_D6D_Z^%_]
M!:M\-_&CZG#F7^Z5/0\EG)$)P:E\+?\ (W:7_P!?"_SJ*X_U)J7PK_R-VE_]
M?"_SKV*WPOT/C<#_ !(^J/H.BBBO /T CDA61E8Y#+T*G!H#2"1@ZKY>,A@?
MYBI** &I(DJ!D8,I[@TZHWBRA$3>6Q.<J!R?>D,IC9$=6.[C>HXS_2@"6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDTT=O"\TSJD: LS,< "@!]%
M9UCKVEZC;/<6M["\2':Q+;<'WS65XG\6VVD:"]Y93P7$[.(X@KAAN[YQZ"K4
M)-\MM3*5>G&#FWH=')+'%CS)$3<<#<P&33BRA=Q( ]2:^<=:U[4M=U$W-]+N
M)&%5> @]A4"ZAJ(LC9&_N&M=V[RBY*@UU+!/N>2\Z@F[1TZ'TC<7$=M TTIP
MB]:@M=06YF,> IV[E&>37D/A?QKJ-T8]$OKD-;,"BR,N77'0$]Z[V"=5O0H.
M)HE!5@<9&*YJE-TW9GIX;$0Q$.>)UM%4M/NFGW(_)4 Y^N:NUF= 5%<_\>LW
M^XW\JEJ*Y_X]9O\ <;^5-;BELSP&BBBOI3\Q/7_ O_(L1?\ 71_YUTE<WX%_
MY%B+_KH_\ZZ2OG\1_%EZGZ)@/]UI^B_(****Q.L**** "BBB@ HHHH ****
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M]NP^M0,;K.H:?8V3KJ-]%9QSJ8P\CA>3QQ^=>;Z?X=&A&266]CNY[J4GSD7
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MI") /W4(X+Y/R@Y( SU[=*TO!WAG_A&=%$-Q</=ZE<'S;Z\D8LTTIZ\GG Z
M>E>.?:'0T444 %>%ZY_R'K__ *^'_P#0C7NE>%ZY_P AV_\ ^OA__0C7HY=\
M4CYSB+^'#U9S]T29&&> 3Q7L?PR_Y$R+_KM)_.O'+K_6M]:]C^&7_(F1?]=I
M/YUICO@^9SY'_'^7^1V-%5-4NGLM*NKJ(*9(HF=0PR,@=ZIV>H7!U".WEF@N
M(Y(#*9(4*^41C@\D<Y_2O-4&U<^FE6C&?(_ZN:]%9\.L6\SQ_NYDBESY4SJ
MDF 3QSGH"1D#.*A;6A)837-O:SX$#31.RC;( /8_H<&CV<NPO;T[7N:U%9D6
MK_Z+;/+:SB>< )$ N7.,DCYL #W(IW]M6Y2$I'.\DKM&(U3YE=1DJ>>.G7I[
MT<DA^WI]S1HK.&LP%N89Q$'$33%1L5SQM//KQD9&>]5M1UEEMY39QS-Y<R1-
M.%78#O 8<G)ZXX!H5.3=A2Q%-1<KFU1114&P5Y9\4+.PM[JUEAMQ'=3;GE=>
M-PR,$^_6O4ZXGXE:?:3Z&+N0.+E&$<3+TY.2#[8!KHPLK54>?FD.?"R\M?N/
M(CL\T#=A\=*=L4>M0M;M!\S#>/;J*E\QEC$A0$$=0:]GU/BWY,CG0DKD[4')
MJOM>4MY:D(QYJ?\ >SN8R0 >3["GRDKB"(<XZBDU?4I.V@UE$DJKNPH7/!Y-
M,?R1&VR0@GKCO2Q1L@W;6W,,+QQ750^%]'U/38!I^I%=5=!FVF7:K/W /\JF
M4E%79K2I.H[1>WFM?\SE%;RU#-EG?&*]H\ P2SZ+:7DRA1'&T2#'OUKG_"'P
MXS+]LUN)U$;82V;'S>Y]J]/CC2*-8XT5$4855& !7GXNM&2Y%T/H<IP52DW6
MGI=6L.HHHKA/<"HKG_CUF_W&_E4M17/_ !ZS?[C?RIK<4MF> T445]*?F)Z_
MX%_Y%B+_ *Z/_.NDKF_ O_(L1?\ 71_YUTE?/XC^++U/T3 ?[K3]%^04445B
M=84444 %%%% !1110 5FZ@[17"M)DPN-@] ??ZUI4R:&.>)HI%W(PY%# P[F
MZBM5RYY/11U-0%DU"T<*60$X]Z;KFG06<<3Q%LL2"&.<UE0?:8E:>$'8OWCV
MJ&BC2LVDCS;3!BZ=&[$5"XFM;:YDP 2VY<'.,U''=374PD"*!$I. V,U.%%]
M '9V\MOX0,?G4@<UXH\+OXB@MI(KV.W2.,ES(I;/?.>W>J&CRKIRV$EHZ72>
M1]D+(V%9DX/\A74:K8F72IK1&<021M&X4_, 1U!]17!Q>'&\*V2_:=9%VUS.
M7B!39C/4]3WQ^)KNP.'H3C-M_O'9)6>J^78Y\UQF*>&IQ3]VF[Z6OKOTUT;W
M.@U ZJC&5=+>4L26Q(HVUA^(]<N+S3[?2GLC:8<.<N&).,#I]36C>>)[^UL]
MZRVR-&,8E0DOZ8P:Q-,M[CQ!J_VV[;AG#2$#  ]OY5K2@J*=6<4N7;??[SS*
ME1XF,:-.3?-O?EV[Z(])M;O38-,MV^Q1^6$"@E1G &.:DO-3B33F^RJD:E=V
M ,54?REBV?+LQ@*/Y5DOITS1@"7 Z[#GBO&5."?,DD_0]W6UF]"PEPD\8?<,
MGJ,]#4$L\ )1Y$]P321:>B ^: S9]>*@GTY7DW*VU3U&/Y4V,0W$((6'YCGD
M*.U5XXA'++(58EF...U3PVRVH9V?.1UZ8I=RNN5((]14LI%C19+@>(K 6H(<
MN=P(_@_BS^%>H5Y[X043^(LJ<^1$S-^.!C]:]"K>C\)G/<****U("BBB@ HH
MHH **** "BBB@#,\1?\ (MZE_P!>[_RI?#__ "+FF_\ 7K'_ .@BD\1?\BWJ
M7_7N_P#*E\/_ /(N:;_UZQ_^@BMO^77S_0Y/^8O_ +=_4TJYOPE_K=;_ .PC
M)725S?A+_6ZW_P!A&2B'\.7R"M_'I?/\CI****Q.L*S-=EABL5,\JQ*T@4,V
M<9P:TZYGQW_R+Z_]=U_DU14?+!LWPU-5:T8/JS)U2)SIQ,9#AV4*4.0W/M6=
MI?DV.LVAO+F&!O,&(V;+'\!T^IQ7(ZI/+%IY:.1U9'5E*L00>F1^!/YUS)DE
M+@(Y$DK+$&SS\Y"_UKSGB+S22/H8Y'%4YU)3T2?3R/?O",375K<:_<*1<ZJ_
MG*&ZI .(D_[YY^K&M1-;TN34#8)J%LUV"5,(E&[(ZC'K[5.5-G8!+: RF) L
M<2L%S@8 R>!7G#Z9,\\5LMS<06#:LTD$JR6A"S>86X_C/S9^7KZUZA\N>GUG
M7NK16%_;03X$<P/S^AR/TYIURKQVBJ\AD=5 9R "QQUP*\_U%F:\?<Q//<YH
M ]/SD9%>*ZQ<00:W?&.W#R^>_P \G(')Z#I^>:]!\*ZM//\ Z#*K2*BY63^Z
M/0UYIKG_ "';_P#Z^'_]"->AEZO*1\[Q#)JG"W=F3+>A2\4UO%+'N)QMVD$G
M)P1SU/TKUWX<&(^$(C"'"&:3ACDCFO%[K_6M]:]D^&7_ ")D7_7:3^=:8U)0
MT[F&22;K:]O\CJ-1M3?:;<VH8*9HV3<1G&15/^Q_(NTGM&2$.@CN8PORRKC@
MX'1AZU0\:W4UKHT3P3S0$W"*S1,5;'.>E9^C:HT-]JEQ#>7=UI-K#N8W+%G$
M@&2!GGL:Y(4Y^SYDSUZV(I+$>SDM=-?O?W;W-BQT(V4D*JEH4AR%E\L^9C!
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MU==X1N'?1FTF\(>\TQC9SAOXU4?(_P!&3:?SK7BTVP@CBCBLK>..)_,C5(E
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MO_7K'_Z"*3Q%_P BWJ7_ %[O_*E\/_\ (N:;_P!>L?\ Z"*V_P"77S_0Y/\
MF+_[=_4TJYOPE_K=;_[",E=)7-^$O];K?_81DHA_#E\@K?QZ7S_(Z2BBBL3K
M"J&L(SV6%4G#9./H:OUR_CRZGL]!BFMY7BD6X7#(V#T:JA3]I)0[F.(K*A2E
M5:O;4Q]6!&GOD8Y7^=4M C=]:M2J,0'!.!T%8EQXOU"2VB2Y2&98Y [$I@R
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M X@B_P!5'*"-S>N#V%=;I>A6^F,T@8S3'CS' X'H/2M2M(T[:LER[!1116I
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MS-&-IJ7-E<,Q090>8.X)&?\ Z]=JC;T5L8R :YC1=)N)I4N;O=Y0!PK'K_\
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MF2]Y[OOK^%O+U&AWE#A5:/'"LPZ_A2I$ JAR9&7D,P&<U)16984444 %%%%
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MU%<_\>LW^XW\JE;FTMF> T445]*?F)Z_X%_Y%B+_ *Z/_.NDKF_ O_(L1?\
M71_YUTE?/XC^++U/T3 ?[K3]%^04445B=84444 %%%% !1110 8&<XHHHH *
M*** "BBB@ HHHH IZAI.GZJJ+?V<-R(R2GF+G:3Z5ROBKP/;WFD+%H>GVD%R
M)06( 4E<'(S]2/RKMJ*UIUITVG%[&%;#TZT7&2W^\K:=:FRTRTM"03!"D9([
M[5 _I5FBBLV[NYLE9604444AA1110 4444 %%%% !1110 4444 %%%% !111
M0!F>(O\ D6]2_P"O=_Y4OA__ )%S3?\ KUC_ /012>(O^1;U+_KW?^5+X?\
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M^==%7SU?^+(_1,!_NT%V5ONT"BBBLCK"BBB@ HHHH **** "BBB@ H[T4=Z
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MQ\T[F(PJ]">.*Y#XBRI/\<_"<T9RCK:LI(QP9"13_B'_ ,G"^&?K;?\ HQJ
M-J'XS:E:>+K32/$/A2;28+MU6-I&;S%#'"L00 1GKBN@\??$M/"&HV>C6&G-
MJ>LW>#';AL!03A<XY))S@#TKA/CI_P CWX3_  _]&BE^)L4_ACXRZ/XON[6:
M7208B\B+N"%<J1['&"/6@#:U;XL^)] UC2M,UGPE;64]\RCF\\P8+!<C;G&/
M0UZ^1@D5\U_$GQ3IGBSQWX6N])-Q);(R*)9(&C#GS0?EW#)Q7THWWC]: $HH
MHH **** "BBB@ HHHH **** "BBB@#.U_P#Y%[4?^O=_Y5<\/?\ (MZ9_P!>
ML?\ Z"*R_%4X@\-WF3S(OEJ!W+'%;>EP&UTFS@88,<**1] *V_Y=?/\ 0Y%K
MBWY17XM_Y%NN2\,_\?&N?]A&2NMKDM%Q;>(]=LVX8S"=1ZAN_P#*E#X)+T_,
M*^E>D_-K\/\ @'04445D=84444 %%%% !1110 4444 %%%% '@?[0LVHIJNC
M)-YYT0H69(SA6DW?-D]-VW&,U2TZ/X):_;I9B*^T>Z?"K+/+(#GUW99/S KO
M_B'XZD\+ZU'8ZGX;_M;P_<6X:5O*W!'R00<@J>,<''UKR#Q9<^$_&1MK;P+X
M1U"#4VE_>,D85"N,8V*S <XYXH ]@\<>-I?AAX>T"WL;2'48WC%N'E<KE410
M&&WUK.UKXL^(_#;6-[K/@PVND79 27[4'DZ9Z#@''.#BN1^,&FW6B^ /!.FW
MLGF7-JC1RD'/(5>,]\=/PJ;XD^,+'QKH&D>%O#MO>7NHB2-I4^S.AC(3;C!&
M>IZ],=Z +?Q_NX;_ $GPM>6S[X)R\D;>JD*16_\ %+Q)8^';'PX;SPWINL&>
M/"&]7/E8"_=X[Y_2N2^,NF/HO@[P5IDK!I+6,Q.0>-P5<_K5OX^?\>'A'_<;
M^24 >A^-_B/8>"+*Q1K1[S4+Q ;>TB....2>PSP.,FJ>G>-_%T>L:9:^(?!G
MV"TU&588[F*Y#^6QY&\#./H<5R'Q:T34[7Q-X<\76UE->V5I'")TB7<4V-NY
M'H0>OM78V?Q<T+7M8TS3-#ANKVXNYU6?? RK;)U+,2.HZ<<>] &9X;\36%W\
M9M4T2+PUIEM<P^=NU*)<328QG)QWSS4$_P 8M3C\:ZGX=MO"[ZA):O(D*VC,
M9)"O0L.P]:PO!O\ R<IKO_;Q_(4>!?\ DXOQ%]+G^8H ZKP1\5[GQ%XLF\-Z
MUH9TO4%#%%#$X*C)5@W(..:=KGQ4O1XR?PMX4T'^V+^$D3,\NQ 0/F /MT))
M S7)P''[4[GW/_HBJ.DZA%\,OC-K-QXBAN(K*]\WR;H1EP0S!@1CJ.QQR#0!
MV^@_%'5]2^)"^$=2\/PZ?( WF_Z1YCH1'OZCY3G^1KT^OGKPUJ<.M?M*/J-J
MDRP3!V031E&QY&,E3R,XS]#7T+0 4444 %%%% !1110 4444 %%%% !4<_\
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M]^%_PI/[;TK_ *"5I_W^7_&C^V]*_P"@E:?]_E_QH_>>87P_E^ O]CZ9_P!
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MC+_X1O1?^@9:_P#?L4?\(WHO_0,M?^_8K4HH]I/NP^K4?Y%]R,O_ (1O1?\
MH&6O_?L4?\(WHO\ T#+7_OV*U**/:3[L/JU'^1?<C+_X1O1?^@9:_P#?L4?\
M(WHO_0,M?^_8K4HH]I/NP^K4?Y%]R,O_ (1O1?\ H&6O_?L4?\(WHO\ T#+7
M_OV*U**/:3[L/JU'^1?<C+_X1O1?^@9:_P#?L4?\(WHO_0,M?^_8K4HH]I/N
MP^K4?Y%]R,O_ (1O1?\ H&6O_?L4?\(WHO\ T#+7_OV*U**/:3[L/JU'^1?<
MC+_X1O1?^@9:_P#?L4?\(WHO_0,M?^_8K4HH]I/NP^K4?Y%]R,O_ (1O1?\
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M%_Z!EK_W[%'_  C>B_\ 0,M?^_8K4HH]I/NP^K4?Y%]R,O\ X1O1?^@9:_\
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MJ>??-=LB[$5?08HRJI4FI\[N@Q<8JW*+1117K'&%%%% !1110 4444 %%%%
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MS;EB:#M).4;[K>WFCM=*U2>]U+6+>54"6<ZQQE1R04!Y_$UEGQ/<)X"?6Y3
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MS@\=:ZGQ2+75]=L=&N+(DQ8N5N9&*H.V 1U]_3BMIK2&?3WMGAT[RI 494;
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M8A?,3C!]Q3PDJ"E^\WZ=@K*HU[I3O_#WEW NM.49Z-#G&?H35C2=*:.<W=S
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MX2T;3KV.[@M6\Z($1&29Y!'G^Z&) _"MNBLW5F]VR>>7<S/$7_(MZE_U[O\
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M^TZE,"RKU,:GI^+%?RKUVO /%?AC7_B+\898&AO]-TNT4Q0W[VK[%"#.Y2<
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M)3+:_+J6C7UNXZE$WJ?H:</&6F8_U5[_ . YJ?85.Q2QV'ZRMZZ?F=#17/\
M_"9:9_SRO?\ P'-'_"9:9_SRO?\ P'-'L*G\H?7L-_.CH**Y_P#X3+3/^>5[
M_P" YH_X3+3/^>5[_P" YH]A4_E#Z]AOYT=!17/_ /"9:9_SRO?_  '-'_"9
M:9_SRO?_  '-'L*G\H?7L-_.CH**Y_\ X3+3/^>5[_X#FC_A,M,_YY7O_@.:
M/85/Y0^O8;^='045S_\ PF6F?\\KW_P'-'_"9:9_SRO?_ <T>PJ?RA]>PW\Z
M.@HKG_\ A,M,_P">5[_X#FC_ (3+3/\ GE>_^ YH]A4_E#Z]AOYT=!1FN?\
M^$RTS_GE>_\ @.:/^$RTS_GE>_\ @.:/85/Y0^O8;^='045S_P#PF6F?\\KW
M_P !S1_PF6F?\\KW_P !S1["I_*'U[#?SHZ"C-<__P )EIG_ #RO?_ <T?\
M"9:9_P \KW_P'-'L*G\H?7L-_.CH**Y__A,M,_YY7O\ X#FC_A,M,_YY7O\
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M6F?\\KW_ ,!S1_PF6F?\\KW_ ,!S1["I_*'U[#?SHZ"BN?\ ^$RTS_GE>_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img56423468_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img56423468_1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MIL*"Q\IW^4%N@)H \G\'?M"Z?K6NWNFZC-;PV37$<.D216UYYESYDC(/-R)
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MVW1;82S[9K?:,-.B;1(['[P&,X .G\#_ !/@\:3W>E/;2Z5K6G@^=976"0.
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M3\6:+HD@@U*_LK*4@$1W%U!"Y!Z$+(ZG![<4 <Q\2O&<OA/PM=>(M(^SW4D
MMS"7S) XEN886/[J1"PVR,5*R#Y@"<C((!TWA/59==T73]4N BS7UE:W,BQ@
MA \T"2.$#,S!0S$*&9B!C+$\T =!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MQ0N5#;))0^Q&&X<,5/(..: +>D^(M+UX,=+O+6^$?WS;3Q3;<_WO*=L9]\4
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M_AI_R4;Q3_VR_P#0A0!]*T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'A7[0_A6_P#%?A?RM+C:XFLKN*[,*#=))&D4\3B-1RS*)M^T LP4A06(% #-
M,^/>AZA;V]M8P7<VK2F*)M-CMI@\#L51M[^68EAC))W*SML ^0'( !SWA?\
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M!O ^G?#[31I&E>8T0D>5I)BC2R.Y&6=D2-20H5%P@PB*#DY) .QH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#E/%_A&W
M\96L=I<3W=D;>=;B*>RF\B=)%CEB!63:^!LE?(QSQZ4 87A+X6Z7X2OI-76:
M]U+4ID\HWFHW!N)Q&2"45MJ* < 9VEL#&[!((!Z10 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M * "@ H * "@ H * "@!DDJ1#+L$'3+$ 9_&FDWLON)E*,-9-)>;L0_;(/\
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M8>UI_P \?_ E_F'VR#_GI'_WVO\ C1R2[/[F'M:?\\?_  )?YA]L@_YZ1_\
M?:_XT<DNS^YA[6G_ #Q_\"7^8?;(/^>D?_?:_P"-')+L_N8>UI_SQ_\  E_F
M'VR#_GI'_P!]K_C1R2[/[F'M:?\ /'_P)?YA]L@_YZ1_]]K_ (T<DNS^YA[6
MG_/'_P "7^8?;(/^>D?_ 'VO^-')+L_N8>UI_P \?_ E_F'VR#_GI'_WVO\
MC1R2[/[F'M:?\\?_  )?YA]L@_YZ1_\ ?:_XT<DNS^YA[6G_ #Q_\"7^8?;(
M/^>D?_?:_P"-')+L_N8>UI_SQ_\  E_F'VR#_GI'_P!]K_C1R2[/[F'M:?\
M/'_P)?YA]L@_YZ1_]]K_ (T<DNS^YA[6G_/'_P "7^8?;(/^>D?_ 'VO^-')
M+L_N8>UI_P \?_ E_F'VR#_GI'_WVO\ C1R2[/[F'M:?\\?_  )?YA]L@_YZ
M1_\ ?:_XT<DNS^YA[6G_ #Q_\"7^8?;(/^>D?_?:_P"-')+L_N8>UI_SQ_\
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M8>UI_P \?_ E_F'VR#_GI'_WVO\ C1R2[/[F'M:?\\?_  )?YA]L@_YZ1_\
M?:_XT<DNS^YA[6G_ #Q_\"7^8?;(/^>D?_?:_P"-')+L_N8>UI_SQ_\  E_F
M'VR#_GI'_P!]K_C1R2[/[F'M:?\ /'_P)?YA]L@_YZ1_]]K_ (T<DNS^YA[6
MG_/'_P "7^8?;(/^>D?_ 'VO^-')+L_N8>UI_P \?_ E_F'VR#_GI'_WVO\
MC1R2[/[F'M:?\\?_  )?YA]L@_YZ1_\ ?:_XT<DNS^YA[6G_ #Q_\"7^8?;(
M/^>D?_?:_P"-')+L_N8>UI_SQ_\  E_F'VR#_GI'_P!]K_C1R2[/[F'M:?\
M/'_P)?YA]L@_YZ1_]]K_ (T<DNS^YA[6G_/'_P "7^8?;(/^>D?_ 'VO^-')
M+L_N8>UI_P \?_ E_F'VR#_GI'_WVO\ C1R2[/[F'M:?\\?_  )?YA]L@_YZ
M1_\ ?:_XT<DNS^YA[6G_ #Q_\"7^8?;(/^>D?_?:_P"-')+L_N8>UI_SQ_\
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MNCZ[B/YW]T?\@_L7 ?\ /A?^!5/_ )(/^$(T7_GV7_ON7_XNCZ[B/YW]T?\
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M_P ^%_X%4_\ D@_X0C1?^?9?^^Y?_BZ/KN(_G?W1_P @_L7 ?\^%_P"!5/\
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M&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\
M?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1
M_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\
MGPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R
M0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/
MLO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=
MQ'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0
M?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_
M\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$
M:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__
M !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'
M\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#
M_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)
M!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^
MR_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T
M?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+
M@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P#
MJG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B
M_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\
M71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H
M_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/
M^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D
M'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]
M]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71
M]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D'
M]BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I
M_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+
M_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_
M /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^
M0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"
M_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_
MPA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_W
MW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?
MSO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?
MV+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG
M_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\
M^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_
M ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._N
MC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_
M  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\
M"$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\
MWW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[
M^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@
M/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?
M_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S
M[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='
MUW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z
M/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO
M_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA
M&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\
M?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1
M_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\
MGPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R
M0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/
MLO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=
MQ'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0
M?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_
M\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#_GPO_ JG_P D'_"$
M:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__
M !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^R_\ ?<O_ ,71]=Q'
M\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T?7<1_._NC_D']BX#
M_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+@/\ GPO_  *I_P#)
M!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P# JG_R0?\ "$:+_P ^
MR_\ ?<O_ ,71]=Q'\[^Z/^0?V+@/^?"_\"J?_)!_PA&B_P#/LO\ WW+_ /%T
M?7<1_._NC_D']BX#_GPO_ JG_P D'_"$:+_S[+_WW+_\71]=Q'\[^Z/^0?V+
M@/\ GPO_  *I_P#)!_PA&B_\^R_]]R__ !='UW$?SO[H_P"0?V+@/^?"_P#
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M[)]55]R=P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 7;;[I^O\ 04 3T % %6Y[?C_2@"K0!5NK*"^3RKJ..= =
MVV1%=<C(!PP(R,GGKR:B4(S7+.*:[-)K[F*U]Q5LX(X?LRQHL&TKY011'M/5
M=@&W!R<C&#0HQ4>1)*.UK*UNUM@MTZ%./0].B5XX[6W1)0 ZK#& X!R P"X8
M \@'.#SUK-4:<4TH02>Z44K^NFHK)=$7;:TALD$5M&D,8)(2-5103U.U0!SW
MXK2,8P7+!**[))+[D-*VB*L>C6$&\QVT"><I63;%&-ZMRROA1N4]PV0>]0J5
M.-[0BKJSM%*Z>Z>FJ?F%DNB)[2PMM/4I:Q1P*QR5B14!.,9(4 $X &>N*J,(
MTU:G%179)+\@22VT(IM*L[B47$T$,DRXQ(\2,XV\KABI88/(P>.U)TX2?/*$
M7)=7%-Z;:VN%EO8T*U&8S>'=+<EFL[4DG))@B))/4D[.M<_L*3U=.'_@$?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!=MONGZ_P!!0!/0 4 5;GM^/]* *M !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MX4 '_"/6_P#>E_[^'_"@ _X1ZW_O2_\ ?P_X4 '_  CUO_>E_P"_A_PH /\
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M (1ZW_O2_P#?P_X4 '_"/6_]Z7_OX?\ "@ _X1ZW_O2_]_#_ (4 '_"/6_\
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M_P"]+_W\/^% !_PCUO\ WI?^_A_PH /^$>M_[TO_ '\/^% !_P (];_WI?\
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M?\* #_A'K?\ O2_]_#_A0 ?\(];_ -Z7_OX?\* #_A'K?^]+_P!_#_A0 ?\
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MX4 '_"/6_P#>E_[^'_"@ _X1ZW_O2_\ ?P_X4 '_  CUO_>E_P"_A_PH /\
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M(??& !DEEVGD;<]"*Z*4IS5ZL.1WVYE+336Z_+R*5WNK&K6Y04 % !0 4 %
M!0 4 % &%XDUV+PY827TOS%!MC3^_(WW5^F>6/903VKFKU5AZ;J/ILN[>R_K
MH3)\JN?.^J78W+J.O[KR]N%$D-IN*111-]QIMN&4,/F2&,J67YY'&[GY6I+7
MVN)O.<E>,+V44]G*VJONHJU]V]3E?>6_8K:;JLNK7"VEOIMA,9#@1K"RD#N3
M*) Z@#G>SX'?/2IA4=22A"C3=^G+;\;W7JV).^B2.HT63[#YNI>'=\,UGS?:
M8\GF(\:DAG@?)+JN#@G<ZGHQ!"R=E)\EZV%NI0_B4F[II;N+ZI?-KOT=K36'
M3='N^EZC#JUK%>VYS%.H9?4=BI]U8%6]P:^DIS56*J0V:O\ UZ;'2G=70FH]
M(O\ KLG]:U&:% 'FGC;X@Q^'&-E9JLU[@%MWW(@1D;L$%F(P0H(X.2>@/D8K
M&+#_ +NFKSZWVCZ^?D92GRZ+<\.N_&NMWCEWO)U)[1.8E'T6/8/TSZU\Y+%5
MY.[J27H^7\%8YN:7<J?\)/J__/\ 7G_@3-_\74?6*W_/R?\ X'+_ #%S/N_O
M#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_
M (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F'
M,^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_
M ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_
M / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7
M_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;
M_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O
M#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_
M (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F'
M,^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_
M ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_
M / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7
M_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;
M_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O
M#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F',^[^\/\ A)]7_P"?Z\_\"9O_
M (NCZQ6_Y^3_ / Y?YAS/N_O#_A)]7_Y_KS_ ,"9O_BZ/K%;_GY/_P #E_F'
M,^[^\/\ A)]7_P"?Z\_\"9O_ (NCZQ6_Y^3_ / Y?YAS/N_O&KXEU9.%O;M<
MG/%Q*.?7[_6CZQ6_Y^3_ / Y?YAS/N_O'?\ "3ZO_P _UY_X$S?_ !='UBM_
MS\G_ .!R_P PYGW?WA_PD^K_ //]>?\ @3-_\71]8K?\_)_^!R_S#F?=_>'_
M  D^K_\ /]>?^!,W_P 71]8K?\_)_P#@<O\ ,.9]W]X?\)/J_P#S_7G_ ($S
M?_%T?6*W_/R?_@<O\PYGW?WA_P )/J__ #_7G_@3-_\ %T?6*W_/R?\ X'+_
M ##F?=_>'_"3ZO\ \_UY_P"!,W_Q='UBM_S\G_X'+_,.9]W]X?\ "3ZO_P _
MUY_X$S?_ !='UBM_S\G_ .!R_P PYGW?WA_PD^K_ //]>?\ @3-_\71]8K?\
M_)_^!R_S#F?=_>'_  D^K_\ /]>?^!,W_P 71]8K?\_)_P#@<O\ ,.9]W]X?
M\)/J_P#S_7G_ ($S?_%T?6*W_/R?_@<O\PYGW?WA_P )/J__ #_7G_@3-_\
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M)[LQR?\ ZWH*_/I2<VYRW;N_F<!7J1!0 4 % !0 4 % !0 4 % !0!Z+X/\
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MH4 % !0 4 % !0 4 % !0 4 % !0 4 % '.Z_KDVD&&.UMGO9[EF5(T8)C:
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M.II!7DCZWK[@[0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#/TO\ X]U_X%_Z$: -"@ H * "@ H * "@ H Y+2/%/]J:K=Z5Y/E_8?\
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M)R=FK:WM^GGT*OS27+T.3NO#LWB+5M7CMF(D@DEE6/M*PE(VGGK@MMX^\1G
MR:XI4)5ZM=0>L6Y)=WS;?G;S(Y;N5CV#P)XHCU^S$+A8KNT58Y8@-O"C:KJO
M&%.,%0,(WR\ KGW<)B%7ARO2<=&MMM+I=OR?R-X2NK=4=S7I&@4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ',>(+6*ZFM=MT+&^C=VM795=
M7) CE0QOM$A:-RH575QG>N=C5QUHJ3A:?)43;@VDT^DE9[W3V33ZK8A]-;/H
M86JZI>&+5-+O#!-Y6FRS++ KQ[=\3KY<L;R2[7)!9,2'* -CG YJE2=JU&?*
M[4I23BFK735I)N5GU6NVI+;UB^W0W]#T^>.VMI6O+ET$,9\IEM0F"@^7*VRR
M8';$F[@98\YZ:4)*,&ZDFN5:-0MMMI!/\;E):+5_A_D>>VTTIT."VO$6+3);
MN3SKI&:1XU2^DD DBV((E>11'YPDF"#YF0%AM\N+?L(PFDJ3F^::=VDJC>L;
M+E3:MS7E;=K4S^RD]K[_ #.KNI+I?$3FQ2&5SID7^ME>-0/M,V""D,Q;GM\O
M'\5=TG-8A^R46_9+XI-+XY=HRO\ AZEZ\VG;]2K=Z4=%MM)M&?S&75$=F *@
MM(MU(VU23M4,Y"C/09/)-9RI^QC0IWNU63;VU:FW9=M16Y5%>?\ F1:CI\MY
MJ6HRVG%Y:1V$]N?5T6ZRG3I*A:,CH=PSTI3@Y5*LH?'!4I1]4IZ?]O*Z^8FM
M7;=6:_$S+76&NM'OYK('SM2U!H8$X#;[B* $?,54,B;SEBH!7D@<UC&KS4:L
MJ?Q5*CC%=;R4>]M4K]MA7T=NKT^=C;T7.D:N+46\UG;7UJBQK,8&)FLU"''D
M2RJ,VY4G=M+%"0" <=%+]U6Y.64(S@DE+E^*FK?9D_LVWM>Q2T=K637ET]/(
MM:;:067B.Z2WC2%6LH7(C54!9II,L0H +'N3R>]73C&&)FH))>SB]$EJY/73
MJ-*TG;L=#XA9TTN\:/[XM9RN.NX1/C]:ZZUU2J-;\DK>O*RI;/T9SNJ3FR\/
M0V]@,RW4,%K;JN!EID5<@DJH(CWODD#C)(&37)4?)AXQI;RC&$4N\E;R6UV2
M](V7DD4M*E&@ZH8G@EL;.ZM%VB8P-^]LD"L1Y$LH -MM)W8+&,D @<9TW["K
MRN+A"4-.;E^*FM?A;^Q]]A+W7M9->73T\CGTFNK:"'7Y+69)/MC7DLQ-OY8M
M;@"(H!YS3D"#RBNZ(%67/ &ZN5.48QQ3A)/G<W+W;<DO=M\3E\-OLZ6^9&J]
MZW6_39G:>)2&OM)(Y!NVP?\ MA)7H5_CH?XW_P"DLTEO'U%O?^1DL_\ KSN?
M_0XZ<_\ >:?^"?YH'\2]&.M76X\1326Q#1Q6:PW#+]WS_.+(C$<&1(]^>Z!@
M#C( (M2Q$G#90496VYN:Z3\TK^EP7Q:=M?4G\/82\U-(_P#4B\!7_KH]O TP
M_P"^SDCU)]<FJ.DZR7P\^GJX1<OQ''=^OZ'4UVEA0 4 % ')S^&Y;29[K19_
ML3RG=) R"2UD;NWEY4Q.W\3Q,I;N"<FN%T'!N>'ER-ZN+5X-][:6;ZM-$<MM
M8NWY"?\ %2D;<::O^V#<M^(C*COR 9#Z9H_VG;]TO/W_ ,K?J'O>7XDUAX<*
M3B^U*9KZZ3_5EE"10YZ^3$"54_[9+/CN*J%"TO:59.<UM=6C'_#'9>NK!1ZO
M5_D=/7869^H](O\ KLG]: -"@#QOQ[\.Y-2E;4]* ,S\S09"[SWD0D@!SQN4
MX#<L#O)#>!C,$ZC=:A\3^*.U_->?===]]\)POK$\)NK&XL',=S%)"XX*R*RG
M\B!7S<H2@[33B_-6.:UMRK4""@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#H-
M'\4ZGX?1HM/F,*2-N8;(W!; &?WB-C@ <5U4L15H)JE+E3U>B?YIEJ3CL5-6
MUN]UR037\K3NHPN< */154*JY[X SWK.I5G6?-5DV^G2WHEHA-M[F56)(4 %
M !0 4 % !0 4 % !0 4 % !0 4 % &QI>@7^LN$LH))<G!8*0B_[SG"K^)K>
MG1J57:G%OSMHO5[(I)O9'TEX(\&)X5A9Y")+R8#S''W57J(TSS@'DL0"QQP
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M% !0 4 % &?)_P ?:?[C4 :% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<GWD]W_P.BT$E96-6MB@H * "@ H * "@ H S]1Z1?\ 79/ZT :% !0 4 %
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M/]QJ -"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-_S]3_F* #^R9O\ GZG_ #% !_9,W_/U/^8H /[)F_Y^I_S% !_9,W_/U/\
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MS]3_ )B@ _LF;_GZG_,4 ']DS?\ /U/^8H /[)F_Y^I_S% !_9,W_/U/^8H
M/[)F_P"?J?\ ,4 ']DS?\_4_YB@ _LF;_GZG_,4 ']DS?\_4_P"8H /[)F_Y
M^I_S% !_9,W_ #]3_F* #^R9O^?J?\Q0 ?V3-_S]3_F* #^R9O\ GZG_ #%
M!_9,W_/U/^8H /[)F_Y^I_S% !_9,W_/U/\ F* *TVERJZ#[3,<D\DCCZ4 6
M?[)F_P"?J?\ ,4 ']DS?\_4_YB@ _LF;_GZG_,4 ']DS?\_4_P"8H /[)F_Y
M^I_S% !_9,W_ #]3_F* #^R9O^?J?\Q0 ?V3-_S]3_F* #^R9O\ GZG_ #%
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MY^I_S% !_9,W_/U/^8H /[)F_P"?J?\ ,4 ']DS?\_4_YB@ _LF;_GZG_,4
M']DS?\_4_P"8H /[)F_Y^I_S% !_9,W_ #]3_F* *;Z9*+A$^TS9*D[LC(]A
M0!<_LF;_ )^I_P Q0 ?V3-_S]3_F* #^R9O^?J?\Q0 ?V3-_S]3_ )B@ _LF
M;_GZG_,4 ']DS?\ /U/^8H /[)F_Y^I_S% !_9,W_/U/^8H /[)F_P"?J?\
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M_61?[Q_E0!;H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQ%[:X"CH))XW\T_5F0,?K7U%%<E:M%;7A*WG)/F^]JYTQT<EZ/[SH]1Z1?\
M79/ZUZ!H2W]T+&VEN2,B")Y"/4(I;^E1.7)&4_Y4W]RN)Z*Y\77=U)>S/<3D
MO)*Q=B>[,<G_ .MZ"OSZ4G-N<MV[OYG 5ZD04 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!ZE\)]4>TU4V63Y=W&PV]O,C!D5OJ
M$$@]\^PKV<NJ.%7V?2:>GFM4_NN;4W9V[GT%IOW'_P"NK_TKZTZS0H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"I<?Z
MR+_>/\J += !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % &?I?\ Q[K_ ,"_]"- &A0 4 % !0 4 % !0!P/BSX@6GAA
M_LRH;FZ&TM$"8PJ,,AC(48$GC"J#UY(Q7F8C&0PSY$N:>FFUD^M[/\#*4U'3
MJ=-J.MPZ5I[:G<@B-(U<JO))? 51G )+,!G@=S@5USJQI4W6GLDG;UV7WLMO
ME5V<5!\17C:VDU"QDL[.^.(;CSEDR.@9D"*5'(/)SM.Y0PZ^>L:UR.K3<(3^
M&7,G]ZLK?Y:JYGS[75DS6UGQBUCJ TC3[5[^\V;V02+$JC&[EV5AG;@] .5
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M?_KJ_P#2OL#K-"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * *EQ_K(O]X_RH MT % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9^E_\>Z_\"_\ 0C0!H4 % !0
M4 % !0 4 >+_ !<UBTDM4TQ7S=QW$<K1[7&(S%*-V[;L/++P&)YZ<&OG\RJP
M<%13]]24FK/;EEK>UNJZG/4:M;K<U=>GB\6>&)/[)8W!@\H,JHX)>(1LZ@,J
MDD(V[@$'H"36]9K$X5^P][EM?1[JS:U2Z.Y3]Z/NG#:KJ2>*=/TK1-/61[N
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M3P:=:Q2Y$B6T*OG@[EC4-D=CD&N^BG&G",MU&*?JDBULO0U:V*"@ H * "@
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MMVP.RJ#A1]2>2:^PP^'CAH<BU;UD^[_R70ZXQY%9&QIOW'_ZZO\ TKL+-"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M*EQ_K(O]X_RH MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 9^E_\>Z_\"_\ 0C0!H4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!R^L^%(=8N!=FXO+241"$FUF$09 SL PV-GEV_#%<=7#JK+GY
MYQ=N7W)<MU=O71]R'&^MVO0N:#X>M/#D)@LPV';>[NVYW;U8X';H  .O&2<W
M1HPP\>6G?5W;>K;\QJ*CHC<KI*"@ H * "@ H * "@ H * "@#/D_P"/M/\
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M6@#0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H S]-^X__ %U?^E &A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % %2X_UD7^\?Y4 6Z "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,_2_\ CW7_ (%_
MZ$: -"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#/D_X^T_W&H T* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *-Y#
M<R[?LTHAQG=E V>F.O3'/YT 4OLFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C
M_P _*_\ ?I: #[)J/_/RO_?I: #[)J/_ #\K_P!^EH /LFH_\_*_]^EH /LF
MH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I: #[)J/_/RO_?I: #[
M)J/_ #\K_P!^EH /LFH_\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@
M^R:C_P _*_\ ?I: #[)J/_/RO_?I: #[)J/_ #\K_P!^EH /LFH_\_*_]^EH
M /LFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I: #[)J/_/RO_?I
M: #[)J/_ #\K_P!^EH /LFH_\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R:C_S\K_W
MZ6@ ^R:C_P _*_\ ?I: *=Y:WRA-]PK9D4#]THP><'WQZ4 7/LFH_P#/RO\
MWZ6@ ^R:C_S\K_WZ6@ ^R:C_ ,_*_P#?I: #[)J/_/RO_?I: #[)J/\ S\K_
M -^EH /LFH_\_*_]^EH /LFH_P#/RO\ WZ6@ ^R:C_S\K_WZ6@ ^R:C_ ,_*
M_P#?I: #[)J/_/RO_?I: #[)J/\ S\K_ -^EH /LFH_\_*_]^EH /LFH_P#/
MRO\ WZ6@ ^R:C_S\K_WZ6@ ^R:C_ ,_*_P#?I: #[)J/_/RO_?I: #[)J/\
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MLFH_\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I:
M#[)J/_/RO_?I: #[)J/_ #\K_P!^EH /LFH_\_*_]^EH /LFH_\ /RO_ 'Z6
M@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I: #[)J/_/RO_?I: #[)J/_ #\K_P!^
MEH /LFH_\_*_]^EH K36M^'0&X4DDX/E*,4 6?LFH_\ /RO_ 'Z6@ ^R:C_S
M\K_WZ6@ ^R:C_P _*_\ ?I: #[)J/_/RO_?I: #[)J/_ #\K_P!^EH /LFH_
M\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I: #[)J
M/_/RO_?I: #[)J/_ #\K_P!^EH /LFH_\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R
M:C_S\K_WZ6@ ^R:C_P _*_\ ?I: #[)J/_/RO_?I: #[)J/_ #\K_P!^EH /
MLFH_\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I:
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MLFH_\_*_]^EH /LFH_\ /RO_ 'Z6@ ^R:C_S\K_WZ6@ ^R:C_P _*_\ ?I:
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M_)![1^7]?,/^%OZO_P \;/\ []S?_'Z/[2K?RP^Z7_R0>T?E_7S#_A;^K_\
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M0JZ;]Q_^NK_TJ@-"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * *EQ_K(O]X_RH MT % !0 4 % !0 4 % !0 4 % !0
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M/GBHT>:?,KMTV_LO5)<C=VKI1O8--+JT;OT_X8TU_L_^T-/_ +&\KR?-OO\
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MOIR<R-\J]D0<*@]@.OJ<D\DU\#6JNM-U)==EV71' W=W,:L"0H * "@ H *
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MLSL-"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MEU6WY'FE>08A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 210O.XBB4N[G"JH)8D]  .2?I32<G:*N^B0SZ8^'?@]_#MNUS=@"\N0
M 5Z^5&#D)D<;F.&?'0A1V.?K\%AGAXN<_CET[+MZ]6=<(\NKW.XTW[C_ /75
M_P"E>L:FA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % %2X_UD7^\?Y4 6Z "@ H * "@ H * "@ H * "@ H * "@ H
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M8YYP,</06&BXIWDW>4MKO\?S)C'E5CIJ["PH * "@ H * "@ H * "@ H *
M"@ H * "@".:(3(T;9 =2IQUP1@X]Z35TT^N@%;3;"/2[6*SA+&.!%C4L06(
M48!8@*,^N ![5$(*E&-.-[122OOI]PDK*R+M:#"@#GAX>5GC-Q<W-S'#-YZ1
M2M$4$@9F0EEA29A&S917E91A<@A1CE]CJN:<Y*,N91;C:][K514G9O1-M;=B
M>7NV=#744% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?J/2+_
M *[)_6@#0H 1E# @C(/!!Z$>E '(W7@+0KQS)):1ACR?+:2(?]\Q.B_I7#+!
MT)N[IKY-Q_!-$<D>Q5_X5MX>_P"?3_R/<?\ QZL_J.'_ )/_ ":?_P D+DCV
M_,/^%;>'O^?3_P CW'_QZCZCA_Y/_)I__)!R1[?F'_"MO#W_ #Z?^1[C_P"/
M4?4</_)_Y-/_ .2#DCV_,/\ A6WA[_GT_P#(]Q_\>H^HX?\ D_\ )I__ "0<
MD>WYA_PK;P]_SZ?^1[C_ ./4?4</_)_Y-/\ ^2#DCV_,/^%;>'O^?3_R/<?_
M !ZCZCA_Y/\ R:?_ ,D')'M^8?\ "MO#W_/I_P"1[C_X]1]1P_\ )_Y-/_Y(
M.2/;\P_X5MX>_P"?3_R/<?\ QZCZCA_Y/_)I_P#R0<D>WYA_PK;P]_SZ?^1[
MC_X]1]1P_P#)_P"33_\ D@Y(]OS#_A6WA[_GT_\ (]Q_\>H^HX?^3_R:?_R0
M<D>WYA_PK;P]_P ^G_D>X_\ CU'U'#_R?^33_P#D@Y(]OS#_ (5MX>_Y]/\
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M -=7_I0!H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!4N/]9%_O'^5 %N@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#/TO\ X]U_X%_Z$: -"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#/D_P"/
MM/\ <:@#0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\
MR)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(
MG^- !]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?
MXT 'VG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\ R)_C
M0!&\FI.58_9\H<C_ %E $GVG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\
MR)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(
MG^- !]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?
MXT 'VG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\ R)_C
M0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^-
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M0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^-
M!]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT '
MVG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:
M=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU
M/TMO_(G^- !]IU/TMO\ R)_C0!"6U(R"7_1]R@@?ZS&#0!-]IU/TMO\ R)_C
M0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^-
M!]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT '
MVG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:
M=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU
M/TMO_(G^- !]IU/TMO\ R)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_
M2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\ R)_C0 ?:=3]+
M;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\B?XT 'VG4_2V_P#(G^- !]IU/TMO
M_(G^- !]IU/TMO\ R)_C0 ?:=3]+;_R)_C0 ?:=3]+;_ ,B?XT 'VG4_2V_\
MB?XT 'VG4_2V_P#(G^- !]IU/TMO_(G^- !]IU/TMO\ R)_C0!KV+SO'FYV;
M]Q_U><8P,?>YSU_2@"Y0 4 5;GM^/]* *M !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MZP.X* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M ("K?B?2\0V^O4/:?P_9POVM[2?-^%K_ ".H\3:_JVA$S6<%NVG*L825N?O
M<!4F4[<\+A,8[XYKAPU"C7]VI*:JW=XK3;S<7KWU/>S+'XW+_P!YAJ5%X1*"
MC-Z[K9*-6+MT5HVMU.B\*7QU+3(;IDCA,AE)2)=B B60$A<G!;&YN3EB3WKB
MQ4/95I4TVTN763N_A3WTVV7D>UE=9XG"4Z[C"#ESMQIQY8)JI-:*[WM=ZZMM
M]3HJXSV0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 7;;[I^O]!0!/0 4 5;GM^/\ 2@"K0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %VV^Z?K_04 3T % &9J)N
M5V_9HA+UW9<+CICKUSS0!F[M1_Y]E_[^I_C0 ;M1_P"?9?\ OZG^- !NU'_G
MV7_OZG^- !NU'_GV7_OZG^- !NU'_GV7_OZG^- !NU'_ )]E_P"_J?XT &[4
M?^?9?^_J?XT &[4?^?9?^_J?XT &[4?^?9?^_J?XT &[4?\ GV7_ +^I_C0
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M4_QH -VH_P#/LO\ W]3_ !H -VH_\^R_]_4_QH -VH_\^R_]_4_QH -VH_\
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M_J?XT &[4?\ GV7_ +^I_C0 ;M1_Y]E_[^I_C0 ;M1_Y]E_[^I_C0 UI;]"
M;=<MP/WJ_6@!V[4?^?9?^_J?XT &[4?^?9?^_J?XT &[4?\ GV7_ +^I_C0
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M4_QH -VH_P#/LO\ W]3_ !H -VH_\^R_]_4_QH -VH_\^R_]_4_QH -VH_\
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M1_Y]E_[^I_C0 ;M1_P"?9?\ OZG^- !NU'_GV7_OZG^- !NU'_GV7_OZG^-
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M /EH?\+8TK_GE=_]\1?_ !^C^S:W\T/OE_\ (A_K+@_^?=?_ ,!I_P#RT/\
MA;&E?\\KO_OB+_X_1_9M;^:'WR_^1#_67!_\^Z__ (#3_P#EH?\ "V-*_P">
M5W_WQ%_\?H_LVM_-#[Y?_(A_K+@_^?=?_P !I_\ RT/^%L:5_P \KO\ [XB_
M^/T?V;6_FA]\O_D0_P!9<'_S[K_^ T__ ):'_"V-*_YY7?\ WQ%_\?H_LVM_
M-#[Y?_(A_K+@_P#GW7_\!I__ "T/^%L:5_SRN_\ OB+_ ./T?V;6_FA]\O\
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M_P# :?\ \M#_ (6QI7_/*[_[XB_^/T?V;6_FA]\O_D0_UEP?_/NO_P" T_\
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M9<'_ ,^Z_P#X#3_^6A_PMC2O^>5W_P!\1?\ Q^C^S:W\T/OE_P#(A_K+@_\
MGW7_ / :?_RT/^%L:5_SRN_^^(O_ (_1_9M;^:'WR_\ D0_UEP?_ #[K_P#@
M-/\ ^6A_PMC2O^>5W_WQ%_\ 'Z/[-K?S0^^7_P B'^LN#_Y]U_\ P&G_ /+0
M_P"%L:5_SRN_^^(O_C]']FUOYH??+_Y$/]9<'_S[K_\ @-/_ .6A_P +8TK_
M )Y7?_?$7_Q^C^S:W\T/OE_\B'^LN#_Y]U__  &G_P#+0_X6QI7_ #RN_P#O
MB+_X_1_9M;^:'WR_^1#_ %EP?_/NO_X#3_\ EH?\+8TK_GE=_P#?$7_Q^C^S
M:W\T/OE_\B'^LN#_ .?=?_P&G_\ +0_X6QI7_/*[_P"^(O\ X_1_9M;^:'WR
M_P#D0_UEP?\ S[K_ /@-/_Y:'_"V-*_YY7?_ 'Q%_P#'Z/[-K?S0^^7_ ,B'
M^LN#_P"?=?\ \!I__+0_X6QI7_/*[_[XB_\ C]']FUOYH??+_P"1#_67!_\
M/NO_ . T_P#Y:'_"V-*_YY7?_?$7_P ?H_LVM_-#[Y?_ "(?ZRX/_GW7_P#
M:?\ \M#_ (6QI7_/*[_[XB_^/T?V;6_FA]\O_D0_UEP?_/NO_P" T_\ Y:'_
M  MC2O\ GE=_]\1?_'Z/[-K?S0^^7_R(?ZRX/_GW7_\  :?_ ,M#_A;&E?\
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M 'Q%_P#'Z/[-K?S0^^7_ ,B'^LN#_P"?=?\ \!I__+0_X6QI7_/*[_[XB_\
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MR3?ZI(TAQ'@I.TE5@N\H1LO_  &<G^!W>GZE;:I$)[.19HSQN4YP?0CJI]B
M?:O+G3E2?+43B^S_ *_(^HH5Z6)A[7#SC.'>+V?9K=/R:3+M9G2% !0 4 %
M!0 4 % !0 4 % !0 4 5[3_5#\?YF@"Q0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!7;_ %R_[K?S% %B@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * /-?BA8F;3H[Q =]G,K9'9'^4_\ C_E_
ME7L9?/EJNF]IQ:^:U_*Y\;Q%1<\-'$1^*C43OVC+1_\ DW(>;:S?SZU=R^(;
M<$1V#6F,?PDC]!YH/TW 'D\^Q2A&C".$GO453^O_  '\CX[%5JF,K5,VHZ1H
M/#_*_P"G.G]ZOJ=MX35/$6N:AJK@/ %\E,\95QL' ]8HR#_O^IKS<3?#4*5!
M:2OS/U6O_I3_  /I<M4<PQ^+QTES4TO9QOU4O=6G^"#O_B\SF[75G\'1:KHS
MDAQ_Q[YR.9,1EA[F)DD!S_!WKLE26+=#$+;[?RUM_P"!)KYGC4\3+)X8[+I-
M\W_+KI\5HW7FX2C-?X>I<U?2?[(\(0HPQ)--'-)]9 Q4?@FT$>H-9TJGM<9)
MK:,7%?*U_O=SHQ6&^J9-3BU:<ZD*DO62=E\H\J];G4>&8)L6C-HMO$GEQG[8
M)+8O]P$3;1&)-S<'&[<">3D&N+$-?O$L1)N[_=VG;?X;WM9>ECV\OA.U!O+J
M4(\L'[=3HN7PJU3E4>>\M[7NKZLZ./5M8:X$3Z9M@,@4S?;(3B/=@R>6%W'"
M_-LSN/W>M<CI45'F5:\K7Y?9RWMM>]M]+[=3V(XG&NJH2P5J?.DZGUBF[1O9
MSY+7=E[W+OTW/)+BPN+C6]2N[(XNK"0W,8_O;'&]<=\J2<?Q8V_Q5[T9QC0H
MTZGP5%R/RNM']_W;]#X*=&I4QV,KX9VK8>;JP\^67O1MUO%O3K:W4W_ VH+J
MOB&\O(QM6>W#X_NDM#E?P.1GOBN3&0=+#4Z;^S*WX2U^9ZN3UUBLRQ&(CHIT
MN:W9MT[KY.Z,Z3PYJ'@ZWFO;BWTV_AWJS^:C22("VT;-ZQ@ EAD#<<X..*V5
M>GBY1IPG6IRLTN5J*>E];-]O(XY8#$9/2J8FK2PE>GS)RYXN<XINRY>:,4DV
MU>U_0]&AMK'Q!I4%X+-)?+B:2"V)"('QCRQTC"LR[0S+M .XJ.17D.53#U94
M_:-7DE*>[MW[W2=[)WZ7/KXTZ&/PE+$+#QERP<J5%VC%2M\"VA9R5DY*R6ME
MJCA?#D8@\4,+B :7*\3>7:Q[61LID_.A"?=5G^50I(['KZ==WPBY)>U2DKS=
MTUKV>N[2U=SYC 15/-FJM)86;@^2C"THOW=?>B^79.6B2;71C/'NE+9:I8W0
MEFE:ZG8E97#)&$>'"Q#:"B_.>,GH,8[O!5'.E5ARQ2A%:I6;NI:RUU>A.=89
M4<7AJRG4DZM5MJ<KQARRIV4%9<J]YZ7?0]NKYL_2@H * "@ H * "@ H * "
M@ H * "@"O<_P?\ 71: +!( R> * VU9\O\ C/Q1+XANV5&(LXF(A3L<<>81
MW9N2,_=4A?7/VF%PZP\$VO?:]Y_IZ+\6?B>:YC/,*S46U0@[0CT=M.=]W+==
MD[=[\;7HGSP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;7_"-ZK_ ,^5
MW_X#R_\ Q%<WMZ/_ #\A_P"!Q_S/1^H8S_H&K_\ @JI_\B9Z65Q),;9(I&F4
ME3&$8N&7A@4 W J001C([ULYQ2YVTH[WNK:[:[:G(J-24W1C"3J)M."BW)-;
MIQM>ZZJVA)=Z7>:> UU!-;@G ,L;H"?0;E&34QJ0GI3E&7HT_P BZN'K8=)U
MZ52FGHN>$HW].9(FM]$U"\C$UO:W$L;9VO'#(ZG!(.&52#@@@X/!!'6IE6IP
M?+*<4UT<DFODV:4\'B:L54I4*LX.]I1ISE%V=G9I-.S33\]"%],NXIA:O!,L
M[_=B,;B0YSC"$;CG!Z#L?2J52#CSJ4>5;NZLOGL9O#UHS5"5.:J/:#A)3?I&
MUWL]ET#^S+OS_L?D3?:1_P L?+?S?N[O]7C=]WYNGW>>E'M(<OM.:/)_-=<N
M]M]M]/4/J];VGU?V=3VO_/ODES[<WPVYOAUVVUV%CTN\EF:UC@F:=!EHEC<R
M*!C)9 NX#D=1W'K0ZD%%3<HJ+V=U9^CO8(X>M*;H0I5'4CJX*$G-;;Q2NMUN
MNJ(H;&XN)3;PQ223#(,:(S."OWAL +?+@YXX[U3G&*YY22CW;26NVNVI$*-2
MI/V-.$Y5%?W(Q;EIO[J5].NF@RXMI;.0PSH\,BXW(ZE&&0",JP!&001D="#3
MC)27-!IKHT[K[T3.G.E)TZL90FMXR3C)75U=.S6COZ&G_P (YJN,_8KO'_7O
M+_\ $5C[>E_S\A_X''_,[?J&+W^KU_\ P54_^1*$-A<SS&VBBE>9<YC5&9QM
M^]E "PQWXX[UHYQBN>4DH]VTEKY['+&C5G-T:=.<JBO>"C)R5M_=2OIUTT+,
M^AZA:(9)[6XB1>2SPR*H'N64 5$:U.3M&<&^RDF_P9M/!XFDG.I0JPBMW*G.
M*7JVDC+K<XBY9Z==:@2+2&6<I@L(HW?:#TSM!QG!QFLY3A3^.48WVNTOS.BE
M0JU[JA3G4:WY(RE:^U^5.UR>YT6_LD,MS;7$,8P"\D,B*">!EF4#D\#GFIC5
MIS?+"<6^RDF_N3-*F$Q%&/M*U&K"*^U*G.*UVU:2U'1:%J,R"6.UN70C(989
M"I!YR"%QCWI.M2B^5S@GV<DG]URHX/$SCSPH57%JZ:IS:MWNHVL9C*4)5@00
M<$'@@CJ".Q%;;ZHXFFG9Z-:-=C3@T+4;E!+#:W,D;C*ND,C*1ZA@I!'T-8NM
M2@^64X)K=.237RN=L,'B:D5.G0JRB]5*-.;3]&HV9%=Z3>Z>HDNK>>!"=H:6
M)T!."< LH!. 3CK@&JC5A-VISC)]E)/\F9U<-7PZ4J]*I3BW9.<)15][)R25
M[)Z%6W@>ZE2"(;I)65$&0,LQ"J,D@#)(&20!W-7)J*<I;)-OT6YA"$JLHTH*
M\I-1BM%=MV2N[):OKH7-4TBZT2;[->IY4NT-MW(WRG.#E&8<X/&<UG3JPK1Y
MZ3O&]KV:U^:1TXG"U<%/V.)CR3LI6O&6CO9WBVNG<S:V.,U+_1KO3(H+BZC\
MN.[3S(6W(V]<(V<*Q*\.IPP4\],@XPA5A4<H0=W!VDK-6>JZI7V>QVUL)6PT
M*56M'EA6CS4WS1?-&T7>R;:TE'223U]2E;6TMY*EO I>61@JJ.I)Z#_ZYX Y
M/%:RDH)RD[)*[9S4Z<JTXTJ2<IR:44MVW_7IW+]WH5]8W0L)(B;HC(BC*ROR
M">D3/S@%MOW@N&(P0:RC6ISA[6,K0_F=XK_R9+TOM?0ZZN#KT*OU6<&ZUK\D
M&JDMF]J;EK97MO;6UFF$V@ZE;(9)K2YC102S-!(J@#DDDJ  .Y-"K4I/EC.#
M?1*2;_,4L%B:<7.I0K1BM6Y4YI)=VW&R!=#O&L6U01_Z(C;3)N3AMP7&S=OZ
ML!D+CGTH]M!5%0O[[5[6>V^]K=.X+!UW0>-4/W"?*Y<T=[I6Y;\V[70R:W.$
M* "@ H * '(C2,$0%F8X  R23V ')-)NVKT0TG)J,4VWHDM6WY(T)]&O[2,S
M3VUQ%&.KO#(JC/ ^9E Y/'6LHU:<GRQG%OLI)O[DSKGA,12C[2K1JP@OM2IS
MC'[VDB6TT*]OK:2]MX_,@M\F0J\>Y !DDQ[O,QCG(7& 3V.)E6A3DJ<W:4MM
M'9_.UOQ+I8.O7I3Q-&'-3I_&U*-XVUNX<W/:VM^6V_9F170< 4 % !0 4 %
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M$8"J JJ   ,  <  #H!V%?([ZL_8$E%*,59+1):))=$+2&% !0 4 % !0 4
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MJQ%WS)6MI;9KM?KW.I8^K'"2RY*'LI2YF[2Y[\REH^;EM=+[.Q8G\7WLOV'
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MQ))_$FO3244HK9))>B/F)S=24JDW>4FY-]VW=O[R*J("@ H * "@ H * "@
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M>*4N:3E9*[O9;+TNV>W2A[*$:?-*?*DN:=G)V[M**;\[:[O74L5!L% !0 4
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MNE!1DJ6'O4E)IJ,JDHN,(P;24N52E*3BVHMJ+:=T=-7&>T% !0 4 % !0 4
M% !0 4 % %>Y_@_ZZ+0!8H S=5TBTUJ$VU[&)8\Y&<@J?[RL,%3[@\C@Y!(K
M:G5G1ESTW9_GY-''B<+1QD/8XF"E'==&GWBUJGZ>CT/,;KX1P.Q-M=O$G97B
M$A'XAX_Y5[,<SDE[]--^4K?A9GQ=3ABFW>C7E&/:4%-_>I0_(K?\*@_Z?O\
MR6_^WU?]I_\ 3K_R?_[4P_U7_P"HG_RC_P#=0_X5!_T_?^2W_P!OH_M/_IU_
MY/\ _:A_JO\ ]1/_ )1_^ZA_PJ#_ *?O_);_ .WT?VG_ -.O_)__ +4/]5_^
MHG_RC_\ =0_X5!_T_?\ DM_]OH_M/_IU_P"3_P#VH?ZK_P#43_Y1_P#NH?\
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MWT?VG_TZ_P#)_P#[4/\ 5?\ ZB?_ "C_ /=0_P"%0?\ 3]_Y+?\ V^C^T_\
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M_P!1/_E'_P"ZA_PJ#_I^_P#);_[?1_:?_3K_ ,G_ /M0_P!5_P#J)_\ */\
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M L4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M]9_R% !_:TW_ #ZS_D* #^UIO^?6?\A0 ?VM-_SZS_D* #^UIO\ GUG_ "%
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MY]9_R% !_:TW_/K/^0H /[6F_P"?6?\ (4 ']K3?\^L_Y"@ _M:;_GUG_(4
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M0 ?VM-_SZS_D* #^UIO^?6?\A0 ?VM-_SZS_ )"@ _M:;_GUG_(4 ']K3?\
M/K/^0H /[6F_Y]9_R% !_:TW_/K/^0H /[6F_P"?6?\ (4 ']K3?\^L_Y"@
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M9<'_ ,^Z_P#X#3_^6A_PMC2O^>5W_P!\1?\ Q^C^S:W\T/OE_P#(A_K+@_\
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M^LN#_P"?=?\ \!I__+0_X6QI7_/*[_[XB_\ C]']FUOYH??+_P"1#_67!_\
M/NO_ . T_P#Y:'_"V-*_YY7?_?$7_P ?H_LVM_-#[Y?_ "(?ZRX/_GW7_P#
M:?\ \M#_ (6QI7_/*[_[XB_^/T?V;6_FA]\O_D0_UEP?_/NO_P" T_\ Y:'_
M  MC2O\ GE=_]\1?_'Z/[-K?S0^^7_R(?ZRX/_GW7_\  :?_ ,M#_A;&E?\
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M-#[Y?_(A_K+@_P#GW7_\!I__ "T/^%L:5_SRN_\ OB+_ ./T?V;6_FA]\O\
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M!_\ /NO_ . T_P#Y:7['XE:->.$9I+8GH9D 7_OI&<#ZL0/>LIX"M!724O\
M"_T:7X'71S_!5GRRE.GV]I&R^^+DEZNR\SO(Y$E421D.C %64@@@\@@C@@]B
M*\MIQ=FK-='I8^HC)32E!IQ:NFG=-/JFM&F/I%!0 4 % !0 4 % !0 4 % !
M0 4 5YOOQ_[Q_P#030!8H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H KVG^J'X_P S0!8H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H KM_KE_W6_F* +% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!%//';(99F6.-?O,[!5';
MEB0!SQR:I)R?+%-OHDKO[B)SC2BYU)*,5NY-)+U;LD2U)84 % !0 4 % !0
M4 % !0!!;74-VI>WD25 2I:-E8!AU!*DC([CJ*J490=I)I[V::T^9E3J0JKF
MI2C.*;5XR4E=;JZ;U75$]2:A0 4 % $%M=0WB^9;R)*@)7=&RNN1U&5)&1W'
M454HR@[233[--?F94ZD*JYZ,HSC=J\9*2NMU=-JZZHGJ34* "@ H * "@ H
MKW/\'_71: +!( R> * VU9\O^,_%$OB&[948BSB8B%.QQQYA'=FY(S]U2%]<
M_:87#K#P3:]]KWG^GHOQ9^)YKF,\PK-1;5"#M"/1VTYWW<MUV3MWOQM>B?/!
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!Z7\._%,FF7::;.Q-K<MM4'GRY6/
MRE?178A6'3)#<8.?&QV'52#K15IQ5WYQ6]_-+5?<?99%F,L-6C@ZKO1J.T4_
ML3ELUV4GHUM=\W>_T/7R9^MA0 4 % !0 4 % !0 4 % !0 4 5YOOQ_[Q_\
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MA3Z$J3@^QYJY0E3TG%QOM=-?F84ZU*NFZ$X32=FX24K/L^5NS+50;A0 4 %
M!0!7;_7+_NM_,4 6* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M3S' 4)3E['G5+NK.<6H]4VDG%+K=K5F'X>O;;3+NUN[,N/(MI7U,MYFW< ^
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MPW_"Q'_7W]#U6O#/N0H * "@ H KM_KE_P!UOYB@"Q0 4 % !0 4 % !0 4
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MK3<Y[]%V78_8<'A*6!HQH4-MW+K*3WD_7IT2T1L5SGH!0 4 % !0 4 % !0
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M H * "@ H * "@ H * "@ H * "@ H * "@ H KVG^J'X_S- %B@ H * "@
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MRHU:..6,PD<0IRIJ\Z-%5DWK'E<6XI>[&-VW+=>[W7PEX6O)=.OXKW?:G42
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %>T_U0_'^9H L4 %
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M /\ A(+?^[+_ -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\
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M)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV: #_A(+?\ NR_]^S0
M?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H /\ A(+?^[+_ -^S
M0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV: #_A(+?\ NR_]
M^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H /\ A(+?^[+_
M -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV: #_A(+?\
MNR_]^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H /\ A(+?
M^[+_ -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV: #_A(
M+?\ NR_]^S0!"VNV_F!]LN I'W#WQ0!-_P )!;_W9?\ OV: #_A(+?\ NR_]
M^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H /\ A(+?^[+_
M -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV: #_A(+?\
MNR_]^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H /\ A(+?
M^[+_ -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV: #_A(
M+?\ NR_]^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H /\
MA(+?^[+_ -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\ OV:
M#_A(+?\ NR_]^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?^_9H
M /\ A(+?^[+_ -^S0 ?\)!;_ -V7_OV: #_A(+?^[+_W[- !_P )!;_W9?\
MOV: #_A(+?\ NR_]^S0 ?\)!;_W9?^_9H /^$@M_[LO_ '[- !_PD%O_ '9?
M^_9H TK2[2]3S(PP&2/F&TY&.WXT 6J "@"K<]OQ_I0!5H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P"9FL12>BE^$O\ (]-K@.L* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ME"I27JM'^C_$]LUS2]#O/ KSZ>D=W:VMC.UE-/&CRQ9SNVLR!HW5EV-MVME
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_P  -5/$75X1MZ__ &Q[G7DGH!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %VV^Z?
MK_04 3T % %6Y[?C_2@"K0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % %VV^Z?K_ $% $] !0!F:E>0VFSSF";LXX/;&>@/K
M0!E_VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_P ]!^3?X4 ']L6G_/0?DW^%
M !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_ #T'Y-_A0 ?VQ:?\]!^3?X4
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M ']L6G_/0?DW^% !_;%I_P ]!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0
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M #T'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\
M/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_P ]
M!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_ #T'
MY-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\ /0?D
MW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_P ]!^3?
MX4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_ #T'Y-_A
M0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\ /0?DW^%
M!_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_P ]!^3?X4 '
M]L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_ #T'Y-_A0 ?V
MQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\ /0?DW^% !_;%
MI_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_P ]!^3?X4 ']L6G
M_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_ #T'Y-_A0 ?VQ:?\
M]!^3?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\ /0?DW^% !_;%I_ST
M'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_/0?DW^% !_;%I_P ]!^3?X4 ']L6G_/0?
MDW^% !_;%I_ST'Y-_A0 ?VQ:?\]!^3?X4 ']L6G_ #T'Y-_A0 ?VQ:?\]!^3
M?X4 ']L6G_/0?DW^% !_;%I_ST'Y-_A0 ?VQ:?\ /0?DW^% !_;%I_ST'Y-_
MA0!LZ?<1W,9>([EW$9Y'.!ZXH O4 % #617^\ <>HS0 WR(_[J_D/\* #R(_
M[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_
M[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_
M[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_
M[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_
M[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_[J_D/\* #R(_
M[J_D/\* *UQ#&-F%7[Z]A0!9\B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@
M\B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@
M\B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@
M\B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@
M\B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@ \B/^ZOY#_"@
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M +J_D/\ "@ \B/\ NK^0_P * #R(_P"ZOY#_  H /(C_ +J_D/\ "@ \B/\
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M#&$8*T$DO))'D.3EK)M^K,ZK)"@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * +
M5I?7&GN);262"13D/$[(P/J&4@@_C4N*EI))KS0TW'6+:]-#Z3^%WQPNHKF/
M2?$LGGP3,$BO'P)(G/"K,W&^-CQYA^="<NS)]SQ,3@HV=2@K-;QZ/T[/RV?K
MOZ=#$M/DJNZ>SZKU\CZ\KYT]D* "@ H * "@ H * "@ H * "@ H KVG^J'X
M_P S0!8H * "@ H * "@#F?$W@[2?&$<<.LP?:4@8O&/,FCVLPP3F&2,G([$
MD5O3K3HMND[-[Z)_FF93IQJ64U>VVK7Y6/FKX->!-%U^ZU-]0MO.;3KR,6Q\
MV=/+ >8C_5R*'Y1?O[NGN<^WBZ]2DJ:A*W-%WT6NW=:;]#S,/2A-SYE?E:MJ
M]-_,Z[QG\7-5\-W]U;PRZ*L=K(52"4W<UW*!V_T;=!$YY&V9HRIQO KGHX2%
M2,6U4NUJURJ*_P# M6O2_D;5*\J<FDX:='=M_=HOG8Y_XL>)O^$P\ Z;K)C\
MAKG4%W1YW!6CCOH7P>/E+1EESR%(!YS6N%I^PQ,Z5[VAOZN#_4RKS]I1C.UK
MRV]%)'I_A'Q_?^.=:N4TI+9=!L"$>>19#<S2,&V^4!*JHC$$@O&WR+_>?:G#
M5H1P].+J.7M9:I*W*EYZ:OT>_P"/73JRJS:A;DCUZM^6OZ'F&I?M"7<DL\NF
MC3H;:!RL4-TMZ]U<J#]^-X$%M'N'(65UV],MC)[XX"*24^=MK5QY5&/DTWS/
MY(Y'BW=N/*DMD^:[]+:+YG::O\7[E[+2!HEK&^I:_P#ZM+AF\F$B3R3N*%&<
M&3<%(9,(I9ADA:Y881*53VLFH4]VMWI?SMH;RQ#M#V:]Z>U]EK;\SG?"K:D/
MB5<G6A;+>#3OWGV0R&#'EV^TIYP$@^7&X-T.<$C!K:KR?5(^RYN7GTYK7W>]
MM#.'-]8?/:_+TO;9=RAJWQSU?2'+LVB3A9"IM(&O)+@*#@DW";K/CN5D;/\
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MTA4P\MG%R7DU_P &QOB%R2A6CO>S\T_Z9[]7D'H!0 4 % !0 4 % !0 4 %
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MMG]F2?RV^1,X2H22DEW75,[OXL:!I[V.F>+-&@CLK;580LUO$%2..=4!&Q%
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ME%D=9':4#8@.X!BJA=P3Y:VEBTE-4J:A*?Q2NW]RLK;LS6'=X\\W)1V5K?\
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MNYW<.G=>GEY?,X*^'57WX:2_!_\ !\SY3U#X9>*-,D,4NF7CD'&8(6G4^X>
M2+C\:]^.)HR5U.*]7;\'8\ET:D='!_)7_(H?\('XC_Z!6I?^ 5S_ /&JOV]+
M_GY#_P "C_F3[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P#
MH_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_
M)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!
M_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_
M .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@
M%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JC
MV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0
M_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA
M[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P
M%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P (
M'XC_ .@5J7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5
MJ7_@%<__ !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__
M !JCV]+_ )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_
M )^0_P# H_YA[*I_)+_P%_Y!_P ('XC_ .@5J7_@%<__ !JCV]+_ )^0_P#
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M;TO^?D/_  */^8>RJ?R2_P# 7_D'_"!^(_\ H%:E_P" 5S_\:H]O2_Y^0_\
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MLJG\DO\ P%_Y!_P@?B/_ *!6I?\ @%<__&J/;TO^?D/_  */^8>RJ?R2_P#
M7_D'_"!^(_\ H%:E_P" 5S_\:H]O2_Y^0_\  H_YA[*I_)+_ ,!?^0?\('XC
M_P"@5J7_ (!7/_QJCV]+_GY#_P "C_F'LJG\DO\ P%_Y!_P@?B/_ *!6I?\
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M3_&@ _M&U_Y[1?\ ?Q/\: *]OJ%LH;,T0^=C]]?7ZT 6/[1M?^>T7_?Q/\:
M#^T;7_GM%_W\3_&@ _M&U_Y[1?\ ?Q/\: #^T;7_ )[1?]_$_P : #^T;7_G
MM%_W\3_&@ _M&U_Y[1?]_$_QH /[1M?^>T7_ '\3_&@ _M&U_P">T7_?Q/\
M&@ _M&U_Y[1?]_$_QH /[1M?^>T7_?Q/\: #^T;7_GM%_P!_$_QH /[1M?\
MGM%_W\3_ !H /[1M?^>T7_?Q/\: #^T;7_GM%_W\3_&@ _M&U_Y[1?\ ?Q/\
M: #^T;7_ )[1?]_$_P : #^T;7_GM%_W\3_&@ _M&U_Y[1?]_$_QH /[1M?^
M>T7_ '\3_&@ _M&U_P">T7_?Q/\ &@ _M&U_Y[1?]_$_QH /[1M?^>T7_?Q/
M\: #^T;7_GM%_P!_$_QH /[1M?\ GM%_W\3_ !H /[1M?^>T7_?Q/\: #^T;
M7_GM%_W\3_&@ _M&U_Y[1?\ ?Q/\: *\NH6Q>,B:+ )S\Z\<'WH L?VC:_\
M/:+_ +^)_C0 ?VC:_P#/:+_OXG^- !_:-K_SVB_[^)_C0 ?VC:_\]HO^_B?X
MT ']HVO_ #VB_P"_B?XT ']HVO\ SVB_[^)_C0 ?VC:_\]HO^_B?XT ']HVO
M_/:+_OXG^- !_:-K_P ]HO\ OXG^- !_:-K_ ,]HO^_B?XT ']HVO_/:+_OX
MG^- !_:-K_SVB_[^)_C0 ?VC:_\ /:+_ +^)_C0 ?VC:_P#/:+_OXG^- !_:
M-K_SVB_[^)_C0 ?VC:_\]HO^_B?XT ']HVO_ #VB_P"_B?XT ']HVO\ SVB_
M[^)_C0 ?VC:_\]HO^_B?XT ']HVO_/:+_OXG^- !_:-K_P ]HO\ OXG^- !_
M:-K_ ,]HO^_B?XT ']HVO_/:+_OXG^- !_:-K_SVB_[^)_C0 ?VC:_\ /:+_
M +^)_C0 ?VC:_P#/:+_OXG^- !_:-K_SVB_[^)_C0 ?VC:_\]HO^_B?XT 5[
M74+98P#-$",]74=S[T 6/[1M?^>T7_?Q/\: #^T;7_GM%_W\3_&@ _M&U_Y[
M1?\ ?Q/\: #^T;7_ )[1?]_$_P : #^T;7_GM%_W\3_&@ _M&U_Y[1?]_$_Q
MH /[1M?^>T7_ '\3_&@ _M&U_P">T7_?Q/\ &@ _M&U_Y[1?]_$_QH /[1M?
M^>T7_?Q/\: #^T;7_GM%_P!_$_QH /[1M?\ GM%_W\3_ !H S-9@TK7[.33M
M0:*:UG $D?G;-P#!A\T;JX^90?E8=,=,U<)RIR4X.TEL]'^>A,HJ:<9;/I_P
MQ+I@TW1K6*PLGBBM[9!'$GFAMJ*, ;G=F.!W9B?4T2DYMSENW=_T@BE%*,=$
MMB]_:-K_ ,]HO^_B?XU!0?VC:_\ /:+_ +^)_C0 ?VC:_P#/:+_OXG^- !_:
M-K_SVB_[^)_C0 ?VC:_\]HO^_B?XT ']HVO_ #VB_P"_B?XT ']HVO\ SVB_
M[^)_C0 ?VC:_\]HO^_B?XT ']HVO_/:+_OXG^- !_:-K_P ]HO\ OXG^- !_
M:-K_ ,]HO^_B?XT ']HVO_/:+_OXG^- !_:-K_SVB_[^)_C0 ?VC:_\ /:+_
M +^)_C0!7;4+;SE/G18"MSO7U'O0!8_M&U_Y[1?]_$_QH /[1M?^>T7_ '\3
M_&@ _M&U_P">T7_?Q/\ &@ _M&U_Y[1?]_$_QH /[1M?^>T7_?Q/\: #^T;7
M_GM%_P!_$_QH /[1M?\ GM%_W\3_ !H /[1M?^>T7_?Q/\: #^T;7_GM%_W\
M3_&@ _M&U_Y[1?\ ?Q/\: #^T;7_ )[1?]_$_P : #^T;7_GM%_W\3_&@ _M
M&U_Y[1?]_$_QH /[1M?^>T7_ '\3_&@ _M&U_P">T7_?Q/\ &@ _M&U_Y[1?
M]_$_QH /[1M?^>T7_?Q/\: #^T;7_GM%_P!_$_QH /[1M?\ GM%_W\3_ !H
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M10 ?V=;?\\D_[Y% !_9UM_SR3_OD4 ']G6W_ #R3_OD4 ']G6W_/)/\ OD4
M']G6W_/)/^^10 ?V=;?\\D_[Y% !_9UM_P \D_[Y% !_9UM_SR3_ +Y% !_9
MUM_SR3_OD4 ']G6W_/)/^^10 ?V=;?\ /)/^^10 ?V=;?\\D_P"^10 ?V=;?
M\\D_[Y% !_9UM_SR3_OD4 ']G6W_ #R3_OD4 ']G6W_/)/\ OD4 ']G6W_/)
M/^^10 ?V=;?\\D_[Y% !_9UM_P \D_[Y% !_9UM_SR3_ +Y% !_9UM_SR3_O
MD4 ']G6W_/)/^^10 ?V=;?\ /)/^^10 ?V=;?\\D_P"^10 ?V=;?\\D_[Y%
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M_P \D_[Y% !_9UM_SR3_ +Y% !_9UM_SR3_OD4 ']G6W_/)/^^10 ?V=;?\
M/)/^^10 ?V=;?\\D_P"^10 ?V=;?\\D_[Y% !_9UM_SR3_OD4 ']G6W_ #R3
M_OD4 ']G6W_/)/\ OD4 ']G6W_/)/^^10 ?V=;?\\D_[Y% !_9UM_P \D_[Y
M% !_9UM_SR3_ +Y% !_9UM_SR3_OD4 ']G6W_/)/^^10 ?V=;?\ /)/^^10
M?V=;?\\D_P"^10 ?V=;?\\D_[Y% !_9UM_SR3_OD4 ']G6W_ #R3_OD4 ']G
M6W_/)/\ OD4 ']G6W_/)/^^10 ?V=;?\\D_[Y% !_9UM_P \D_[Y% !_9UM_
MSR3_ +Y% !_9UM_SR3_OD4 ']G6W_/)/^^10 ?V=;?\ /)/^^10 ?V=;?\\D
M_P"^10 ?V=;?\\D_[Y% !_9UM_SR3_OD4 ']G6W_ #R3_OD4 ']G6W_/)/\
MOD4 ']G6W_/)/^^10 ?V=;?\\D_[Y% !_9UM_P \D_[Y% !_9UM_SR3_ +Y%
M !_9UM_SR3_OD4 ']G6W_/)/^^10 ?V=;?\ /)/^^10 ?V=;?\\D_P"^10 ?
MV=;?\\D_[Y% !_9UM_SR3_OD4 ']G6W_ #R3_OD4 ']G6W_/)/\ OD4 ']G6
MW_/)/^^10 ?V=;?\\D_[Y% !_9UM_P \D_[Y% !_9UM_SR3_ +Y% !_9UM_S
MR3_OD4 ']G6W_/)/^^10 ?V=;?\ /)/^^10 ?V=;?\\D_P"^10 ?V=;?\\D_
M[Y% !_9UM_SR3_OD4 ']G6W_ #R3_OD4 ']G6W_/)/\ OD4 ']G6W_/)/^^1
M0 ?V=;?\\D_[Y% !_9UM_P \D_[Y% !_9UM_SR3_ +Y% !_9UM_SR3_OD4 '
M]G6W_/)/^^10 ?V=;?\ /)/^^10 ?V=;?\\D_P"^10 ?V=;?\\D_[Y% !_9U
MM_SR3_OD4 ']G6W_ #R3_OD4 ']G6W_/)/\ OD4 ']G6W_/)/^^10 ?V=;?\
M\D_[Y% !_9UM_P \D_[Y% !_9UM_SR3_ +Y% !_9UM_SR3_OD4 ']G6W_/)/
M^^10 ?V=;?\ /)/^^10 ?V=;?\\D_P"^10 ?V=;?\\D_[Y% !_9UM_SR3_OD
M4 ']G6W_ #R3_OD4 ']G6W_/)/\ OD4 ']G6W_/)/^^10!JV4*01E8U"#<3@
M# S@>E %R@ H JW/;\?Z4 5: "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H J&^MUE^SF6,3'I&74/R,CY,[N1STZ<U'/%
M/DYES=KJ_P!VYNJ-5P]LJ<_9_P _++EWM\5K;Z;[ENK, H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %VV^Z?K_04 3T % %6Y
M[?C_ $H JT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!=MONGZ_T% $] !0!4NB!C/'7^E %3</44 &X>HH -P]10 ;AZB@
M W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -
MP]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</
M44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U%
M !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10
M;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X
M>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J
M* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@
M W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -
MP]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</
M44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U%
M !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10
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M'_/+_P ?D_\ BZ #_A'K#_GE_P"/R?\ Q= !_P (]8?\\O\ Q^3_ .+H /\
MA'K#_GE_X_)_\70 ?\(]8?\ /+_Q^3_XN@ _X1ZP_P">7_C\G_Q= !_PCUA_
MSR_\?D_^+H /^$>L/^>7_C\G_P 70!!/H-BFW;'C+J#\[]#U_BH G_X1ZP_Y
MY?\ C\G_ ,70 ?\ "/6'_/+_ ,?D_P#BZ #_ (1ZP_YY?^/R?_%T '_"/6'_
M #R_\?D_^+H /^$>L/\ GE_X_)_\70 ?\(]8?\\O_'Y/_BZ #_A'K#_GE_X_
M)_\ %T '_"/6'_/+_P ?D_\ BZ #_A'K#_GE_P"/R?\ Q= !_P (]8?\\O\
MQ^3_ .+H /\ A'K#_GE_X_)_\70 ?\(]8?\ /+_Q^3_XN@ _X1ZP_P">7_C\
MG_Q= !_PCUA_SR_\?D_^+H /^$>L/^>7_C\G_P 70 ?\(]8?\\O_ !^3_P"+
MH /^$>L/^>7_ (_)_P#%T '_  CUA_SR_P#'Y/\ XN@ _P"$>L/^>7_C\G_Q
M= !_PCUA_P \O_'Y/_BZ #_A'K#_ )Y?^/R?_%T '_"/6'_/+_Q^3_XN@ _X
M1ZP_YY?^/R?_ != !_PCUA_SR_\ 'Y/_ (N@ _X1ZP_YY?\ C\G_ ,70 ?\
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M/_BZ #_A'K#_ )Y?^/R?_%T '_"/6'_/+_Q^3_XN@ _X1ZP_YY?^/R?_ !=
M!_PCUA_SR_\ 'Y/_ (N@ _X1ZP_YY?\ C\G_ ,70 ?\ "/6'_/+_ ,?D_P#B
MZ #_ (1ZP_YY?^/R?_%T '_"/6'_ #R_\?D_^+H /^$>L/\ GE_X_)_\70!!
M+H-BCH!'PQ(/SOZ$_P!Z@"?_ (1ZP_YY?^/R?_%T '_"/6'_ #R_\?D_^+H
M/^$>L/\ GE_X_)_\70 ?\(]8?\\O_'Y/_BZ #_A'K#_GE_X_)_\ %T '_"/6
M'_/+_P ?D_\ BZ #_A'K#_GE_P"/R?\ Q= !_P (]8?\\O\ Q^3_ .+H /\
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M_P"/R?\ Q= !_P (]8?\\O\ Q^3_ .+H /\ A'K#_GE_X_)_\70 ?\(]8?\
M/+_Q^3_XN@ _X1ZP_P">7_C\G_Q= !_PCUA_SR_\?D_^+H /^$>L/^>7_C\G
M_P 70 ?\(]8?\\O_ !^3_P"+H /^$>L/^>7_ (_)_P#%T '_  CUA_SR_P#'
MY/\ XN@ _P"$>L/^>7_C\G_Q= !_PCUA_P \O_'Y/_BZ (&T&Q$JJ(^"I.-[
M]01_M4 3_P#"/6'_ #R_\?D_^+H /^$>L/\ GE_X_)_\70 ?\(]8?\\O_'Y/
M_BZ #_A'K#_GE_X_)_\ %T '_"/6'_/+_P ?D_\ BZ #_A'K#_GE_P"/R?\
MQ= !_P (]8?\\O\ Q^3_ .+H /\ A'K#_GE_X_)_\70 ?\(]8?\ /+_Q^3_X
MN@ _X1ZP_P">7_C\G_Q= !_PCUA_SR_\?D_^+H /^$>L/^>7_C\G_P 70 ?\
M(]8?\\O_ !^3_P"+H /^$>L/^>7_ (_)_P#%T '_  CUA_SR_P#'Y/\ XN@
M_P"$>L/^>7_C\G_Q= !_PCUA_P \O_'Y/_BZ #_A'K#_ )Y?^/R?_%T '_"/
M6'_/+_Q^3_XN@ _X1ZP_YY?^/R?_ != !_PCUA_SR_\ 'Y/_ (N@ _X1ZP_Y
MY?\ C\G_ ,70 ?\ "/6'_/+_ ,?D_P#BZ #_ (1ZP_YY?^/R?_%T '_"/6'_
M #R_\?D_^+H /^$>L/\ GE_X_)_\70 ?\(]8?\\O_'Y/_BZ #_A'K#_GE_X_
M)_\ %T '_"/6'_/+_P ?D_\ BZ #_A'K#_GE_P"/R?\ Q= !_P (]8?\\O\
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M % %&XU.TM&V3SPQ,.SR(I_)B#6;G&.DI)>K2.F&'K55>E3G)=XPDU^"*_\
M;^F_\_=M_P!_XO\ XJI]K3_GC_X$O\S7ZGB?^?%7_P %S_R#^W]-_P"?NV_[
M_P 7_P 51[6G_/'_ ,"7^8?4\3_SXJ_^"Y_Y!_;^F_\ /W;?]_XO_BJ/:T_Y
MX_\ @2_S#ZGB?^?%7_P7/_(/[?TW_G[MO^_\7_Q5'M:?\\?_  )?YA]3Q/\
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M_P ^*O\ X+G_ )!_;^F_\_=M_P!_XO\ XJCVM/\ GC_X$O\ ,/J>)_Y\5?\
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!7F^_'_O'_T$T 6* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M*]I_JA^/\S0!8H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H KM_KE_W6_F* +% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M .@F@"Q0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@X89'6HE!3LI+;5:M->C5FCHI5IT&W2=N96DFHRBUV<9)Q?S10?2-.M(I$D
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M,H1C3@YJTIPBU.735MOII>UU?2Q>U3PQ:ZI.MV6FM[A1M\R!]C$=,$E6[<9
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MC?5WU_X"1ABL94QKC*JHIPCRKE36GG=O4VJW/."@ H * "@"NW^N7_=;^8H
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MT:DETZIFY70>:% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M _F2>I)/))KVHP5-*,%9(^#K5IXB;JU7>3W?Y)+HET1);=&_WV_G5F!8H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"O
M-]^/_>/_ *": +% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % %>T_U0_'^9H L4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5V_UR_[K?S% %B@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M:OHN^F[,J4X4*-1J5ZU1>S4;/W(-WE)MKE;E9))-V3;?8W=P]170>:&X>HH
M-P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #<
M/44 &X>HH -P]10 ;AZB@ W#U% !N'J* *URP^3D?ZQ: +.X>HH -P]10 ;A
MZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>H
MH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J*
M#</44 &X>HH -P]10 ;AZB@ W#U% %>V8 -R/OM_.@"QN'J* #</44 &X>HH
M -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #
M</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#
MU% !N'J* #</44 &X>HH K3,-\?(^\?_ $$T 6=P]10 ;AZB@ W#U% !N'J*
M #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@
MW#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P
M]10 ;AZB@ W#U% !N'J* *]HP\H<CO\ S- %C</44 &X>HH -P]10 ;AZB@
MW#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P
M]10 ;AZB@ W#U% !N'J* #</44 &X>HH -P]10 ;AZB@ W#U% !N'J* #</4
M4 &X>HH -P]10 ;AZB@"LS#SEY_A;^8H L[AZT &X>M !N'K0 ;AZT &X>M
M!N'K0 ;AZT &X>M !N'K0 ;AZT &X>M !N'K0 ;AZT &X>M !N'K0 ;AZT &
MX>M !N'K0 ;AZT &X>M !N'K0 ;AZT &X>M !N'K0 ;AZT &X>M !N'K0 ;A
MZT &X>M !N'K0 ;AZT &X>M !N'K0 ;AZT &X>M !N'K0 ;AZT +0 4 % %*
M\TZWO]IG7?LSCYF&,XS]TCT% %+_ (1ZP_YY_P#C[_\ Q5 !_P (]8?\\_\
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M /\ A'K#_GG_ ./O_P#%4 '_  CUA_SS_P#'W_\ BJ #_A'K#_GG_P"/O_\
M%4 '_"/6'_//_P ??_XJ@ _X1ZP_YY_^/O\ _%4 '_"/6'_//_Q]_P#XJ@ _
MX1ZP_P">?_C[_P#Q5 !_PCUA_P \_P#Q]_\ XJ@ _P"$>L/^>?\ X^__ ,50
M ?\ "/6'_//_ ,??_P"*H /^$>L/^>?_ (^__P 50 ?\(]8?\\__ !]__BJ
M#_A'K#_GG_X^_P#\50 ?\(]8?\\__'W_ /BJ #_A'K#_ )Y_^/O_ /%4 '_"
M/6'_ #S_ /'W_P#BJ #_ (1ZP_YY_P#C[_\ Q5 !_P (]8?\\_\ Q]__ (J@
M _X1ZP_YY_\ C[__ !5 !_PCUA_SS_\ 'W_^*H /^$>L/^>?_C[_ /Q5 !_P
MCUA_SS_\??\ ^*H /^$>L/\ GG_X^_\ \50 ?\(]8?\ //\ \??_ .*H /\
MA'K#_GG_ ./O_P#%4 '_  CUA_SS_P#'W_\ BJ #_A'K#_GG_P"/O_\ %4 '
M_"/6'_//_P ??_XJ@ _X1ZP_YY_^/O\ _%4 '_"/6'_//_Q]_P#XJ@ _X1ZP
M_P">?_C[_P#Q5 !_PCUA_P \_P#Q]_\ XJ@ _P"$>L/^>?\ X^__ ,50 ?\
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M_P#BJ #_ (1ZP_YY_P#C[_\ Q5 !_P (]8?\\_\ Q]__ (J@ _X1ZP_YY_\
MC[__ !5 !_PCUA_SS_\ 'W_^*H /^$>L/^>?_C[_ /Q5 !_PCUA_SS_\??\
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M !5 !_PCUA_SS_\ 'W_^*H /^$>L/^>?_C[_ /Q5 !_PCUA_SS_\??\ ^*H
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M (1ZP_YY_P#C[_\ Q5 !_P (]8?\\_\ Q]__ (J@ _X1ZP_YY_\ C[__ !5
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MP*/E0Q(V-Q\IP 8-]\0-,L+RTB>>U&GWUK<W0U!KJ);=1;RVL*J'/[IQ*]R
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M<@@]"#Z4 8MKXFTB^FFMK6]M)I[0.;B*.XA>2 1G:YF17+1A&^5RX7:>#@T
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M0T8(8E<?>% #]0\4:/I,GD7]]9VLH*+LGN88G!D!,8VNZG+A6*#&6"DKG!H
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MY7*K+,^V.)6(+NR@=: +_AK7O[;TU=3G-FB.&;=9W@O+<(G#$W/DVZ[D(99
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ME0-K ]"* .1T;X@#59;")K<0C46U=2QFW"(:5<FW)/[I=PGQOZIY7W<R?>H
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M.AAE5I061OWC( :V@^$M5T[495=(A8Z-'=+H9D<,CO?'S"94C_>1K8J/L4?
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M/!FLQC[5;K/&;77]0U!(;1['[1)#=(\4<\ O5EL?-4RNY2Y\IPC3,CI-L60
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MFX\&:K;:Y>-;1K)I3Z-J4-FWF(&CN;Z>VE:T*.X8()(I987 $,<<BP901("
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M+F1D -GPWX1OM+B\+(UNL)TBTGCO0K0_NI)K-58?(Y\SS+@9<Q;PS_O&/\5
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M:,]!0!K(BQJ$0!54   8  X  '  '  Z4 .H * "@ H * "@ H * "@ H *
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M010*S 8#,(E4,0. 3DXXH UJ "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-UW1K@YY%;E!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M67A2U,"K>76J0Z?:W=Q8WUA;21RVSW;W/V*[=;HF%(9X?)$X6698R)XTD.P
M74Y/$T7B/2+-KZS0RVVJ,_EVEU]GF6)[$JTEM_:*XD"R[(B9I!"1*X+B?RX@
M"IHOB&ZB(TO2(K6TN=1UW7(_-E2XFA1;2YGDFF:(W*223SD+^[2>")6=W15C
MC$1 +D?C?6;R:STRW6RBO9M0U#3KF9XYG@#65N\PN((EFC?:X56,#S$J2T)G
MROFD [3P9KEUKEI,U^(A<V=[=V4C0*R12&VG>(2)&[R/&'4*2C22%6R-[#%
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M1W6F)KMW)+;,EIK9A4ZG?O9VT$+6.GD(LY@NA&/-D.R(1JC/(QR&/S &1/\
M$?4M9M],N=#CM-\VN2Z;<J+P2VTWE6UU*H@NTLYBUO,J).)UABF1D6$Q$/(R
M &M#XOETNXU)#%+<7SZK9V$-L]X7M_M$]A:RE89&MD:VM8U,DDG[J5V*23+'
MOE$*@%NY^(=S9(UM-8*=3AU&UT^6VCN@8<WB"2">*Y>",O$4(W!X(G5UD3:=
MJM( =-X9\13ZS+>V=[;I:7FEW"03)%,;B%O,MXKF-XY6AMV8-',NX-"A5@1R
M,&@#JZ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#"\0>'
MK7Q-;I9W^7M5GBGDAPACG\EO,2*='1P\/F!)&0;=Q1024W*P!RU[\*]"G9C9
M0C2DGMWM;F/3X[>WCNH))896CG00,&_U)C#KLD$4TZ!OG!4 TH?A[H=A>VVH
MZ9:0:9<6;NP:R@M[?SDDC:-X9]D7[R([@X7Y661$96&"" ;6F:%!I-S>WD+2
M-)J<Z7$P<J55T@BMP(P%4A=D*DABYW%CD A0 <GI/PVM],M;;39;[4+W3K#R
MS#9SM:+#F$AHO--K9VTTZHP#>5/-)"[!3)&Y5< '9)I>S4'U+S[@^9 D'V8R
M9M4V.[^:D6WY9WW['DW'<BHN!MR0#,UKP?IGB.ZANM6B2^2UCECCMKB.*6V#
M3-&6F,4D;;I@(@B,6(1&D"J"[&@#(@^&^DV4N^R#V<'VZWU%;6W$,5LES;PF
M#='$L(V+,FWSU!^=XU=2C%RX!@^$O $\4*MK4USL@U2\OH=/+6GV57-]<3VL
MY:&'[0YPZ7"QRW3HLI!:(-&JH =3#X&L8+6"R5Y_+M=2;5$):/<9WN9;HHQ\
ML Q>9,P"@!]@4>86!8@&;:_#:TLY;<QWE[]EL;V34+>S)M!!'/(T[M\RVBW4
MB9N)<":XD(R/FRH- 'H,T;2QLB.T3,I4.FTLA(P&4.KH64\C>C+D?,K#((!R
MWA?PG_PBQGV7MY>I=327#I<BSP)YG,DLBFVM+=@78G*EFC4<(BT ,UGP=%JU
M]_:D5U=6%R;8V<K6WV8^;;^89!&WVFVN"F'9B'@,3G=\S':FT 31/!%EH+0-
M;O.QM=-BTI/,9#F")MRNVV-<S$_>880CI&* *NG^ +72/[/-A<W=L^E6JV*L
MIMG-S:J\;^5<B6VD7!:,'?;K;RC>X5UR, #8OA]:VD5DEE<W=I+I9N?(GC-L
MTICO)/-N(I!-;2PM&[!#D1+(OEKMD!W%@#=T[0X-!M[I+99+D75Q=7CQN8R7
MDN6:1XER(T"%CM02'@'YW/)H \M3X>7FG>!X]!LT9=0EN+&YFQ+&[QNNH6L\
MH$LV8Y#9V\0AB9PPDCMXU"/D*0#NXO!(B\^?^T-0.H71@WZANM!<+';$M% D
M:6BV8A!>4LAM&\PRNTA9@A0 9I_@"RL+F&_::YN+N"\FOGFE, :>>:T:Q)F2
M&"*(*MN0J+!'#\R*[[V+EP">T\#6-E;Z;:QO.4T2X>YMRS1[G=X[B,B4B,!E
MVW+D!!&<A/F(!# &GX@\.Q>($@W2S6D]E.+BVN+<QB6&4(\1*B:*:)E>*22-
MTEB=&5L[0P5E ,"W^'EI;0.BW5Z;MKYM26^+P?:8KN2%;>1X\6XM]DD09&@>
MW>#;(ZB,((UC -!?!Z.UK->7EY>S6%X;V.6=K<$R&V>U\MDAMX8EA$<C,$AC
MB)ES(S,S/N *\O@*R=&\F:YM[C^T)=3ANHFB\ZWN)PR2B+?"\+1/$\D+13Q3
M*R.2<NJ.@ Y? EG*YEU":YU)Y+*YL)C=/%^^@NYA-+O$,,(4@J(XQ"(DCB&U
M4W , "&7P+]KM+C3KW4M2N[6ZLYK+RY7M (HI@JLZ-%9QO),JJ%26Z:X8 N3
MDR.6 -"^\&:?J<YFO \ROITNF/"S 1O;3/&[[MJK()"8P Z2+M!) #88 &5>
M^%Y[+2+^V,][K[7%D]M%:W<EH@($<BB-6B@M$#2EPLD]PTDF%4A\@A@!D'@V
MYTWPU!X=T^X:&9?(6YNUDDCF;=.DM_-'(F9!<7 ,VQBRD/*&9_EY /0&C#H8
MSG!!7KS@C'4YY]SF@#S[2OAQ;Z;;6NG37U_?:?I_E&"SN&M%A!@P8#(;6TMI
MIQ$0&6.>66)G"N\;NB,H!UFF:)!I5Q>74+.7U*X6YE#E2JNMO!; 1@*I"[($
M)#%CO+'=@A0 <O+\/+7]T]K=WEG-;ZA>ZE'-$;5G6:_\\3KMGM9HC%MN)%16
MC+J,$N6&Z@#8T_PK#IZ7+&XNKB\OD\N>^E=!<E5#B(1^5'%! L/F,8D@@C0.
M6E96E>1W -S3;+^S;6&S\R6X^SQ1Q>=._F32^6@3S)I,#?*^-TCX&YR3@9Q0
M!Q"_#J%1<VYU#4?L%]<W%U/9*]K'"[74S3S1^=%:1WRQ,[D%5NP2F8V9D9E8
M NZQX%MM4N6NH;F[T\S6BV$Z69@1)[5&D9(F\VWE:(IYLJI+;-!,JN0L@*H5
M *Y^'\$"0C3KR^TV6"QATYYK9K8R3V]NN(1,)[6>,21;I"DT,<,@,CC=MVJH
M!:G\"V,]I?V+27 CU:[2\F.]"ZR(MJH6-FC.$(M(\[Q(Y+.=_*[0!]QX.5KF
M:YLKZ^TY+QUEN;>V:W\J:4 (TF9[::>!Y(U1)#:S0 [!( LQ>1@!+CP-8W-K
M>V3/.(]3ODOYB&CW+,CVSA8R8R!&3:QY#!VP7PXRI4 +GP-8W5KJ%F[SB/5[
MQ;V<AH]RRHMJH6(F,A8\6D>0X=LL_P PRNT 6X\'*US-<V5]?:<EXZRW-O;-
M;^5-* $:3,]M-/ \D:HDAM9H =@D 68O(P!L>(-#@\1V3:==-(D3O#(3&5#Y
M@FCG3!97&"\2AOER5) (." #.O/"%G>R:E+(\P;6[..RN K( D427**T.8SM
MD(NI,ES(N0F%&&# &5J'P]M;UR\5W>V?G6,>GW(MW@ N;:(2"-9#);RO&ZB6
M0"2V:!\.?FX7  ES\/8+JW33Y+Z_.FK';1O9%K5H95M5B5 SM:M<Q;Q"AD%M
M/ "^YT".[,0#2C\();7LEW9WEY:0W%P+J>SB: 6\LX*EG8O;O<QB4HAFCAN8
MHI<-O0^9+Y@!DV/PWM+":TD2[OGM],NI;JSM'>W\B!IEN%:,;;99Y(P+AQ'Y
M\TLD85520*9 X 0?#>UL?LSZ?=WME/90W%NLT7V1Y'AN;@7,D;BXM)XP!* 4
M:*.*0+PSM0!H:!X%L?#DEG+:R3N=.L9=/B\UT8-#--#.S28C4M*'@0*P*KM+
M90DA@ ;'B#0(/$5LMM.\L#1317$,T)5989H7#QR1ETDC)!&"LD;HREE=&4D4
M <E?>"Q8:7K"Q&YUJ\UF!A(ES);(9I!;?9HU#1Q6T,*E0NXA0$P61=V%(!I:
M=X,;3=(LM)M;Z[LI;$!GN;8PE[B5U?[0TRW4%S%()YI7G8O&7$N'#@YR 06_
MP\M+'[+)97-W:W-D]T_VF,VS23?;I5GNQ,DMM);[9Y45R(88?*(Q!Y2DJ0"_
M_P (3I[:;=Z1(97M]1N;F[D)<+(DUS<-=%HG14*>3,0\!P60HI9G()(!ROBG
MP%/-I.H"UFN=3U;4!:1?:+EK5)5AMKE)4BB$<-M:1I%NGFQY.Z21V\QI<1JH
M!M3?#RUO8KE=0NKR^N+Y8(Y+J8VRS)#;3">*&)8+:&W2,2[G8B#S'+MO<[8]
M@!MW&@P0WEWK*I)<W%U91VKV^Z,1R) UQ(B+O"A7D:X=&:23R\;>% 8D Y+P
M[X+O-!\(#0[*3[-J5Q WFSF5B\4]Q@2NLRAW=[5&\NW?C=Y,7*#E0#TNW@%M
M$D*EW$:*@:1F=R%  +NQ+.QQEF8EF.222: .3/@>Q_L-_#>^?[)(TC%]R><#
M+<M=-AO+V8$C$#]V?DP#EOFH BN_!1FOKK4;74=0L&U$1"XCMOL6QO)C\I2K
M364T\9V=6CF1@3N4J0" #4'ABV@M[.SLI+BQ@TZ=)T2WF9?.VK(#%=,^]YXI
M&D,DP=M\LJK([E@20"UXBT*#Q-IMSI%VTB07L30R-$5$@5Q@E"RNH;T)5A[4
M %_H<&HWMGJ$K2++ICS21!2H1C-"\#>8"I) 1R5VLA#8))'! .4L?AO:6$UI
M(EW?/;Z9=2W5G:.]OY$#3+<*T8VVRSR1@7#B/SYI9(PJJD@4R!P#1M/ UC96
M^FVL;SE-$N'N;<LT>YW>.XC(E(C 9=MRY 01G(3YB 0P!5MOA]:VL<=L+J[:
MTMKY+^VMF-MY=O(DTL_EQNMLL[0L\IW+--*X555)$P<@%K_A!K'[-]DWS[/[
M5_MC.Z/=]I^V_;MF?+QY'F_+MQYGE\>9N^>@#A;KP==RZI#;646I0:;#JZZF
MXGFTW^SU99&N9'MDA=]39IYS\D%P4MXS-))L0QQ)0!V<O@"SF2^MGGNOL>IR
M-.]J&@6.&Z>2.;[5;R" 723+/&)D#W$D2R$D18VA0".3X>VEW%<+?7-W>7-Y
M)9/+=RFW6;987"7-M BPVT-O'"LJLS!( [^;(6<ML9 #I;30H+/4KK5T:0SW
M\5M#(I*^6JVIG,90!0P9OM#[RS,#A=H7!W &-)X,2YO(KJ[O;VZAMKIKV"TE
M:V,$4Y\PJRR+;+>%(S*_E1O=-&B[8]IB54 !HZ_X<BU\6[F6>SN;&;S[:YMS
M$)8G,;Q/@3130LLD4CQNDD3J5;( 8*P ,2P^'UE8-#(9[N>6WU*75?,E>(M)
M=36[VTGF!(401E9&<1Q+&$? 3;$HC  D7P_M7=7U2ZO-76*UN+.)+UK<B."Z
M1([A2]O;6\TS2QQHCO<R3.<;MWF%G( 2> H[NTFTV_U#4;VRGM9+,6\TEL%C
MCD" ,KPVL4TLL:H%22ZEN&Y8OO9V8@!!X#$4\M[)J6HRW<UJMFLY-G$\$22^
M<GDI;64$(99,Y,D4@=6,<H>,*J@ OP]M'$\MS<WES?7,MO-]N=K>.YBDM%9;
M8Q+;VT%L/)WR</;N)1*\=QYT6V-0#I='TJ72UD$]Y=:B\K!O,NOLX* *%"(E
MK;VT*KP6)$>]F8EG("A0#8H * ,?Q!IIU?3[BS0X>6,A#TQ(/FC)] '"Y]NG
M-85H>UIRIK=K3UW7XV):NFCFK&*3Q3 )MZVL: 1R0Q I*MPA7SUE<!73:=RH
MD;*2NUV8A]B\<$\3'FNHI:.,=)<RMS*3T:MJDDUT;>ME"][R_P RY_9]SH0\
MV,&_MP/GA*AYUY;YXG<[I !M#1.S,1N:-MP\M].25#5>_'K'>2WUBWJ^ET[O
MJG?1NW+YK\1H\3:;*3';Q?:)1D"*-%,A(;:,H<&/(^?,FP*N-Q&:7MZ;T@N9
M]DE?>VW3OK:RW#F709X>D;6-0GU<@)#'$EG#M.Y248O<,K8&Y!*0BN  X3(Q
MTI46ZM25?:*2IQ[:.\FGU7-HGUL$=6Y?+_,V]=\.V/B..**_61A:S"XA:&XN
M+:2.94DC#K+;2PR@[)9%QOP0QR"0,>B:&=)X)TR:U%E,+N:-9UN8WEU#4)9X
MID4JLD%U)=-<P$*67$,J J[J01(X8 +'P/H^F^6;>!@T-XU^K//<2/\ :W@-
MN\[O)*[R.\3$/YA<,Q,C RDO0 1>!](@)*12!/M27JQ?:;HP1W*3-<+)#;F8
MP0YF=I'6&-$D8GS%:@"TWA/2VA:U,/[J2]&HLOF2\W8G6Y$N=^1^_57\L$1<
M;=FS*T <+JOP_EU35EG2WM[2S&HV^H2RIJ-](99+9HY0PTHP)I\4T\D,<<UP
M)'D,1E?+22&@#TO5-)M=:A%M>IYL2RPS!=SK^\@E2:)LHRGY)8T;&=K8PP*D
M@@&/J_@O2-<N#=7L+/(Z)'*$GN(H[B.-BR1W4,,L<5W$I9L1W*2IM=UV[78$
M V+32+6QN9[R"/9/>>5Y[;F._P E/+C^4L53:GR_(JYZMD\T 5]9\/V6O"/[
M8C[[=B\,L,TUM/$S*4;R[BVDBGC#H2KA9 KK\K@CB@#%NOA_HEXL:2PR8B@-
ML2MU=H9K=F+M#=LDZM>Q,[.S)=F=6,DI()EDW &_:Z+965U)?P1".XFAAMW9
M2P!AMS(84$>?+0(99,;%4D-AB0J@ %$>$]+73$T00 6, 411[Y-T11MZ/'-O
M\Z.6-_GCF202QL R.K $ %8>"=*^S/9ND\R2RI.7FO+R:X66+'E2174UP]S"
MT>T>689DV$L5P68D 8? VDLD*;+@-:R22QS"^OA<AY0!+NNQ<BZD60*@>.29
MXV5(P5Q&@4 EG\%:1/ ;8PLB_:YKX/%/<13)=3N[S317$4J3PM(TD@812(NQ
MVCV^62M $]IX3TNQ^R_9X ATYYI+<[Y"RR7".D\DC,Y:>242.9))S([NQD9C
M(=U &CINDVND+*EFGE"XGEN9!N9MTT[EY7^=FQN8D[5PJ]%4#B@#1H * "@#
MS'XJZ,^HZ6MU""SV3F1@/^>3#$A]?E(1CV"AB>E>/F%)U*2G'>#N_P#"]_T?
MI<QJ*ZOV/*?AC/Y.O0KT\U)D_P#(;/\ S2O%P#M7BNZDOP;_ $,:>DCW[PD=
MUB&88E9V,V2"WG\>=NPB'<)-RX.XJ %W$  ?38;^'=[W?-_B^U?1:WNNOJ=,
M=OZW/F?QE/\ :=:O7'.+AT'_   [/_9>*^1Q3YJU1_WFONT_0Y)?$_4^BO &
MC/HFCQ13#;+,3,Z_W3)C:#[A H/H<BOJL'2=&C&,M&_>?S_X%CJ@N5&AXD\-
M)XD6V#7%Q92V%TMW!-;>1O6589H>1<07$3*4G?(,><[2",<^@:&==>#&OHH1
M=:C?RW=G<?:;6](L$N(&,30NB+%8I;/')')(KK-;RDASR"$V@$%A\/K*P:&0
MSW<\MOJ4NJ^9*\1:2ZFMWMI/,"0H@C*R,XCB6,(^ FV)1& !(/A]:V\:VPN;
MLVD%_'J%O;$VWEP3)<O=E(W%L)VBDFD;<LTTK!,+&\8% %I_ MB]J]F7G$<N
MIC5B=T>X7 NUO-@/EX\GS4"[2"_EY'F;OF !PNH>#;NXU2.UL8M2@TY=8AU2
M3SIM-_LX/',+N62!8G?5&>>=2%AF*VZ2322E%"1K0!ZGK^A0>(K86=TTB1K/
M;7 ,94-OMIX[B,997&TO$H<8R5)"E3A@ 8.L^ K369[F8W%W;1:DD<6H6\#Q
M+#>QQ H%E+PR31;X6,$CVDUM))#M5GRB,H!NZ=H%MI=Y=W\!</?^1YB';Y:"
MWB\F,1*JJ5&P?,"S<_=VCB@"KKWAE-<FMKQ+BYL+NP,ODSVWD%PLZ!)8V2Y@
MN861PJ,<Q;@R*59><@'"3_#N?3[O2;?2+F\@MK*359IKP/:27"/?$2[3]I@E
M20/(SKGR'=5 +N&^<@'7:?X&L=-DLYHGG:73Y+J?S'=6:XGO5(N9K@[!N=RQ
M<"+RD0D*B+&JQ@ 6X\'*US-<V5]?:<EXZRW-O;-;^5-* $:3,]M-/ \D:HDA
MM9H =@D 68O(P!P?B'P?>7U[)8Z=%J4-E>:E:7UPSS:;_9FZ*:VN)YD0.^JE
MY!;[%AQ'!]I<S%57,A .JU7X<6FJ27>;N^M[;4IXKFYM87MUA>XB$(67+VSS
MJ2+>(.BSB)]O,?)H FN_A[97$CW$4]U;7+ZDVJ)/&;=GAN&M$LV$:3V\T)C,
M*?=EBE978NKJ0NT C3X=6L=K]G%W>_:/[1.J+>%K8W"7;1F)W53:_9=KQLZF
M-K9HU$C!%4!-@!/+X LYDN=\]T;B[NK>^^TAH5FANK:"&".:'; (@2L(+H\4
MD3EY%,?E-Y8 '1> ;-55IIKJXN?M\&HRW4K0^=//;@)"L@CACA6%(U6,1P0P
M@*N?OL[L ;^G:%!IEY>W\32&74Y8II@Q4JK0V\5LHC 4$*8X5+!F<ERQ! (4
M &S0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M"FW?Y_D3&%G=GJ5>R;!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
) % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>wve-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-08T20:21:34.6863+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.wavelifesciences.com/20230930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:wve="http://www.wavelifesciences.com/20230930" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" id="Role_StatementUnauditedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Unaudited Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" id="Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" id="StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2">
        <link:definition>100030 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>100040 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" id="StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit">
        <link:definition>100050 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" id="Role_StatementUnauditedConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Unaudited Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompany" id="Role_DisclosureTheCompany">
        <link:definition>100070 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100090 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRestrictedCash" id="DisclosureRestrictedCash">
        <link:definition>100100 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100110 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100120 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>100130 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare" id="DisclosureNetIncomeLossPerOrdinaryShare">
        <link:definition>100140 - Disclosure - Net Income (Loss) Per Ordinary Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureGeographicData" id="Role_DisclosureGeographicData">
        <link:definition>100160 - Disclosure - Geographic Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactions1" id="DisclosureRelatedPartyTransactions1">
        <link:definition>100170 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100180 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100190 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationTables" id="DisclosureSharebasedCompensationTables">
        <link:definition>100200 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables" id="DisclosureNetIncomeLossPerOrdinaryShareTables">
        <link:definition>100210 - Disclosure - Net Income (Loss) Per Ordinary Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" id="Role_DisclosureTheCompanyAdditionalInformationDetail">
        <link:definition>100220 - Disclosure - The Company - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>100230 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail" id="DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail">
        <link:definition>100250 - Disclosure - Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" id="DisclosureCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail" id="DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Net Income (Loss) Per Ordinary Share (Additional Information) (Details) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail" id="DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail">
        <link:definition>100280 - Disclosure - Net Income (Loss) Per Ordinary Share - Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail" id="DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail">
        <link:definition>100290 - Disclosure - Net Income (Loss) Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Earnings (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="wve_CollaborationAndLicenseAgreementResearchTerm" name="CollaborationAndLicenseAgreementResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_UpFrontConsiderationReceived" name="UpFrontConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_ShinNipponBiomedicalLaboratoriesLtdMember" name="ShinNipponBiomedicalLaboratoriesLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" name="OptionToReachMaximumTargetsForPreclinicalPrograms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CollaborationAgreementInPremium" name="CollaborationAgreementInPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_CollaborationAgreementCommencementDate" name="CollaborationAgreementCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_GeographicDataAbstract" name="GeographicDataAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_PaymentsRelatedToContractResearchServices" name="PaymentsRelatedToContractResearchServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" name="PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_MaximumTargetsForPreclinicalPrograms" name="MaximumTargetsForPreclinicalPrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_ServicePeriodOfOctober12022ThroughDecember312024Member" name="ServicePeriodOfOctober12022ThroughDecember312024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CategoryOneProgramsAndCategoryTwoProgramsMember" name="CategoryOneProgramsAndCategoryTwoProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementMonthAndYear" name="CollaborationAndLicenseAgreementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_EmployeeSharePurchasePlanMember" name="EmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AtTheMarketEquityProgramMember" name="AtTheMarketEquityProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" name="USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAgreementCommittedCash" name="CollaborationAgreementCommittedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementDate" name="CollaborationAndLicenseAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" name="OptionsToEmployeesAndNonEmployeeDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_PerformanceBasedRestrictedStockUnitsMember" name="PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" name="CollaborationBudgetedResearchAndPreclinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_MaximumTerminationNoticePeriod" name="MaximumTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CollaborationAgreementUpfrontPayment" name="CollaborationAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_TimeBasedRestrictedStockUnitsMember" name="TimeBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_NetIncomeLossAvailableToCommonStockholders" name="NetIncomeLossAvailableToCommonStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" name="SharePurchasePriceAtEqualToFairMarketValuePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_FundReceivableForResearchAndPreclinicalActivities" name="FundReceivableForResearchAndPreclinicalActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_CategoryOneProgramsMember" name="CategoryOneProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock" name="ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CategoryTwoProgramsMember" name="CategoryTwoProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_GSKEquityInvestmentMember" name="GSKEquityInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" name="EquityInvestmentAgreementOfficialClosureDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" name="ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" name="DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" name="PercentageOfOwnershipInterestInOrdinarySharesOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_C9AlsFtdProgramMember" name="C9AlsFtdProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TotalTransactionPrice" name="TotalTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" name="AcheivementOfMilestoneIncludedInCurrentPortionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" name="TwoThousandNineteenEmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AmortizationOfRightOfUseAssets" name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_PfizerIncMember" name="PfizerIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAndSharePurchaseAgreementsAbstract" name="CollaborationAndSharePurchaseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ScientificAdvisorMember" name="ScientificAdvisorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ConsultingAgreementMember" name="ConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_GskCollaborationAgreementMember" name="GskCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_GeographicDataDisclosureTextBlock" name="GeographicDataDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_EmployeeAndNonEmployeeStockOptionMember" name="EmployeeAndNonEmployeeStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAndSharePurchaseAgreementsMember" name="CollaborationAndSharePurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>wve-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-08T20:21:37.7158+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ConsultingAgreementMember" xlink:label="wve_ConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" xlink:label="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementCommencementDate" xlink:label="wve_CollaborationAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ShinNipponBiomedicalLaboratoriesLtdMember" xlink:label="wve_ShinNipponBiomedicalLaboratoriesLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ScientificAdvisorMember" xlink:label="wve_ScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock" xlink:label="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EmployeeSharePurchasePlanMember" xlink:label="wve_EmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryTwoProgramsMember" xlink:label="wve_CategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementCommittedCash" xlink:label="wve_CollaborationAgreementCommittedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PerformanceBasedRestrictedStockUnitsMember" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementMember" xlink:label="wve_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_FundReceivableForResearchAndPreclinicalActivities" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_UpFrontConsiderationReceived" xlink:label="wve_UpFrontConsiderationReceived"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementUpfrontPayment" xlink:label="wve_CollaborationAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PfizerIncMember" xlink:label="wve_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GeographicDataDisclosureTextBlock" xlink:label="wve_GeographicDataDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementInPremium" xlink:label="wve_CollaborationAgreementInPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryOneProgramsAndCategoryTwoProgramsMember" xlink:label="wve_CategoryOneProgramsAndCategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_MaximumTargetsForPreclinicalPrograms" xlink:label="wve_MaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TimeBasedRestrictedStockUnitsMember" xlink:label="wve_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" xlink:label="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PaymentsRelatedToContractResearchServices" xlink:label="wve_PaymentsRelatedToContractResearchServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GSKEquityInvestmentMember" xlink:label="wve_GSKEquityInvestmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GskCollaborationAgreementMember" xlink:label="wve_GskCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_MaximumTerminationNoticePeriod" xlink:label="wve_MaximumTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_C9AlsFtdProgramMember" xlink:label="wve_C9AlsFtdProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AgreementTerminationNoticePeriod" xlink:label="wve_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TotalTransactionPrice" xlink:label="wve_TotalTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" xlink:label="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndSharePurchaseAgreementsMember" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementDate" xlink:label="wve_CollaborationAndLicenseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ServicePeriodOfOctober12022ThroughDecember312024Member" xlink:label="wve_ServicePeriodOfOctober12022ThroughDecember312024Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_NetIncomeLossAvailableToCommonStockholders" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" xlink:label="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryOneProgramsMember" xlink:label="wve_CategoryOneProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EmployeeAndNonEmployeeStockOptionMember" xlink:label="wve_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementResearchTerm" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GeographicDataAbstract" xlink:label="wve_GeographicDataAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs to Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense not yet recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration and license agreement, deferred revenue current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-qualified share option granted for service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, Series A preferred shares and shareholders' deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Employees and Non-Employee Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options to Employees and Non-Employee Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to employees and non-employee directors member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity investment aggregate purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrant outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In-Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net of accumulated depreciation of $41,596 and $37,846 as of September 30, 2023 and December 31, 2022, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ShinNipponBiomedicalLaboratoriesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shin Nippon Biomedical Laboratories Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ShinNipponBiomedicalLaboratoriesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shin Nippon Biomedical Laboratories Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ShinNipponBiomedicalLaboratoriesLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shin Nippon Biomedical Laboratories Ltd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from termination of collaborative arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares under ESPP, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of share options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Ordinary Share Equivalents, Presented Based on Amounts Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Ordinary Share Equivalents Outstanding [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of ordinary share equivalents outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) attributable to ordinary shareholders, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Share Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee share purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options and RSUs Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of ordinary shares, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, no par value; 99,011,901 and 86,924,643 shares issued an outstanding at September 30, 2023 and December 31, 2022, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses related to CROs and CMOs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit (provision)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax benefit (provision)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of global costs and potential profits sharing ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Global Costs And Potential Profits Sharing Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of global costs and potential profits sharing ratio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category Two Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category Two Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Category two programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommittedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, committed cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommittedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Committed Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommittedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement committed cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license agreement month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration-budgeted research and preclinical expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Budgeted Research And Preclinical Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">collaboration-budgeted research and preclinical expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract research services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund receivable for research and preclinical activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fund Receivable For Research And Preclinical Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund receivable for research and preclinical activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary share purchase price at equal to fair market value percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Price At Equal To Fair Market Value Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase price at equal to fair market value percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share attributable to ordinary shareholders-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share attributable to ordinary shareholders basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_UpFrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front consideration received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_UpFrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Consideration Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_UpFrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Up-front consideration received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants , net of offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Equity Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share attributable to ordinary shareholders-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share attributable to ordinary shareholders diluted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercises, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Series A preferred shares and shareholders' equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In-Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of pre-funded warrants, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of combined voting power of securities outstanding immediate effect of exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of ownership interest in ordinary shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ownership interest in ordinary shares outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Share Purchase Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and Share Purchase Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of employee share plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Shares Excluded from Computation of Diluted Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Data</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Data Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Geographic Data Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders-basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders basic.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee share purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Share Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive shares excluded from computation of diluted earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementInPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement in Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementInPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement in premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsAndCategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Category one programs and category two programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsAndCategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category One Programs And Category Two Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsAndCategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category 1 Programs and Category 2 Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in Operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturity of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to reach maximum targets for preclinical programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Reach Maximum Targets For Preclinical Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to reach maximum targets for preclinical programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: net income attributable to participating securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum targets for preclinical programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Targets For Preclinical Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum targets for preclinical programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time-based RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time-based restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Tax Guidance Relating to Capitalization of Research and Development Expenditures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. Tax Guidance relating to Capitalization of Research and Development Expenditures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. tax guidance relating to capitalization of research and development expenditures member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual life of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in operating lease right-of-use assets and lease liabilities related to lease extension</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PaymentsRelatedToContractResearchServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments related to contract research services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PaymentsRelatedToContractResearchServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related to Contract Research Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PaymentsRelatedToContractResearchServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments related to contract research services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GSKEquityInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK Equity Investment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GSKEquityInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G S K Equity Investment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GSKEquityInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK equity investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GskCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GskCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GSK Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GskCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement termination period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Data</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_C9AlsFtdProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">C9-ALS/FTD program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_C9AlsFtdProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C9-ALS/FTD Program Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_C9AlsFtdProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C9-ALS/FTD Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TotalTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TotalTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TotalTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Ordinary Shares Pursuant To At-the-market Equity Program Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of ordinary shares pursuant to at-the-market equity program net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acheivement of milestone included in current portion receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acheivement Of Milestone Included In Current Portion Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acheivement of milestone included in current portion receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and share purchase agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Share Purchase Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and Share Purchase Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment agreement official closure month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investment Agreement Official Closure Date Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity investment agreement official closure date month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercise Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, No Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Ordinary Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ServicePeriodOfOctober12022ThroughDecember312024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service period of October 1, 2022 through December 31, 2024.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ServicePeriodOfOctober12022ThroughDecember312024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Period Of October 1 2022 Through December 31 2024 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ServicePeriodOfOctober12022ThroughDecember312024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Period of October 1, 2022 Through December 31, 2024 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at September 30, 2023 and December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss) attributable to ordinary shareholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net income (loss) available to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net income (loss) available to common stockholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developmental milestone related to HD Category 1 Program, which pertained to completion of new, non-clinical study of WVE-003 in non-human primates or NHPs member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license agreement, deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda pharmaceutical company limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) attributable to ordinary shareholders, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants (Member)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Interest and Dividend, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend income and interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest and Dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category One Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category One Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Category one programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee And Non Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeAndNonEmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee and non employee stock option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders-diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of RSUs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock award vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AmortizationOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AmortizationOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AmortizationOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research term under collaboration and license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Professional and Contract Services Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting service expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional and Contract Services Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued under equity agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Data [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Geographic data.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ConsultingAgreementMember" xlink:to="wve_ConsultingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" xlink:to="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementCommencementDate" xlink:to="wve_CollaborationAgreementCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ShinNipponBiomedicalLaboratoriesLtdMember" xlink:to="wve_ShinNipponBiomedicalLaboratoriesLtdMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ScientificAdvisorMember" xlink:to="wve_ScientificAdvisorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock" xlink:to="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EmployeeSharePurchasePlanMember" xlink:to="wve_EmployeeSharePurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:to="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CategoryTwoProgramsMember" xlink:to="wve_CategoryTwoProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementCommittedCash" xlink:to="wve_CollaborationAgreementCommittedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PerformanceBasedRestrictedStockUnitsMember" xlink:to="wve_PerformanceBasedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementMember" xlink:to="wve_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:to="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:to="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_FundReceivableForResearchAndPreclinicalActivities" xlink:to="wve_FundReceivableForResearchAndPreclinicalActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:to="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_UpFrontConsiderationReceived" xlink:to="wve_UpFrontConsiderationReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AtTheMarketEquityProgramMember" xlink:to="wve_AtTheMarketEquityProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementUpfrontPayment" xlink:to="wve_CollaborationAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PfizerIncMember" xlink:to="wve_PfizerIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:to="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:to="wve_CollaborationAndSharePurchaseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GeographicDataDisclosureTextBlock" xlink:to="wve_GeographicDataDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:to="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementInPremium" xlink:to="wve_CollaborationAgreementInPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CategoryOneProgramsAndCategoryTwoProgramsMember" xlink:to="wve_CategoryOneProgramsAndCategoryTwoProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:to="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_MaximumTargetsForPreclinicalPrograms" xlink:to="wve_MaximumTargetsForPreclinicalPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TimeBasedRestrictedStockUnitsMember" xlink:to="wve_TimeBasedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" xlink:to="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PaymentsRelatedToContractResearchServices" xlink:to="wve_PaymentsRelatedToContractResearchServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GSKEquityInvestmentMember" xlink:to="wve_GSKEquityInvestmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GskCollaborationAgreementMember" xlink:to="wve_GskCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_MaximumTerminationNoticePeriod" xlink:to="wve_MaximumTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_C9AlsFtdProgramMember" xlink:to="wve_C9AlsFtdProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AgreementTerminationNoticePeriod" xlink:to="wve_AgreementTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TotalTransactionPrice" xlink:to="wve_TotalTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" xlink:to="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" xlink:to="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndSharePurchaseAgreementsMember" xlink:to="wve_CollaborationAndSharePurchaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:to="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementDate" xlink:to="wve_CollaborationAndLicenseAgreementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ServicePeriodOfOctober12022ThroughDecember312024Member" xlink:to="wve_ServicePeriodOfOctober12022ThroughDecember312024Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_NetIncomeLossAvailableToCommonStockholders" xlink:to="wve_NetIncomeLossAvailableToCommonStockholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" xlink:to="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PreFundedWarrantsMember" xlink:to="wve_PreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CategoryOneProgramsMember" xlink:to="wve_CategoryOneProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EmployeeAndNonEmployeeStockOptionMember" xlink:to="wve_EmployeeAndNonEmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AmortizationOfRightOfUseAssets" xlink:to="wve_AmortizationOfRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementResearchTerm" xlink:to="wve_CollaborationAndLicenseAgreementResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GeographicDataAbstract" xlink:to="wve_GeographicDataAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>wve-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-08T20:21:34.9225+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="wve-20230930.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" xlink:href="wve-20230930.xsd#Role_StatementUnauditedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:href="wve-20230930.xsd#Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="wve-20230930.xsd#StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:href="wve-20230930.xsd#StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:href="wve-20230930.xsd#Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompany" xlink:href="wve-20230930.xsd#Role_DisclosureTheCompany" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="wve-20230930.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="wve-20230930.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRestrictedCash" xlink:href="wve-20230930.xsd#DisclosureRestrictedCash" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="wve-20230930.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="wve-20230930.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:href="wve-20230930.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="wve-20230930.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureGeographicData" xlink:href="wve-20230930.xsd#Role_DisclosureGeographicData" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:href="wve-20230930.xsd#DisclosureRelatedPartyTransactions1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="wve-20230930.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="wve-20230930.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:href="wve-20230930.xsd#DisclosureSharebasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" xlink:href="wve-20230930.xsd#Role_DisclosureTheCompanyAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="wve-20230930.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:href="wve-20230930.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail" xlink:href="wve-20230930.xsd#DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="wve-20230930.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="wve-20230930.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="wve-20230930.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_NetIncomeLossAvailableToCommonStockholders" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="wve_NetIncomeLossAvailableToCommonStockholders" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_18"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="wve_AmortizationOfRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompany" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRestrictedCash" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureGeographicData" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GeographicDataAbstract" xlink:label="wve_GeographicDataAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GeographicDataDisclosureTextBlock" xlink:label="wve_GeographicDataDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_GeographicDataAbstract" xlink:to="wve_GeographicDataDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock" xlink:label="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="wve_AccruedExpensesAndOtherCurrentLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EmployeeAndNonEmployeeStockOptionMember" xlink:label="wve_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" xlink:label="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TimeBasedRestrictedStockUnitsMember" xlink:label="wve_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PerformanceBasedRestrictedStockUnitsMember" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EmployeeSharePurchasePlanMember" xlink:label="wve_EmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandFourteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_EmployeeAndNonEmployeeStockOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TimeBasedRestrictedStockUnitsMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_PerformanceBasedRestrictedStockUnitsMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_EmployeeSharePurchasePlanMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" order="10.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GskCollaborationAgreementMember" xlink:label="wve_GskCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryOneProgramsMember" xlink:label="wve_CategoryOneProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementUpfrontPayment" xlink:label="wve_CollaborationAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GSKEquityInvestmentMember" xlink:label="wve_GSKEquityInvestmentMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PfizerIncMember" xlink:label="wve_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementMember" xlink:label="wve_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryTwoProgramsMember" xlink:label="wve_CategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TotalTransactionPrice" xlink:label="wve_TotalTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndSharePurchaseAgreementsMember" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryOneProgramsAndCategoryTwoProgramsMember" xlink:label="wve_CategoryOneProgramsAndCategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementInPremium" xlink:label="wve_CollaborationAgreementInPremium"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_C9AlsFtdProgramMember" xlink:label="wve_C9AlsFtdProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" xlink:label="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_FundReceivableForResearchAndPreclinicalActivities" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementResearchTerm" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementCommittedCash" xlink:label="wve_CollaborationAgreementCommittedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_MaximumTargetsForPreclinicalPrograms" xlink:label="wve_MaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementCommencementDate" xlink:label="wve_CollaborationAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_MaximumTerminationNoticePeriod" xlink:label="wve_MaximumTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_UpFrontConsiderationReceived" xlink:label="wve_UpFrontConsiderationReceived"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementDate" xlink:label="wve_CollaborationAndLicenseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" xlink:label="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_GskCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryOneProgramsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementUpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="wve_GSKEquityInvestmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_PfizerIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryTwoProgramsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_TotalTransactionPrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_TakedaPharmaceuticalCompanyLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndSharePurchaseAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryOneProgramsAndCategoryTwoProgramsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementInPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_C9AlsFtdProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementMonthAndYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_FundReceivableForResearchAndPreclinicalActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementResearchTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommittedCash" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTargetsForPreclinicalPrograms" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommencementDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTerminationNoticePeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_UpFrontConsiderationReceived" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementDate" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="wve_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_NetIncomeLossAvailableToCommonStockholders" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="wve_NetIncomeLossAvailableToCommonStockholders" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" xlink:label="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ServicePeriodOfOctober12022ThroughDecember312024Member" xlink:label="wve_ServicePeriodOfOctober12022ThroughDecember312024Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AgreementTerminationNoticePeriod" xlink:label="wve_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ScientificAdvisorMember" xlink:label="wve_ScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ConsultingAgreementMember" xlink:label="wve_ConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ShinNipponBiomedicalLaboratoriesLtdMember" xlink:label="wve_ShinNipponBiomedicalLaboratoriesLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PaymentsRelatedToContractResearchServices" xlink:label="wve_PaymentsRelatedToContractResearchServices"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_ServicePeriodOfOctober12022ThroughDecember312024Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="wve_AgreementTerminationNoticePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="wve_ScientificAdvisorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="wve_ConsultingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="wve_ShinNipponBiomedicalLaboratoriesLtdMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="wve_PaymentsRelatedToContractResearchServices" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>wve-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-08T20:21:34.5993+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" xlink:href="wve-20230930.xsd#Role_StatementUnauditedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" xlink:href="wve-20230930.xsd#StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="wve-20230930.xsd#StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:href="wve-20230930.xsd#Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="wve-20230930.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssets" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="wve_NetIncomeLossAvailableToCommonStockholders" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="wve_NetIncomeLossAvailableToCommonStockholders" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_NetIncomeLossAvailableToCommonStockholders" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="wve_AmortizationOfRightOfUseAssets" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities" order="13" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="wve_AccruedExpensesAndOtherCurrentLiabilities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="wve_NetIncomeLossAvailableToCommonStockholders" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="wve_NetIncomeLossAvailableToCommonStockholders" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_NetIncomeLossAvailableToCommonStockholders" xlink:label="wve_NetIncomeLossAvailableToCommonStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>wve-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-11-08T20:21:34.6240+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:href="wve-20230930.xsd#StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:href="wve-20230930.xsd#Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:href="wve-20230930.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="wve-20230930.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail" xlink:href="wve-20230930.xsd#DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="wve-20230930.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="wve-20230930.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" xlink:label="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="wve_AmortizationOfRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EmployeeAndNonEmployeeStockOptionMember" xlink:label="wve_EmployeeAndNonEmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" xlink:label="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TimeBasedRestrictedStockUnitsMember" xlink:label="wve_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PerformanceBasedRestrictedStockUnitsMember" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EmployeeSharePurchasePlanMember" xlink:label="wve_EmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_EmployeeAndNonEmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_OptionsToEmployeesAndNonEmployeeDirectorsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TimeBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_EmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GskCollaborationAgreementMember" xlink:label="wve_GskCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryOneProgramsMember" xlink:label="wve_CategoryOneProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementUpfrontPayment" xlink:label="wve_CollaborationAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_GSKEquityInvestmentMember" xlink:label="wve_GSKEquityInvestmentMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PfizerIncMember" xlink:label="wve_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementMember" xlink:label="wve_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryTwoProgramsMember" xlink:label="wve_CategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TotalTransactionPrice" xlink:label="wve_TotalTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndSharePurchaseAgreementsMember" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CategoryOneProgramsAndCategoryTwoProgramsMember" xlink:label="wve_CategoryOneProgramsAndCategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementInPremium" xlink:label="wve_CollaborationAgreementInPremium"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_C9AlsFtdProgramMember" xlink:label="wve_C9AlsFtdProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" xlink:label="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_FundReceivableForResearchAndPreclinicalActivities" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementResearchTerm" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementCommittedCash" xlink:label="wve_CollaborationAgreementCommittedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_MaximumTargetsForPreclinicalPrograms" xlink:label="wve_MaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAgreementCommencementDate" xlink:label="wve_CollaborationAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_MaximumTerminationNoticePeriod" xlink:label="wve_MaximumTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_UpFrontConsiderationReceived" xlink:label="wve_UpFrontConsiderationReceived"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_CollaborationAndLicenseAgreementDate" xlink:label="wve_CollaborationAndLicenseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" xlink:label="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_GskCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryOneProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="wve_GSKEquityInvestmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_PfizerIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryTwoProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_TotalTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndSharePurchaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryOneProgramsAndCategoryTwoProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementInPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_C9AlsFtdProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_FundReceivableForResearchAndPreclinicalActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommittedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTargetsForPreclinicalPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_UpFrontConsiderationReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="wve_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" xlink:label="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ServicePeriodOfOctober12022ThroughDecember312024Member" xlink:label="wve_ServicePeriodOfOctober12022ThroughDecember312024Member"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_AgreementTerminationNoticePeriod" xlink:label="wve_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ScientificAdvisorMember" xlink:label="wve_ScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ConsultingAgreementMember" xlink:label="wve_ConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_ShinNipponBiomedicalLaboratoriesLtdMember" xlink:label="wve_ShinNipponBiomedicalLaboratoriesLtdMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:loc xlink:type="locator" xlink:href="wve-20230930.xsd#wve_PaymentsRelatedToContractResearchServices" xlink:label="wve_PaymentsRelatedToContractResearchServices"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_ServicePeriodOfOctober12022ThroughDecember312024Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="wve_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="wve_ScientificAdvisorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="wve_ConsultingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="wve_ShinNipponBiomedicalLaboratoriesLtdMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="wve_PaymentsRelatedToContractResearchServices" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659098049344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WVE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WAVE LIFE SCIENCES LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">U0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001631574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,053,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1356880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Straits View #12-00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Marina One<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">East Tower<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">018936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6236 3388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">$0 Par Value Ordinary Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659098120080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 139,942<span></span>
</td>
<td class="nump">$ 88,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,514<span></span>
</td>
<td class="nump">7,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">158,572<span></span>
</td>
<td class="nump">98,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $41,596 and $37,846 as of September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">13,770<span></span>
</td>
<td class="nump">17,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">23,738<span></span>
</td>
<td class="nump">26,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="nump">3,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">41,346<span></span>
</td>
<td class="nump">47,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">199,918<span></span>
</td>
<td class="nump">146,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,608<span></span>
</td>
<td class="nump">16,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,624<span></span>
</td>
<td class="nump">17,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">68,251<span></span>
</td>
<td class="nump">31,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="nump">5,496<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">99,980<span></span>
</td>
<td class="nump">71,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">105,380<span></span>
</td>
<td class="nump">79,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">27,170<span></span>
</td>
<td class="nump">32,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">132,550<span></span>
</td>
<td class="nump">112,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">232,530<span></span>
</td>
<td class="nump">183,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at September 30, 2023 and December 31, 2022</a></td>
<td class="nump">7,874<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value; 99,011,901 and 86,924,643 shares issued an outstanding at September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">841,405<span></span>
</td>
<td class="nump">802,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">126,885<span></span>
</td>
<td class="nump">119,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(182)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,008,594)<span></span>
</td>
<td class="num">(967,337)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' deficit</a></td>
<td class="num">(40,486)<span></span>
</td>
<td class="num">(45,091)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, Series A preferred shares and shareholders' deficit</a></td>
<td class="nump">$ 199,918<span></span>
</td>
<td class="nump">$ 146,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659097937984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Net of accumulated depreciation</a></td>
<td class="nump">$ 41,596<span></span>
</td>
<td class="nump">$ 37,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A preferred stock, shares issued</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A preferred stock, shares outstanding</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">99,011,901<span></span>
</td>
<td class="nump">86,924,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">99,011,901<span></span>
</td>
<td class="nump">86,924,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659097244992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 49,214,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="nump">$ 84,249,000<span></span>
</td>
<td class="nump">$ 2,410,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">31,642,000<span></span>
</td>
<td class="nump">27,575,000<span></span>
</td>
<td class="nump">95,935,000<span></span>
</td>
<td class="nump">84,778,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,128,000<span></span>
</td>
<td class="nump">11,609,000<span></span>
</td>
<td class="nump">37,628,000<span></span>
</td>
<td class="nump">36,789,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,770,000<span></span>
</td>
<td class="nump">39,184,000<span></span>
</td>
<td class="nump">133,563,000<span></span>
</td>
<td class="nump">121,567,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">4,444,000<span></span>
</td>
<td class="num">(38,899,000)<span></span>
</td>
<td class="num">(49,314,000)<span></span>
</td>
<td class="num">(119,157,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividend income and interest income, net</a></td>
<td class="nump">1,960,000<span></span>
</td>
<td class="nump">596,000<span></span>
</td>
<td class="nump">6,084,000<span></span>
</td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">171,000<span></span>
</td>
<td class="num">(701,000)<span></span>
</td>
<td class="nump">1,296,000<span></span>
</td>
<td class="nump">297,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">2,131,000<span></span>
</td>
<td class="num">(105,000)<span></span>
</td>
<td class="nump">7,380,000<span></span>
</td>
<td class="nump">1,043,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">6,575,000<span></span>
</td>
<td class="num">(39,004,000)<span></span>
</td>
<td class="num">(41,934,000)<span></span>
</td>
<td class="num">(118,114,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">677,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">677,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">7,252,000<span></span>
</td>
<td class="num">(39,004,000)<span></span>
</td>
<td class="num">(41,257,000)<span></span>
</td>
<td class="num">(118,114,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Less: net income attributable to participating securities</a></td>
<td class="num">(257,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_NetIncomeLossAvailableToCommonStockholders', window );">Net income (loss) attributable to ordinary shareholders, basic and diluted</a></td>
<td class="nump">$ 6,995,000<span></span>
</td>
<td class="num">$ (39,004,000)<span></span>
</td>
<td class="num">$ (41,257,000)<span></span>
</td>
<td class="num">$ (118,114,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to ordinary shareholders basic</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders basic.</a></td>
<td class="nump">106,025,063<span></span>
</td>
<td class="nump">93,900,484<span></span>
</td>
<td class="nump">104,529,266<span></span>
</td>
<td class="nump">73,754,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to ordinary shareholders diluted.</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders diluted</a></td>
<td class="nump">106,975,231<span></span>
</td>
<td class="nump">93,900,484<span></span>
</td>
<td class="nump">104,529,266<span></span>
</td>
<td class="nump">73,754,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 7,252,000<span></span>
</td>
<td class="num">$ (39,004,000)<span></span>
</td>
<td class="num">$ (41,257,000)<span></span>
</td>
<td class="num">$ (118,114,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(32,000)<span></span>
</td>
<td class="num">(76,000)<span></span>
</td>
<td class="num">(153,000)<span></span>
</td>
<td class="num">(304,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 7,220,000<span></span>
</td>
<td class="num">$ (39,080,000)<span></span>
</td>
<td class="num">$ (41,410,000)<span></span>
</td>
<td class="num">$ (118,418,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_NetIncomeLossAvailableToCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) available to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_NetIncomeLossAvailableToCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659087876080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Equity Program [Member]</div></th>
<th class="th"><div>Series A Preferred Shares [Member]</div></th>
<th class="th"><div>Ordinary Shares [Member]</div></th>
<th class="th">
<div>Ordinary Shares [Member] </div>
<div>At-The-Market Equity Program [Member]</div>
</th>
<th class="th"><div>Additional Paid-In-Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 32,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,980<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="num">$ (805,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,841,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">3,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares under the ESPP</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(37,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,814)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,951<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(843,328)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,859,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">32,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,980<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(805,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,841,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(118,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="num">(4,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,535<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(923,628)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">86,841,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,951<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(843,328)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,859,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">51,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,464,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants , net of offering costs.</a></td>
<td class="nump">14,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">6,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(41,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">30,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,169<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(884,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,724,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares under the ESPP</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(39,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,004)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="num">(4,519)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,535<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(923,628)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">86,841,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(45,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,442<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(967,337)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,924,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">$ 34,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,683,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares under the ESPP</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(27,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,405)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">(34,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 837,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,192<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(994,742)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,104,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(45,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,442<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(967,337)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,924,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (41,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="num">(40,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,885<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="num">(1,008,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">99,011,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">$ (34,714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 837,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,192<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(994,742)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,104,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">2,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(21,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">(51,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 839,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,601<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(1,015,846)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,566,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">2,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares under the ESPP</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">7,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,252<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="num">(40,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 841,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,885<span></span>
</td>
<td class="num">$ (182)<span></span>
</td>
<td class="num">$ (1,008,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">99,011,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="nump">$ 1,376<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock award vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659097155280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (41,257)<span></span>
</td>
<td class="num">$ (118,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">3,105<span></span>
</td>
<td class="nump">2,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">3,919<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7,443<span></span>
</td>
<td class="nump">14,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">418<span></span>
</td>
<td class="num">(835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,101)<span></span>
</td>
<td class="nump">3,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,953)<span></span>
</td>
<td class="nump">8,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(4,928)<span></span>
</td>
<td class="num">(3,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">62,299<span></span>
</td>
<td class="num">(2,006)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(3,947)<span></span>
</td>
<td class="num">(3,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">13,808<span></span>
</td>
<td class="num">(94,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(759)<span></span>
</td>
<td class="num">(1,157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(759)<span></span>
</td>
<td class="num">(26,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of offering costs</a></td>
<td class="nump">34,623<span></span>
</td>
<td class="nump">51,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of pre-funded warrants, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet', window );">Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of share options</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the ESPP</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">38,572<span></span>
</td>
<td class="nump">67,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">51,468<span></span>
</td>
<td class="num">(53,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">92,157<span></span>
</td>
<td class="nump">154,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">$ 143,625<span></span>
</td>
<td class="nump">100,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in operating lease right-of-use assets and lease liabilities related to lease extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,006<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in Operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of ordinary shares pursuant to at-the-market equity program net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659095539360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. THE COMPANY</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd. (together with its subsidiaries, &#8220;Wave&#8221; or the &#8220;Company&#8221;) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, Wave&#8217;s proprietary discovery and drug development platform that enables the precise design, optimization, and production of novel stereopure oligonucleotides, Wave is working to develop first- or best-in-class medicines that target the transcriptome (the full set of ribonucleic acid (&#8220;RNA&#8221;) molecules produced from the human genome) to treat diseases with a high degree of unmet need.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#8220;Wave USA&#8221;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#8220;Wave Japan&#8221;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (&#8220;Wave Ireland&#8221;) was formed as a wholly</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (&#8220;Wave UK&#8221;) was formed as a wholly</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company&#8217;s differentiated portfolio, building the Company&#8217;s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#8217;s intellectual property, and assuring adequate capital to support these activities.</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has not generated any product revenue and has incurred recurring operating losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include upfront and milestone payments from collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategy.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects that its existing cash and cash equivalents will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company&#8217;s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#8217;s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#8217;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#8217;s research and development efforts will be successful, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and in U.S. dollars.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659094893632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies described in the Company&#8217;s audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 23, 2023, as amended (the &#8220;2022 Annual Report on Form 10-K&#8221;), have had no material changes during the nine months ended September 30, 2023, except as described below.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company&#8217;s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company&#8217;s analysis of contracts with contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions and conditions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Data</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim consolidated balance sheet as of September 30, 2023, the related interim consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of Series A preferred shares and shareholders&#8217; equity (deficit) for the three months ended March 31, June 30, and September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2023 and 2022 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or any other interim period or future year or period.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659092760336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.304%;"></td>
        <td style="width:2.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.145%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.145%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,457</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12,287</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses related to CROs and CMOs</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,080</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,516</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,087</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,749</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12,624</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17,552</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659096281200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. SHARE-BASED COMPENSATION</span></p><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2021 Equity Incentive Plan was approved by the Company&#8217;s shareholders and went into effect on August 10, 2021 and was amended effective as of August 9, 2022 and August 1, 2023 (as amended, the &#8220;2021 Plan&#8221;). The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#8220;2014 Plan&#8221;), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan was originally </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,450,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, and was subsequently increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11,450,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17,950,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in August 2022 and August 2023, respectively, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2021 Plan authorizes (and the 2014 Plan previously authorized) the board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (&#8220;RSUs&#8221;), and performance awards to eligible employees and directors of the Company. The Company accounts for grants to its non-employee directors as grants to employees.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options generally vest over periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_59cf8e65-320f-4b29-af97-3896ca1e1d01;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_540eabce-9c76-47de-9406-1bc8ab641938;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f5411f6a-e73e-4d8f-a9d0-7e8d4a09dbbe;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, the Company granted an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5,646,300</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to employees and non-employee directors and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">152,475</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> time-based RSUs to employees.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,124,732</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ordinary shares remained available for future grant under the 2021 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below shows the options and RSUs outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.56%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.8%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14,238,590</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,732,711</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">633,283</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">999,771</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan, as amended (the &#8220;ESPP&#8221;) allows full-time and certain part-time employees to purchase the Company&#8217;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning every January 15th and July 15th. Ordinary shares are purchased at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s ordinary shares on the first business day or the last business day of an offering period. The aggregate number of ordinary shares authorized for issuance under the ESPP was originally </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and was subsequently increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in August 2023. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">225,913</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares were issued under the ESPP. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,490,500</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares available for issuance under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659185761376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. COLLABORATION AGREEMENTS</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GSK Collaboration and Equity Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 13, 2022, Wave USA and Wave UK entered into a Collaboration and License Agreement (the &#8220;GSK Collaboration Agreement&#8221;) with GlaxoSmithKline Intellectual Property (No. 3) (&#8220;GSK&#8221;). Pursuant to the GSK Collaboration Agreement, Wave and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including an exclusive global license to WVE-006. The discovery collaboration component has an initial four-year research term and combines Wave&#8217;s proprietary discovery and drug development platform, PRISM, with GSK&#8217;s unique insights from human genetics and its global development and commercial capabilities. On January 27, 2023, the GSK Collaboration Agreement became effective, and GSK paid Wave an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Simultaneously with the execution of the GSK Collaboration Agreement, Wave entered into a Share Purchase Agreement (the &#8220;SPA&#8221;) on December 13, 2022, with Glaxo Group Limited (&#8220;GGL&#8221;), an affiliate of GSK, pursuant to which Wave agreed to sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,683,761</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of its ordinary shares to GGL at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.68</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the &#8220;GSK Equity Investment&#8221;). The GSK Equity Investment closed on January 26, 2023, following the completion of customary closing conditions. The ordinary shares purchased by GGL are subject to lock-up and standstill restrictions and carry certain registration rights, customary for transactions of this kind. The Company did not incur any material costs in connection with the issuance of the ordinary shares under the SPA.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Collaboration Agreement has three components:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An exclusive global license for GSK to WVE-006, the Company&#8217;s preclinical, first-in-class A-to-I(G) RNA editing candidate for alpha-1 antitrypsin deficiency, with development and commercialization responsibilities transferring to GSK </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after the Company completes the first-in-patient study (the &#8220;AATD Collaboration&#8221;). The Company will be responsible for preclinical, regulatory, manufacturing, and clinical activities for WVE-006 through the initial Phase 1/2 study, at the Company&#8217;s sole cost. Thereafter, GSK will be responsible for advancing WVE-006 through pivotal studies, registration, and global commercialization at GSK&#8217;s sole cost;</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discovery research collaboration which enables GSK to advance up to eight programs leveraging PRISM and the Company&#8217;s oligonucleotide expertise and discovery capabilities (the &#8220;Discovery Research Collaboration&#8221;); and </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A discovery collaboration which enables the Company to advance up to three programs leveraging targets informed by GSK&#8217;s novel insights (&#8220;Wave&#8217;s Collaboration Programs&#8221;). </span></div></div><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the GSK Collaboration Agreement, each party grants to the other party certain licenses to the collaboration products to enable the other party to perform its obligations and exercise its rights under the GSK Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the GSK Collaboration Agreement. The parties&#8217; exclusivity obligations to each other are limited on a target-by-target basis with regard to targets in the collaboration. GSK may terminate the GSK Collaboration Agreement for convenience, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the GSK Collaboration Agreement on a target-by-target basis if the other party, or a related party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product that is subject to the GSK Collaboration Agreement. In the event of any material breach of the GSK Collaboration Agreement by a party, subject to cure rights, the other party may terminate the GSK Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that GSK and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the GSK Collaboration Agreement and directed to a particular target, the Company may terminate the GSK Collaboration Agreement with respect to such target. Either party may terminate the GSK Collaboration Agreement for the other party&#8217;s insolvency. In certain termination circumstances, the Company would receive a license from GSK to continue researching, developing and manufacturing certain products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Collaboration Agreement, unless terminated earlier, will continue until the date on which: (i) with respect to a validation target, the date on which such validation target is not advanced into a collaboration program; or (ii) with respect to a collaboration target, the royalty term has expired for all collaboration products directed to the applicable collaboration target. The GSK Collaboration Agreement includes options to extend the research term for up to three additional years, which would increase the number of programs available to both parties. The Company will lead all preclinical research for GSK and the Company&#8217;s collaboration programs up to investigational new drug (&#8220;IND&#8221;)-enabling studies. The Company will lead IND-enabling studies, clinical development and commercialization for the Company&#8217;s collaboration programs. GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GSK Collaboration Agreement is managed by a joint steering committee in which both parties are represented equally. In addition, the AATD Collaboration is overseen by a joint development committee, a joint patent committee advises on intellectual property activities, and the Discovery Research Collaboration is overseen by a joint research committee. Both parties are represented equally for these committees and report to the joint steering committee.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term. The Company identified the following material promises under the arrangement: (1) the exclusive global license for WVE-006; (2) the research and development services for WVE-006 through the Phase 1/2 study; (3) the discovery research services under the Discovery Research Collaboration to perform target validation programs; (4) research and development license for the Discovery Research Collaboration; and (5) the research and development services for the GSK collaboration programs through completion of a candidate selection. The research and development services for WVE-006 were determined to not be distinct from the exclusive global license and should therefore be combined into a single performance obligation for the AATD Collaboration. The research and development services for the Discovery Research Collaboration were determined to not be distinct from the research and development license for the Discovery Research Collaboration and should therefore be combined into a single performance obligation. In addition, the Company determined that the option to advance up to eight programs from the Discovery Research Collaboration was priced at fair value and did not provide a material right to GSK.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on these assessments, the Company identified two performance obligations in the GSK Collaboration Agreement: (1) AATD Collaboration consisting of the research and development services through completion of the Phase 1/2 study and research and development license for WVE-006 and (2) Discovery Research Collaboration which consists of research and development services for validating the targets and license for research and development license for targets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the outset of the arrangement, the transaction price included fixed consideration of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in premium related to the GSK Equity Investment and the estimated variable consideration related to the additional target validation research funding. The Company allocated the estimated variable consideration to the Discovery Research Collaboration programs and</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">then </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocated the fixed consideration to the performance obligations on a relative standalone selling price basis. The Company determined that the GSK Collaboration Agreement did not contain a significant financing component. The program initiation fees to research and preclinically develop the GSK collaboration programs and the additional potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the GSK Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period, and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company developed the estimated standalone selling price for the global license for WVE-006, under the AATD Collaboration, using a discounted cash flow model. For the performance obligation associated with the research and development services under the Discovery Research Collaboration and the research and development services for WVE-006 under the AATD Collaboration, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with the AATD Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The revenue associated with the Discovery Research Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet. Additional funding related to the Company&#8217;s research activities related to Discovery Research Collaboration will be recorded as accounts receivable when contractually enforceable and recorded as deferred revenue, or as revenue as the services are provided.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023, the Company recognized revenue of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, under the GSK Collaboration Agreement using the input method described above.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue on September 30, 2023 is approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in current liabilities </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and approximately </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in long-term liabilities.</span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Collaboration and Equity Agreements</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA and Wave UK entered into a global strategic collaboration (the &#8220;Takeda Collaboration&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#8220;CNS&#8221;). The Takeda Collaboration provides the Company with at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">230.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in committed cash and Takeda with the option to co-develop and co-commercialize the Company&#8217;s CNS development programs in (1) Huntington&#8217;s disease (&#8220;HD&#8221;); (2) amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal dementia (&#8220;FTD&#8221;); and (3) the Company&#8217;s discovery-stage program targeting </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATXN3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of spinocerebellar ataxia 3 (&#8220;SCA3&#8221;) (collectively, &#8220;Category 1 Programs&#8221;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#8217;s disease and Parkinson&#8217;s disease (collectively, &#8220;Category 2 Programs&#8221;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as an upfront payment. Takeda also agreed to fund the Company&#8217;s research and preclinical activities in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by Wave that exceed that amount.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Simultaneously with Wave USA and Wave UK&#8217;s entry into the collaboration and license agreement with Takeda (the &#8220;Takeda Collaboration Agreement&#8221;), the Company entered into a share purchase agreement with Takeda (the &#8220;Takeda Equity Agreement,&#8221; and together with the Takeda Collaboration Agreement, the &#8220;Takeda Agreements&#8221;) pursuant to which it agreed to sell to Takeda </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,096,892</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of its ordinary shares at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54.70</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company did not incur any material costs in connection with the issuance of the shares.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#8220;Category 2 Research Term&#8221;). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> targets at </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any one time</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (&#8220;IND&#8221;)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company&#8217;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#8217;s research and preclinical activities in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda&#8217;s global commercial sales of products from each Category 2 Program.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Takeda Collaboration Agreement commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 2, 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Takeda may terminate the Takeda Collaboration Agreement for convenience on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">180</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#8217;s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Takeda Collaboration is managed by a joint steering committee in which both parties are represented equally. The joint steering committee is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and therefore were combined into a single performance obligation.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the outset of the arrangement, the transaction price included the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront consideration received and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. Prior to the Amendment (as defined below), revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation was recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 15, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the &#8220;Amendment&#8221;), which discontinued the Category 2 component of the Takeda Collaboration. The Category 1 Programs under the Collaboration Agreement remain in effect and are unchanged by the Amendment. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as full payment for reimbursable Category 2 Programs collaboration-budgeted research and preclinical expenses. The Company received this payment from Takeda related to the Category 2 component and recognized the full amount as collaboration revenue in the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company announced its decision to discontinue clinical development of WVE-004 for C9orf72-associated ALS and FTD (&#8220;C9 for ALS/FTD&#8221;), one of the Category 1 Programs. In July 2023, the joint steering committee that manages the Takeda Collaboration terminated C9 for ALS/FTD as a target under the collaboration (the &#8220;C9 Target&#8221;) and consequently Takeda and the Company&#8217;s rights and obligations under the Takeda Collaboration were terminated with respect to the C9 Target. As a result of the termination of the C9 for ALS/FTD Category 1 Program, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue during the three months ended September 30, 2023, which represented the remainder of the deferred revenue for the C9 for ALS/FTD Category 1 Program as of June 30, 2023.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company achieved a developmental milestone related to the HD Category 1 Program, which pertained to the positive results from a non-clinical study of WVE-003 in non-human primates (&#8220;NHPs&#8221;). As a result of achieving the milestone, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue during the three months ended September 30, 2023, which was not previously recorded in deferred revenue, as it was fully constrained at the inception of the Takeda Collaboration. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the achievement of the milestone is included in the current portion of accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has recognized revenue of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collaboration revenue under the Takeda Collaboration Agreement in the Company&#8217;s consolidated statements of operations and comprehensive income (loss). During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement, respectively. During the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized revenue of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement, respectively.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31.6</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included in current liabilities and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79.8</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included in long-term liabilities. The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in current liabilities and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is included in long-term liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each remaining Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each remaining Category 1 Program option upon Takeda&#8217;s exercise or termination of such option, or immediately as each option expires unexercised.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659100065360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Ordinary Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Ordinary Share</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. NET INCOME (LOSS) PER ORDINARY SHARE</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the two-class method to calculate its basic and diluted net income (loss) per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,093,656</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vested and exercisable pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;) outstanding to purchase ordinary shares for the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, provided that, unless and until the Company obtains shareholder approval for the issuance of the shares underlying the Pre-Funded Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of our ordinary shares beneficially owned by the holder (together with its affiliates) to exceed </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of our ordinary shares outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net income (loss) per share as the exercise price is negligible and the warrants are fully vested and exercisable.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic loss per share is computed by dividing net income (loss) attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net income (loss) per share when their effect is dilutive.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of as of September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,901,348</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Series A preferred shares outstanding; the Series A preferred shares are participating securities under the two-class method. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the nine months ended September 30, 2023 and the three and nine months ended September 30, 2022, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods and holders of Series A preferred shares do not participate in losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below sets forth the computation of the Company&#8217;s basic and diluted net income (loss) attributable to ordinary shareholders:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.663%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Numerator</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,252</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39,004</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41,257</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118,114</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Less: net income attributable to <br/>&#160;&#160;&#160;&#160;&#160;&#160;participating securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">257</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) attributable to ordinary <br/>&#160;&#160;&#160;shareholders, basic and diluted</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,995</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39,004</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41,257</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118,114</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Denominator</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br/>&#160;&#160;&#160;computing net income (loss) per share <br/>&#160;&#160;&#160;attributable to ordinary shareholders&#8212;basic</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106,025,063</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93,900,484</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104,529,266</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73,754,417</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of employee share plans</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">950,168</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br/>&#160;&#160;&#160;computing net income (loss) per share <br/>&#160;&#160;&#160;attributable to ordinary shareholders&#8212;diluted</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106,975,231</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93,900,484</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104,529,266</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73,754,417</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br/>&#160;&#160;ordinary shareholders&#8212;basic</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.07</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.42</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.39</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.60</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br/>&#160;&#160;&#160;ordinary shareholders&#8212;diluted</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.07</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.42</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.39</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.60</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes awards that were excluded from the computation of diluted earnings as their inclusion would have been anti-dilutive.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.58%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,470,166</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,332,977</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,303,670</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,907,290</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62,899</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">521,146</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85,648</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">802,355</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659188049360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. INCOME TAXES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three and nine months ended September 30, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company recorded an income tax benefit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million due to a provision to return adjustment in connection with the recent U.S. tax guidance relating to the capitalization of research and development expenditures. During the three and nine months ended September 30</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> income tax benefit or provision.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintained a full valuation allowance for the three and nine months ended September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in all jurisdictions due to uncertainty regarding future taxable income.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659095495056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Data<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_GeographicDataAbstract', window );"><strong>Geographic Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_GeographicDataDisclosureTextBlock', window );">Geographic Data</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. GEOGRAPHIC DATA</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#8217;s long-lived assets were located in the United States as of September 30, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_GeographicDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Geographic data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_GeographicDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_GeographicDataDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Geographic Data Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_GeographicDataDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659100068880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following related party transactions:</span></p><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company&#8217;s founders and a member of the Company&#8217;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand per month, plus reimbursement for certain expenses. In October 2022, the compensation committee of the Company&#8217;s board of directors granted Dr. Verdine a non-qualified share option for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">163,467</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares in lieu of cash as payment under this consulting agreement for the service period of October 1, 2022 through December 31, 2024, the monthly vesting of which is subject to Dr. Verdine&#8217;s continued service under the consulting agreement. </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, the Company engaged Shin Nippon Biomedical Laboratories Ltd. (&#8220;SNBL&#8221;), one of the Company&#8217;s shareholders, to provide approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain NHP contract research services to the Company. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company paid SNBL $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the aforementioned contract research services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During the three months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t make any payments to SNBL.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659096325168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company&#8217;s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company&#8217;s analysis of contracts with contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions and conditions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Data</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Data</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim consolidated balance sheet as of September 30, 2023, the related interim consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of Series A preferred shares and shareholders&#8217; equity (deficit) for the three months ended March 31, June 30, and September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2023 and 2022 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or any other interim period or future year or period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659100068880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.304%;"></td>
        <td style="width:2.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.145%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.145%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,457</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12,287</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses related to CROs and CMOs</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,080</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,516</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,087</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,749</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12,624</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17,552</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659096251744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Options and RSUs Outstanding</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below shows the options and RSUs outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.56%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.8%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14,238,590</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,732,711</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">633,283</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">999,771</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659094230400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Ordinary Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below sets forth the computation of the Company&#8217;s basic and diluted net income (loss) attributable to ordinary shareholders:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.663%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.644%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.523%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.969999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Numerator</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,252</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39,004</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41,257</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118,114</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;Less: net income attributable to <br/>&#160;&#160;&#160;&#160;&#160;&#160;participating securities</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">257</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) attributable to ordinary <br/>&#160;&#160;&#160;shareholders, basic and diluted</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6,995</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39,004</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41,257</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118,114</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Denominator</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br/>&#160;&#160;&#160;computing net income (loss) per share <br/>&#160;&#160;&#160;attributable to ordinary shareholders&#8212;basic</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106,025,063</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93,900,484</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104,529,266</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73,754,417</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effect of employee share plans</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">950,168</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br/>&#160;&#160;&#160;computing net income (loss) per share <br/>&#160;&#160;&#160;attributable to ordinary shareholders&#8212;diluted</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106,975,231</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93,900,484</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104,529,266</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73,754,417</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br/>&#160;&#160;ordinary shareholders&#8212;basic</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.07</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.42</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.39</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.60</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income (loss) per share attributable to <br/>&#160;&#160;&#160;ordinary shareholders&#8212;diluted</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.07</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.42</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.39</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.60</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Shares Excluded from Computation of Diluted Earnings</a></td>
<td class="text"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes awards that were excluded from the computation of diluted earnings as their inclusion would have been anti-dilutive.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.58%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.18%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.46%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Nine Months Ended September 30,</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9,470,166</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,332,977</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10,303,670</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,907,290</span></p></td>
        <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;">
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62,899</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">521,146</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85,648</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">802,355</span></p></td>
        <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659096466592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Company - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 139,942<span></span>
</td>
<td class="nump">$ 88,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659094190352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 8,457<span></span>
</td>
<td class="nump">$ 12,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses related to CROs and CMOs</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 12,624<span></span>
</td>
<td class="nump">$ 17,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659092199456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued</a></td>
<td class="nump">92,815<span></span>
</td>
<td class="nump">133,098<span></span>
</td>
<td class="nump">88,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,683,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,464,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_OptionsToEmployeesAndNonEmployeeDirectorsMember', window );">Options to Employees and Non-Employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,646,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_TimeBasedRestrictedStockUnitsMember', window );">Time-based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_EmployeeSharePurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares authorized for issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Ordinary shares reserved for issuance</a></td>
<td class="nump">2,490,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_SharePurchasePriceAtEqualToFairMarketValuePercentage', window );">Ordinary share purchase price at equal to fair market value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,950,000<span></span>
</td>
<td class="nump">11,450,000<span></span>
</td>
<td class="nump">5,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for future grant</a></td>
<td class="nump">8,124,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,124,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Minimum [Member] | Time-based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Maximum [Member] | Time-based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_SharePurchasePriceAtEqualToFairMarketValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share purchase price at equal to fair market value percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_SharePurchasePriceAtEqualToFairMarketValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wve_OptionsToEmployeesAndNonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wve_OptionsToEmployeesAndNonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wve_TimeBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wve_TimeBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wve_EmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wve_EmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wve_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wve_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659096511296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase ordinary shares</a></td>
<td class="nump">14,238,590<span></span>
</td>
<td class="nump">9,732,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs</a></td>
<td class="nump">633,283<span></span>
</td>
<td class="nump">999,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659086576336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">68 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>Target </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,380<span></span>
</td>
<td class="nump">$ 79,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,623<span></span>
</td>
<td class="nump">$ 51,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,214<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">84,249<span></span>
</td>
<td class="nump">2,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Collaboration and license agreement, deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,251<span></span>
</td>
<td class="nump">31,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=wve_GSKEquityInvestmentMember', window );">GSK Equity Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under equity agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,683,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_FundReceivableForResearchAndPreclinicalActivities', window );">Fund receivable for research and preclinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_UpFrontConsiderationReceived', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_GskCollaborationAgreementMember', window );">GSK Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAgreementUpfrontPayment', window );">Upfront payment under collaboration agreement</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAgreementInPremium', window );">Collaboration Agreement in Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Collaboration and license agreement, deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Collaboration and license agreement, deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Category One Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio', window );">Percentage of global costs and potential profits sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAgreementUpfrontPayment', window );">Upfront payment under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementMonthAndYear', window );">Collaboration and license agreement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_FundReceivableForResearchAndPreclinicalActivities', window );">Fund receivable for research and preclinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementResearchTerm', window );">Research term under collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAgreementCommencementDate', window );">Collaboration agreement commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  02,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_MaximumTerminationNoticePeriod', window );">Collaboration agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAgreementCommittedCash', window );">Collaboration agreement, committed cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,100<span></span>
</td>
<td class="nump">79,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio', window );">Percentage of global costs and potential profits sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementDate', window );">Collaboration and License Agreement Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,900<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">36,900<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">118,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Collaboration and license agreement, deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400<span></span>
</td>
<td class="nump">111,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Collaboration and license agreement, deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 31,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_FundReceivableForResearchAndPreclinicalActivities', window );">Fund receivable for research and preclinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementResearchTerm', window );">Research term under collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_MaximumTargetsForPreclinicalPrograms', window );">Maximum targets for preclinical programs | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_OptionToReachMaximumTargetsForPreclinicalPrograms', window );">Option to reach maximum targets for preclinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">any one time<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_CollaborationBudgetedResearchAndPreclinicalExpenses', window );">Collaboration-budgeted research and preclinical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember', window );">Collaboration and Share Purchase Agreements [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under equity agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,096,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear', window );">Equity investment agreement official closure month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_C9AlsFtdProgramMember', window );">C9-ALS/FTD Program [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from termination of collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable', window );">Acheivement of milestone included in current portion receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember', window );">Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from termination of collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acheivement of milestone included in current portion receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementCommittedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement committed cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementCommittedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementInPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement in premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementInPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAndLicenseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAndLicenseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAndLicenseAgreementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAndLicenseAgreementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAndLicenseAgreementResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement research term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAndLicenseAgreementResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationBudgetedResearchAndPreclinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>collaboration-budgeted research and preclinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationBudgetedResearchAndPreclinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity investment agreement official closure date month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_FundReceivableForResearchAndPreclinicalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund receivable for research and preclinical activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_FundReceivableForResearchAndPreclinicalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_MaximumTargetsForPreclinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum targets for preclinical programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_MaximumTargetsForPreclinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_MaximumTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_MaximumTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_OptionToReachMaximumTargetsForPreclinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to reach maximum targets for preclinical programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_OptionToReachMaximumTargetsForPreclinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of global costs and potential profits sharing ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_UpFrontConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-front consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_UpFrontConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=wve_GSKEquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=wve_GSKEquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_GskCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_GskCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wve_CategoryOneProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wve_CategoryOneProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wve_CategoryTwoProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wve_CategoryTwoProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_C9AlsFtdProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_C9AlsFtdProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659098074144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Ordinary Share (Additional Information) (Details) - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A preferred stock, shares outstanding</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A preferred stock, shares outstanding</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=wve_PreFundedWarrantsMember', window );">Pre Funded Warrants (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-funded warrant outstanding</a></td>
<td class="nump">7,093,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding', window );">Minimum percentage of combined voting power of securities outstanding immediate effect of exercise</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest in ordinary shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=wve_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=wve_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659097889440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Ordinary Share - Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 7,252<span></span>
</td>
<td class="num">$ (21,104)<span></span>
</td>
<td class="num">$ (27,405)<span></span>
</td>
<td class="num">$ (39,004)<span></span>
</td>
<td class="num">$ (41,296)<span></span>
</td>
<td class="num">$ (37,814)<span></span>
</td>
<td class="num">$ (41,257)<span></span>
</td>
<td class="num">$ (118,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Less: net income attributable to participating securities</a></td>
<td class="num">(257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_NetIncomeLossAvailableToCommonStockholders', window );">Net income (loss) attributable to ordinary shareholders, basic and diluted</a></td>
<td class="nump">$ 6,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,257)<span></span>
</td>
<td class="num">$ (118,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders-basic</a></td>
<td class="nump">106,025,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,900,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,529,266<span></span>
</td>
<td class="nump">73,754,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of employee share plans</a></td>
<td class="nump">950,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders-diluted</a></td>
<td class="nump">106,975,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,900,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,529,266<span></span>
</td>
<td class="nump">73,754,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to ordinary shareholders-basic</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (1.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share attributable to ordinary shareholders-diluted</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (1.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_NetIncomeLossAvailableToCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income (loss) available to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_NetIncomeLossAvailableToCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659087733856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Earnings (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted earnings</a></td>
<td class="nump">9,470,166<span></span>
</td>
<td class="nump">8,332,977<span></span>
</td>
<td class="nump">10,303,670<span></span>
</td>
<td class="nump">7,907,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from computation of diluted earnings</a></td>
<td class="nump">62,899<span></span>
</td>
<td class="nump">521,146<span></span>
</td>
<td class="nump">85,648<span></span>
</td>
<td class="nump">802,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659098068576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">$ 677,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 677,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember', window );">U.S. Tax Guidance Relating to Capitalization of Research and Development Expenditures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139659098030544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ScientificAdvisorMember', window );">Scientific Advisor [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_AgreementTerminationNoticePeriod', window );">Consulting agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting service expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ScientificAdvisorMember', window );">Scientific Advisor [Member] | Consulting Agreement [Member] | Service Period of October 1, 2022 Through December 31, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Non-qualified share option granted for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ShinNipponBiomedicalLaboratoriesLtdMember', window );">Shin Nippon Biomedical Laboratories Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Contract research services</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wve_PaymentsRelatedToContractResearchServices', window );">Payments related to contract research services.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_PaymentsRelatedToContractResearchServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to contract research services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_PaymentsRelatedToContractResearchServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ScientificAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ScientificAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=wve_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=wve_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_ServicePeriodOfOctober12022ThroughDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_ServicePeriodOfOctober12022ThroughDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ShinNipponBiomedicalLaboratoriesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ShinNipponBiomedicalLaboratoriesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>wve-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:wve="http://www.wavelifesciences.com/20230930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wve-20230930.xsd" xlink:type="simple"/>
    <context id="C_b0103dac-17ed-4d3e-b978-10b5e0f32584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_c3f6c33e-1898-4179-94ee-85f8a300f503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_59ab39c1-8765-403a-8d50-7defda76d4c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_031576dd-6bf3-4f90-aea3-59700962dfb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ec9ca9b5-ccad-4c2b-9ec4-b7bea741597b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:C9AlsFtdProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_a97c8ae9-b044-4820-96e5-a71d47eaadf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_e6729cef-6185-408f-8064-d6b87f459534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_60b075bf-4787-4dda-9217-73cdf8491478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_201df0c5-2f9f-47b0-8746-12e41626744b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_8020a29b-f7f7-45cc-88f8-6951be62c024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76f837ad-ce37-4a72-b121-93223dc95d69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7a8994db-d61b-431c-a197-e1e739d2ccf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_a04b64a0-15b9-4cd7-a1a3-3e35f0aae6c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_d76d5b9d-2f04-4715-8806-517e6f2315cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_373691fb-08ed-497e-9cf8-b3671c52971a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_7f906dd5-bc79-446d-adfc-71bac06784f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0f8ac8dc-ad38-47bb-bee3-820517d4de91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_fc35d10c-0d48-4c9e-abb1-dc91feb594a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:GSKEquityInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="C_570400f0-19c4-42b7-ba7f-514509f5a992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:EmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_1f8ea7fd-3044-4c36-9304-529ddf0e84c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_3abbdbcd-9d9e-40d7-bd45-c1f8652ed620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_604ade02-22f4-4b35-9117-540972b59c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">wve:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ScientificAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_cd2a4a95-ce73-44cb-9465-c2c5da963d29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_ec472920-af11-4b8e-ab46-31b361f6eeb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_833bb004-b15e-4e44-9c08-c7223704a04a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5ee08ac2-8a9a-4c40-92e9-b73ab7051fa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:OptionsToEmployeesAndNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_8ceac785-d0e4-4aac-b036-774e9a55619b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_43e449a1-c4a0-4f65-a9bf-139d62938bee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_9d5aa44f-3484-4f2c-b16b-289c55dc6ac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_50ef92aa-d66d-4705-8a6c-621cfb4e0838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_ea2de7e1-ba02-4ca3-bc26-5a09679f28d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:C9AlsFtdProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_7e637694-fa20-42ed-887e-0196d4053e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_5b444e81-468e-4a28-afad-15b895940ca5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_feb4d052-987c-4678-af34-398b68e10a90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_53b91417-a246-4bc6-83db-9e8a41010b3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_77f5b6ef-f560-4092-beba-520c88cb4208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="C_883042b4-2458-4bfa-b9a2-8b427c1b5850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_840fd055-64a1-4ec7-a0cc-cb9b2c7fb2fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="C_ac1fc334-0f8b-4953-924e-cff0d0ea9a58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0053e917-12df-482b-a1b1-4cf6b49da388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_057199ca-f556-4877-bcce-76b3e2df83a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_8257ee6a-7c25-48ed-80dd-852b2a1ee5f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_3191a85c-f3b2-48d6-8581-322638c1e7a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_069c6b44-6229-411e-bbb8-49186918c1be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_8adc395c-a848-43c3-81d7-7bf7b1af08f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_7ccbca11-eac3-41df-97e1-6373fedbb104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ca05b972-3868-479c-9caa-f39e6f757273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_3b49a495-e20c-4db7-93d9-124b08adfa81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_fcce8355-0cd7-4000-b527-e0b8174914e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_5140a810-8f0d-4fdc-a8ea-09de8f50f3ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_527f6f22-23ca-4707-bf9b-bef67aa616a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_a43e788a-cf11-428f-8ee5-ea64fab1594f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_ed60e8fb-2b52-4f3b-bd07-879599965982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_5bac94f8-c57f-4a0c-8372-0194e5de1432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_18bc13d9-5690-4a43-97b0-b95ab8bdc359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_560af56f-fc78-4a72-851b-af2add5880d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_eb7a3370-5e9c-4bba-9912-d41ddf5d3118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_6a37111d-91fa-4fde-b91f-100be35676a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_9bd1bce8-1ec5-4990-b178-f06fa824bbff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_a17689c5-8054-49b6-8e0c-c74a6d530b3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_57950620-43a2-4507-aaea-bddaf12233fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ShinNipponBiomedicalLaboratoriesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_33aa57c2-493d-4ba2-a29e-f3b3aff746a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_181f3afe-396d-4ffd-a95b-40aadae0a1b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_5335805a-7dbf-45b8-95e4-abf4ef8a5bc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_073c80a2-e6c4-48a5-8c06-850081b3c583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_5297058f-1335-4562-8740-d05d615ccae7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_94bdf4a5-d105-4b29-bf1b-6287987ba4ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_3237fbdb-d95d-4cfe-b9f1-61899a543f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_f6824cde-b172-405b-bbd6-fc57065305e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_e9be0c66-eeb0-4d40-b8a8-bef5175660c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ShinNipponBiomedicalLaboratoriesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_10087a5f-b7dd-4e5a-b0de-5322b540ff23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0e8e072b-2447-4085-9e05-53042061b71e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">wve:USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_7c2ffaa3-8a8f-48ce-9822-3cfeaeb473c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_2c12b888-5c51-44db-8ef5-cea86938cf76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_44ca1475-425a-4297-bd8a-940ba67acc8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:GSKEquityInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="C_718175b2-0b3b-4964-aae7-ad8959e6fab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3fd28c55-542d-4350-976c-ab012247df20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_00b8ed9d-656c-4ce6-a17b-1713a99a3935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">wve:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ScientificAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:ServicePeriodOfOctober12022ThroughDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_2219b93b-3833-4eb7-8a14-84b6377f1837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_b1cc32b4-5c83-4f9e-9124-5240a39712b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_f388230d-6596-4497-8c1d-93584b70794e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_984b526b-31b9-492a-a2fd-be71e501c555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_7ed5c27e-cc4c-49b1-84c5-c1e7b5ece75b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0423170f-46b0-46fd-9d6a-f9ddcaa37597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7f9d681a-3066-4ee8-9ecd-b527dd2f4e9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0fda8411-f581-4b47-ab60-7fcc4a2e2534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_929ba747-8e45-447c-88e7-e51ab1e75ceb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c5faabcb-be56-4b08-bc24-70fe0b903474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_88f078e5-7f55-4c1c-a31f-bbef6752eb47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_f3db33f7-84dd-4c09-bd63-ab26c7341876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_9c7c3c88-24e4-486a-88b6-f2916fcfb70c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_cf4df239-e091-4dea-a22c-442719bad5aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_3ac4d4e1-f240-4794-bcf4-e1187c6640aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_4d8668ee-4d05-4c91-8b3d-392dfe7aafc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_f171fb21-e8be-445f-a99b-bee1ca07227d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_c7648e40-cd9d-4899-a7d2-538b38a342e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="C_3d27d437-20db-40a7-8a31-79dc5b79363e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_21febb15-521e-425b-9fd0-a8ee30908050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3160b90d-92fd-4f20-8899-bd69ca3f321d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_8d17bd9b-fc3b-4ebf-a913-cc842346df8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_031a13b4-1502-40ec-87b3-130a5d96f105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_c5edc625-147f-4242-abcb-34c2ad06e65c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_dbf83c0e-e95e-428b-ab66-63c3c348927d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ad580d82-9ef7-4699-b3e9-1f9292c5d61b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7e102754-2c0a-4b97-a8a7-084bee04df37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_60168293-95c2-4194-a4bf-2c7a29d5b380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_ba4f1a9d-c900-4002-8f99-c4ecdde3a741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_c39743c8-fdc8-49a0-ab6b-18dcad1a2377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="C_48607354-e4f1-4154-a753-18ac7e90279b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_55d600e9-4b00-4f6b-9908-ad3bd243a1bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_6a3a2265-ad67-4510-96a2-aae424a5f323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_5fe920df-49d4-4e5f-a9a3-7bb9c0f95914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:GskCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-27</startDate>
            <endDate>2023-01-27</endDate>
        </period>
    </context>
    <context id="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_6400cc97-e4a5-49ec-8444-d2e2844fe3ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_2b385b66-69ef-4b47-a1f9-aaee7fd51b80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_e729bf0c-f0b3-47e5-a084-8d1595c64779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_2fe29c86-e07c-4543-8cde-57f6ad77b97d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_d16ff73c-b9ec-427d-b56c-2031a5ccc0f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_2f99c07b-5657-4e59-9506-e7a0651e9e56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_fb5251fa-7c39-49df-b15b-5c68f20d47c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_fda03e0b-63d3-4280-b99e-297c22e0b692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">wve:USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_deb104c1-49f6-405f-aa32-79ca3de0a224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_fc3001b7-e63c-414e-93fa-1a04b0fba6dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_3135871c-4f8d-45bd-ac2a-b5c1f0447408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_878fd094-b224-474e-b2c6-88e67084090b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="C_2ed14954-a596-4947-9acd-47caf500b6f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_5bc05ff7-8cc5-4878-970b-926a4d26e663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_ffc4f0bd-1ed1-49eb-882b-b9fd1a18891e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ShinNipponBiomedicalLaboratoriesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_92b7c4c9-c8c0-4b4a-8126-4f88d02330de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_dca3ae87-1bee-4d72-a16c-3f7596e1d46d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_aaeb1ca3-95e6-48fb-8268-9d462b4bf5df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_6b5223d2-51e2-46ce-b962-d9b615c02b42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_5d950313-80c4-4f92-b61d-13e608cecd5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Target">
        <measure>wve:Target</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_8beb7387-5c79-44d8-9b5b-f7bd6eee8e48">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_20c50bbd-0950-4405-a41c-46113e32956a">0001631574</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_852bd4e7-289f-4cfe-856d-d2b7add5b5fe">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_f88d25c5-cb9d-4ddf-8e17-5b60ded6d0c5">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_55d600e9-4b00-4f6b-9908-ad3bd243a1bd"
      id="F_59cf8e65-320f-4b29-af97-3896ca1e1d01">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_55d600e9-4b00-4f6b-9908-ad3bd243a1bd"
      id="F_540eabce-9c76-47de-9406-1bc8ab641938">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_9c7c3c88-24e4-486a-88b6-f2916fcfb70c"
      id="F_f5411f6a-e73e-4d8f-a9d0-7e8d4a09dbbe">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_b457ccaf-189d-41a6-840e-703789ce31af">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_b72ff4c2-4b59-48b6-b4e3-4a78bb0c718e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_2bd37342-34c8-4372-9b14-ea6995759809">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_41ad8ee9-e7fb-4c9b-be33-eb1fc0d10c2e">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_68053579-28c2-421f-872a-eac4e27b1085">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_ee797c8e-b2e7-4c3d-a99a-faa29af8eb04">001-37627</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_c41072ab-797e-491e-b325-df109f37b662">WAVE LIFE SCIENCES LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_89cdbb8d-f40d-4d23-a25e-1d9a6c014622">U0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_0f0b5efa-634b-4e8a-a7f8-4cbccecb43ce">98-1356880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_f47ca9e5-f762-4174-be94-e662b9410854">7 Straits View #12-00</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_398a1857-1a31-4bd7-8455-40d4e38bdece">Marina One</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_028f8256-e9fa-4553-99e4-bb19eb797350">East Tower</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_ecffe5e1-e04b-46ac-a90d-e27081b632b7">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_cdab9d2e-a36d-4181-9026-9423ad9f7036">018936</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_05bd1b37-a1e7-416e-b597-75a3d5952895">+65</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_5d89cca2-7725-40cd-80ca-706c6bce3470">6236 3388</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_29f97c98-8867-4d01-8167-470cc08a02fc">$0 Par Value Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_2fbfc50f-4944-4f3f-a5b6-d55a1d83ccfa">WVE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_83217c28-40de-4389-8793-724d651bdd51">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_9930f141-b2f5-43c7-9adf-92d1307f4083">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_70abb957-5c94-47a3-8f22-3a5995f40125">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_49c57d31-88d0-42ac-bd01-12618cb5c02f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_57514f7a-648e-4778-aa68-d21c50383e9f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_38390a94-c608-4895-8eca-2dc137ac8029">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_d9fe96d1-7b8e-47d6-810c-7b659b2b3cd9">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_c39743c8-fdc8-49a0-ab6b-18dcad1a2377"
      decimals="INF"
      id="F_fef5da68-e179-4a1c-a1ea-a4d2941d5f55"
      unitRef="U_shares">99053902</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_b15ced6c-2b0e-4249-b8cc-0605a74c8ede"
      unitRef="U_USD">139942000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_99ed6dfc-c247-49c5-a45e-6819d6956059"
      unitRef="U_USD">88497000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_1dce024e-20d8-40ce-9529-d4780e64262d"
      unitRef="U_USD">7000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_24962636-9f68-4e4a-9497-b8144025a1d7"
      unitRef="U_USD">7514000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_5521839c-fbb6-4f24-b5c8-094a8b3b9a08"
      unitRef="U_USD">7932000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_2de03b90-7963-4fa5-a5cd-758a83820cf9"
      unitRef="U_USD">4116000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_adfe3a5b-2ed1-448f-87e5-df26f363a2af"
      unitRef="U_USD">2108000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_a8dffef2-a7f6-4d22-83ae-c77a7a231ad6"
      unitRef="U_USD">158572000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_2616aac3-d69a-4e50-a51a-de2be45f2931"
      unitRef="U_USD">98537000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_fae316f6-b095-4179-a5e1-dd128dda567d"
      unitRef="U_USD">41596000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_5587cf49-35d1-4a88-bc10-ca1e57794900"
      unitRef="U_USD">37846000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_377635b0-02a0-43aa-a9ac-9378892b1114"
      unitRef="U_USD">13770000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_1813a412-b522-476a-aef4-ad650396eaab"
      unitRef="U_USD">17284000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_f341b771-157c-4a84-b3a3-b8c8df13b677"
      unitRef="U_USD">23738000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_e9b26805-dbe7-49cc-8235-81cdb4483096"
      unitRef="U_USD">26843000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_49ba01a4-492b-42c0-9124-824a1fe01806"
      unitRef="U_USD">3683000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_c4e6948a-dd3f-4911-98d1-0912bc1736df"
      unitRef="U_USD">3660000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssets
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_8374c218-1e5d-4ead-8830-9ba70824de1f"
      unitRef="U_USD">155000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_8bcf6ec8-0a7d-4759-8fd9-1db0e3af5645"
      unitRef="U_USD">62000</us-gaap:OtherAssets>
    <us-gaap:AssetsNoncurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_03d5f2e1-7916-4f9d-86a0-465f154aa732"
      unitRef="U_USD">41346000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_d5f7c389-85e7-4881-bc9b-d8dcbdd75344"
      unitRef="U_USD">47849000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_b811521e-ccad-4cf2-a68b-271edc7f27f1"
      unitRef="U_USD">199918000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_5aeefb22-8e2d-478a-92a1-54817f878a88"
      unitRef="U_USD">146386000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_905f174a-1e1d-429f-bc0f-4b605b0fc967"
      unitRef="U_USD">12608000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_48a8e820-924b-4a3c-be9d-f5ac4e8e23c8"
      unitRef="U_USD">16915000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_2f3dd5b8-1c42-4135-9e44-e08f97bb9ce2"
      unitRef="U_USD">12624000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_1901132b-8714-42a7-9be8-f06f7fbd58d7"
      unitRef="U_USD">17552000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_8877b8ee-d46b-46bd-b0a4-9a84669718fc"
      unitRef="U_USD">68251000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_1a8f133d-fabc-4a7e-be89-4eddda344012"
      unitRef="U_USD">31558000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_d129644e-9a1a-4807-ab7b-3dc4a4eb801c"
      unitRef="U_USD">6497000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_aa4cd2ce-502e-4c7d-82d9-ca71054d735c"
      unitRef="U_USD">5496000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_5e701ad2-ee07-4d3d-83b9-5daaf8c82090"
      unitRef="U_USD">99980000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_613ab02a-0a00-48b4-add5-c0157446c8af"
      unitRef="U_USD">71521000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_fb0b2d49-c645-4100-aaf3-e462e950884a"
      unitRef="U_USD">105380000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_cf4a99bb-579b-42b2-87a3-c5dd6ae94ce1"
      unitRef="U_USD">79774000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_6444d933-d453-423a-abb1-09f3eb0480c8"
      unitRef="U_USD">27170000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_758bdabe-5e4b-4f45-b5b8-0f046d109018"
      unitRef="U_USD">32118000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_5d190652-f34e-4470-aa6e-b8a3044585cf"
      unitRef="U_USD">190000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_9f8a72ec-afcb-4b11-b615-53549bfacc03"
      unitRef="U_USD">132550000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_c6a49589-b656-440f-8a54-234a8ce69355"
      unitRef="U_USD">112082000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_7c141377-628b-4522-80f0-a533a035e901"
      unitRef="U_USD">232530000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_6190d0f5-1321-43cd-b3eb-faf81bf98c76"
      unitRef="U_USD">183603000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_a147626c-1bc1-43ca-9870-35dd1a52ff4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="INF"
      id="F_43a3a73b-87da-4c5d-b7b8-b41d2cc19eae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="INF"
      id="F_9b547dbe-c519-4aeb-ab53-79a182ddcfe0"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_07cd0f9a-7175-483d-9ecb-37a73adafa7b"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_475448fc-dff8-4621-84b1-ba0c04ebbc9c"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="INF"
      id="F_5d760e63-24b6-463e-a506-b4d3bd997956"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_74290b93-4132-452c-9f35-8bbaa8e506f0"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_65738fce-ec62-40a8-ba1c-6c93ed72da10"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockNoParValue
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_a33064ad-19c1-424a-b407-be2d2b89285d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="INF"
      id="F_46e0cc51-2dba-48de-b68f-67da97030226"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_458d8d76-3941-4af9-a3b6-3ef999685287"
      unitRef="U_shares">99011901</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_0ded6d67-d539-4a07-88bb-c9d891326a89"
      unitRef="U_shares">99011901</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="INF"
      id="F_bc2102f4-cb80-4010-bad8-8fa54f970e6b"
      unitRef="U_shares">86924643</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="INF"
      id="F_20897ae3-5ab9-4d84-91ee-a81802e324b5"
      unitRef="U_shares">86924643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_2643e669-0581-4ea5-b3e3-8e6974b85bd3"
      unitRef="U_USD">841405000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_24907302-02c0-4624-b280-d93438dd2d26"
      unitRef="U_USD">802833000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_4477c510-af63-41fd-9d88-7d2b59c333a7"
      unitRef="U_USD">126885000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_c73b375b-8165-403c-9deb-657ed95baf6b"
      unitRef="U_USD">119442000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_5ba40856-909c-42d9-a9f4-9a7773c6bca6"
      unitRef="U_USD">-182000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_cb9ff337-043e-4740-a326-50ec0371c41b"
      unitRef="U_USD">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_6150f40c-1d0e-4a65-befb-eabe4a504093"
      unitRef="U_USD">-1008594000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_b788f0b9-837a-4d8a-a828-2af2b21df2bd"
      unitRef="U_USD">-967337000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_ec21da53-509c-4939-b318-8a3d7411dd4c"
      unitRef="U_USD">-40486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_9f95c2a8-2b6e-4b52-aa35-5dee1ee250e2"
      unitRef="U_USD">-45091000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_b6edca20-414b-43f2-bd2d-acce3fcefa50"
      unitRef="U_USD">199918000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_5304eead-60d1-4fc2-a25f-634a904cac45"
      unitRef="U_USD">146386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_00429002-dac2-4570-82da-8b14f3e31fd1"
      unitRef="U_USD">49214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_93d4a342-3e46-43a4-b916-0630d7efda77"
      unitRef="U_USD">285000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_9cc5786e-1591-402a-9a4e-4b1cc0c1d628"
      unitRef="U_USD">84249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_85687675-a163-496a-af17-cded196e6196"
      unitRef="U_USD">2410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_f5964c29-3a3a-43e4-9f2f-e027ab47fce8"
      unitRef="U_USD">31642000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_17493a6f-3680-4d15-89f8-e40b975f34ee"
      unitRef="U_USD">27575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_b7354a19-5c4d-4b01-9f76-953b68fe2df0"
      unitRef="U_USD">95935000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_9d4c4557-b471-4a04-9f9c-23428cd40668"
      unitRef="U_USD">84778000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_60f6f84c-b74d-4008-b04e-8091db71af28"
      unitRef="U_USD">13128000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_f4d64782-4886-4a49-af22-2066c491b5a6"
      unitRef="U_USD">11609000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_a46f5640-5beb-4fc8-9fa3-d90a19a87362"
      unitRef="U_USD">37628000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_80528a2b-7880-469e-927e-7f997d89798d"
      unitRef="U_USD">36789000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_0bd6e3c2-4e58-435c-aa6a-508fce22428b"
      unitRef="U_USD">44770000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_9d47c019-cf87-413d-b86a-256bae7e078c"
      unitRef="U_USD">39184000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_561fe215-096d-4cff-a823-2cf6704ac50d"
      unitRef="U_USD">133563000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_5a8038ea-115c-4e5f-92e3-cf51d73e0117"
      unitRef="U_USD">121567000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_8c8e25df-9526-42ba-9b8f-e02aac2417f1"
      unitRef="U_USD">4444000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_0d4f6b8a-5d22-4053-a315-99382be5dda5"
      unitRef="U_USD">-38899000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_c29d445e-0900-4109-8a77-763d6962fb52"
      unitRef="U_USD">-49314000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_21a809aa-cbb2-43ee-a49e-1c5eeb7cc27b"
      unitRef="U_USD">-119157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_97707880-9252-49f0-b959-8ef4708f3373"
      unitRef="U_USD">1960000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_3b3b0920-9bab-4314-8c64-e0a7cd97bc19"
      unitRef="U_USD">596000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_cc3c7fd8-e1de-4a1e-899c-24f64e45130c"
      unitRef="U_USD">6084000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_21158d4b-40d2-4350-bfd9-6b363c24afd1"
      unitRef="U_USD">746000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_700032e7-18ce-4491-bf63-ec6b5c6f08ab"
      unitRef="U_USD">171000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_1a7b519b-eeaa-4506-86a0-257cbdaf7198"
      unitRef="U_USD">-701000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_95bfec7a-1d9d-4619-ac0e-da0f16212198"
      unitRef="U_USD">1296000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_558ca743-642f-433d-9a59-0270f94b2953"
      unitRef="U_USD">297000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_bf1bc1be-58dc-4251-96a3-5aed94a439d6"
      unitRef="U_USD">2131000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_c5957e1e-5892-4053-bddf-3e2c2a72db7b"
      unitRef="U_USD">-105000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_de884102-d85c-4366-a919-6852a9d42804"
      unitRef="U_USD">7380000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_6655ffaf-1ad5-4292-b4f5-bdfde3fa74af"
      unitRef="U_USD">1043000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_20f99965-394f-4c9e-9ec7-3dea6321e1d0"
      unitRef="U_USD">6575000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_698b8e21-376b-480d-8434-f0e06458d28b"
      unitRef="U_USD">-39004000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_b30e371c-26f0-4f57-a2f3-4d1733187d10"
      unitRef="U_USD">-41934000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_6808731f-61ab-477f-a19f-ae1ce0ad024b"
      unitRef="U_USD">-118114000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_34d6587e-5715-4d59-b983-966ea332a8f7"
      unitRef="U_USD">-677000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_85a46b16-2c8a-40c0-a9a5-bf976680a90a"
      unitRef="U_USD">-677000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_b0fd47f3-7c08-4f4a-87f9-a8ea943766b2"
      unitRef="U_USD">7252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_213dc01f-497b-4941-a792-f13580b09135"
      unitRef="U_USD">-39004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_12a894a1-ebea-47a5-b004-2d9a15a8b13d"
      unitRef="U_USD">-41257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_e2923c51-d1b9-401f-9a38-81f9396c8294"
      unitRef="U_USD">-118114000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_e0322cb7-6620-4090-b31f-ab90170356a7"
      unitRef="U_USD">-257000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_458d6c5e-a402-42b5-8cee-1a1f09deb0e5"
      unitRef="U_USD">6995000</wve:NetIncomeLossAvailableToCommonStockholders>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_50a85584-ff95-4e89-b20a-02d79601c8b6"
      unitRef="U_USD">-39004000</wve:NetIncomeLossAvailableToCommonStockholders>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_10dfbea4-0a56-4222-ba18-3ebf87ab4a12"
      unitRef="U_USD">-41257000</wve:NetIncomeLossAvailableToCommonStockholders>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_9604ac9a-fed4-4009-aaa2-cc4b9cd09deb"
      unitRef="U_USD">-118114000</wve:NetIncomeLossAvailableToCommonStockholders>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="2"
      id="F_fbfe3b78-6afd-4e67-a426-57c6d498d85c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="2"
      id="F_7a43c5f3-6e3e-43a3-9a7f-d2c52dd5eeed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="2"
      id="F_f107b48a-89af-4064-84b5-eed6ce2a8798"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="2"
      id="F_d7c7ba0f-9e6b-47d6-846b-c0a98bf31192"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="0"
      id="F_718a030c-a3ba-4d65-8674-874d40b98f33"
      unitRef="U_shares">106025063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="0"
      id="F_4313f334-9aac-4a8f-be5c-070defa1b135"
      unitRef="U_shares">93900484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="0"
      id="F_7d63d686-e1a0-43db-ae0c-962ad866f43e"
      unitRef="U_shares">104529266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="0"
      id="F_1f15b056-6ad4-4357-b80f-972ad40ec768"
      unitRef="U_shares">73754417</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="2"
      id="F_c103bc38-27fb-4b0c-9452-22961285c328"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="2"
      id="F_0813fb1d-8deb-4bce-a827-e9c08947df86"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="2"
      id="F_d28e3fdd-d717-433e-9c46-a54c6493e0dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="2"
      id="F_d167e66d-6d99-485c-b0ac-aa230b8d4942"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="0"
      id="F_03dd9a9b-d45d-4098-88ee-65076c0ae05a"
      unitRef="U_shares">106975231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="0"
      id="F_48dfa3a9-9093-4927-b919-99c6a748fa35"
      unitRef="U_shares">93900484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="0"
      id="F_26c4f817-e3eb-44f2-96f3-1b2683da3ead"
      unitRef="U_shares">104529266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="0"
      id="F_09f0b8a8-d8a4-4f18-a299-c3d95f2128c0"
      unitRef="U_shares">73754417</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_00598778-0c96-413d-afd7-cdefc1d04308"
      unitRef="U_USD">7252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_76a2925a-b954-4272-90eb-22deb14dd5ca"
      unitRef="U_USD">-39004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_d37fcb40-7cbb-4374-828a-52392a09505f"
      unitRef="U_USD">-41257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_4f673569-1331-442d-8169-d38a52767359"
      unitRef="U_USD">-118114000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_dcb81694-087f-47e6-8a2a-9ff348855e69"
      unitRef="U_USD">-32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_7e640d40-487e-4d17-a246-33725410ded9"
      unitRef="U_USD">-76000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_ce277d1b-9cc7-412a-886b-b39b64e3a31d"
      unitRef="U_USD">-153000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_bbef14a6-7682-4a75-a63e-f9dcd929a056"
      unitRef="U_USD">-304000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_3198c93d-cac1-4d8d-83cd-ff44d647ad11"
      unitRef="U_USD">7220000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_6f3ade78-b333-4fec-b0cd-bfd035f2cc59"
      unitRef="U_USD">-39080000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_5c6a0a49-434f-4e25-91ef-ce557ac60a82"
      unitRef="U_USD">-41410000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_78fc45ca-d1f6-414e-9700-3cbde2e33dd9"
      unitRef="U_USD">-118418000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_76f837ad-ce37-4a72-b121-93223dc95d69"
      decimals="INF"
      id="F_d69b9d54-d7b7-408d-aa4a-4c6d119c3860"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_76f837ad-ce37-4a72-b121-93223dc95d69"
      decimals="-3"
      id="F_042abf6b-d28d-4a37-9126-985e4cfdf327"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_dbf83c0e-e95e-428b-ab66-63c3c348927d"
      decimals="INF"
      id="F_b7c6d58f-c346-448d-ba8d-346b9e2411ee"
      unitRef="U_shares">59841116</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dbf83c0e-e95e-428b-ab66-63c3c348927d"
      decimals="-3"
      id="F_535dff10-3000-4208-a8ac-aadfb06bdfff"
      unitRef="U_USD">749851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_10087a5f-b7dd-4e5a-b0de-5322b540ff23"
      decimals="-3"
      id="F_145ea3f9-9727-4039-8bb3-1f53b815f61e"
      unitRef="U_USD">87980000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0423170f-46b0-46fd-9d6a-f9ddcaa37597"
      decimals="-3"
      id="F_d6a53068-63f5-4582-b3d2-abbc1382b595"
      unitRef="U_USD">181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8020a29b-f7f7-45cc-88f8-6951be62c024"
      decimals="-3"
      id="F_3349bf2a-3c5a-4849-a6df-43fd6c32a005"
      unitRef="U_USD">-805514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0053e917-12df-482b-a1b1-4cf6b49da388"
      decimals="-3"
      id="F_dcd596ef-cfba-41d7-8fb3-cea61f79c4de"
      unitRef="U_USD">32498000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a17689c5-8054-49b6-8e0c-c74a6d530b3e"
      decimals="INF"
      id="F_36170ef2-c88e-441d-92e5-71c0a0bfecb9"
      unitRef="U_shares">458092</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a17689c5-8054-49b6-8e0c-c74a6d530b3e"
      decimals="-3"
      id="F_e5e43989-af81-4e00-a97a-4f504df5d883"
      unitRef="U_USD">1167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_073c80a2-e6c4-48a5-8c06-850081b3c583"
      decimals="-3"
      id="F_d14f5088-2241-4964-8f90-d06b28aa7915"
      unitRef="U_USD">1167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_88f078e5-7f55-4c1c-a31f-bbef6752eb47"
      decimals="-3"
      id="F_be82eb22-5840-4c5a-b04e-799b993e856f"
      unitRef="U_USD">3971000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5"
      decimals="-3"
      id="F_c021445c-92d2-40e6-a062-59b474540e92"
      unitRef="U_USD">3971000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a"
      decimals="INF"
      id="F_70d93e1c-a20c-4189-8844-fa5153e38d3a"
      unitRef="U_shares">468226</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a"
      decimals="INF"
      id="F_51b98b81-f08a-4423-959f-a5c84d72c228"
      unitRef="U_shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a"
      decimals="-3"
      id="F_daa5e290-139e-4afe-95bd-30117101bf63"
      unitRef="U_USD">37000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5"
      decimals="-3"
      id="F_a2bb1a4d-816f-41a1-95ab-d73121e351ac"
      unitRef="U_USD">37000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a"
      decimals="INF"
      id="F_8b4c19ce-079d-4d3f-8287-1ee02755e193"
      unitRef="U_shares">77534</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0391fd63-e1f1-4a65-a6cf-2cda1024930a"
      decimals="-3"
      id="F_382a8b63-e88b-4be7-9a62-7fabc8707626"
      unitRef="U_USD">174000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5"
      decimals="-3"
      id="F_58381bbe-486f-4c8c-a753-38ba7b4560fe"
      unitRef="U_USD">174000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_18bc13d9-5690-4a43-97b0-b95ab8bdc359"
      decimals="-3"
      id="F_f2cc6c2f-6599-45a2-8718-c90a4eda6629"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5"
      decimals="-3"
      id="F_433bf3a9-664d-44cd-9891-a9fcfaf1a82c"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_7c2ffaa3-8a8f-48ce-9822-3cfeaeb473c7"
      decimals="-3"
      id="F_378c4bfa-6135-40c5-b2d4-e91e0451e521"
      unitRef="U_USD">-37814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ca76d726-01a8-4ea9-97ff-a84f86e604c5"
      decimals="-3"
      id="F_bf8255d9-fac7-4ed1-8ea3-8b2e26095855"
      unitRef="U_USD">-37814000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_3191a85c-f3b2-48d6-8581-322638c1e7a9"
      decimals="INF"
      id="F_957d12fa-b45b-4e8d-aa55-8647de766d2a"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_3191a85c-f3b2-48d6-8581-322638c1e7a9"
      decimals="-3"
      id="F_33201577-6ac4-421f-9c9c-022423ac3992"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_3ac4d4e1-f240-4794-bcf4-e1187c6640aa"
      decimals="INF"
      id="F_f828d421-3765-4267-a049-37f9e41faef1"
      unitRef="U_shares">60859968</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3ac4d4e1-f240-4794-bcf4-e1187c6640aa"
      decimals="-3"
      id="F_6e29c05e-10de-4180-bb83-13fa90f61541"
      unitRef="U_USD">751229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50ef92aa-d66d-4705-8a6c-621cfb4e0838"
      decimals="-3"
      id="F_b5e1ce05-9299-47ce-bab3-60d52c6b176f"
      unitRef="U_USD">91951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_94bdf4a5-d105-4b29-bf1b-6287987ba4ff"
      decimals="-3"
      id="F_25886973-08e8-4ac9-a630-1b93c6d7cec7"
      unitRef="U_USD">95000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9bd1bce8-1ec5-4990-b178-f06fa824bbff"
      decimals="-3"
      id="F_e1bebe8b-a897-42c6-a796-2ec3f1d7d9a8"
      unitRef="U_USD">-843328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2f99c07b-5657-4e59-9506-e7a0651e9e56"
      decimals="-3"
      id="F_d875fe0f-a37c-48f7-bed4-493b8eb50e01"
      unitRef="U_USD">-53000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e729bf0c-f0b3-47e5-a084-8d1595c64779"
      decimals="INF"
      id="F_22785eb1-c07e-40c4-a7e2-c44715cab69a"
      unitRef="U_shares">25464483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e729bf0c-f0b3-47e5-a084-8d1595c64779"
      decimals="-3"
      id="F_5ad0ff87-06ca-41ab-af34-2bdf00e0b483"
      unitRef="U_USD">51220000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c"
      decimals="-3"
      id="F_d981d10f-8452-40fc-923c-ca3d216a6938"
      unitRef="U_USD">51220000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_984b526b-31b9-492a-a2fd-be71e501c555"
      decimals="-3"
      id="F_2b0867f3-e134-4d05-a1cc-da14670f2099"
      unitRef="U_USD">14268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c"
      decimals="-3"
      id="F_75dbdf7d-e687-4cec-aa3e-b513fb0a6820"
      unitRef="U_USD">14268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_984b526b-31b9-492a-a2fd-be71e501c555"
      decimals="-3"
      id="F_7803a6ae-43e1-40f2-a58b-0e0af412b1c2"
      unitRef="U_USD">6950000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c"
      decimals="-3"
      id="F_dd78aaca-b5ee-4cdf-a033-68bfc8db47c7"
      unitRef="U_USD">6950000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_e729bf0c-f0b3-47e5-a084-8d1595c64779"
      decimals="INF"
      id="F_0922b64f-8c76-4b52-90fd-824eff351fd5"
      unitRef="U_shares">400207</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ba4f1a9d-c900-4002-8f99-c4ecdde3a741"
      decimals="-3"
      id="F_e1e83025-e1f1-42f7-8d55-1311f17767f7"
      unitRef="U_USD">-142000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c"
      decimals="-3"
      id="F_50ab1b7c-ac79-4455-8b09-c8839bf918df"
      unitRef="U_USD">-142000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_cf4df239-e091-4dea-a22c-442719bad5aa"
      decimals="-3"
      id="F_3547e4d4-54fe-4c7f-a1d1-63c6406619f1"
      unitRef="U_USD">-41296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f1f5b103-93fe-47e6-84f7-9fc67f3d8b8c"
      decimals="-3"
      id="F_343f81a9-13ed-4dd8-9573-6e6506131e9e"
      unitRef="U_USD">-41296000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_2b385b66-69ef-4b47-a1f9-aaee7fd51b80"
      decimals="INF"
      id="F_c42f7a9a-4cc1-4116-9a5f-1c6fbdd8b90b"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_2b385b66-69ef-4b47-a1f9-aaee7fd51b80"
      decimals="-3"
      id="F_1772f88a-abff-4f16-b121-d03d520e4ba1"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_eb7a3370-5e9c-4bba-9912-d41ddf5d3118"
      decimals="INF"
      id="F_5e71b208-597f-4914-873a-876b85bce9be"
      unitRef="U_shares">86724658</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eb7a3370-5e9c-4bba-9912-d41ddf5d3118"
      decimals="-3"
      id="F_fb886070-23f9-44cf-8f42-8b74bebfedbc"
      unitRef="U_USD">802449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_069c6b44-6229-411e-bbb8-49186918c1be"
      decimals="-3"
      id="F_33b67a30-9921-4f4a-83c1-c3982c8c7e70"
      unitRef="U_USD">113169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7ed5c27e-cc4c-49b1-84c5-c1e7b5ece75b"
      decimals="-3"
      id="F_1589c54e-e896-467c-a9db-9bcd66802a21"
      unitRef="U_USD">-47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7f9d681a-3066-4ee8-9ecd-b527dd2f4e9d"
      decimals="-3"
      id="F_7c45ac23-db89-465b-975e-2271e47fc115"
      unitRef="U_USD">-884624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6400cc97-e4a5-49ec-8444-d2e2844fe3ec"
      decimals="-3"
      id="F_fef0b8c7-dec3-4701-a641-59357357e3c3"
      unitRef="U_USD">30947000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_4d8668ee-4d05-4c91-8b3d-392dfe7aafc5"
      decimals="-3"
      id="F_4486afe6-c61f-48b7-8a07-9e2a04b2ef0e"
      unitRef="U_USD">3366000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_89b21a97-6f4f-4b4e-9095-0c65f00dbcb2"
      unitRef="U_USD">3366000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249"
      decimals="INF"
      id="F_fd348d35-077f-4e41-b144-7f888079e70a"
      unitRef="U_shares">8338</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249"
      decimals="INF"
      id="F_27b14ef7-dfc9-4cf1-9490-3d658d9abcbc"
      unitRef="U_shares">20000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249"
      decimals="-3"
      id="F_af2d7b04-c4cf-421a-bdaa-a69283249535"
      unitRef="U_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_dad6c615-bd40-481e-a1ca-b7326946ef54"
      unitRef="U_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249"
      decimals="INF"
      id="F_1c820051-ff51-4ef7-82ec-18a560242037"
      unitRef="U_shares">88527</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b7faaa66-7ed1-463f-b9b6-ad66ad593249"
      decimals="-3"
      id="F_9556adac-d12b-490c-b1c0-b4ca7b5cae0b"
      unitRef="U_USD">198000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_213cad4d-a243-49ec-9601-94da408263cf"
      unitRef="U_USD">198000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_cd2a4a95-ce73-44cb-9465-c2c5da963d29"
      decimals="-3"
      id="F_f14ad416-25fc-42f7-94e7-3301033f24e1"
      unitRef="U_USD">-76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_514feb99-b76d-4983-a2a9-8a16968704c1"
      unitRef="U_USD">-76000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_aaeb1ca3-95e6-48fb-8268-9d462b4bf5df"
      decimals="-3"
      id="F_ced1d56a-de3c-49ea-b551-cf572ac60e68"
      unitRef="U_USD">-39004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_21b5cec1-8245-48ab-a6cc-390326cd082a"
      unitRef="U_USD">-39004000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e6729cef-6185-408f-8064-d6b87f459534"
      decimals="INF"
      id="F_9b8d6703-fbe7-41ef-a3ec-07f01b79b0c8"
      unitRef="U_shares">3901348</us-gaap:SharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_e6729cef-6185-408f-8064-d6b87f459534"
      decimals="-3"
      id="F_ef34d80b-525a-4635-93a5-0f79b655b5bc"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_5335805a-7dbf-45b8-95e4-abf4ef8a5bc2"
      decimals="INF"
      id="F_887a866b-e8d4-45eb-bd87-b1c0ba5848a4"
      unitRef="U_shares">86841523</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5335805a-7dbf-45b8-95e4-abf4ef8a5bc2"
      decimals="-3"
      id="F_a85d4211-06f8-43b5-aac6-7499d8b87fd1"
      unitRef="U_USD">802697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_48607354-e4f1-4154-a753-18ac7e90279b"
      decimals="-3"
      id="F_8fe9696f-7f9d-4289-87e7-67044fcdddf5"
      unitRef="U_USD">116535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f3db33f7-84dd-4c09-bd63-ab26c7341876"
      decimals="-3"
      id="F_05013560-b062-4073-a745-8bcca82c86dc"
      unitRef="U_USD">-123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2ed14954-a596-4947-9acd-47caf500b6f6"
      decimals="-3"
      id="F_5a7171cf-8fe9-4e07-96d7-86637c30e729"
      unitRef="U_USD">-923628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646"
      decimals="-3"
      id="F_2779beab-e08e-4425-ae74-1b4b1f4c5e74"
      unitRef="U_USD">-4519000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_21febb15-521e-425b-9fd0-a8ee30908050"
      decimals="INF"
      id="F_91218ec9-5604-44ef-848f-eaaf60e1ca6c"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_21febb15-521e-425b-9fd0-a8ee30908050"
      decimals="-3"
      id="F_4176e850-69de-452b-90b1-f95e74510311"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_ad580d82-9ef7-4699-b3e9-1f9292c5d61b"
      decimals="INF"
      id="F_d3a272dc-f9c7-4e7f-a20d-4cc5ca110a06"
      unitRef="U_shares">86924643</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ad580d82-9ef7-4699-b3e9-1f9292c5d61b"
      decimals="-3"
      id="F_e8fde7db-6225-4327-aa7a-efdb49e68ed7"
      unitRef="U_USD">802833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3d27d437-20db-40a7-8a31-79dc5b79363e"
      decimals="-3"
      id="F_7a968a5b-f8b0-41a9-8038-6cff617ca375"
      unitRef="U_USD">119442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_718175b2-0b3b-4964-aae7-ad8959e6fab2"
      decimals="-3"
      id="F_001e1df0-fdd8-46ad-817e-17ffe42aa7e9"
      unitRef="U_USD">-29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ac1fc334-0f8b-4953-924e-cff0d0ea9a58"
      decimals="-3"
      id="F_1a5e90c4-f7a7-4264-840a-1c4cc7d5012a"
      unitRef="U_USD">-967337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_5b13fbe3-bf6c-4e27-8a5f-fe66dadc7717"
      unitRef="U_USD">-45091000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="INF"
      id="F_786ebb5e-abe7-4a68-b1a3-105dbfa826fb"
      unitRef="U_shares">10683761</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="-3"
      id="F_eb5aa9ad-4e47-4b90-a0f8-e3f845191869"
      unitRef="U_USD">34623000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104"
      decimals="-3"
      id="F_64515d90-7c70-4e63-adb8-4656415158ac"
      unitRef="U_USD">34623000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_1f8ea7fd-3044-4c36-9304-529ddf0e84c8"
      decimals="-3"
      id="F_bc5cc3a7-9416-43b9-8ce2-7952b72362de"
      unitRef="U_USD">2750000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104"
      decimals="-3"
      id="F_cbb5f812-d049-49cb-9f6d-03538c0f68bd"
      unitRef="U_USD">2750000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="INF"
      id="F_b87b0a57-7bae-42a9-8242-3b0bad1f2255"
      unitRef="U_shares">363161</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="INF"
      id="F_dfae9b8e-a790-4281-94e8-657ab44bde2f"
      unitRef="U_shares">181</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="-3"
      id="F_0fbff281-bf1a-4bea-8669-8c14e61ecab6"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104"
      decimals="-3"
      id="F_76904d28-73a2-45cb-ab45-80ba6e9d5151"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="INF"
      id="F_43f27622-7b8c-41c2-afa5-7272102af520"
      unitRef="U_shares">133098</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0d5ec55f-c3da-426b-aa9d-66c3a064b96a"
      decimals="-3"
      id="F_1174b2d1-02e7-4bde-a650-878f294713ce"
      unitRef="U_USD">429000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104"
      decimals="-3"
      id="F_e6d772a0-fd2c-45d8-aafb-d2105b546ad6"
      unitRef="U_USD">429000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_929ba747-8e45-447c-88e7-e51ab1e75ceb"
      decimals="-3"
      id="F_d6ee2cbc-0fcb-4cbb-bd5b-b5c3a9d3fa37"
      unitRef="U_USD">-21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104"
      decimals="-3"
      id="F_fd38c35b-7121-4548-8fc6-2b460c1a830f"
      unitRef="U_USD">-21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_604ade02-22f4-4b35-9117-540972b59c0a"
      decimals="-3"
      id="F_983818d7-dc19-4b85-a16d-b6ceb1ea4147"
      unitRef="U_USD">-27405000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7ccbca11-eac3-41df-97e1-6373fedbb104"
      decimals="-3"
      id="F_ddcb039f-a4f2-41e1-a683-57d331049016"
      unitRef="U_USD">-27405000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_560af56f-fc78-4a72-851b-af2add5880d5"
      decimals="INF"
      id="F_7ece15bc-b3df-45dd-a7b3-64d51f5c4003"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_560af56f-fc78-4a72-851b-af2add5880d5"
      decimals="-3"
      id="F_6b787309-5b1a-4c77-b405-09ca9e0b9778"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_3237fbdb-d95d-4cfe-b9f1-61899a543f68"
      decimals="INF"
      id="F_2d8503a2-126d-494c-88f4-f13d90fda6ba"
      unitRef="U_shares">98104844</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3237fbdb-d95d-4cfe-b9f1-61899a543f68"
      decimals="-3"
      id="F_d07167f9-f95c-4a83-94ae-876b5ae1c2c7"
      unitRef="U_USD">837886000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7e102754-2c0a-4b97-a8a7-084bee04df37"
      decimals="-3"
      id="F_7d5c518a-0f34-462a-9c13-85640f897462"
      unitRef="U_USD">122192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9d5aa44f-3484-4f2c-b16b-289c55dc6ac4"
      decimals="-3"
      id="F_b0676443-1a1a-4f6c-827f-3592e3fdc3cf"
      unitRef="U_USD">-50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ed60e8fb-2b52-4f3b-bd07-879599965982"
      decimals="-3"
      id="F_32a98b48-c210-481a-b609-4844a4ac9431"
      unitRef="U_USD">-994742000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0fda8411-f581-4b47-ab60-7fcc4a2e2534"
      decimals="-3"
      id="F_927856b2-624e-417e-9a77-6bef68e4a93d"
      unitRef="U_USD">-34714000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_833bb004-b15e-4e44-9c08-c7223704a04a"
      decimals="0"
      id="F_a4174599-4d39-4b71-afb6-7263d8be9d41"
      unitRef="U_shares">429051</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_833bb004-b15e-4e44-9c08-c7223704a04a"
      decimals="-3"
      id="F_1177ae8f-f32c-471a-a7c6-d1442c482123"
      unitRef="U_USD">1704000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224"
      decimals="-3"
      id="F_0b5d4b08-1caf-426d-9cea-1d8e776b0769"
      unitRef="U_USD">1704000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_fcce8355-0cd7-4000-b527-e0b8174914e9"
      decimals="-3"
      id="F_b5c234d6-1d26-4161-9240-5f5e1b2d7594"
      unitRef="U_USD">2409000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224"
      decimals="-3"
      id="F_16b01a09-5f5b-45dc-a972-0093d93ccb4a"
      unitRef="U_USD">2409000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb"
      decimals="0"
      id="F_9ad0c548-3033-4dab-9197-90c0b15d7a5b"
      unitRef="U_shares">9234</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb"
      decimals="0"
      id="F_469b131e-1ffc-4816-bcaf-4e67943e3626"
      unitRef="U_shares">23687</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_51ea6d82-fa9d-4758-a141-2eeb40ae59eb"
      decimals="-3"
      id="F_dbecfe6d-9516-4768-95e9-63f6630c2675"
      unitRef="U_USD">85000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224"
      decimals="-3"
      id="F_a08f2b4b-baef-4817-bab7-875ee52d7937"
      unitRef="U_USD">85000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3fd28c55-542d-4350-976c-ab012247df20"
      decimals="-3"
      id="F_a24c8e86-f439-4f52-abf8-b52ab77b7756"
      unitRef="U_USD">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224"
      decimals="-3"
      id="F_f7dce58e-ee9e-4f92-9505-9939bf91ce8f"
      unitRef="U_USD">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_c3f6c33e-1898-4179-94ee-85f8a300f503"
      decimals="-3"
      id="F_4e4c2aba-cbb0-4a82-baa3-bce9c1a15d1e"
      unitRef="U_USD">-21104000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_deb104c1-49f6-405f-aa32-79ca3de0a224"
      decimals="-3"
      id="F_ac3521ee-d9c0-4aeb-9f60-7db2d09d36af"
      unitRef="U_USD">-21104000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_d16ff73c-b9ec-427d-b56c-2031a5ccc0f1"
      decimals="INF"
      id="F_246fd9da-3097-42a2-bfa0-756880b44ef3"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_d16ff73c-b9ec-427d-b56c-2031a5ccc0f1"
      decimals="-3"
      id="F_84dab08a-13ef-4858-b851-53fb8bec0d92"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_031576dd-6bf3-4f90-aea3-59700962dfb0"
      decimals="INF"
      id="F_4e2ffb74-8410-4073-8ac1-b7f9e613e686"
      unitRef="U_shares">98566816</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_031576dd-6bf3-4f90-aea3-59700962dfb0"
      decimals="-3"
      id="F_dc689bc1-f217-433f-849a-9cb83f8b0016"
      unitRef="U_USD">839675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_33aa57c2-493d-4ba2-a29e-f3b3aff746a1"
      decimals="-3"
      id="F_623f86e8-72cd-46c6-8a77-4cb6febba031"
      unitRef="U_USD">124601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_43e449a1-c4a0-4f65-a9bf-139d62938bee"
      decimals="-3"
      id="F_8c2a523f-a9b9-482c-b211-b05bfde0ce28"
      unitRef="U_USD">-150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5edc625-147f-4242-abcb-34c2ad06e65c"
      decimals="-3"
      id="F_6a172297-272a-41ce-a5b5-0a261906aefe"
      unitRef="U_USD">-1015846000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1cc32b4-5c83-4f9e-9124-5240a39712b1"
      decimals="-3"
      id="F_ce6eb56f-0994-45e7-a86e-170edbd9631d"
      unitRef="U_USD">-51720000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_fc3001b7-e63c-414e-93fa-1a04b0fba6dd"
      decimals="INF"
      id="F_764cb045-ac29-4465-858e-27cc9f269e62"
      unitRef="U_shares">322637</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_fc3001b7-e63c-414e-93fa-1a04b0fba6dd"
      decimals="-3"
      id="F_04e81059-967c-45fc-bbc8-e3e71ccd0c44"
      unitRef="U_USD">1376000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_6b5223d2-51e2-46ce-b962-d9b615c02b42"
      decimals="-3"
      id="F_90db9d3a-060b-48a7-8cf7-a38b98430e93"
      unitRef="U_USD">1376000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_2fe29c86-e07c-4543-8cde-57f6ad77b97d"
      decimals="-3"
      id="F_1435d60d-3d2c-4028-8e16-b31f6d8a4156"
      unitRef="U_USD">2284000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_114e52f1-4a0f-47e7-b4ae-d1aed54a332f"
      unitRef="U_USD">2284000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a"
      decimals="INF"
      id="F_1345ba21-a58f-447e-ba24-30baafeee373"
      unitRef="U_shares">16657</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a"
      decimals="INF"
      id="F_cb77eb62-f228-4b02-bed9-40530a01126b"
      unitRef="U_shares">12976</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a"
      decimals="-3"
      id="F_e03ecdb4-a23b-4d2b-86eb-666c5c4c374d"
      unitRef="U_USD">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_32fc96c3-0b6b-4c2f-8a67-8953356dac6d"
      unitRef="U_USD">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a"
      decimals="INF"
      id="F_0a50607c-f457-44c0-8cc9-fb813c37d434"
      unitRef="U_shares">92815</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_373691fb-08ed-497e-9cf8-b3671c52971a"
      decimals="-3"
      id="F_73819bfb-6f00-4999-a225-8533f617f57b"
      unitRef="U_USD">319000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_a571f774-4c74-41f8-b64d-4aa29dedc70b"
      unitRef="U_USD">319000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_fb5251fa-7c39-49df-b15b-5c68f20d47c3"
      decimals="-3"
      id="F_45948983-fdab-4959-86a8-26ace539a6d5"
      unitRef="U_USD">-32000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_1207c103-1869-49b0-bc8c-553930c468fd"
      unitRef="U_USD">-32000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_f171fb21-e8be-445f-a99b-bee1ca07227d"
      decimals="-3"
      id="F_985e24ae-34c8-4db4-811d-d62d2b2a029c"
      unitRef="U_USD">7252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_c90c397f-20af-46c3-83b7-9be1fe301d6b"
      unitRef="U_USD">7252000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7a8994db-d61b-431c-a197-e1e739d2ccf8"
      decimals="INF"
      id="F_7bbe48ec-0ae7-4ded-b285-bfacffbb5bf7"
      unitRef="U_shares">3901348</us-gaap:SharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7a8994db-d61b-431c-a197-e1e739d2ccf8"
      decimals="-3"
      id="F_4b286e4e-617d-4d74-a836-961aa3988923"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_60168293-95c2-4194-a4bf-2c7a29d5b380"
      decimals="INF"
      id="F_2acc9cce-4ac7-4c6d-9336-3cfe7b0d1262"
      unitRef="U_shares">99011901</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_60168293-95c2-4194-a4bf-2c7a29d5b380"
      decimals="-3"
      id="F_0ef0000e-4dd0-4bd6-9c3f-1f1ea3ef0d6c"
      unitRef="U_USD">841405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d76d5b9d-2f04-4715-8806-517e6f2315cf"
      decimals="-3"
      id="F_df996865-41ab-4317-9852-5442eb51e9a0"
      unitRef="U_USD">126885000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7e637694-fa20-42ed-887e-0196d4053e95"
      decimals="-3"
      id="F_cb825cb4-540c-4266-bc05-1b88d1fbe5aa"
      unitRef="U_USD">-182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3b49a495-e20c-4db7-93d9-124b08adfa81"
      decimals="-3"
      id="F_b742e8d4-a2b5-4b75-8719-fce1b68daae3"
      unitRef="U_USD">-1008594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_4ced5282-8931-4619-963a-babc54668388"
      unitRef="U_USD">-40486000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_2e64ae20-926f-4d7a-97a6-f5328d617db4"
      unitRef="U_USD">-41257000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_8b54d502-4e89-4827-be09-3d1ac01b8401"
      unitRef="U_USD">-118114000</us-gaap:ProfitLoss>
    <wve:AmortizationOfRightOfUseAssets
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_9bc72875-c575-4575-9be2-1af3b9f1b45d"
      unitRef="U_USD">3105000</wve:AmortizationOfRightOfUseAssets>
    <wve:AmortizationOfRightOfUseAssets
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_db546b93-aa5f-4f4a-8bae-899cb1cb19b5"
      unitRef="U_USD">2557000</wve:AmortizationOfRightOfUseAssets>
    <us-gaap:Depreciation
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_088337f7-145a-469d-95fe-acaf88c175b7"
      unitRef="U_USD">3919000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_14268336-f275-4efc-a871-4a6ad90c5514"
      unitRef="U_USD">5062000</us-gaap:Depreciation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_78b08d25-812f-41dc-99fd-954c9c8181b4"
      unitRef="U_USD">7443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_47dcc47a-3810-4914-ad65-85d84642d885"
      unitRef="U_USD">14287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_35bb6ff2-d9a9-44bc-8e8e-00929d62b182"
      unitRef="U_USD">7000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_2e852c66-017c-4744-a97d-1a1397d3aa4e"
      unitRef="U_USD">-418000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_c962a0ab-eeee-494c-8b3d-f4e42d19a713"
      unitRef="U_USD">835000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_16fef326-2ebe-41fc-984e-209a50a9542c"
      unitRef="U_USD">2101000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_b3727452-6284-4c57-bce5-63ec3556ec41"
      unitRef="U_USD">-3503000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_0bd96524-0432-4820-b2c6-3feebd0874df"
      unitRef="U_USD">-3953000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_6da6de1c-ab8a-4c5d-8fde-353f173390dc"
      unitRef="U_USD">8337000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_f0326b2b-103b-4358-9d26-0784ed3cd692"
      unitRef="U_USD">-4928000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_9969538f-010e-470d-b1ef-cb0fe733d442"
      unitRef="U_USD">-3805000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_8dc9feb5-4c85-4ef1-9871-aaad86a249b5"
      unitRef="U_USD">62299000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_072783b5-9dcb-44b0-ad1a-a371df8c5c23"
      unitRef="U_USD">-2006000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <wve:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_71bbf674-033e-4dc8-88fb-167cbca1af0e"
      unitRef="U_USD">-3947000</wve:IncreaseDecreaseInOperatingLeaseLiabilities>
    <wve:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_74124e9b-955e-4eae-a3d1-8bcda39e8c29"
      unitRef="U_USD">-3327000</wve:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_3f99306d-62b5-4904-a198-f1673fefb216"
      unitRef="U_USD">-190000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_94898331-2cc7-482d-90a8-a5c7926c0047"
      unitRef="U_USD">13808000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_751ec360-67fa-48b9-a9c6-ddcff811b934"
      unitRef="U_USD">-94341000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_637ffce0-75ff-4418-8509-c4bcef179107"
      unitRef="U_USD">759000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_5b127885-cd86-49d1-b075-3d0900985e8e"
      unitRef="U_USD">1157000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_bf630855-36c5-4e10-a841-62ba2d68d1d3"
      unitRef="U_USD">106000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_dcb646bf-91d5-44da-aaa4-cb6c1c623271"
      unitRef="U_USD">75044000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_061c262b-e90f-4792-b45d-70c3bc055647"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_2aa43c46-6c36-458b-a396-5aed4d1baae1"
      unitRef="U_USD">-759000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_48472130-5673-4761-9a81-785db6ac7054"
      unitRef="U_USD">-26095000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_c74b97b6-9098-424c-9fd7-41dbfd3b3901"
      unitRef="U_USD">34623000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_86b5740d-e69a-4571-8fc0-965e4ab085a1"
      unitRef="U_USD">51235000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_7f667fd0-b265-4fa2-ac36-c5dedbb7a993"
      unitRef="U_USD">14272000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <wve:ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_49d56834-9658-4c89-9a4e-dc5ac49b4e57"
      unitRef="U_USD">3080000</wve:ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet>
    <wve:ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_019dcfd6-d75e-4ed4-b19f-6594aa95479a"
      unitRef="U_USD">1167000</wve:ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_02dd0842-c907-46e8-936f-2ae76570552c"
      unitRef="U_USD">121000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_a09360cd-a924-4b8c-9deb-f2a65dd3d896"
      unitRef="U_USD">87000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_a63acf95-d790-4928-a2ec-e5bcb1b59a27"
      unitRef="U_USD">748000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_9f208d06-8f4e-4bb6-a800-44a388e7be6e"
      unitRef="U_USD">372000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_94c97f29-ea8d-43a9-b6c5-324265ca393a"
      unitRef="U_USD">38572000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_891e0255-41e0-466a-b7aa-6da796db324f"
      unitRef="U_USD">67133000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_186803d0-807b-4645-b1e7-9811208f5932"
      unitRef="U_USD">-153000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_fc1f5ffa-efa1-4e74-93c1-cf0e7360524e"
      unitRef="U_USD">-304000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_9f99ccaa-551b-484b-9d09-653745ebfa33"
      unitRef="U_USD">51468000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_3a007d9b-fa75-486f-8c54-e2845d99fbe0"
      unitRef="U_USD">-53607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_96b03a15-b237-4d90-8220-0fdba4d01ee7"
      unitRef="U_USD">92157000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0053e917-12df-482b-a1b1-4cf6b49da388"
      decimals="-3"
      id="F_a9d86029-fed4-4d12-bead-177a986a542e"
      unitRef="U_USD">154215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_889549ff-3768-48fa-9e58-38895dc24c7a"
      unitRef="U_USD">143625000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646"
      decimals="-3"
      id="F_5f746185-fbaf-42f6-8c4b-b71b2b28c7f8"
      unitRef="U_USD">100608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_dab20169-a08c-4002-ba2d-04f8433e9031"
      unitRef="U_USD">12006000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_f4f652e9-7417-4167-a549-c72b71cb9bf7">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. THE COMPANY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Wave Life Sciences Ltd. (together with its subsidiaries, &#x201c;Wave&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, Wave&#x2019;s proprietary discovery and drug development platform that enables the precise design, optimization, and production of novel stereopure oligonucleotides, Wave is working to develop first- or best-in-class medicines that target the transcriptome (the full set of ribonucleic acid (&#x201c;RNA&#x201d;) molecules produced from the human genome) to treat diseases with a high degree of unmet need.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#x201c;Wave USA&#x201d;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#x201c;Wave Japan&#x201d;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (&#x201c;Wave Ireland&#x201d;) was formed as a wholly&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (&#x201c;Wave UK&#x201d;) was formed as a wholly&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;owned subsidiary of Wave Life Sciences Ltd.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company&#x2019;s differentiated portfolio, building the Company&#x2019;s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#x2019;s intellectual property, and assuring adequate capital to support these activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception, the Company has not generated any product revenue and has incurred recurring operating losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include upfront and milestone payments from collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30, 2023, the Company had cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;139.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expects that its existing cash and cash equivalents will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company&#x2019;s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#x2019;s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#x2019;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development efforts will be successful, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and in U.S. dollars.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-5"
      id="F_9908687b-5298-4379-b186-9a3e88519593"
      unitRef="U_USD">139900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_56070c82-e391-4251-918a-4710d4028e31">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant accounting policies described in the Company&#x2019;s audited financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 23, 2023, as amended (the &#x201c;2022 Annual Report on Form 10-K&#x201d;), have had no material changes during the nine months ended September 30, 2023, except as described below.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company&#x2019;s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company&#x2019;s analysis of contracts with contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions and conditions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying interim consolidated balance sheet as of September 30, 2023, the related interim consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of Series A preferred shares and shareholders&#x2019; equity (deficit) for the three months ended March 31, June 30, and September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2023 and 2022 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or any other interim period or future year or period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_eba3d1be-487c-4fef-b49e-87eac612ea7a">&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company&#x2019;s financial statements and related disclosures requires the Company to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company&#x2019;s analysis of contracts with contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions and conditions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_2ec842bd-28d6-422f-af7a-85e7a3e0fbbe">&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying interim consolidated balance sheet as of September 30, 2023, the related interim consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, the consolidated statements of Series A preferred shares and shareholders&#x2019; equity (deficit) for the three months ended March 31, June 30, and September 30, 2023 and 2022, the consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2023 and 2022 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or any other interim period or future year or period.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_da0673c8-c2e4-43d7-afb1-98ea77a6f408">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.304%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.145%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.145%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses related to CROs and CMOs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_40a2cda4-4678-4700-8dea-21e51dc4c129">&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.304%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.145%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.145%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses related to CROs and CMOs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_b3d33126-ca34-493b-91cf-95414367d023"
      unitRef="U_USD">8457000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_382f8790-01f4-4ec2-a166-32aab62b1911"
      unitRef="U_USD">12287000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_dba85cb5-bc35-4396-86ea-e04ea1dba75e"
      unitRef="U_USD">3080000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_09f18e79-f3e9-47d8-a846-accce3153f55"
      unitRef="U_USD">3516000</us-gaap:AccruedLiabilitiesCurrent>
    <wve:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_3dcfb71e-2945-459b-9aa7-a0333eaa90af"
      unitRef="U_USD">1087000</wve:AccruedExpensesAndOtherCurrentLiabilities>
    <wve:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_2f351b03-c1d8-4b0a-b210-d28d5465376a"
      unitRef="U_USD">1749000</wve:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="-3"
      id="F_5b54e4dc-5662-4765-aea6-5aa9d113cd7c"
      unitRef="U_USD">12624000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_7f906dd5-bc79-446d-adfc-71bac06784f0"
      decimals="-3"
      id="F_e0519e76-d454-444d-8824-8a8243b456af"
      unitRef="U_USD">17552000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_c24eac7d-9201-4ddf-9ab0-9bb26b922576">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Wave Life Sciences Ltd. 2021 Equity Incentive Plan was approved by the Company&#x2019;s shareholders and went into effect on August 10, 2021 and was amended effective as of August 9, 2022 and August 1, 2023 (as amended, the &#x201c;2021 Plan&#x201d;). The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#x201c;2014 Plan&#x201d;), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan was originally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,450,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares, and was subsequently increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11,450,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;17,950,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in August 2022 and August 2023, respectively, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2021 Plan authorizes (and the 2014 Plan previously authorized) the board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (&#x201c;RSUs&#x201d;), and performance awards to eligible employees and directors of the Company. The Company accounts for grants to its non-employee directors as grants to employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options generally vest over periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_59cf8e65-320f-4b29-af97-3896ca1e1d01;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_540eabce-9c76-47de-9406-1bc8ab641938;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f5411f6a-e73e-4d8f-a9d0-7e8d4a09dbbe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the nine months ended September 30, 2023, the Company granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,646,300&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options to employees and non-employee directors and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;152,475&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; time-based RSUs to employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,124,732&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ordinary shares remained available for future grant under the 2021 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below shows the options and RSUs outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,238,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,732,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;633,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;999,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan, as amended (the &#x201c;ESPP&#x201d;) allows full-time and certain part-time employees to purchase the Company&#x2019;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning every January 15th and July 15th. Ordinary shares are purchased at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s ordinary shares on the first business day or the last business day of an offering period. The aggregate number of ordinary shares authorized for issuance under the ESPP was originally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and was subsequently increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in August 2023. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;225,913&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares were issued under the ESPP. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,490,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares available for issuance under the ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_3135871c-4f8d-45bd-ac2a-b5c1f0447408"
      decimals="INF"
      id="F_9507548c-b882-4f3e-bf38-b17ed8e2c32d"
      unitRef="U_shares">5450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_77f5b6ef-f560-4092-beba-520c88cb4208"
      decimals="INF"
      id="F_dcaba3b6-6473-4a71-b851-77720ea52b95"
      unitRef="U_shares">11450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_2c12b888-5c51-44db-8ef5-cea86938cf76"
      decimals="INF"
      id="F_ab0e4541-f8df-488c-8ba6-5dfb16c4789b"
      unitRef="U_shares">17950000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_feb4d052-987c-4678-af34-398b68e10a90"
      id="F_90442e40-efc1-49ce-9569-db0a277ea329">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_feb4d052-987c-4678-af34-398b68e10a90"
      id="F_707964e4-1302-41f0-a608-4f23bfc011c2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_8257ee6a-7c25-48ed-80dd-852b2a1ee5f9"
      id="F_225e2f8b-6836-433a-8f90-dcc264b927c4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_5ee08ac2-8a9a-4c40-92e9-b73ab7051fa6"
      decimals="INF"
      id="F_723ce041-e00f-46e4-8588-75d99a28e253"
      unitRef="U_shares">5646300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_f6824cde-b172-405b-bbd6-fc57065305e3"
      decimals="INF"
      id="F_3cd5fd26-bf3f-4c1c-9fd6-4b312b02c7c3"
      unitRef="U_shares">152475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_60b075bf-4787-4dda-9217-73cdf8491478"
      decimals="INF"
      id="F_80d4253d-b772-48c7-a8cb-1112e76cdcbb"
      unitRef="U_shares">8124732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_f0e56a46-b93a-4530-8612-3abe96e85a29">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below shows the options and RSUs outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,238,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,732,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;633,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;999,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_6c273dcd-92a6-443b-9954-70c081cd28bd"
      unitRef="U_shares">14238590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646"
      decimals="INF"
      id="F_42bc8857-109f-4d3a-a7dd-bf3ebfc101b1"
      unitRef="U_shares">9732711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5297058f-1335-4562-8740-d05d615ccae7"
      decimals="INF"
      id="F_905ecbad-ddbb-4260-896a-465e2bef68bf"
      unitRef="U_shares">633283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5facce8a-aaa9-49ff-a1ce-5fd8df9b8646"
      decimals="INF"
      id="F_57f12720-60d3-401b-ae2a-3ab28c52e8ac"
      unitRef="U_shares">999771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <wve:SharePurchasePriceAtEqualToFairMarketValuePercentage
      contextRef="C_570400f0-19c4-42b7-ba7f-514509f5a992"
      decimals="2"
      id="F_c1e6ba1c-63cb-4e39-afc2-f439e88ef7ae"
      unitRef="U_pure">0.85</wve:SharePurchasePriceAtEqualToFairMarketValuePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_b0103dac-17ed-4d3e-b978-10b5e0f32584"
      decimals="INF"
      id="F_cc8824c5-5a0c-48bc-84b4-ecc022437ac1"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_201df0c5-2f9f-47b0-8746-12e41626744b"
      decimals="INF"
      id="F_584b8ab0-7022-4c10-93c1-21d22414c714"
      unitRef="U_shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_570400f0-19c4-42b7-ba7f-514509f5a992"
      decimals="INF"
      id="F_51e7ed96-6c47-4f30-b06a-d1a613fecfae"
      unitRef="U_shares">225913</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b0103dac-17ed-4d3e-b978-10b5e0f32584"
      decimals="INF"
      id="F_31f8d245-8868-40c3-8edf-165ae0ebe003"
      unitRef="U_shares">2490500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_1a99d99f-b275-4e10-bc24-df1f0b3be203">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. COLLABORATION AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GSK Collaboration and Equity Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 13, 2022, Wave USA and Wave UK entered into a Collaboration and License Agreement (the &#x201c;GSK Collaboration Agreement&#x201d;) with GlaxoSmithKline Intellectual Property (No. 3) (&#x201c;GSK&#x201d;). Pursuant to the GSK Collaboration Agreement, Wave and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including an exclusive global license to WVE-006. The discovery collaboration component has an initial four-year research term and combines Wave&#x2019;s proprietary discovery and drug development platform, PRISM, with GSK&#x2019;s unique insights from human genetics and its global development and commercial capabilities. On January 27, 2023, the GSK Collaboration Agreement became effective, and GSK paid Wave an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Simultaneously with the execution of the GSK Collaboration Agreement, Wave entered into a Share Purchase Agreement (the &#x201c;SPA&#x201d;) on December 13, 2022, with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, pursuant to which Wave agreed to sell &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,683,761&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of its ordinary shares to GGL at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share (the &#x201c;GSK Equity Investment&#x201d;). The GSK Equity Investment closed on January 26, 2023, following the completion of customary closing conditions. The ordinary shares purchased by GGL are subject to lock-up and standstill restrictions and carry certain registration rights, customary for transactions of this kind. The Company did not incur any material costs in connection with the issuance of the ordinary shares under the SPA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The GSK Collaboration Agreement has three components:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;An exclusive global license for GSK to WVE-006, the Company&#x2019;s preclinical, first-in-class A-to-I(G) RNA editing candidate for alpha-1 antitrypsin deficiency, with development and commercialization responsibilities transferring to GSK &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;after the Company completes the first-in-patient study (the &#x201c;AATD Collaboration&#x201d;). The Company will be responsible for preclinical, regulatory, manufacturing, and clinical activities for WVE-006 through the initial Phase 1/2 study, at the Company&#x2019;s sole cost. Thereafter, GSK will be responsible for advancing WVE-006 through pivotal studies, registration, and global commercialization at GSK&#x2019;s sole cost;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A discovery research collaboration which enables GSK to advance up to eight programs leveraging PRISM and the Company&#x2019;s oligonucleotide expertise and discovery capabilities (the &#x201c;Discovery Research Collaboration&#x201d;); and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A discovery collaboration which enables the Company to advance up to three programs leveraging targets informed by GSK&#x2019;s novel insights (&#x201c;Wave&#x2019;s Collaboration Programs&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the GSK Collaboration Agreement, each party grants to the other party certain licenses to the collaboration products to enable the other party to perform its obligations and exercise its rights under the GSK Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the GSK Collaboration Agreement. The parties&#x2019; exclusivity obligations to each other are limited on a target-by-target basis with regard to targets in the collaboration. GSK may terminate the GSK Collaboration Agreement for convenience, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the GSK Collaboration Agreement on a target-by-target basis if the other party, or a related party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product that is subject to the GSK Collaboration Agreement. In the event of any material breach of the GSK Collaboration Agreement by a party, subject to cure rights, the other party may terminate the GSK Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that GSK and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the GSK Collaboration Agreement and directed to a particular target, the Company may terminate the GSK Collaboration Agreement with respect to such target. Either party may terminate the GSK Collaboration Agreement for the other party&#x2019;s insolvency. In certain termination circumstances, the Company would receive a license from GSK to continue researching, developing and manufacturing certain products.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The GSK Collaboration Agreement, unless terminated earlier, will continue until the date on which: (i) with respect to a validation target, the date on which such validation target is not advanced into a collaboration program; or (ii) with respect to a collaboration target, the royalty term has expired for all collaboration products directed to the applicable collaboration target. The GSK Collaboration Agreement includes options to extend the research term for up to three additional years, which would increase the number of programs available to both parties. The Company will lead all preclinical research for GSK and the Company&#x2019;s collaboration programs up to investigational new drug (&#x201c;IND&#x201d;)-enabling studies. The Company will lead IND-enabling studies, clinical development and commercialization for the Company&#x2019;s collaboration programs. GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development and commercialization.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The GSK Collaboration Agreement is managed by a joint steering committee in which both parties are represented equally. In addition, the AATD Collaboration is overseen by a joint development committee, a joint patent committee advises on intellectual property activities, and the Discovery Research Collaboration is overseen by a joint research committee. Both parties are represented equally for these committees and report to the joint steering committee.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;) and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term. The Company identified the following material promises under the arrangement: (1) the exclusive global license for WVE-006; (2) the research and development services for WVE-006 through the Phase 1/2 study; (3) the discovery research services under the Discovery Research Collaboration to perform target validation programs; (4) research and development license for the Discovery Research Collaboration; and (5) the research and development services for the GSK collaboration programs through completion of a candidate selection. The research and development services for WVE-006 were determined to not be distinct from the exclusive global license and should therefore be combined into a single performance obligation for the AATD Collaboration. The research and development services for the Discovery Research Collaboration were determined to not be distinct from the research and development license for the Discovery Research Collaboration and should therefore be combined into a single performance obligation. In addition, the Company determined that the option to advance up to eight programs from the Discovery Research Collaboration was priced at fair value and did not provide a material right to GSK.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on these assessments, the Company identified two performance obligations in the GSK Collaboration Agreement: (1) AATD Collaboration consisting of the research and development services through completion of the Phase 1/2 study and research and development license for WVE-006 and (2) Discovery Research Collaboration which consists of research and development services for validating the targets and license for research and development license for targets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the outset of the arrangement, the transaction price included fixed consideration of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in premium related to the GSK Equity Investment and the estimated variable consideration related to the additional target validation research funding. The Company allocated the estimated variable consideration to the Discovery Research Collaboration programs and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;then &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;allocated the fixed consideration to the performance obligations on a relative standalone selling price basis. The Company determined that the GSK Collaboration Agreement did not contain a significant financing component. The program initiation fees to research and preclinically develop the GSK collaboration programs and the additional potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the GSK Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period, and as uncertain events are resolved or other changes in circumstances occur, the Company will adjust its estimate of the transaction price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company developed the estimated standalone selling price for the global license for WVE-006, under the AATD Collaboration, using a discounted cash flow model. For the performance obligation associated with the research and development services under the Discovery Research Collaboration and the research and development services for WVE-006 under the AATD Collaboration, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue associated with the AATD Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The revenue associated with the Discovery Research Collaboration performance obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet. Additional funding related to the Company&#x2019;s research activities related to Discovery Research Collaboration will be recorded as accounts receivable when contractually enforceable and recorded as deferred revenue, or as revenue as the services are provided.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three and nine months ended September 30, 2023, the Company recognized revenue of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;47.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, under the GSK Collaboration Agreement using the input method described above.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue on September 30, 2023 is approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;92.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;65.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in current liabilities &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in long-term liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Takeda Collaboration and Equity Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Wave USA and Wave UK entered into a global strategic collaboration (the &#x201c;Takeda Collaboration&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#x201c;CNS&#x201d;). The Takeda Collaboration provides the Company with at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;230.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in committed cash and Takeda with the option to co-develop and co-commercialize the Company&#x2019;s CNS development programs in (1) Huntington&#x2019;s disease (&#x201c;HD&#x201d;); (2) amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal dementia (&#x201c;FTD&#x201d;); and (3) the Company&#x2019;s discovery-stage program targeting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATXN3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the treatment of spinocerebellar ataxia 3 (&#x201c;SCA3&#x201d;) (collectively, &#x201c;Category 1 Programs&#x201d;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease (collectively, &#x201c;Category 2 Programs&#x201d;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as an upfront payment. Takeda also agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by Wave that exceed that amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Simultaneously with Wave USA and Wave UK&#x2019;s entry into the collaboration and license agreement with Takeda (the &#x201c;Takeda Collaboration Agreement&#x201d;), the Company entered into a share purchase agreement with Takeda (the &#x201c;Takeda Equity Agreement,&#x201d; and together with the Takeda Collaboration Agreement, the &#x201c;Takeda Agreements&#x201d;) pursuant to which it agreed to sell to Takeda &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,096,892&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of its ordinary shares at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;54.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company did not incur any material costs in connection with the issuance of the shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#x201c;Category 2 Research Term&#x201d;). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; targets at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;any one time&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (&#x201c;IND&#x201d;)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company&#x2019;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda&#x2019;s global commercial sales of products from each Category 2 Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term of the Takeda Collaboration Agreement commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 2, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Takeda may terminate the Takeda Collaboration Agreement for convenience on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#x2019;s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Takeda Collaboration is managed by a joint steering committee in which both parties are represented equally. The joint steering committee is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and therefore were combined into a single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the outset of the arrangement, the transaction price included the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront consideration received and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. Prior to the Amendment (as defined below), revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation was recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 15, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the &#x201c;Amendment&#x201d;), which discontinued the Category 2 component of the Takeda Collaboration. The Category 1 Programs under the Collaboration Agreement remain in effect and are unchanged by the Amendment. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as full payment for reimbursable Category 2 Programs collaboration-budgeted research and preclinical expenses. The Company received this payment from Takeda related to the Category 2 component and recognized the full amount as collaboration revenue in the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company announced its decision to discontinue clinical development of WVE-004 for C9orf72-associated ALS and FTD (&#x201c;C9 for ALS/FTD&#x201d;), one of the Category 1 Programs. In July 2023, the joint steering committee that manages the Takeda Collaboration terminated C9 for ALS/FTD as a target under the collaboration (the &#x201c;C9 Target&#x201d;) and consequently Takeda and the Company&#x2019;s rights and obligations under the Takeda Collaboration were terminated with respect to the C9 Target. As a result of the termination of the C9 for ALS/FTD Category 1 Program, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in revenue during the three months ended September 30, 2023, which represented the remainder of the deferred revenue for the C9 for ALS/FTD Category 1 Program as of June 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company achieved a developmental milestone related to the HD Category 1 Program, which pertained to the positive results from a non-clinical study of WVE-003 in non-human primates (&#x201c;NHPs&#x201d;). As a result of achieving the milestone, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in revenue during the three months ended September 30, 2023, which was not previously recorded in deferred revenue, as it was fully constrained at the inception of the Takeda Collaboration. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the achievement of the milestone is included in the current portion of accounts receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Through September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has recognized revenue of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;118.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as collaboration revenue under the Takeda Collaboration Agreement in the Company&#x2019;s consolidated statements of operations and comprehensive income (loss). During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;34.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the Takeda Collaboration Agreement, respectively. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and nine months ended September 30, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recognized revenue of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the Takeda Collaboration Agreement, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;111.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;31.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included in current liabilities and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;79.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included in long-term liabilities. The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;81.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in current liabilities and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;79.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in long-term liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each remaining Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each remaining Category 1 Program option upon Takeda&#x2019;s exercise or termination of such option, or immediately as each option expires unexercised.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <wve:CollaborationAgreementUpfrontPayment
      contextRef="C_5fe920df-49d4-4e5f-a9a3-7bb9c0f95914"
      decimals="-5"
      id="F_582f2252-b00c-40e2-a19a-a5088aaa5c8f"
      unitRef="U_USD">120000000</wve:CollaborationAgreementUpfrontPayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_44ca1475-425a-4297-bd8a-940ba67acc8a"
      decimals="INF"
      id="F_b600da16-7016-41b6-9c5d-40368cc24918"
      unitRef="U_shares">10683761</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_fc35d10c-0d48-4c9e-abb1-dc91feb594a7"
      decimals="INF"
      id="F_0915414d-7f6f-47a9-8302-4811f5a2392f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.68</us-gaap:SaleOfStockPricePerShare>
    <wve:CollaborationAgreementUpfrontPayment
      contextRef="C_840fd055-64a1-4ec7-a0cc-cb9b2c7fb2fa"
      decimals="-5"
      id="F_98e06675-dde5-4bba-b0b7-1a379c03eb54"
      unitRef="U_USD">120000000</wve:CollaborationAgreementUpfrontPayment>
    <wve:CollaborationAgreementInPremium
      contextRef="C_840fd055-64a1-4ec7-a0cc-cb9b2c7fb2fa"
      decimals="-5"
      id="F_acd93661-73ff-43a7-a38c-50c69c17021c"
      unitRef="U_USD">15400000</wve:CollaborationAgreementInPremium>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6a37111d-91fa-4fde-b91f-100be35676a6"
      decimals="-5"
      id="F_bf662f65-a339-4ca6-94c3-d951640418b7"
      unitRef="U_USD">14300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a43e788a-cf11-428f-8ee5-ea64fab1594f"
      decimals="-5"
      id="F_30924a4b-179f-4b30-86bb-23e826cf5e3f"
      unitRef="U_USD">47400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56"
      decimals="-5"
      id="F_b183433c-1c9b-40f1-bc7f-bb7df7b69a54"
      unitRef="U_USD">92200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56"
      decimals="-5"
      id="F_b173c683-d6ae-4afe-aa39-c89c6837947a"
      unitRef="U_USD">65900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_ac00fa33-ff48-4bcb-83e3-d9d13fc90f56"
      decimals="-5"
      id="F_845c1af9-a3b4-486b-af44-d3bef0d48cbb"
      unitRef="U_USD">26300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <wve:CollaborationAndLicenseAgreementMonthAndYear
      contextRef="C_92b7c4c9-c8c0-4b4a-8126-4f88d02330de"
      id="F_2fc86c32-ee41-4f8d-9572-49101cbfb7ad">2018-02</wve:CollaborationAndLicenseAgreementMonthAndYear>
    <wve:CollaborationAgreementCommittedCash
      contextRef="C_6a3a2265-ad67-4510-96a2-aae424a5f323"
      decimals="-5"
      id="F_b693b26f-c9e8-4d60-8134-bc1fbd32b319"
      unitRef="U_USD">230000000.0</wve:CollaborationAgreementCommittedCash>
    <wve:CollaborationAgreementUpfrontPayment
      contextRef="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02"
      decimals="-5"
      id="F_494e3a99-1db3-4e6a-ac0b-b8c886e3d499"
      unitRef="U_USD">110000000.0</wve:CollaborationAgreementUpfrontPayment>
    <wve:FundReceivableForResearchAndPreclinicalActivities
      contextRef="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02"
      decimals="-5"
      id="F_f1637540-993e-4be2-928f-4b3aa4dc7bd6"
      unitRef="U_USD">60000000.0</wve:FundReceivableForResearchAndPreclinicalActivities>
    <wve:CollaborationAndLicenseAgreementResearchTerm
      contextRef="C_d69647d7-873f-49c7-8ec5-d2e68e2fab02"
      id="F_2883d5c0-268f-4cb8-9d70-2dd4f7eb2998">P4Y</wve:CollaborationAndLicenseAgreementResearchTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc"
      decimals="INF"
      id="F_68f6a281-f9be-4ef2-81b3-1a5e5c8c2378"
      unitRef="U_shares">1096892</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_ca05b972-3868-479c-9caa-f39e6f757273"
      decimals="INF"
      id="F_a4dab16e-5be2-495e-8f03-16a3be5f2fd9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">54.70</us-gaap:SaleOfStockPricePerShare>
    <wve:EquityInvestmentAgreementOfficialClosureDateMonthAndYear
      contextRef="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc"
      id="F_a1b63084-ec9d-4d68-a612-8a502d1627ba">2018-04</wve:EquityInvestmentAgreementOfficialClosureDateMonthAndYear>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e3e98347-efe8-40f4-8cb4-1a0aa5a273fc"
      decimals="-5"
      id="F_527ef5be-ce6a-454f-aae7-f6dcc5bccf07"
      unitRef="U_USD">60000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio
      contextRef="C_181f3afe-396d-4ffd-a95b-40aadae0a1b4"
      decimals="2"
      id="F_401a5f1d-9fee-415b-9aa5-28ff1f1788f5"
      unitRef="U_pure">0.50</wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio>
    <wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio
      contextRef="C_f388230d-6596-4497-8c1d-93584b70794e"
      decimals="2"
      id="F_e35a3a73-efe5-4e31-89b3-da5afbc2c76e"
      unitRef="U_pure">0.50</wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio>
    <wve:CollaborationAndLicenseAgreementResearchTerm
      contextRef="C_5d950313-80c4-4f92-b61d-13e608cecd5c"
      id="F_61f4c0d1-0389-44f5-8297-27c16a3b591b">P4Y</wve:CollaborationAndLicenseAgreementResearchTerm>
    <wve:MaximumTargetsForPreclinicalPrograms
      contextRef="C_5d950313-80c4-4f92-b61d-13e608cecd5c"
      decimals="INF"
      id="F_28cdf3d5-e1c0-4dce-baec-e2d6e6c61769"
      unitRef="U_Target">6</wve:MaximumTargetsForPreclinicalPrograms>
    <wve:OptionToReachMaximumTargetsForPreclinicalPrograms
      contextRef="C_dca3ae87-1bee-4d72-a16c-3f7596e1d46d"
      id="F_329f88bb-5953-4abe-80ec-4a810e1c78f7">any one time</wve:OptionToReachMaximumTargetsForPreclinicalPrograms>
    <wve:FundReceivableForResearchAndPreclinicalActivities
      contextRef="C_5d950313-80c4-4f92-b61d-13e608cecd5c"
      decimals="-5"
      id="F_50d547c6-1568-4519-9631-a3224a84e565"
      unitRef="U_USD">60000000.0</wve:FundReceivableForResearchAndPreclinicalActivities>
    <wve:CollaborationAgreementCommencementDate
      contextRef="C_c7648e40-cd9d-4899-a7d2-538b38a342e1"
      id="F_21ba0585-de74-4e2f-929f-ee87a33bd8a6">2018-04-02</wve:CollaborationAgreementCommencementDate>
    <wve:MaximumTerminationNoticePeriod
      contextRef="C_c7648e40-cd9d-4899-a7d2-538b38a342e1"
      id="F_0921f111-491b-4edf-9357-5d742867eefb">P180D</wve:MaximumTerminationNoticePeriod>
    <wve:UpFrontConsiderationReceived
      contextRef="C_a04b64a0-15b9-4cd7-a1a3-3e35f0aae6c4"
      decimals="-5"
      id="F_6e7b8d6b-0045-4477-a0d8-decaf6f3a46a"
      unitRef="U_USD">110000000.0</wve:UpFrontConsiderationReceived>
    <wve:FundReceivableForResearchAndPreclinicalActivities
      contextRef="C_a04b64a0-15b9-4cd7-a1a3-3e35f0aae6c4"
      decimals="-5"
      id="F_2cd6b1cd-b20f-4159-b495-7a590aea167c"
      unitRef="U_USD">60000000.0</wve:FundReceivableForResearchAndPreclinicalActivities>
    <wve:CollaborationAndLicenseAgreementDate
      contextRef="C_878fd094-b224-474e-b2c6-88e67084090b"
      id="F_95347802-8b98-472b-88c0-98f103f82a95">2021-10-15</wve:CollaborationAndLicenseAgreementDate>
    <wve:CollaborationBudgetedResearchAndPreclinicalExpenses
      contextRef="C_ec472920-af11-4b8e-ab46-31b361f6eeb4"
      decimals="-5"
      id="F_35ebc3ac-7d56-4c2d-9c9e-9a2a9cb78b52"
      unitRef="U_USD">22500000</wve:CollaborationBudgetedResearchAndPreclinicalExpenses>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_ec9ca9b5-ccad-4c2b-9ec4-b7bea741597b"
      decimals="-5"
      id="F_1711fc04-cab6-4072-86ec-f8cae9c143b6"
      unitRef="U_USD">28000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_057199ca-f556-4877-bcce-76b3e2df83a1"
      decimals="-5"
      id="F_989175dd-5e57-4e69-9137-803c9a56aa62"
      unitRef="U_USD">7000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <wve:AcheivementOfMilestoneIncludedInCurrentPortionReceivable
      contextRef="C_ea2de7e1-ba02-4ca3-bc26-5a09679f28d4"
      decimals="-5"
      id="F_9e5f5b39-95f1-459d-91cf-b1111408677b"
      unitRef="U_USD">7000000</wve:AcheivementOfMilestoneIncludedInCurrentPortionReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5bc05ff7-8cc5-4878-970b-926a4d26e663"
      decimals="-5"
      id="F_1e92a5bf-a648-418e-8afe-47dab0b46f78"
      unitRef="U_USD">118100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_527f6f22-23ca-4707-bf9b-bef67aa616a8"
      decimals="-5"
      id="F_10bc5e89-3a52-476d-b4be-b6806b7f8f91"
      unitRef="U_USD">34900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8ceac785-d0e4-4aac-b036-774e9a55619b"
      decimals="-5"
      id="F_553c348e-bf02-4a86-b8c0-2408782757fe"
      unitRef="U_USD">36900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5140a810-8f0d-4fdc-a8ea-09de8f50f3ee"
      decimals="-5"
      id="F_13613545-953e-4441-9e65-c7d116eddd7f"
      unitRef="U_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0f8ac8dc-ad38-47bb-bee3-820517d4de91"
      decimals="-5"
      id="F_99aeb193-2f6b-4482-8559-b03fee6ba824"
      unitRef="U_USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_59ab39c1-8765-403a-8d50-7defda76d4c8"
      decimals="-5"
      id="F_95075990-b022-4ab3-ab2d-0a738ed2d06e"
      unitRef="U_USD">111300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_59ab39c1-8765-403a-8d50-7defda76d4c8"
      decimals="-5"
      id="F_957c9596-8396-485e-939d-f1d803cadccc"
      unitRef="U_USD">31600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_59ab39c1-8765-403a-8d50-7defda76d4c8"
      decimals="-5"
      id="F_876bd480-b2db-4381-98b7-5bbcda637667"
      unitRef="U_USD">79800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e"
      decimals="-5"
      id="F_643bf861-4e3c-40ae-b4f7-6998ed8e39b1"
      unitRef="U_USD">81400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e"
      decimals="-5"
      id="F_c10d4a39-adc3-4a78-8de7-5208d1e74340"
      unitRef="U_USD">2300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_cd9800c5-48d2-4d35-9dc8-5eedf50d497e"
      decimals="-5"
      id="F_619d6fd9-e158-488a-9835-b38c78686f41"
      unitRef="U_USD">79100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_911ea568-ed6a-439b-bfb0-8b234984afd0">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. NET INCOME (LOSS) PER ORDINARY SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies the two-class method to calculate its basic and diluted net income (loss) per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,093,656&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vested and exercisable pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) outstanding to purchase ordinary shares for the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, provided that, unless and until the Company obtains shareholder approval for the issuance of the shares underlying the Pre-Funded Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of our ordinary shares beneficially owned by the holder (together with its affiliates) to exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of our ordinary shares outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net income (loss) per share as the exercise price is negligible and the warrants are fully vested and exercisable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic loss per share is computed by dividing net income (loss) attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net income (loss) per share when their effect is dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of as of September 30, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,901,348&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Series A preferred shares outstanding; the Series A preferred shares are participating securities under the two-class method. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the nine months ended September 30, 2023 and the three and nine months ended September 30, 2022, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods and holders of Series A preferred shares do not participate in losses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below sets forth the computation of the Company&#x2019;s basic and diluted net income (loss) attributable to ordinary shareholders:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.663%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;39,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;41,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;118,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: net income attributable to &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;participating securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss) attributable to ordinary &lt;br/&gt;&#160;&#160;&#160;shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;39,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;41,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;118,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average ordinary shares used in &lt;br/&gt;&#160;&#160;&#160;computing net income (loss) per share &lt;br/&gt;&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,025,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,900,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;104,529,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;73,754,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effect of employee share plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;950,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average ordinary shares used in &lt;br/&gt;&#160;&#160;&#160;computing net income (loss) per share &lt;br/&gt;&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,975,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,900,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;104,529,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;73,754,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss) per share attributable to &lt;br/&gt;&#160;&#160;ordinary shareholders&#x2014;basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss) per share attributable to &lt;br/&gt;&#160;&#160;&#160;ordinary shareholders&#x2014;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes awards that were excluded from the computation of diluted earnings as their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,470,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,332,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,303,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,907,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;62,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;521,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;85,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;802,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852"
      decimals="0"
      id="F_67b6e5d8-b313-4c42-8c0e-de964d21717b"
      unitRef="U_shares">7093656</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852"
      decimals="4"
      id="F_f7367751-2741-417a-9f18-e24897e3df26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <wve:PercentageOfOwnershipInterestInOrdinarySharesOutstanding
      contextRef="C_031a13b4-1502-40ec-87b3-130a5d96f105"
      decimals="4"
      id="F_ba5bef29-ea6e-4864-aa11-fff500d64070"
      unitRef="U_pure">0.1999</wve:PercentageOfOwnershipInterestInOrdinarySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7a8994db-d61b-431c-a197-e1e739d2ccf8"
      decimals="INF"
      id="F_032f85d7-c5eb-4677-aec7-5b09fefaef5b"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e6729cef-6185-408f-8064-d6b87f459534"
      decimals="INF"
      id="F_3079027d-54e6-4410-ad3f-04552264ca35"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_a0d53aac-e36e-453e-957b-886c078df7ee">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below sets forth the computation of the Company&#x2019;s basic and diluted net income (loss) attributable to ordinary shareholders:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.663%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.644%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.969999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;39,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;41,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;118,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: net income attributable to &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;participating securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss) attributable to ordinary &lt;br/&gt;&#160;&#160;&#160;shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;39,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;41,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;118,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average ordinary shares used in &lt;br/&gt;&#160;&#160;&#160;computing net income (loss) per share &lt;br/&gt;&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,025,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,900,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;104,529,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;73,754,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effect of employee share plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;950,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Weighted-average ordinary shares used in &lt;br/&gt;&#160;&#160;&#160;computing net income (loss) per share &lt;br/&gt;&#160;&#160;&#160;attributable to ordinary shareholders&#x2014;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;106,975,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;93,900,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;104,529,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;73,754,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss) per share attributable to &lt;br/&gt;&#160;&#160;ordinary shareholders&#x2014;basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net income (loss) per share attributable to &lt;br/&gt;&#160;&#160;&#160;ordinary shareholders&#x2014;diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_c69f0213-c1d9-43ba-8416-39bf075aaca9"
      unitRef="U_USD">7252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_60ed7fe0-9409-490c-9554-73599b7ad8f3"
      unitRef="U_USD">-39004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_2d9c64cb-3c16-416e-9be5-d26b82596dda"
      unitRef="U_USD">-41257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_00674efe-6e54-455d-b278-29a45f076f9a"
      unitRef="U_USD">-118114000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_7eb3d8c4-d3e2-4ae1-aa60-e4fd3ebaeb61"
      unitRef="U_USD">-257000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="-3"
      id="F_ec1a5e0b-f406-4af2-b6b5-c01736fbfd9b"
      unitRef="U_USD">6995000</wve:NetIncomeLossAvailableToCommonStockholders>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="-3"
      id="F_239cd6ee-b7d9-4a84-a008-52bdb40c1764"
      unitRef="U_USD">-39004000</wve:NetIncomeLossAvailableToCommonStockholders>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="-3"
      id="F_27569a5f-abbd-440c-99ab-f6499feee621"
      unitRef="U_USD">-41257000</wve:NetIncomeLossAvailableToCommonStockholders>
    <wve:NetIncomeLossAvailableToCommonStockholders
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="-3"
      id="F_60cbd849-7e0f-4881-ba13-67dff7c3d39b"
      unitRef="U_USD">-118114000</wve:NetIncomeLossAvailableToCommonStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="0"
      id="F_1931bbfb-6b8a-481c-82c6-0df09c82bcea"
      unitRef="U_shares">106025063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="0"
      id="F_15f42d10-735a-47c1-9b37-d3d2fb7d38e8"
      unitRef="U_shares">93900484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="0"
      id="F_37c29f07-d216-4a6b-971c-0091a5e345e2"
      unitRef="U_shares">104529266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="0"
      id="F_4cb73cd2-38b6-488a-b4c3-ca9e46618c5e"
      unitRef="U_shares">73754417</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="0"
      id="F_9bdf9e08-1231-4434-a4f0-e20f3a5680d7"
      unitRef="U_shares">950168</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="0"
      id="F_9f899093-9538-4697-a0a6-f4b62c15c3e0"
      unitRef="U_shares">106975231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="0"
      id="F_191e1dd3-2fc3-4560-8f52-0a132bbf245f"
      unitRef="U_shares">93900484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="0"
      id="F_ed7273a8-e9de-47e1-aa53-4ddbbfbb3062"
      unitRef="U_shares">104529266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="0"
      id="F_2e13390d-b58e-45c3-a2fc-a465b8ed80a5"
      unitRef="U_shares">73754417</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="2"
      id="F_388d7700-ecf4-4c89-be82-1a54d2495d02"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="2"
      id="F_e6ffe73e-fdf9-4266-a844-36a448ae7d1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="2"
      id="F_878a959d-6e73-4fee-986a-ec183ba2bae4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="2"
      id="F_dafaa54c-5464-41a4-b5f3-81028f4cd3f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53b91417-a246-4bc6-83db-9e8a41010b3f"
      decimals="2"
      id="F_99f5b96f-67f4-459e-9e96-8ab15b27fc3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="2"
      id="F_95cd0744-08b7-41b3-b69c-af89fadc70e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      decimals="2"
      id="F_f1a7c3ee-6d76-41f8-b580-a822751a777f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="2"
      id="F_2c84e9da-89df-4d0a-90cb-c1df73a89a52"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_16f0377b-22a2-43ee-8684-91657a586a17">&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes awards that were excluded from the computation of diluted earnings as their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.18%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9,470,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,332,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,303,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,907,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;"&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;62,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;521,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;85,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;802,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b444e81-468e-4a28-afad-15b895940ca5"
      decimals="INF"
      id="F_581da5fc-837f-40ed-a7d6-e3e42a166105"
      unitRef="U_shares">9470166</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8d17bd9b-fc3b-4ebf-a913-cc842346df8b"
      decimals="INF"
      id="F_2dee1b04-0575-424a-b232-cdc076db1fda"
      unitRef="U_shares">8332977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_883042b4-2458-4bfa-b9a2-8b427c1b5850"
      decimals="INF"
      id="F_40e42138-b622-4f0d-8563-da34bf106f2f"
      unitRef="U_shares">10303670</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c5faabcb-be56-4b08-bc24-70fe0b903474"
      decimals="INF"
      id="F_e3e24b15-a3db-4708-bb52-d5faeec6c659"
      unitRef="U_shares">7907290</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3160b90d-92fd-4f20-8899-bd69ca3f321d"
      decimals="INF"
      id="F_e8ae3cfb-5d9e-41ef-9266-3f1861ee8843"
      unitRef="U_shares">62899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a97c8ae9-b044-4820-96e5-a71d47eaadf7"
      decimals="INF"
      id="F_f684bccf-2e51-4d36-8ec4-ab6dab98c92d"
      unitRef="U_shares">521146</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8adc395c-a848-43c3-81d7-7bf7b1af08f5"
      decimals="INF"
      id="F_f62a7f4d-5bfc-437c-a3e4-599a34ac9f94"
      unitRef="U_shares">85648</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3abbdbcd-9d9e-40d7-bd45-c1f8652ed620"
      decimals="INF"
      id="F_30d64865-43d8-4372-b75d-df9ea90648ea"
      unitRef="U_shares">802355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_107d6194-71a2-411d-9e0b-c14708db4b15">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. INCOME TAXES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three and nine months ended September 30, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company recorded an income tax benefit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million due to a provision to return adjustment in connection with the recent U.S. tax guidance relating to the capitalization of research and development expenditures. During the three and nine months ended September 30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; income tax benefit or provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintained a full valuation allowance for the three and nine months ended September 30, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in all jurisdictions due to uncertainty regarding future taxable income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0e8e072b-2447-4085-9e05-53042061b71e"
      decimals="-5"
      id="F_397a2a00-b5de-4526-a87f-f856928e9b5a"
      unitRef="U_USD">-700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fda03e0b-63d3-4280-b99e-297c22e0b692"
      decimals="-5"
      id="F_734c5ab7-909a-49c1-85f1-de033a0a88f6"
      unitRef="U_USD">-700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2219b93b-3833-4eb7-8a14-84b6377f1837"
      decimals="INF"
      id="F_c1ff3fb4-34c6-4447-b00e-ecf6e0071fd7"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5bac94f8-c57f-4a0c-8372-0194e5de1432"
      decimals="INF"
      id="F_0e0b31e4-a190-4e13-9106-75804acaeabe"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <wve:GeographicDataDisclosureTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_555e4c0d-d913-49c0-94a2-5031e15dfd35">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. GEOGRAPHIC DATA&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Substantially all of the Company&#x2019;s long-lived assets were located in the United States as of September 30, 2023 and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</wve:GeographicDataDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac"
      id="F_b9473b5b-0312-4022-9303-5338b6d63009">&lt;p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had the following related party transactions:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company&#x2019;s founders and a member of the Company&#x2019;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand per month, plus reimbursement for certain expenses. In October 2022, the compensation committee of the Company&#x2019;s board of directors granted Dr. Verdine a non-qualified share option for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;163,467&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares in lieu of cash as payment under this consulting agreement for the service period of October 1, 2022 through December 31, 2024, the monthly vesting of which is subject to Dr. Verdine&#x2019;s continued service under the consulting agreement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2023, the Company engaged Shin Nippon Biomedical Laboratories Ltd. (&#x201c;SNBL&#x201d;), one of the Company&#x2019;s shareholders, to provide approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in certain NHP contract research services to the Company. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the nine months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company paid SNBL $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the aforementioned contract research services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; During the three months ended September 30, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t make any payments to SNBL.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <wve:AgreementTerminationNoticePeriod
      contextRef="C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6"
      id="F_367d8f8d-1a66-4d5f-9941-75e6fcc89885">P14D</wve:AgreementTerminationNoticePeriod>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6"
      decimals="-3"
      id="F_5d636404-0514-4ff0-ac90-72143e70d1a3"
      unitRef="U_USD">13000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_00b8ed9d-656c-4ce6-a17b-1713a99a3935"
      decimals="INF"
      id="F_5abe5884-81fc-4a5f-857a-2e8964ff0764"
      unitRef="U_shares">163467</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_e9be0c66-eeb0-4d40-b8a8-bef5175660c7"
      decimals="-5"
      id="F_df4ea494-c629-478e-8a9c-68ded1495493"
      unitRef="U_USD">2800000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <wve:PaymentsRelatedToContractResearchServices
      contextRef="C_ffc4f0bd-1ed1-49eb-882b-b9fd1a18891e"
      decimals="-5"
      id="F_59565b06-b947-4482-abad-ddbbde971fe2"
      unitRef="U_USD">1400000</wve:PaymentsRelatedToContractResearchServices>
    <wve:PaymentsRelatedToContractResearchServices
      contextRef="C_57950620-43a2-4507-aaea-bddaf12233fc"
      decimals="INF"
      id="F_076bc99b-03c7-4921-af6f-73a78eba82d2"
      unitRef="U_USD">0</wve:PaymentsRelatedToContractResearchServices>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MFD+1S/1ISU'2GL-[ZV10:)3N<^6]DP[HXL$I@RXG\;P&[Z0#:%51NKK%.^G
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M+W-H965T-RYX;6RM66UO&S<2_BN$>B@20);?TJ1); ..F[9ID\:(XRL.A_M
M[7*UO'#)#<F5HOOU]\R0^R)'=G/ ?;&EW>7PF9EGGAFNSC;.?PJU4E%\:8P-
MY[,ZQO;%X6$H:M7(L'"MLKA3.=_(B*]^=1A:KV3)BQIS>')T]/2PD=K.+L[X
MVK6_.'-=--JJ:R]"US32;U\IXS;GL^-9?^&#7M61+AQ>G+5RI6Y4O&VO/;X=
M#E9*W2@;M+/"J^I\=GG\XM43>IX?^+M6FS#Y+,B3I7.?Z,N;\GQV1("4444D
M"Q+_UNI*&4.& .-SMCD;MJ2%T\^]]9_9=_BRE$%=.?.G+F-]/OMQ)DI5R<[$
M#V[SJ\K^_$#V"F<"_Q6;_.S13!1=B*[)BX&@T3;]EU]R'+YEP4E><,*XTT:,
M\B<9Y<69=QOAZ6E8HP_L*J\&.&TI*3?1XZ[&NGCQL5;BRC6MM-NSPPB#=/FP
MR(M?I<4G]RQ^+MXY&^L@7MM2E;OK#P%D0'/2HWEU\J#!&]4NQ.G17)P<G9P^
M8.]T\.Z4[9W>8^^]7TFK_R.) '/X:8,SNI2)#[84UUX%96.ZX"KQL[;2%EH:
M<8.+"N2+0?SS<AFB!WW^M2]""<"3_0"HI%Z$5A;J?-;27GZM9A???W?\].CE
M ^X]&=Q[\I#UOTK>@XOW0SM>B(^_OA97[]]=7_[Q#S&-G_A3KI5XJRLE;@JM
M;*&">!O+A7@4W4K%6GE0-]9"(V2A6P9=:NFU"G/Q_7<_GIP<O:3U_/'XI7!>
M8$5_)_N0;SX6.@@I"@#6A30'(4(=Q(<_+D6C2EW C2"*M(+^-SI&58KH4(P&
M%>ZU70D#F =%+>V*OD7(54S)A(R)5KG6*!1S)(U:8=U:!B(!?=9!H<C#0MP&
M^G[]X<W-N[GHL1\_>QE$ZUT+SR)$C)XO'#;=,I]*W[$Y:%U+^XG6R$C*"6]E
M%,K*I0%Z<ATQ+[ 7G@YZ!7*Z-NIFH"H9PS9E5_34M-C%B!"5!_K.*P$FKYSM
M"J-<U"7%F1.$V)$.LMNNQR(J[4,\H+ O%3YH>U 8&<(DH@P0+B&5C ^,MZ'P
MNH4"*>08EZK.  'N X[7R[2Y+J"LNA2/<BZ1IR&/C8/X=N1Q\@5IJKQKV'[=
M-=**E;(P_YB@<I*&^"<N25%#5>'%RBM%VW:VP?Y6*?!NPGZQD4%H6SC?.B^)
M#MJ*&\1 XCL66O%;9[;BY)24Y?B$PUO3DDC0L%"WJ/G;Q<T"FU2Z4+3^2C9+
MK\N5FHMWB)4LZ@[.HP4^O#,#YPQWN!88-FBZ!)LI)QO'I'46>&IERDQE/21P
MM\)N;R[GXHTM%D. ^2%<[J,,LHB?E)$;"4]['$2:1T0\Y;'/>QN=USH9>IS8
MM6>OWR2 [-N-;TSWZ\O/)7V UQTZ0*II( GD,R^:@+BJM9<&"5_,63=@:%/K
MHA:N*#KO80.8T0 @NTN8.LZY6@ ]XK\5I\=\X>G>,+WQB "\>HL:HB3LP,\W
M!UI2RAA6*20IS:9V!@!1'AN+:X-X;<F-^U0/J"Y!'2,2SF?[L_?[?D2WO_]_
MP4P(.5$I36-6FGMT!,$$%(VI72#*Q)":S"V5LKU.$$,IC&KMS'J0OR0D2:9Z
M0:&GB,?*4[L$!>[J$7'!RU9U41>@MBS7U%FI O9@+7550=ALU%Q"H#!4TV@W
M%\M.F_*^9=2VI"_J^8[F$C1H2U?!\XZ[00$J+K7A($RA0)567C94P"1 V"$U
MG3FDSA-^7IS[T,X>R$7HP-T[3:HW^!>XL1W&4,RE'<Q2-U$^;E-90F@29EFJ
MSQVB0>!UQ'- &+J60D,VH2MC8A?@Q.<.-(E;4CW*<0QCGN=3$*Q[UD627I44
MBZ[F9H.0KI7MU*B0-A<GVA4^$#*"FYJE<8%;Y4?P Y:^WB=Q4(//%0E$R;CR
M>@QC>-Z[#@*/Y];D*]IED:<N1+A4RY1-1()<"P0A)['MEH9:#^XZGCV\6FGN
MCB5).*>.C=".7ZW/]#5&+EV/)>NV]N"?]"FLMV"DV?&J2$V+(R>H)#3:A;1C
MX+C!]=$,TA!87:&BE-^-C_K2@@&!\EI@BM:T&)\K'D'5OBC)W$>&<34'@4::
M',#L*:YP\)*Q% J? Q5<YPM"E=2W@;0BR:9#R78MT/<5I $].HNDR&V>G<BU
M;XC:94]=68*2> SL'9#PAL2_)>ZOI38T$HE<?GUL^+A&[$TWE:>2@@<8$*0Q
M2>]@D&MZ2XN]I%FJ+Q69$KRIH6PT*U!7=ITID^!)7%M).@P*C>V0)FRWKTRK
MX32 !"5/4HV.^Z+'ARZ5V[(+-$A!92.18[5%()B!8T_K3S9W"P5<E*%.I*0/
ME,4UJ)/KX&]HAL\7SRDET$2[.W\,-*+YC<G^!7605.\^FQL8HOB'CH8=38)&
MS$.)WBW0*@7=8"9+8Z%57_!AHPRBU_#A;Q<.53V=DDLB1<CH,F$MJUO3]JR&
M82(#BF7-#%BJ-$E!:F)2PVF8Z%$,8(QP)$Z?<K2"Q&OP&Z2E4025JJ-@^;+1
M#)%:B#?5WG2CBC4-@B2)H\;!, [XN(OIBFB+,5"CF'G"K+I(DSB>U:XD4<*8
M04V;=B+"X&9(?%?IA+)4?6>!W300PXSS/#LYK(LJ>XW#0&]8T/DB5RO? JT/
MQ@B,GB>.4UWEDN*,[G-US#"B88<ZG7\5<'Y[,A;8M*!A&ZE6%0W8.LWD?+)I
M2.ZXE_9%DVA$%G(S3D6*=95<0TD(;9G4#]WB$P;\R5*LS 4%I<-U3$,]]CFI
MJNVWNUL0P$1DG' \028LQ*%,#-H@YW%,.B42H?F@PZ<D);>09!\E&C=UCRGA
M-9]V_]V'B5>D 3\I>Q[N*<^$<JE=5$5MG7$K$MZR@W>] F-KFAPB$\WDP3%B
M"K)J(X9E/(QHBP-A'P944%3#27%Z/!WWF@MZ14<ND(,T@7A*XT.#4JF(QHJ[
MD16?U)8(&1PH;N;LF='<JK@'K(BEEH<CM.+.9 'IJ[BO +<D"'L[P_XQ=C)&
MCO,:"Y@G2?.[77ABMQ\.T\%\,KNI"A2(U);[H*?""]01Z%C>#WRLG?V7J)*J
MTL7LH*/INB7YDH:2H)W/.1_&XJ%53V<L("WI+91*VHFZRI#VN]2X+C>"B7>Y
MBN;CG#CD!GY5'GKMNX)IS1/4X."8MP.O:)J\FW?&1$=)Z.>2-"_-I)SI])+@
M@4G\OF!/6@[Z>@A59^;)VHA_)'&57P]]T]P\F$[44F5O>(QXZ"'Q\1Q/9Q9:
M15BH3KYF[S2YZ755MIDNJG(TW@,8$X]NL]:D:POQ^FN)FKY(8D+L"QC)XS18
MD#-(3=?K$ \W]TR6C.=_'%)WNWA2PJ1:H(&R:XW!L#_YH!XU*H/>KO&+DHF@
M4?KIR!JIF?+@U+0JIM$I;5I+WV#(IWK.);8KB8-B+L0K&33S?N<U[=UI Q6+
MR5,EF<'4F&XQJX?WO?3B:1CFPOAJ%^#Q$!V_-1.)=(SC1AE,$RB=CV"TLZDQ
MI)=%9A3T6\LJS>^+PW#*YU=)OUQ>7@_G?/(42_A&23.TAX?[W@$?3E[F@TXK
M_LF">@H@I/?ZP]7A5Y'+]&/ ^'CZ2>6=]"L-$3:JPM*CQ;,?9NA0_#-%^A)=
MRS\-+%V,KN&/M4)%>GH ]RN'U.0OM,'P6]'%?P%02P,$%     @ ZCYI5T>+
M0I03!P  %1,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RE6-N2VS82
M_1644I4:5VDEC>0D7L^E2E;&SNS&]I3EV7W8V@>(;(J(08 !0,UHOSZG 9*2
M)M+$F[Q(O #=IV^G&[Q\L.Z++XF">*RT\5>#,H3Z]7CLLY(JZ4>V)H,WA765
M#+AUZ[&O'<D\;JKT>#J9?#^NI#*#Z\OX[,Y=7]HF:&7HS@G?5)5TVS>D[</5
MX'S0/?BDUF7@!^/KRUJN:4GAOKYSN!OW4G)5D?'*&N&HN!K,SU^_><GKXX)_
M*7KP>]>"+5E9^X5O;O.KP80!D:8LL 2)OPTM2&L6!!B_MC('O4K>N'_=27\;
M;8<M*^EI8?6_51[*J\&K@<BID(T.G^S#3]3:\QW+RZSV\5<\I+6SZ4!DC0^V
M:C<#0:5,^I>/K1_V-KR:G-@P;3=,(^ZD**+\409Y?>GL@W"\&M+X(IH:=P.<
M,AR497!XJ[ O7"_5VJA"9=($,<\RVYB@S%K<6:TR1?YR'*"$EXZS5N";)'!Z
M0N#?Q7MK0NG%C<DI/]P_!K@>X;1#^&;ZK, EU2,QFPS%=#*=/2-OUEL\B_)F
M)^0=L5+\9[[RP2%#_GO,X"3OY7%Y7#6O?2TSNAJ@+#RY#0VNO_WF_/O)Q3-H
M7_9H7SXG_<_$YWF!TY%8WK[[</OV=C'_\%G,%XN/]Q\^WWYX)^X^_GR[N+U9
MBL\E";^G5^[TUIW'<O*94RO*A3(B8,/"5K4TVV^_>34]_^'""]GD*N!UH8PT
MF9):^" #H9X#7GIA"R$-7EL7MV]).D&<,N)'RJA:D1.S\QCTZ3"NY%7&!NC&
ME:-@A^*A5%DII". R'23GT8S-Z8!A$]46Q<$V(!+6IQ/_O;/KT10*(T7#RJ4
M<?&2LL:IP)Y@;#>/62G-.NJME(^,=<;*IY.+Y<TB7IU?O&#%[Z4#YNDLY?.0
M72&KI/:,);>[6.LSJ#N)0U'*#>$GAV_ "X$<NSJA090 $E&+KD,>B"J59E*'
MP@JMF9,.#3UF>,J@=@%>,7./Q+TG#MJ-#XKU^)@F3_V<6>.1(KD\'7I$"W52
MXS]&BY/+Y5A'R;OWH^5(O)O/[T9105HJ(X-#^['8'E>#J#C2$4>N?*:M;U"=
M>/9KHUQ*HDZ2".RZ+R2HMXVW2X].5;-F7BWAE:) +XD[70P)9,N*2R-FL_<4
M_%!H)5=*Q]P88MV&3$-#.,:WJ.@1#=7328@CI(A!/V0[HC]53LX#(( 6H"B+
M&_BM;6R(KJQK9VO$/=">+XX5+6O$UAR@M*V[S/@CJQ&PQN]*ZTA$CD7@P(P*
MC8QQZNT!L?S2Y.OX/HI6'K)M1MZ/]G.+\T\!<0M'!=]Y%?^9A;0()1JY'0I@
M"RIKM'10=B9?Q+B@(KLR:&+& WA-+LXTG'EVI=4ZFN0OQ-GJ!5R$2D*[[;:A
M.1@OTR !5V>$91ED:VTS&4ZNXLR*/CNNJW,IHAR[ST6,P%G^>_VU#'@ AV\
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M0;O/#V<J;C),:B4$GNR4&/YX[FH=V$^9ZX&ZHU<,-@N)-Z +P>\[*BOT'TY
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M /N-SC'LH0SM95LLPS4$6UT_WZO-->DJ"QIW:E4[;B [GZ?Y  -7\,ZG1/#
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MTX(>,M2N@-:W2ME]X#;HGL;D+U!+ P04    " #J/FE7U]B*&HT$  !]"@
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MYL;CN1*&&=Z';,4 ZPMC_&8B ;8OSO'_4$L#!!0    ( .H^:5=*-F=V7@8
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M;@0(3,).]HU9H)#F/* BZI"DMB!QA!;@CP6"JRXG.0<@[T8=(%'4\Q#Q/#3
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MV#_!UV]/HN_X^F_PK>F+R\V=@#L6RC7YM8BU4?CM_#Z6<LTX.,YHZVFJ2YK
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M>0F5RD5%)"S&SKE[>A&:^_;"MQQ6:FM-C"<S(7X8X6,Z=I@!! 7,M;' \?,
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M2',!SQ="Z+5@'MC,II/_ 5!+ P04    " #J/FE7IR.T&ED"  !(!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RM5-%NVC 4_17+JZ96ZDA(* 4&
MD2BH6A^FH=)N#],>3'(A5AT[M0UI]_6[=D)$-:CVL)?X^OJ>XWM.;(\KI9],
M#F#)2R&DF=#<VG(4!";-H6"FHTJ0N+)6NF 6IWH3F%(#RSRH$$$4AOV@8%S2
M9.QS"YV,U=8*+F&AB=D6!=.O-R!4-:%=ND_<\TUN72)(QB7;P!+L8[G0. M:
MEHP7( U7DFA83^BT.YK%KMX7?.=0F8.8."4KI9[<Y"Z;T- U! )2ZQ@8#CN8
M@1"."-MX;CAINZ4#'L9[]ENO';6LF(&9$C]X9O,)'5"2P9IMA;U7U1=H]%PY
MOE0)X[^D:FI#2M*ML:IHP-A!P64]LI?&AP- MW<"$#6 Z%\!<0/PS@5U9U[6
MG%F6C+6JB';5R.8"[XU'HQHNW5]<6HVK''$V><B!S%11,OE*/I%IEG'G+A/D
M3M9'Q'E]/@?+N+C BL?EG)R?79 SPB5YR-76,)F9<6"Q%\<8I,V^-_6^T8E]
MEU!V2!Q>DBB,XB/PV?OP.:0([WIX]!8>H .M#5%K0^3YXA-\W_2&2?[;R[U$
M0Z11@F>U>A1(%AH,2%LGU)K<<LEDRM&G)28!C[4UY.=T9:S&@_GKF!]U [WC
M#;C+.C(E2V%"2[>7W@%-/G[H]L//Q]SY3V1OO(I;K^+WV),9,[DW)74!/&_Y
MC@EGP#'5-57?4[D799=TX^&PA_]L=ZCG[[+!H#>\;JOJ1H.#<^[>F*],;[@T
M1, :<6'G^HH27=_;>F)5Z8_^2EF\2#[,\:D#[0IP?:V4W4_<;6H?S^0/4$L#
M!!0    ( .H^:5=ROR-:LP(  (P'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;*U574_;,!3]*U:&)I V\IUV+(T$Z= F#5%1V!ZF/;C);6/AQ)GM
MM/#O9SMI*"4@T/;2^..>TW.NKZ_C#>.WH@"0Z*ZDE9A8A93UB6V+K( 2BV-6
M0Z5VEHR76*HI7]FBYH!S RJI[3E.9)>85%82F[493V+62$HJF'$DFK+$_/X,
M*-M,+-?:+ER152'U@IW$-5[!'.1-/>-J9O<L.2FA$H15B,-R8IVZ)VFDXTW
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M:L9F6*CG$K@.4/M+QN1VHCMR_P G?P%02P,$%     @ ZCYI5Q#_6>+U"
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M%X1.P/64<W4(=&=W#WGT#U!+ P04    " #J/FE7#>7K&QT2   '!0$ &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6S-W5MSFUBZQO&O0GEW3<U4);9
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M@0ES,6$>)FR)"?,Q80$2K&;F867FX0=-%8:8AL:$+3!A+B;,PX0M,6$^)BQ
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MMI1)YLLD"V22K221M;1K-]JU+RLC/?'BMT4C/5HT7A=;FWK]&5;K3Y&8[=Z
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M.;P4D^K NKIA."M/,U\P8S@I+_<(<LD6!OSW+<;L[:9PT/S;P/P'4$L#!!0
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MN/?@WOLH7K^GXLU_ST:_ 5!+ P04    " #J/FE7EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( .H^:5<@>6:P$@,
M "84   /    >&PO=V]R:V)O;VLN>&ULQ9A+3^,P$(#_BI43>V#3A+8\1)&@
ML&PE1"O:Y;J:)FYCX=B5[?#Z]3M)J' $'>W%ZBGUH\[G23+?).<OVCPMM7YB
MKZ54=A05SFW.XMAF!2_!_M0;KG!DI4T)#IMF'=N-X9#;@G-7RCCM]89Q"4)%
M%^?;M68F]AO:\<P)K;"S[G@4_,5^CM=-]BRL6 HIW-LH:GY+'K%2*%&*=YZ/
MHE[$;*%??FLCWK5R(.>9T5*.HJ0=>.3&B>Q+][R&7,#2-CT.E@^ (*-HV,,%
M5\)8U\QHU@=D?.8XN6U53O\2TG%S#8[?&EUMA%K7R^ N8F\;31RVQS:(9^9_
MPJA7*Y'Q:YU5)5>NC:/AL@94MA ;&S$%)1]%VRD,5,YNE,,@L8EJE\*Y]4[Q
MU).\W;5#7"^&YDS@@)GD#7@XR#\*JEPXGK,QCF@I<J@;5R!!99QYD"D!F>X1
M\F_J01X1D$=[@9S7./A7#[)/0/;W"-F)Y(" '.P3\LB#'!*0P["0BX(C7KD!
M]>8!'1- QV&!YF*M!,X%S#B76:8KS#AJS688OTQPZT&>$) G82$1S%1X+6]>
M<1'+;9,;IZ[@AHTK8SS(4P+R-' D"S#\\ IL<P>6->F7C-VC4G8O+-\850E+
M;9H1=KDVO$XPSK_$":F4P$ZYQW4G*M,E9P=WVMH?;(;7=VIRH<"\^4Y)**DD
M@:WR@;B U\[3D5 .20)+Y);KM8%-(3*&]0OX6)0UDL#:>*@[\6F8@<$B9F$
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MZCYI5TT=HB7N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ ZCYI5YE<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #J/FE71L2-
MR>\%  #!'P  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ ZCYI5[D+VHN&!@  Q1P  !@
M ("!,@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .H^
M:5<XK58Y^@(  %8)   8              " @>X4  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " #J/FE7Z/.F0K<&  #L(0  &
M        @($>&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ ZCYI5Q' D,$L%0  ^AP! !@              ("!"Q\  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .H^:5<M-V=Y4 <  /(@   8
M              " @6TT  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " #J/FE7%:@6PIX*   W&@  &               @('S.P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ZCYI5T>+0I03!P
M%1,  !@              ("!QT8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( .H^:5>M<YP-T (  &P&   8              " @1!.
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #J/FE7K7?[
M]AH'   ^$@  &0              @($640  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( .H^:5=-A^>*3QL  &1Z   9
M  " @6=8  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MZCYI5\W/B>E@!P  @10  !D              ("![7,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " #J/FE7P:^-(_\"  #T!@  &0
M            @(&$>P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( .H^:5>(15B650(  "8%   9              " @;I^  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ZCYI5]?8BAJ-!
M?0H  !D              ("!1H$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " #J/FE72C9G=EX&  !L$0  &0              @($*
MA@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .H^:5?I
MU2,ML (  $X&   9              " @9^,  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ ZCYI5^YL ?B+ @  FP4  !D
M     ("!AH\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .H^:5>,YZ2@70(  -0%   9              "
M@5NE  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ZCYI
M5PWEZQL=$@  !P4! !D              ("![Z<  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " #J/FE7#ZA[7:($  !C(0  &0
M        @(%#N@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( .H^:5<:SRDL+04  $(@   9              " @1R_  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ZCYI5^UI\%)T P  A@X
M !D              ("!@,0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " #J/FE7BNL%[R@#  "2#   &0              @($KR
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .H^:5=QP\U:
M. 0  /86   9              " @8K+  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ ZCYI5WMCBQ(V P  2A,   T
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;72YX;6Q02P4&     "4 )0#Z"0  O-H

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>146</ContextCount>
  <ElementCount>180</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Unaudited Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets</Role>
      <ShortName>Unaudited Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Unaudited Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit</Role>
      <ShortName>Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Unaudited Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Unaudited Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Net Income (Loss) Per Ordinary Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare</Role>
      <ShortName>Net Income (Loss) Per Ordinary Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Geographic Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureGeographicData</Role>
      <ShortName>Geographic Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactions1</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Net Income (Loss) Per Ordinary Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables</Role>
      <ShortName>Net Income (Loss) Per Ordinary Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100220 - Disclosure - The Company - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail</Role>
      <ShortName>The Company - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Net Income (Loss) Per Ordinary Share (Additional Information) (Details) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail</Role>
      <ShortName>Net Income (Loss) Per Ordinary Share (Additional Information) (Details) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Income (Loss) Per Ordinary Share - Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail</Role>
      <ShortName>Net Income (Loss) Per Ordinary Share - Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Net Income (Loss) Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Earnings (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail</Role>
      <ShortName>Net Income (Loss) Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Earnings (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="wve-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="wve-20230930.htm">wve-20230930.htm</File>
    <File>wve-20230930.xsd</File>
    <File>wve-20230930_cal.xml</File>
    <File>wve-20230930_def.xml</File>
    <File>wve-20230930_lab.xml</File>
    <File>wve-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img56423468_0.jpg</File>
    <File>img56423468_1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="433">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "wve-20230930.htm": {
   "nsprefix": "wve",
   "nsuri": "http://www.wavelifesciences.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "wve-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "wve-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "wve-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "wve-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "wve-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wve-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 153,
   "keyCustom": 27,
   "axisStandard": 14,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 21,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 3
   },
   "contextCount": 146,
   "entityCount": 1,
   "segmentCount": 30,
   "elementCount": 312,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://fasb.org/us-gaap/2023": 433
   },
   "report": {
    "R1": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Unaudited Consolidated Balance Sheets",
     "shortName": "Unaudited Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Unaudited Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
     "longName": "100040 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "shortName": "Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_53b91417-a246-4bc6-83db-9e8a41010b3f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_53b91417-a246-4bc6-83db-9e8a41010b3f",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit",
     "longName": "100050 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)",
     "shortName": "Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_0053e917-12df-482b-a1b1-4cf6b49da388",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_073c80a2-e6c4-48a5-8c06-850081b3c583",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Unaudited Consolidated Statements of Cash Flows",
     "shortName": "Unaudited Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompany",
     "longName": "100070 - Disclosure - The Company",
     "shortName": "The Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "longName": "100080 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "100090 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "longName": "100110 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "longName": "100120 - Disclosure - Collaboration Agreements",
     "shortName": "Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare",
     "longName": "100140 - Disclosure - Net Income (Loss) Per Ordinary Share",
     "shortName": "Net Income (Loss) Per Ordinary Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100150 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureGeographicData",
     "longName": "100160 - Disclosure - Geographic Data",
     "shortName": "Geographic Data",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "wve:GeographicDataDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "wve:GeographicDataDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactions1",
     "longName": "100170 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "100180 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "100190 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationTables",
     "longName": "100200 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables",
     "longName": "100210 - Disclosure - Net Income (Loss) Per Ordinary Share (Tables)",
     "shortName": "Net Income (Loss) Per Ordinary Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ce3af19-7ee2-42ed-9522-bd1481b6e6ac",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail",
     "longName": "100220 - Disclosure - The Company - Additional Information (Detail)",
     "shortName": "The Company - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "longName": "100230 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
     "longName": "100240 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_373691fb-08ed-497e-9cf8-b3671c52971a",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5ee08ac2-8a9a-4c40-92e9-b73ab7051fa6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail",
     "longName": "100250 - Disclosure - Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail)",
     "shortName": "Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
     "longName": "100260 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_44ca1475-425a-4297-bd8a-940ba67acc8a",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
     "longName": "100270 - Disclosure - Net Income (Loss) Per Ordinary Share (Additional Information) (Details) - Additional Information (Detail)",
     "shortName": "Net Income (Loss) Per Ordinary Share (Additional Information) (Details) - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_5297058f-1335-4562-8740-d05d615ccae7",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fc9ae55f-8f80-47d6-8a22-0a5e984c2852",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
     "longName": "100280 - Disclosure - Net Income (Loss) Per Ordinary Share - Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders (Detail)",
     "shortName": "Net Income (Loss) Per Ordinary Share - Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_53b91417-a246-4bc6-83db-9e8a41010b3f",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_53b91417-a246-4bc6-83db-9e8a41010b3f",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail",
     "longName": "100290 - Disclosure - Net Income (Loss) Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Earnings (Detail)",
     "shortName": "Net Income (Loss) Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Earnings (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_5b444e81-468e-4a28-afad-15b895940ca5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5b444e81-468e-4a28-afad-15b895940ca5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "100300 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_53b91417-a246-4bc6-83db-9e8a41010b3f",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0e8e072b-2447-4085-9e05-53042061b71e",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
     "longName": "100310 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6",
      "name": "wve:AgreementTerminationNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9ea873e2-95c0-4f1a-97a3-af9533d4e5e6",
      "name": "wve:AgreementTerminationNoticePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wve-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, Series A preferred shares and shareholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r80",
      "r354",
      "r511",
      "r545",
      "r552",
      "r589"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r290",
      "r294",
      "r306",
      "r556",
      "r557",
      "r592"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Series A preferred shares and shareholders' equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r330",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r492",
      "r503",
      "r512",
      "r535",
      "r554",
      "r555",
      "r560",
      "r601"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "wve_NetIncomeLossAvailableToCommonStockholders",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail": {
       "parentTag": "wve_NetIncomeLossAvailableToCommonStockholders",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r72",
      "r82",
      "r96",
      "r110",
      "r113",
      "r117",
      "r128",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r159",
      "r171",
      "r176",
      "r180",
      "r182",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r305",
      "r306",
      "r359",
      "r436",
      "r457",
      "r458",
      "r500",
      "r522",
      "r556"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r237",
      "r265",
      "r266",
      "r268",
      "r505"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r99",
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) attributable to ordinary shareholders, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r137",
      "r138",
      "r139",
      "r140",
      "r147",
      "r148",
      "r160",
      "r163",
      "r171",
      "r176",
      "r180",
      "r182",
      "r500"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r330",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r492",
      "r503",
      "r512",
      "r535",
      "r554",
      "r555",
      "r560",
      "r601"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r440",
      "r441",
      "r444"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactions1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r323",
      "r325",
      "r386",
      "r387",
      "r388",
      "r442",
      "r443",
      "r444",
      "r463",
      "r465"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r444"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r543"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) per share attributable to ordinary shareholders-basic",
        "terseLabel": "Net income (loss) per share attributable to ordinary shareholders basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r150",
      "r161",
      "r162",
      "r163",
      "r167",
      "r304",
      "r305",
      "r345",
      "r362",
      "r498"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of employee share plans",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r163",
      "r236"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r48",
      "r49",
      "r50",
      "r51",
      "r128",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r291",
      "r294",
      "r295",
      "r306",
      "r556",
      "r592",
      "r593"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r322",
      "r323",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r433",
      "r435",
      "r466"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r104",
      "r105",
      "r128",
      "r150",
      "r154",
      "r161",
      "r163",
      "r169",
      "r170",
      "r188",
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r208",
      "r209",
      "r212",
      "r215",
      "r221",
      "r306",
      "r380",
      "r381",
      "r382",
      "r383",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r416",
      "r437",
      "r459",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r532",
      "r544",
      "r550"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r326"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A preferred stock, shares outstanding",
        "periodStartLabel": "Temporary equity, Beginning balance, shares",
        "periodEndLabel": "Temporary equity, Ending balance, shares",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r61",
      "r81",
      "r171",
      "r176",
      "r180",
      "r182",
      "r346",
      "r357",
      "r500"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the ESPP",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r274",
      "r600"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r326"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Non-qualified share option granted for service",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r273"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r591"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid Expense, Current, Total",
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r191",
      "r192",
      "r494"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase ordinary shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "wve_TotalTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "TotalTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction price",
        "label": "Total Transaction Price",
        "documentation": "Total transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity investment aggregate purchase price",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r76",
      "r390",
      "r459",
      "r485",
      "r523"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In-Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r390",
      "r546",
      "r547",
      "r548",
      "r588",
      "r604"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at September 30, 2023 and December 31, 2022",
        "periodStartLabel": "Temporary equity, Beginning balance",
        "periodEndLabel": "Temporary equity, Ending balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r272",
      "r351"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares under the ESPP",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r76"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Data",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of pre-funded warrants, net of offering costs",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Shares [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r559"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r511"
     ]
    },
    "wve_TakedaPharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda [Member]",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "documentation": "Takeda pharmaceutical company limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrant outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "wve_CollaborationAndSharePurchaseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAndSharePurchaseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration And Share Purchase Agreements [Abstract]",
        "documentation": "Collaboration and Share Purchase Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r23",
      "r76"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r229",
      "r231",
      "r260",
      "r261",
      "r262",
      "r327",
      "r328",
      "r370",
      "r407",
      "r408",
      "r468",
      "r470",
      "r472",
      "r473",
      "r478",
      "r490",
      "r491",
      "r501",
      "r502",
      "r504",
      "r513",
      "r516",
      "r553",
      "r558",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Other comprehensive loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r14",
      "r111",
      "r114",
      "r119",
      "r307",
      "r308",
      "r313",
      "r343",
      "r360",
      "r540",
      "r541"
     ]
    },
    "wve_C9AlsFtdProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "C9AlsFtdProgramMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C9-ALS/FTD program.",
        "label": "C9-ALS/FTD Program Member",
        "terseLabel": "C9-ALS/FTD Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r168",
      "r330",
      "r379",
      "r401",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r438",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r517"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "PercentageOfOwnershipInterestInOrdinarySharesOutstanding",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of combined voting power of securities outstanding immediate effect of exercise",
        "label": "Percentage of ownership interest in ordinary shares outstanding",
        "documentation": "Percentage of ownership interest in ordinary shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "wve_ScientificAdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "ScientificAdvisorMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scientific Advisor [Member]",
        "label": "Scientific Advisor [Member]",
        "documentation": "Scientific Advisor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued under equity agreement",
        "terseLabel": "Issuance of ordinary shares, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r76",
      "r380",
      "r459",
      "r485"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r231",
      "r328",
      "r370",
      "r407",
      "r408",
      "r468",
      "r470",
      "r472",
      "r473",
      "r478",
      "r490",
      "r491",
      "r501",
      "r502",
      "r504",
      "r513",
      "r558",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "wve_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r229",
      "r231",
      "r260",
      "r261",
      "r262",
      "r327",
      "r328",
      "r370",
      "r407",
      "r408",
      "r468",
      "r470",
      "r472",
      "r473",
      "r478",
      "r490",
      "r491",
      "r501",
      "r502",
      "r504",
      "r513",
      "r516",
      "r553",
      "r558",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration and license agreement, deferred revenue current",
        "terseLabel": "Current portion of deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r228"
     ]
    },
    "wve_PfizerIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "PfizerIncMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer Inc. [Member]",
        "label": "Pfizer Inc [Member]",
        "documentation": "Pfizer Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r127",
      "r207",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r302",
      "r462",
      "r464",
      "r489"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r228"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "terseLabel": "Purchase of short-term investments",
        "negatedLabel": "Purchase of short-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r231",
      "r328",
      "r370",
      "r407",
      "r408",
      "r468",
      "r470",
      "r472",
      "r473",
      "r478",
      "r490",
      "r491",
      "r501",
      "r502",
      "r504",
      "r513",
      "r558",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Contract with Customer, Liability, Total",
        "terseLabel": "Collaboration and license agreement, deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement By Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Professional and Contract Services Expense, Total",
        "terseLabel": "Consulting service expenses",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "wve_EmployeeAndNonEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "EmployeeAndNonEmployeeStockOptionMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [Member]",
        "label": "Employee And Non Employee Stock Option [Member]",
        "documentation": "Employee and non employee stock option."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of ordinary shares, net of offering costs",
        "label": "Proceeds from issuance of ordinary shares",
        "verboseLabel": "Proceeds from issuance of ordinary shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r206",
      "r210",
      "r324",
      "r495",
      "r497"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In-Capital [Member]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r23",
      "r95",
      "r115",
      "r116",
      "r117",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r168",
      "r189",
      "r190",
      "r223",
      "r269",
      "r270",
      "r271",
      "r281",
      "r282",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r371",
      "r372",
      "r373",
      "r390",
      "r459"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "wve_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan [Member]",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "documentation": "2021 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares granted to employees",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r189",
      "r190",
      "r269",
      "r270",
      "r271",
      "r281",
      "r282",
      "r296",
      "r298",
      "r299",
      "r301",
      "r303",
      "r371",
      "r373",
      "r390",
      "r604"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive shares excluded from computation of diluted earnings",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "wve_AmortizationOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "AmortizationOfRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Amortization Of Right Of Use Assets",
        "documentation": "Amortization of right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsAndRsusOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r206",
      "r210",
      "r324",
      "r496",
      "r497"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_TwoThousandNineteenEmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "TwoThousandNineteenEmployeeSharePurchasePlanMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee share purchase plan.",
        "label": "Two Thousand Nineteen Employee Share Purchase Plan [Member]",
        "terseLabel": "2019 ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based compensation expense not yet recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Issuance of ordinary shares under ESPP, shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r76"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r546",
      "r547",
      "r588",
      "r602",
      "r604"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Shares [Member]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r104",
      "r105",
      "r128",
      "r150",
      "r154",
      "r161",
      "r163",
      "r169",
      "r170",
      "r188",
      "r197",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r208",
      "r209",
      "r212",
      "r215",
      "r221",
      "r306",
      "r380",
      "r381",
      "r382",
      "r383",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r416",
      "r437",
      "r459",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r532",
      "r544",
      "r550"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilities, Current, Total",
        "terseLabel": "Accrued expenses related to CROs and CMOs",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercises, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r76",
      "r246"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation of $41,596 and $37,846 as of September 30, 2023 and December 31, 2022, respectively",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r347",
      "r356",
      "r511"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-Dilutive Shares Excluded from Computation of Diluted Earnings",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "wve_AcheivementOfMilestoneIncludedInCurrentPortionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "AcheivementOfMilestoneIncludedInCurrentPortionReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acheivement of milestone included in current portion receivable",
        "label": "Acheivement Of Milestone Included In Current Portion Receivable",
        "documentation": "Acheivement of milestone included in current portion receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, no par value; 99,011,901 and 86,924,643 shares issued an outstanding at September 30, 2023 and December 31, 2022, respectively",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r350",
      "r511"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r95",
      "r115",
      "r116",
      "r117",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r168",
      "r189",
      "r190",
      "r223",
      "r269",
      "r270",
      "r271",
      "r281",
      "r282",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r371",
      "r372",
      "r373",
      "r390",
      "r459"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r128",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r291",
      "r294",
      "r295",
      "r306",
      "r415",
      "r499",
      "r524",
      "r556",
      "r592",
      "r593"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of share options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r25",
      "r297",
      "r300",
      "r318",
      "r371",
      "r372",
      "r540",
      "r541",
      "r542",
      "r546",
      "r547",
      "r548"
     ]
    },
    "wve_TwoThousandFourteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand fourteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r416",
      "r434",
      "r604",
      "r605"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31",
      "r150",
      "r154",
      "r161"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r467",
      "r469",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r516"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Total",
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r101",
      "r348",
      "r524"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares authorized for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r112",
      "r114",
      "r120",
      "r344",
      "r361"
     ]
    },
    "wve_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants (Member)",
        "documentation": "Pre Funded Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares available for future grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders-diluted",
        "terseLabel": "Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r163"
     ]
    },
    "wve_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "documentation": "Increase (decrease) in Operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders-basic",
        "terseLabel": "Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders basic.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r163"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r126"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Liabilities [Member]",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r85",
      "r125"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r76",
      "r353",
      "r374",
      "r376",
      "r384",
      "r417",
      "r511"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities [Member]",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from maturity of short-term investments",
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r322",
      "r323",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r433",
      "r435",
      "r466",
      "r591"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Options and RSUs Outstanding",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r40"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investment Income, Interest and Dividend, Total",
        "terseLabel": "Dividend income and interest income, net",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_CollaborationAndSharePurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAndSharePurchaseAgreementsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and share purchase agreements.",
        "label": "Collaboration And Share Purchase Agreements [Member]",
        "terseLabel": "Collaboration and Share Purchase Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract research services",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to Purchase Ordinary Shares [Member]",
        "terseLabel": "Options [Member]",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r168",
      "r330",
      "r379",
      "r401",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r438",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r517"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ]
    },
    "wve_ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "ProceedsFromIssuanceOfOrdinarySharesPursuantToAtTheMarketEquityProgramNet",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs",
        "label": "Proceeds From Issuance Of Ordinary Shares Pursuant To At-the-market Equity Program Net",
        "documentation": "Proceeds from issuance of ordinary shares pursuant to at-the-market equity program net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r549"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r467",
      "r469",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r516"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from agreement",
        "label": "Revenues",
        "totalLabel": "Revenues, Total",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r128",
      "r172",
      "r173",
      "r175",
      "r178",
      "r179",
      "r183",
      "r184",
      "r185",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r306",
      "r346",
      "r556"
     ]
    },
    "wve_GeographicDataDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "GeographicDataDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureGeographicData"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Data",
        "label": "Geographic Data Disclosure [Text Block]",
        "documentation": "Geographic Data Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r180",
      "r182",
      "r500"
     ]
    },
    "wve_DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "DevelopmentalMilestoneRelatedToHdCategoryOneProgramWhichPertainedToCompletionOfNewNonClinicalStudyOfWve003InNonHumanPrimatesOrNhpsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member]",
        "label": "Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member]",
        "documentation": "Developmental milestone related to HD Category 1 Program, which pertained to completion of new, non-clinical study of WVE-003 in non-human primates or NHPs member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r110",
      "r113",
      "r123",
      "r128",
      "r135",
      "r143",
      "r144",
      "r171",
      "r176",
      "r180",
      "r182",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r289",
      "r292",
      "r293",
      "r305",
      "r306",
      "r346",
      "r358",
      "r389",
      "r436",
      "r457",
      "r458",
      "r500",
      "r508",
      "r509",
      "r523",
      "r542",
      "r556"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Ordinary Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r164",
      "r165",
      "r166"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r232",
      "r533",
      "r534",
      "r549"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "wve_UpFrontConsiderationReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "UpFrontConsiderationReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Up-front consideration received",
        "label": "Up Front Consideration Received",
        "documentation": "Up-front consideration received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r232",
      "r533",
      "r549"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "PercentageOfGlobalCostsAndPotentialProfitsSharingRatio",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of global costs and potential profits sharing ratio",
        "label": "Percentage Of Global Costs And Potential Profits Sharing Ratio",
        "documentation": "Percentage of global costs and potential profits sharing ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r100",
      "r355"
     ]
    },
    "wve_ServicePeriodOfOctober12022ThroughDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "ServicePeriodOfOctober12022ThroughDecember312024Member",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service period of October 1, 2022 through December 31, 2024.",
        "label": "Service Period Of October 1 2022 Through December 31 2024 [Member]",
        "terseLabel": "Service Period of October 1, 2022 Through December 31, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_CategoryOneProgramsAndCategoryTwoProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CategoryOneProgramsAndCategoryTwoProgramsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category one programs and category two programs.",
        "label": "Category One Programs And Category Two Programs [Member]",
        "terseLabel": "Category 1 Programs and Category 2 Programs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_AgreementTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "AgreementTerminationNoticePeriod",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting agreement termination notice period",
        "label": "Agreement Termination Notice Period",
        "documentation": "Agreement termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r60",
      "r106",
      "r352",
      "r375",
      "r376"
     ]
    },
    "wve_ShinNipponBiomedicalLaboratoriesLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "ShinNipponBiomedicalLaboratoriesLtdMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shin Nippon Biomedical Laboratories Ltd [Member]",
        "label": "Shin Nippon Biomedical Laboratories Ltd [Member]",
        "documentation": "Shin Nippon Biomedical Laboratories Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "wve_OptionToReachMaximumTargetsForPreclinicalPrograms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "OptionToReachMaximumTargetsForPreclinicalPrograms",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to reach maximum targets for preclinical programs",
        "label": "Option To Reach Maximum Targets For Preclinical Programs",
        "documentation": "Option to reach maximum targets for preclinical programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": "wve_NetIncomeLossAvailableToCommonStockholders",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail": {
       "parentTag": "wve_NetIncomeLossAvailableToCommonStockholders",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: net income attributable to participating securities",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r531"
     ]
    },
    "wve_CollaborationAgreementInPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAgreementInPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement in Premium",
        "documentation": "Collaboration agreement in premium."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "wve_GeographicDataAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "GeographicDataAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Data [Abstract]",
        "documentation": "Geographic data."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants , net of offering costs.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r37",
      "r76"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (provision)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "negatedTerseLabel": "Income tax benefit (provision)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r92",
      "r143",
      "r144",
      "r174",
      "r277",
      "r284",
      "r363"
     ]
    },
    "wve_CollaborationAgreementCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAgreementCommencementDate",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement commencement date",
        "label": "Collaboration Agreement Commencement Date",
        "documentation": "Collaboration agreement commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureTheCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r77",
      "r377",
      "r378"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_MaximumTargetsForPreclinicalPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "MaximumTargetsForPreclinicalPrograms",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum targets for preclinical programs",
        "label": "Maximum Targets For Preclinical Programs",
        "documentation": "Maximum targets for preclinical programs."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of RSUs, shares",
        "label": "Stock Issued During Period Shares Restricted Stock Award Vested",
        "documentation": "Stock issued during period shares restricted stock award vested."
       }
      }
     },
     "auth_ref": []
    },
    "wve_PaymentsRelatedToContractResearchServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "PaymentsRelatedToContractResearchServices",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to contract research services.",
        "label": "Payments Related to Contract Research Services",
        "terseLabel": "Payments related to contract research services."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r326"
     ]
    },
    "wve_GskCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "GskCollaborationAgreementMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK Collaboration Agreement [Member]",
        "label": "GSK Collaboration Agreement [Member]",
        "documentation": "GSK collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation of property and equipment",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r109",
      "r128",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r290",
      "r294",
      "r306",
      "r511",
      "r556",
      "r557",
      "r592"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "totalLabel": "Additional Paid in Capital, Total",
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r511",
      "r603"
     ]
    },
    "wve_CollaborationAndLicenseAgreementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAndLicenseAgreementMonthAndYear",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and license agreement month and year",
        "label": "Collaboration And License Agreement Month And Year",
        "documentation": "Collaboration and license agreement month and year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r87",
      "r89",
      "r90",
      "r91"
     ]
    },
    "wve_EmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "EmployeeSharePurchasePlanMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP [Member]",
        "label": "Employee Share Purchase Plan [Member]",
        "documentation": "Employee share purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAdditionalInformationDetailsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Exercise Price Per Share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "wve_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "documentation": "Accrued expenses and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "wve_AtTheMarketEquityProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "AtTheMarketEquityProgramMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Program [Member]",
        "label": "At The Market Equity Program [Member]",
        "documentation": "At-the-market equity program."
       }
      }
     },
     "auth_ref": []
    },
    "wve_CollaborationAgreementCommittedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAgreementCommittedCash",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, committed cash",
        "label": "Collaboration Agreement Committed Cash",
        "documentation": "Collaboration agreement committed cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "wve_USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "USTaxGuidanceRelatingToCapitalizationOfResearchAndDevelopmentExpendituresMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Tax Guidance Relating to Capitalization of Research and Development Expenditures [Member]",
        "label": "U.S. Tax Guidance relating to Capitalization of Research and Development Expenditures [Member]",
        "documentation": "U.S. tax guidance relating to capitalization of research and development expenditures member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r88",
      "r93"
     ]
    },
    "wve_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting percentage.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "wve_CollaborationAndLicenseAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAndLicenseAgreementDate",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreement Date",
        "label": "Collaboration And License Agreement Date",
        "documentation": "Collaboration and license agreement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": []
    },
    "wve_OptionsToEmployeesAndNonEmployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "OptionsToEmployeesAndNonEmployeeDirectorsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to Employees and Non-Employee Directors [Member]",
        "label": "Options to Employees and Non-Employee Directors [Member]",
        "documentation": "Options to employees and non-employee directors member."
       }
      }
     },
     "auth_ref": []
    },
    "wve_PerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-based RSUs [Member]",
        "label": "Performance Based Restricted Stock Units [Member]",
        "documentation": "Performance based restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "wve_CollaborationBudgetedResearchAndPreclinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationBudgetedResearchAndPreclinicalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration-budgeted research and preclinical expenses",
        "label": "Collaboration Budgeted Research And Preclinical Expenses",
        "documentation": "collaboration-budgeted research and preclinical expenses."
       }
      }
     },
     "auth_ref": []
    },
    "wve_MaximumTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "MaximumTerminationNoticePeriod",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement termination period",
        "label": "Maximum Termination Notice Period",
        "documentation": "Maximum termination notice period."
       }
      }
     },
     "auth_ref": []
    },
    "wve_CollaborationAndLicenseAgreementResearchTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAndLicenseAgreementResearchTerm",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research term under collaboration and license agreement",
        "label": "Collaboration And License Agreement Research Term",
        "documentation": "Collaboration and license agreement research term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r70"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r102",
      "r128",
      "r171",
      "r177",
      "r181",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r290",
      "r294",
      "r306",
      "r349",
      "r428",
      "r511",
      "r524",
      "r556",
      "r557",
      "r592"
     ]
    },
    "wve_TimeBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "TimeBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-based RSUs [Member]",
        "label": "Time Based Restricted Stock Units [Member]",
        "documentation": "Time-based restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction."
       }
      }
     },
     "auth_ref": []
    },
    "wve_CollaborationAgreementUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CollaborationAgreementUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment under collaboration agreement",
        "label": "Collaboration Agreement Upfront Payment",
        "documentation": "Collaboration agreement upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "terseLabel": "Effect of foreign exchange rates on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "wve_NetIncomeLossAvailableToCommonStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "NetIncomeLossAvailableToCommonStockholders",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to ordinary shareholders, basic and diluted",
        "label": "Net income (loss) available to common stockholders",
        "documentation": "Net income (loss) available to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Collaboration revenue recognized",
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r175",
      "r178",
      "r179",
      "r183",
      "r184",
      "r185",
      "r226",
      "r227",
      "r330"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r70",
      "r125"
     ]
    },
    "wve_SharePurchasePriceAtEqualToFairMarketValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "SharePurchasePriceAtEqualToFairMarketValuePercentage",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share purchase price at equal to fair market value percentage",
        "label": "Share Purchase Price At Equal To Fair Market Value Percentage",
        "documentation": "Share purchase price at equal to fair market value percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue from termination of collaborative arrangement",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r587"
     ]
    },
    "wve_FundReceivableForResearchAndPreclinicalActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "FundReceivableForResearchAndPreclinicalActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund receivable for research and preclinical activities",
        "label": "Fund Receivable For Research And Preclinical Activities",
        "documentation": "Fund receivable for research and preclinical activities."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Increase in operating lease right-of-use assets and lease liabilities related to lease extension",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r510"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r98",
      "r128",
      "r188",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r291",
      "r294",
      "r295",
      "r306",
      "r511",
      "r556",
      "r592",
      "r593"
     ]
    },
    "wve_CategoryOneProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CategoryOneProgramsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Category One Programs [Member]",
        "label": "Category One Programs [Member]",
        "documentation": "Category one programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares outstanding",
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A preferred stock, par value",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r38"
     ]
    },
    "wve_CategoryTwoProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "CategoryTwoProgramsMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Category Two Programs [Member]",
        "label": "Category Two Programs [Member]",
        "documentation": "Category two programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "ScheduleOfOrdinaryShareEquivalentsOutstandingTableTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Ordinary Share Equivalents, Presented Based on Amounts Outstanding",
        "label": "Schedule of Ordinary Share Equivalents Outstanding [Table Text Block]",
        "documentation": "Schedule of ordinary share equivalents outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareSummaryOfBasicAndDilutedNetIncomeLossAttributableToOrdinaryShareholdersDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income (loss) per share attributable to ordinary shareholders-diluted",
        "terseLabel": "Net income (loss) per share attributable to ordinary shareholders diluted.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r150",
      "r161",
      "r162",
      "r163",
      "r167",
      "r304",
      "r305",
      "r345",
      "r362",
      "r498"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total shareholders' deficit",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r74",
      "r418",
      "r434",
      "r460",
      "r461",
      "r511",
      "r524",
      "r545",
      "r552",
      "r589",
      "r604"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r276",
      "r278",
      "r279",
      "r280",
      "r283",
      "r285",
      "r286",
      "r287",
      "r385"
     ]
    },
    "wve_GSKEquityInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "GSKEquityInvestmentMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK Equity Investment [Member]",
        "label": "G S K Equity Investment [Member]",
        "documentation": "GSK equity investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r439"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.wavelifesciences.com/20230930",
     "localname": "EquityInvestmentAgreementOfficialClosureDateMonthAndYear",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investment agreement official closure month and year",
        "label": "Equity Investment Agreement Official Closure Date Month And Year",
        "documentation": "Equity investment agreement official closure date month and year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted to employees",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) attributable to ordinary shareholders, diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r149",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r163"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.wavelifesciences.com/20230930/taxonomy/role/DisclosureNetIncomeLossPerOrdinaryShareAntidilutiveSharesExcludedFromCalculationOfDilutedEarningsDetail",
      "http://www.wavelifesciences.com/20230930/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs to Employees [Member]",
        "terseLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0000950170-23-061544-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-061544-xbrl.zip
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ME;WR@F&2]P?TV3!MY>+5%RYC;8D=(2<0AA)[AS0JLH9]AF\>*!_ZR=31&(?
MB.NM(W-/4D%N#OH+Q:B01R[I/?70KQOUG_M9GK\SI<\*// 11&^GH2''$I[R
MD7$ZV?$FP_^:;3-N\WRO>$7O_2G'FYNPR9*XQD:JHD=XRF\0PQB__R-AC.*
M^^H*P#--<(#9$!L.]#7DPH&98O#UX^QC@MMP[Z0[G[:3G",X<!N>['#GW0L'
MOH<MW.O[PH%7<?<F<&!_>6JBU*'#$.K6=O.X7Y_.Q?\9'- M@0.STO)4MX*^
M@77'NP\/TV1GAK'@%K/$7C[X3NH)\,R#]]MAT[=S%L<!;^B KB\-[QX5^?(?
M9^TY;AD>)(ABTZ7$/&DO\&5[>-4]"0X8HM_NL43#Z'..RFXCYPWO?#E.RTSJ
M.NZP(W_ @6=B^==888QEP!T0):LAK2&(T8*60HPD2VNTUVK 14BQQ2S/B%!
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M<Q=D:!59PPBWD42+](O$47XHA,ZM,3BR+,Q7$8&T(XO/!@>;K#$42=F[L$*
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MQGCU,/YFOT=EW$C="3V2^^0@ :W]:(Y"WMRHE0B;%TX3[C"50NR$,&;#CJ0
M8A28<E/T>=C)0G8S"W@[4N'^&4=-=&7\<IV%S!O?^AZ;S<7NS4S/Q(DMX;+J
MG\PB] )S\<<CCPD1HQPW18FK2O?9R=UC*2,(L0A7(C13]] ]SO-)[PI/0-1X
M"AJX/7WN'(S])VE^ME.9_9_0F33FN9Z,,.4-T1>;^B5>6-//.LW*<ME$#E)0
M2QC'OZ!P[?&>49<24VKX8?A-I?#H*>THE6>9X#%^RTAD<7?1PG,KHE;ST<>]
M<6>CAB7>=DO?O-R*%0D_!H[("G2L0Y7OPB '';KHLW@P;>5Z<9V)($-SEAK7
M,_]@MUT?V3EAL1#>/,_$;0W.1=%DQE L%27)ZVL-<(0E!,;RO':\9%YN\RH[
MAE;]Y+-[/TV<MG=KG-?JUVP%Z]<07(J$:$H*Z8M[MY+5;[;A=J1>I[2!&DL9
M).[C.Z"R.IO]*)H]=5.-!%[:<_OS,YMM-A%:)T>7,HV)#P;;FG?0\Y.9J5T>
M+\L0R7*%*?,$MG4YTI3-P #0]E*I_"J-Y2A@D5F92E?[M)8?(8)\+>;7ZD+U
MX<+=8B_^QHC>A!U,%$^UUBUM[G-J*7>LT)V-L*[5.'*ZUR>1R:4EX:_^@^9(
M_8(K7N IR*T![I1[5XEH)3O*+T3Y.U$;+]U9#]FMLH3L\('7/W7S2OU"O&>.
MDH(WZQMN#'*00A^PF#KI]\AAZ(=93=V<'8UK4Y[W$9/D(KU([W=$652J(X5M
M^IU_/:3&-A+_D!K_/Y >W[^8I% ??]3LG&U/AX%^)H :#6E$&X40N"67;B+7
M(SDA,:"&Y8\H^8XO$D%RT,I=MZM$#-7&8"1/*X;?]0X9Q53ZMH]^IRDX+[HG
M.)K^14Y5WM!DM=_QIIC&8C#]A^NMD[Y]!6F%-MG>*YHB=AEF;S-O-_%4U;%?
M!^(U;/9D:-U;V*E]P!WWS%&)C04OPT'^GE<\%S.>Y<C&O"YYC+;.>5CR2"HK
MX_@K=Z5B?C:TOG'+4FZH3K6&4DH&'>-!M(ZRBH8/J9G+DJ?\UCQZTZ#'A/J3
M-(V/(1C>I!]^C-I[EM9.'*#?R):6F#UK9PZ6(2/TAF@TH>G1QLCGK%G=FW$S
M&G:#=(8N??QGO'FGFQ9%]BU=CS#:-PL9=PK!H3Z0&K4].I5YMOWKZR^K+2DT
MS)K3H@1)YGDRB[]&&L.88N5CV'=)&6'TY?PO1'#A .43\"\J'SB0PZ4II96&
M7UD_>>9%U1C12]7<&(\H>67@82[B'8AI-_9/*X>5]5ZR4UGU_Q#=TV%\VV'-
M:^'B<8TYRPQQ.8!I "8%Z&0OYUW?KUF'8\2B@GJ:B%G4=60W$['B%EX%,[(V
MU].]O]<83#&SS[?;1VO ?&J=+8@0\ECT#EJ?//)D0XXN@INJCT?!&B,[MMYT
MJJ"=UZ8M)N['H873OAU1BE_!] :E'8#S'JK:K)QM81J,)A27HOF*+PD'(8O0
M\86S_]$%;^@U9M_GPBH[BW[EOE[[%IMIM2&&C_':&M8O'VG-^$9?O! 0CV2L
M2LARCW]](M SY,AB@,F^Z[[QDH APNC]I:J;'Y^R#?$3/:/;=LVZT_P"98'9
M!<R0>(:A\<C<G.&$3D[)>'*C@R=$<  Z8Q/9@E\1$6#[9=SUVZ<<A6\M2TJH
M:+UE<$"G,7E;]&E^*7@=XG!!<J56\Q])DJV3@H4G)IZRH;R_B3<<^(^PE'<9
MW?W9TWUMGJ#.:UZYX;Q6I'J$GUQ\A"GM+WN9^?J7&C?:TS#=IL&0&CDE2<1<
MR"(A#!KEZ$-><_JEZ$9.M^&:W="A<++-_(KX>B94]TT<*&I^:$G.=\$$42GM
MRT:TMW]"63CTJAI:),=:MJ:_CUYN-+A7+!2VK2LSTQT5,&P6I[=;67MV.N6@
M'-E\)YZ@K\^ADZ[4.F-9%\8R:6.WSV8:S_?SPF+%HKRI8<Y,=U+$T*[@,MB/
MB=+LL9X,Y[M/\K ?O5?=DFYK-Z'V,,:5\25/U_6;*ZF.4M1\%2X?B(XGO\JD
MW=FW(N'@M(,)I4,D?'6$!E]^<-=XOJ>X2FO3#(-<=L!/V3+$)^5Q"--Z2+>[
M!NYD,3.LM4);'ZOD&RH;0H6?8/WD,) 5,85J7S/<TO!-Z/'%L57$TYL;,[G/
MB_8SX%U5W[2 .IY93TB2!0UV;EY9_<A<S^6<78<5D[%T:A[)$_N@RIG6>KX>
M!6\%RG]&+!4@@HFH\QU4XTSK0J\5%[L<=?>>GRA0#E#7TTX2="5S_T1WFRH9
MZJY%7NQ_MXX_JGMI?\U"@9DWM_YL3L^AGBJ)RB6M9=>H'+)Y+'.><!]-VA=9
MN4S 7(2XG;CPH:%I8NNS-AG'.>3;.;?'^:S_".W)T+?ZQ5U8+F@-DWK>,MA/
M>DD0)["2>R70-CI$[D8F^H#G<@,[M_U%6R+GN#E-D/BGT8DR T_G>Z<U$[;Q
MY,N,.KJD%+=KY6'*2J%P/UU04Z./K6T?73)GXFM'6;Q!/P>%QB:^<L.%?H'1
MOM(GZV60<HK.NNAB[8'0BI>-ICK]U#$)SMFNAY"J,Q#:\NS2;,ETG$!-G&/]
MC1?G^[V*=>ITGJ9',<O*4OAF09*\"26=(<E+3(0>YLA39THH["T/#GX_543[
ME2OKZKM/ZI0R2\)8,H3G99QU$Z75V'A\[UD#>KG]UV16^+PIWIU=SQ38)C[G
M'^_@<-BJ1NLJ"-OHK+\Y'?8ZC#Q+%0>5U[1-U@C:V]-\X3AD;X8H!TJ2?Z&!
ME=[RYE&8LZ4G&5R(-+OM]FL&0L3\A(J()[0>)_5[#O$S06?$6M?*K.=%KIN=
MO0XH/[V=K(KMO67)#="%$JL7GW:45KV.#9!Y$^ IVCC]A6VM)E0*#5ER5O/;
MKU\P477AHLS2I&R=W1=>CNQ:=[LDA[R&F6$5C_YZE/\/1/3O@IC<OPI]^'6W
MC5?W(0RWW7!@H:T@Y\_4\G=)&]U]G2X<*(^(?W7I?/7(87WBZEY&[H]:-DVZ
MXZ<QJ]4T9?,$#UQLH+8<!N.F,]7+%?TL4B%8Q5DB 3*P$JO^EYEQLW^6_Y#Z
M>:@&+]'JSLF_HHSE-:U'1""[<9G,X9:<XN#%)MJ-7?PYR'V7X>7.0'I^5F+G
MT>X=]8VNF2KSB_X;RJ#X=9?/;Q^+"JB T1:/9CJM?_&B^\DH-2O3LI,9AUK&
M[/5>:^9HE""G9-F!OG88.Y7:X+X=]W.' QSU9]Z,N4W%5OI1>&Z\&Q1&S@8T
MR><7.A_D:FM2G[G-SZ1;8E20-XQ>;=6YLKW82>:M3:7[E>3PE&8T"2$]U@L.
MB!:N6IM'OJ&E]TXRD+A6O?URN\R3SV5*$FFU-]P9EWOCW_2YH(/C*X?7P0WT
M4G=PRLHC7D#=ZKBC"JLMB/DU8KZSF?D&-T+*5+R&>="_FC[-V/L1!B:ZGX_7
M"ZL#<*ZGPU8R*NI;CC7J-K2MDX3-].X:Y!9ZCU:((0F\PHN_G$V*!I*8PYKB
MZE:6=SP" A&0GWKC*.@EC%3Q)A84SP^Z?\[F"X/T.7[G6UZ%;==HUDW!A.>J
M"1_==)\W67KI*\O16J9):4YOVBY?UPPM&2N*Z0KO3[9Q^#^X^/E)VF1&-9Y*
M:D1']!=$8@F=Z4_W8G98&C>>B%=C9BU68L>(-\O(@YZ95X<.0"V.GYV(U#\Y
M,2//=CI4*Q_]2C^T_54F9@#'?N". 'I%5K2DV^M!5C24Z87 1"12CB_J@G*_
MA>G=,4\RZ86N,TCUCNF4T)+T_:63%N2>>DHQ-14.G"?WN_ NQU_[=Z\ZRX!:
M9ET.Y8P7%JZ7;\,231_S9:>O;FZ7WHFMCS&6(M3X&;M^&Y:UX?CFL_ZLRU0_
MQP,AT"G9(F?-]O+0GJZJ"<Q.$D,B0Q4IH_<4ER3T8EBE8[B)/C315I[Y@.-H
M0=_C1+BKJ2YV3\$L0<?S!WO R?>S@J+D2?$-+X@X-,)PH%&G(]M+1Z%2V$K=
MC7IA9_XF-?"?E806:FQ-_"^IS$%!<0G[AS(+ICWBM^F%A6QW*?S47/)>X:G9
MUYHL:V5("TO6Z,]#\N8EG>D>A2+(Z9%&W,G>%M5FUN3IN,X[^1!J=$Z6$!"Q
MW9_4IMJ\JQY4>"GYXF5,K/"^DGB.=F;8<%/3-SISLX<!4/W+]?B_W9W\AN?#
MEU7WXK[<#]#Z(QP85YEY15O1U1#3\8 WO3.*=L7G8ZU'&#A)6&H:"?4..KC6
M%PYAYT6[A.I*<LXM1 T\P+<<;B/JT%X-AK@S/!FT+JW H>&IBF$Y*>!!TG]+
M^*3N1U*LL;T8UK0A['O?GU^GP>CPT/J_"@U#$HS&1O-U:2OE??-'/].:IG5&
MC.?J[PI]2*]L)U:T/GGGZ2XB<0Y$(13# 8)Y_44R1AW6;Y!].=>(MJ3[<?($
M!=VCL_-KE((7L;IW+_<_-]%J]:$&X%DT9CT68&DQO$HSUYG.T+!_\99SYJCU
M[M ^1*LVL0 CAJV9A216'Q$@3,N.@KV]N6&1G3#WVC=2H)0^DY6>C(MN1.7]
M4+R+\OBL C-^8K=#\>+S2W3N"B3DJ+P<2X6L);U+'RW9=Y:ZIES]Y@Z45%-(
MIT_S8GIMJ.39AP=!E^)?BDSR"!A[T@K$Q9+VZT#Z6&M+D'X-HN^U[_GR#N9,
M@<(T1U%FDE"[$OMG>VQL%FDR\V9A/$L-!W+MW4[7B>FLYSH.L^]*OT^.U<U3
MW7!:G+X0,R6B+,\AMINP%GJGG/.KGSRW5&3!.0B78K&_8QN2G%FW1;=.5ZPN
M6GS0JFM]F5I14<G)(PU9'K18ZM\L1?>.@<K1?S-FC:1-U!C9CQP:9V(@XW+2
M,S\(NQ _B@71Q0^_B!>MF/^9KDX&K9YL'OTU"!+V^+:1>[?H\C[E!N(23=V8
M!#-S'2O:-UMGU+TG*UTR_,2\T!$G,HAARQ) U!$PA/KF]WQJH-K(O?L7^__/
M_C3@EA4+Y=70RLX[TXN+TFAOL*>_6_\ER[U4?ANT./T:WY7W=!H.A'.HGKU!
MO2D1E[IZ?I%W$;(M?79_=+N7@Q\#T5U*7Z)()9F\Z3PMC%=ZU+)[MWHUWB+>
M+"Y4( 7\)SNWV&^M5WW0&^SL;U_E2CKAVL4RL:MK@S*0CU6LEUB/#LK<V7@6
M74!-#93E8>A![I1N B@!0J)_8:XE9!E1C6EJV#CVB^-V7W[&(Q4['EIGW7X5
M%N E&@FX"?_^:-8?P@[L+/$>783RVI9P*$R)C?O8$ X3Q$+K,*M/!A"VQR!3
M'GRGLN/=3ABQ'$NO/S]K4Q)20@G^+?S.'Z-W;DR*]!7/MCV?QS_/V+31%/;-
M]TVR6X@BV$*3Z(?QMDG\G;KP$!Q^?]/5 72(/5*H_']7)_[MZSU?_@+CD%N?
M-K -. 0.;.A-@J$0\3MD=5'PO=2^S'W+\I7Z*#:XKRX7_$>]= EX<V;T3%!\
MB^-^\4Z1>:N9?H ><B(!!SY%)$S,,*RF7U[.B/^BH7MZ3]HJJ7MYU@J.F?[C
M<Y&_M3XMST)37/>'ZOE_CTN=\3NZSY\J5@D#_I.=+WU"[8RM2^FC"#^;ITFC
M9>TIFNI>SG3,:"*B@W&LG=^\162;P+W=0<K_RU*R:8_G^JP6$8@EF?-WO(8\
MPWN("3Y"%FN:#BO#8S4X%H4/:,H64<E\)GGA /&E3R?B&)0X9"YH91'U0/\B
M2KPQCTQ&!]BK^U/3R>6NFJH)1H_%IJK_JO(&70IB3[#*,>D]1?64R+#*LL<W
MU-AU^^664_QY)UC)]7]6^O],9WZIOO\@_Y#8NL=YOHT@'%B?-WQ(<55UPW2Y
M.ZTRPZY53W&G??'A /64(0P"ND-K)-[VI;L)M[U!6=VW7Y2_(0^YFI$R%#6\
MK!1__0/<).FN<5/]$)DK_[N3/\2H,^6E #'UF5)?4>OC(MVD[N<N2]8F:Q+'
M$K(FLU<@C)8[Z,0]D8$OWY2ORO)1F)7'N7<$WZ\EN\[:Q1 @RLPX3<9F)>^8
M/G45%*TS4E2H.RA:".+B>AWV2TX/B_"]0<4J19@_T;%_/8\?R]N6VH9$!@<N
M+1HI ,M+@^'L.YK*K<84S '_YTX:YM'*]'V?;+*7)0Y3>SME"L#]@_94+[K#
MR[+^<F&-J=0NLO@@"9/V42?A[$"#7A26J)3ZI5?)_"WG<6Y;KF<:R3>+>LI7
MS!T3#IVDIJ2?)5?":HZ2]SE:^3W#]I_)3IC5QZBHS_\@4CL1IK !=FX)UO+=
ML(DODWOECM(2;,&6>-WT'S9\$K4!M.T(1"_>=E^1J69UVV/LKB1BF9#]PQHF
MC#:;FMA=4RT7]K>$G[%(HFK&?!]@1FSOVF@V'+@64,=&MX6 L5O9/3-N91FJ
MPW9S<02"4OC,,;(!+DFR':3R8X\P-IX'.YQ'^>:Q:L>U=[YK1']B_-7(XIWQ
M6_&/9T5I_)<%;JO8)-H[RCMKYTSKD8/2O</"7R*8SQBB6#Y?AC.#CD<[7*2=
MHVJ+LR,<S6A5[ZG@0'_'I274#@YD$0?P95P.%^AX-D[*'F,'T4\8-;EIS4L[
M<+XB97DJ@6Q9RO+]^**K^B@XRS)+RWJX ,KOR;D0_$/I+8' 1JQ+@"C+Q\M=
M.$"S_(!?L.^(F?SIN\6#Q;AV[CF::I+U:0G#^\+KJ?0*R'L):2 !?#4.X6(,
M8[R1+&\@OG1VYJ*GC%NG0X2L!#3V3M&O#%JEG^"?&G:EX^VFL1XO!Y6>Q3G1
M57(Q)LH2O]@>1MW\R>5D*,^_)*X#R/^+OZQRU_S&9344OS&:IHCH[X/&KW\[
M6ZR\51?XT.GQ5:2O5>?]SXINNUU'$GWZ$11"SHXPF3&T__:GD!C;<']EPW#P
MAFZI0J?X\7$I>%9:'FH;.^YDMR;J/EQO^B)5)M\>#@S$BSWA  VQ[!K$G=H>
MP8$ UP=49>;VS\ E.>K-R^'\W*(LVB6O<;3G9A&K.HK+?"#%!:>(:38A\4"=
MNT;MT+)JG[R.XJI!2D'88B)H".WPGNIR#X0.59[=\R>YAQS====;ZP[\Q#F1
M1*4L6"<E];/M$]%V614G(K%U0+R44?J@:@WV["=48XDP-:E"&!%<"Q#]T$O.
ME[0:$E*-[D,BZT:XQ&E/KLF2\%J)T Y6O&^[-AIZRP?A;QS]@%D:XRXAYS]%
M_O;KC@ JZ<I: T4$L1TD? 4;>;>NTBN)+W]\0'*42C/BHA?4D7L9MXY.0;Q#
M+!/4+.S@Y9/_B<9:]==(,!>N_0MI[[06SJ4 MEMP4S <D#NJV:PZ#'0^D5XJ
M?!GS ('QFN5,5Q<HL$A&,7<;V]-$J%KTKK30+SP/TR<:."(:37=:L8XTOK*@
MQ$*X<3][_L1WN9YNBTX_7EVE>'!?=( W1>0]S:PG]4 W\?@A+WH7RM($393
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MP0P59&*NK]Y\^LH?0M/<),%]M@IA4:=7H:(EBH.I7JL@J4HO/,UY73WZF5X
MAB:'<6'9I]?""3E.=N7(.H^ 8Z99-'O?C2[A%*GBMQ4[TXBY<#6N,V_<1.Y7
M>0BGD3(L%IF2VB,U3<=>A]L.45IUF[H;PZ:=#CK1#BG:QX]63]V5%)W>SO2J
MAE$M%U3A#4LX7TK?S3)B2E'7-U9R-M!B-^6M,LIH5T]0&F!P?=2DZ9!>0TUS
M\(%W#IDJ^&D1CZ\M_SK-#+[8^G;!()34])SGL%-;M_(86T4S(7R._@+[A6Y?
M8H"A28%JIF8<,'DDTC'OA?F.'#9%:"IV36!71_AR>/H45G7FHD8DYLDK[^Z"
MGM4Z?(-@KDA)19GP4 FR0K8RQ;@ (_L5[ZW\8D&W1'3R?N]R@#V61WA<O1C%
MW@%-/7^JQ&H2UX3CS@>SGA.$Q%RE$Y^&Y:U<2_^X52 PA8XBC#%^TU[1*$Q^
M<?\1  6?=HUI:S-6A]U'7SIS;QF?%)!2IZ_=W:@Q%KB2">+LS::F$!(P*+-K
M-2FFJ.4K2% 3G>J<T8D[%E=&N^M8W'OI#'W28S!-GERC@9J66'T\+(F_V,^B
M&F$$<PQ2S"WIAO0V3#E0V,4!B']F_] _-0FE3S!\YML"=PD>Y>A'M1Y"%1D2
M15'#*#( M*Z%\V.,U1;-<0%[2>.4I1!GNP5O,=2'LI+GXA\!=DO2"G;2!-AF
M8>^_$AK8<D5UDZ6S=9VPT?NTYQ?EPDE>Z$<MV0TJ>IC(9)#1*%9N$5>&C6IW
MY*M_[=V5VJRPWB]%*;,CY:5('*NI">::'3YU5Y')]&=N2L=D\5!Y'7I8611+
M\5*RE6>-<\GU57M=2NC2+/='-X6>O$\"![;NKXF:4^R<G7'JAK*PXPJ[])Q=
MB'&^)B=>,!+(6S%+^PQNL@L8;3K,QZ0*%O%%CW6I;)D8ZV8&T\.&_IIW#_R;
MIR_R_^:)#:CYC\A0?W&:<6-JW"O,YW5+]]^,,TG:$WKHO8@3AD_XI/]6GI _
MY SI\9&<Y=IN\=4N5OVHN;O*3>+X&LX%>TI%*X0R59Y3.SO)^0! &-S62,VS
M4YO#:]\HY\Y%K15#3HAQO@KNZ4W)-KXQXE3Y=(#IUC 81E<-6^T0\4DESKR5
MU5^/!:44>WU"=00:A,Q7!O/\@@*0!9:UF+-@1>RM?2YAG0X!N-LI([,E%[2C
M!1#133:!:*+(:\,D#7$&Y%@\.P4H\FF_G'Y)\2G/GZY3:CZZ3+!EJMS VQ[9
MPKMYI<J10IN5O##?4D"*^]96\G*U>KM$=!=+Q42#T0LV"?IJ?9V]2@=6<OH-
MRVZ=%6B5>/P] 8GHA%KR[I.'_"S(T05]V]@T:AU 9Q!;!WM&;7L'G=P&M[_Z
M?L3E!W;U$HL>UIU:4JTY#0HW'>XG?HX@<',^Z/AJ=FX *9&3YX'IVQ=."A]Q
MW+ VCZC$/*H8&UL'YY/Y1T %>4KS94]+.DK(PL<E></JQ.0*J5EX8IN5U$FX
MV:E&NO>EZ@**=67 ^)!OY+BXU$WNR^'T^?Y3BS/.K7!V$>\5Z)1Z6M/1:;W\
M4PF.36L%I_)60^[5_0F*O\RROH(YI86-9$_EZ7073\C<260,==:T"GU=?1Q*
M)^[M=3-<"R;1OF)<L?JX<?@)?BKJ<P<DS825A%M[7^"+>B$QVB/ +_@F%Y2Q
M!*Q&18NB>\]D5LG6SV,RG^>ORQ75VSL(< =A#UUY:#?43YP3O5(-QIK8@[/6
M1;EVZ%C>=T*(ZBLE+R."9OXWQVM%F]9/5^[3EEWH-UO\D-N3\H>1>.&*0.';
MNEH7[5P@Y%/:()JG+7#QY/AUK28SWJP,H8QB<M.LV[,@#F/7?#'>"0T_+YZU
M#0NUR,VC3P;'K=X.BMYRYHUE^ @J4G!]2C 96H=;?5=J!0?;LR!;<1RV?\:G
M;6>AVN^9'Y1*D]U(QBDYA,2\L5[M]8UV+7E2A[PUX8$D0J:N-!'IT&K-W-J@
M-E44N8@PAN!E%]>0T'8K(<9($&.#8+%8^LZ-YV9"NB5KBS&;UH+D0"V#=%UM
MX')H*;G-VFPY%V?>=(E!]%"+1>!L9U_]?=*^<%W8R^5Z*0B_&^ZUO=0V;U=X
MBIV''8K/0X?FAW URP^4$D0_M !KNS /3H,[#U@3E>9G<T7T(18E5ICFND@:
M\:^#)1;)5=O9OBW3MO;@MNR/[2S-BE-[?M#,+MXR5AT8R&_\:@HH.TQ&SW,'
M9*R2H&A<!2.2U[B1L?11*.%U>;XKBMI9?&] 'O7C;0MJ.-T]UGC5'C<UO<X^
M).[R=F S;/R0%BMDJK*0RX_@RM8SO^8Z&/H1Q!P54>?%]RQJ0@&'F$_)C^/)
M,[T/^>= W- IK@H@Q6G7QW;I&AA$1O=UE@L2VM5J8/!Q3D_JPYQXY?@>N JY
MIH\A/",;HKO?EXS6"+7$L$^4;']%B6]5EHI9GSC><AQ+Z)GY7IS03SO5*T6Y
MJ>Z46656OYPM4@]O.!=8/5;YLS*%:K:-^"-BV_HC ./ ZU6,?))L>4VD0'5D
M/=J>]WB!(F\M4_'TB\8XFC:M;+=^'<Z&+MIYGNXEQ;N=9G.IT;M,%YB1:7FW
M%9KE5_-S\J'T+&'CI"XM8#XM4_/X%9++4(>O+7EXV@??8GZ"&"&S;S20R[[
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M\_Y3B;82_C1^T?^+Q^^?QG!4P8[6/B50S5@_>X_0=T^0_MGX!W%EPUPU@TA
M#WCV>Y0$ 3L97?QZ)&OB<LG7,-5DG?H4+&@-R(EV1U76!-8?1J9Z/RM]M614
MS%DIMZ!5A)\<3ZIW(31>?24H)UXLG!//U,$;H;;PR#+1<R"3AGG?)/),<E.5
M^NAYH6O2@QA(]*$FL>WHK-4JG?A+L+864=&SU>67C=?0:0$U06U1/Q/YOD=
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M!U9_9( !R(9^-:_F_ZO!0+K-.L?6/^MMR;<@@G7%H*M.P/!.@E/Y0"%QEYV
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MF"^!(O.M-O44%B,G#C^L]R\E^'H !U""$H/[MPT96M'CYYGV#=J?9P7!/R"
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M=Q90Y#V>7!I^"Y5^)N"6AJ?DY4[ZE:<UAO:4+%!3-AJ:G%KM1,Z#Y \A'ON
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M$,90"-7G.P9-T ("9>S^ZR3^OU@)8/H1^(3^E,T0.<@SO*=O5I9];K9BHIW
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MCST>HCQ?Y#D7&6YN9YV&6$U$22KY2:&P$C%J9A+4*]@WW1H)R-\1]&O+4E5
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MB >,'E6'O#E0N;[D5OI@S^WA3UCR"ZJN6%LQ6?WUNED-H+OQ@I_OPD:,RW1
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M4@N>D<E(4X7OZV1$]8YQ/OCD(/^.!DV7GT9H!"?0Y0)06]"")Z+YQ@/ZAHJ
MM>18&OE=$^/%Y*LN;C(-'Z/67P.,WW?Y+Y[Y!":XT(2C*C-7S&:C?U@PDT'-
MY%<WE/.(PFBQXN;F>[L\!N/K\(!U,35C7G\GVQG=IL;''"/RS13#MN_'D.4G
MS18[SMT@ ^J<EPLZ("ZE67QY5BKFQ-\3#U/7"I1?YYNX-O\ZH#-.F/F^Y$W
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MK[CGT;]?UZ@OG>8#+W?N .-!@G]G\,%A%%@:=;-Z77AOX>__5]-KW_+K1W<
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MD\#LX:%LE5Q4E+$B:PH*:!??[543_"CTHYH\[%=57Q^>@D0<CD195-YV?>,
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M=^S:L^$!>YZ?D1=,L!G.;J#R>?&='IN(=7#5/6VH0PW_4:W$\WV/EP\'V.6
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M5WEJ9K0CU$%V_SU)7(S'?XDD^OV1\20*6H1X(@"R.O[=&66DFO'[B<&-P:F
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M41;MF?F9&(<@?/\FH3*N$8>-$[*HG79SDW?>0Q6F35N5#^BS+QR'"3JX(?K
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MK9>!]Z5YY^42_AALZ _9"& #A_?/7H5P_;KFG<2?!!<"AN^NVGQI9HS_XL@
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M]ZURAH:D6.UMIDU5Y8B%:%QI:O6!MTL6[8K<C3CE>/=CAM#<_/0FO\8S!.0
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M+P:+.P/;O;+NEOD[B*0UCBOTF^#\*\K-O2OY,Q%2FMZIMSDWT6R.E]^4TR5
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MX/.!E61!*US-/BD8.3O_&\O]?J$$:9+=<?=[1R8).=^=[@\*+BJN"ZZ3# H
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M\JT7^Q$=,S"'XO)9U;9'"*,ZD!3-B_?6A@5XC+JA1/X;Z%)8F/PTJ3M5XDU
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M8EAK6/RM/+(]=^F+$O7 <..3GROYN=N2(@[L%N_9N?([5_SSHO*:GNK&&*!
M:LN)J*HH*.Y.;[1W00]0QA@+S=4)W:2K>J41A0RL!0)SLGBB0D+9KO9HSFK&
M9$\-A]CRHYR=^UN\Y/_7W*U*$M710ND%L_=/7" />PW\1XQ;."(DZ'_R^-;D
M/]8^_OAS8H:&U];%6LEHAY@V/]/=&M30W?+\]]0;)/.@4IH[+L\G->)Y!Z*.
M^OL*&#?2E!([14-]$!AQJ%?"U GTVNGUT2R?M'H'4:/+(2X,QI@/O]+R]8R1
M>UA^PD-UY',&P-N1QO5.46< M?HM7U)?XZG>&2 W[23K#$!\3J(E.Y7SG2D_
M ]AE':N34O[43?4TUS?O#+![^PP0XWN<Z]N0?@9 K9_$G0%6=WRA9X#>PI.T
M,P".:M>$E.F[%7$&<*$ZT&;=.3T#1(V?UD6LRAVY_$>_U[T,$N8,T*=.TC@#
MK&6< 2@_DM+JMPS/ .7=_S49N7[?HZ S0)O<:9_<Y"O?WGV2JN_>D5SI&6!Q
MD*1^!A@./"H\ VC('2J? :H"_TP@Y;VT4\G_Z%E[_.H,H',&6.(\ W"= ?;/
M_P7(GP'4QP_YSP C"Z3>\]F;',J=V]JL2_6G+\X LZRD)=:-7+G%XS, 1_VQ
M-^NP[\[R&>!\^.KS/Z#Y YK_3]"H3!T YR[ZC(0*L6ZN+SB< 63^"B_@OYQH
M?VC]#VC^@.8<&DVQ V!1K,_(?M#Y'N\-/0-T>?X5=E'_:J+]H?6_KG4;GUM-
M^=<'0Y='V1]03;P,)SO=@DH31H@YT=NQ9X!K@AT]3$)WS@ >GQ$RVM#<^MI.
MW>.$A2/.P+<U,O3A^*=QQYVC/\?7Q=)7KM[QU(LPJ 6M[;*,<&0:AQQ9_WZS
M(2)\L&6:9;4?/:"YZUT3&Q]9:=2:\Q>]Y+]<"N!O(K0CIX[G\HYWO+H2_ ^I
MZ\4U!JDM($8"GZ[,6[\U+QR4]N:Z&+]7.KZ]+#?#!2 -))&\K4\" *S#O;Y=
M^6> +^F7C@WL#G?3MNX ?&'@,X!L"4GA/=4JM'Y^P/?GJPNG6+&3HZY#2H <
M+N<,D*9_!GCPC.Q?EQWYHWX.*=_N'#H7Z0]=Y7V_+I^ONW^-F?]WLKM\RS8J
M7;SLZ^S7#3)Z&:Z+OO\:T_[O8'<+F >"4 WET'&&WG3_ YJ_R.[B-6]-[= +
M<*'EGY?^V&)_98O=R%.=PW@GO@U@HZ-?DDBG.+]G__EF^6_+[@(2:C_(79ME
MHZ8R?,):V/.>[]?_BVY6M&N^'TE5_(#7Z>0""+/B4(+]\AT;8?V?.JR:]CQ9
M]SC;+X\LQ,WI\"B$0D#%KX*)^.QX0C+M8-,IPU P*DV<M9GI#55CATW7HG&V
MXU&/WKNB+;N3:%D#U*T)=-WK8^!A ^7XH?2Y37:Q\/]>UK7WOZJFFOX?7MCU
MC\*X?^#W;X3?@\"IG%BZ^\TN[4*3#]><S@ RN7\5F:0_5/?/I+K_??A!?5JG
M=,/<)^FSRS@S$@ FQXOTWX^*+HT5IUXLI>W1/(?CE,'DPZ"RW _==\4QBWM[
MD<7'4S/QF.)MJ9\S0&T@_<W0"[J:?XK?9_.C,N-MAS8/842[%\V7V#A$D%>3
M#:J@1)&CG%)H1/:KO^3\)JVWDC;/ +_ ?ST9[J^1OQ),]3>1@O'E^-,!DME[
MOG]D=\H+=[9;WW[23S /\]F6NJ(Q$L=^H8LI,3LYC4_++A.TOO;0*8RKLB\J
M5'<-S%YK6/P"Q_$_E_J6A[O<&(XOC^1X!HH+BWUOVD>3'1H^G9L78TD&?92Z
M!\7*6FDO*>3-(;DZN7'N>" $49#4[_)B]U'&?SS_"JY/+&3.\&=4.H>;4MMR
M9)\ED)ZY54.'J^UF#UB6('J8H(6FQ*2&9HD3,2T@T+*+\W#54M 2^,]"U0J=
M3EAWNVTN_KA_/160_K0_3?"@JYGFX--J+%V(^-?/6D6M+*;,0Y5L<BXJ)D:G
M.?=N?ML %WH7>I!20S:MISP*S*4;2C3@KSZ6LG6/J+D1VUV&I-SJ&8V#MG_\
M0W F0YY(;;Y,M!R&EA0]+>?'R<^WQT:TZ75#/NLR"S]W^)C&R!RH<W]9T<!!
MS\?!<)S KS?J':?XM?V&@;ADP8ZME*)<D<3;04O.+$/(MEO]K]TMZ^6_D*=W
MP=BNGO6X]0P@+_+WUTS_RYGL__/BE<@)'[I>(MS*<+U$@C)/1I4)((// ^*W
MFI^.X6U)4YSBO2$I0*YFV]E'4:K5=B^>CDWQYC;]DFQG]!Y4NHXB([N>_=&/
M?&*7+E/#_ETQ6+0;([IEYC^IRX/D5GKE!>('">:$062<'Z%%>(;'1XS7CD6*
M"+/)8G%+Q^I9<$ZRCS^P'!1:Y=)&=KA>O9W* ,D^C,GO/O]#"!+/U=954N+J
M@\SK&.6ZB$6>XC;X87Q._N+FC)@ 67^TN&QK8J6"]D[RGX::)/QI9,Z"VFW@
M4 40U%4RB^C O4+\S=4&_VYR4[7I&9'X>S'\M2&DIL524Z_C=:9 $8W$[YG9
M/N]934FKZ@6O+QA]PU1*Z?*!T9Z2^+R%HZ?NXNMC XUO9H:1NCK,+U(J^\6=
MN)[6=:0U52'-<K)@+ &^5D<&RF\1,S /L["+3<M%*18V7W+YKUU?AQ3H!-^C
MA($<7=!].DGQ#S5#[+37HD%J1T#G?HCQH,1R;S@9=6 <I5#V,D@;1=[R*VK6
M,726?"MG$6^28*"+$-"UEF./+SDP]BC(T8^->W9!>=N-O]NH%/ODD]%%VA>V
M.JYAK7:$OABVX%#3>_=<^AV7KRW2TEH3B<1QL/-6,J:+!ZU9JT(0%2FD=R+J
MP?2KHJIZ\(Z\O+S5L'X@%K+H!K/+]1!DBNM5D_9WL7@,Z$CPH -11N/VFJ.$
M=9P^-* 5LIG03H]0=,<$D<-2]1>5+D1CX_Q]CA!L0#[:[#0YBT>4A[0F'!*"
MLN8:T[+UE.&P=8.]Q@QI?MMDWFT?43$3I.W-=>_IW+Q.<9^#:?3G9>&\=YE*
M%'02?&F"HMD+6GZ)<Z7II0BD6,? <J17MYTA;UV75F*X'+6FMC6>0%ELU!W.
M2GT/)*P76ELZ6)*;A7JBX>=6XRPJ+9<[;KN L'RL3-DN8FR@_,"5NOIA^5=+
MRL#[EN\JGY1^LQPODX8II-S#LU@+O*XNRR^(MATM]RDW'.X<]*Y@. @UV.MG
MYNK50M]\W: &5M ,CG^"MEDI9 &.#<X9#83LKMJ"GZIZV9"M"X2F201#&_CD
M55D?48VIJ$T KJ<[=ORFXPGCT%!S'+[;FRA4';NZKJI8;CWT<+.BTA0)"N-8
MUW'<KTT!Y0GYJ:D/]>S/$'MT'51==TH(#&.H/?V"RSPMG>"N.HK5N*EQ&U<;
M7=<;3+EBO&3;MQTW5$P-O1B,-@.?&"VU]80><GIQ".A8W\O2+2G9$A]X0KN2
MIZ/=ZVSMX:2)4=3)0E@MYH6!;@=7V1IM5G67_AH_  FPM$ ,N*:/GQ0W6X55
M -E*_1ZPA]+E*==$W4:<Y@'?J-SQ-N;)MGEZV(/(TBT&.NGS0JI=:@OV.(^5
MLC*DG=E8S88_L0@L.<7DH+<)*)O6A'JW^,1VW205W-,BKQRU@7*?E_D#4://
MV35J;%E8ZQFS5+G9KJC8+Z?JV4ST\;Q"TTJ^PW.W"(-S5OD3;86V>[IJ"?/!
MA9_0/'01UD\7U/(YR-LH0&G-%(J=<*Q97TR6MTY5["JN_: E371\J,,@4H>;
M1H5!>)/^5A"#TO6;LI9;@PA[^LW* FTH:4_D,!KIYMJ?@K3.!(VIK9W&KIBK
MTW^.Z.?1VU.C2]5I)R> ;KZ:#YESL@6.Z/S$>G&#1@E5OI_7! KBQCSX5ZT$
M1O+G/KGG4*^[/&=:FY)(\<.\CX3?CXP,[4TA;[AIKQD#1ZJT"8@5(S9!FZ!5
M&&_P)UFD05&6KC8:C!\+ +D\T(I.U @)T <J9*?$1(5)B0Q7X0AV=T>!,*21
M-">L.-\T4&/N9R2-S'='Y7K0?*,B*/\.#K0V/JEFDC&>T*G]+=82/ Q6HMB;
MCWDSCE?YN7DWR<[N:H)9$;I<]8!M:^@YM\:=QNODC=88"T<@)];Y%9J3IU^@
MKS8YI;=$/5'*=4M<J(^[%^77D(L"FD&58[-[02G@_OSU@64]-/M>MXT!,G%Q
MX7[X84ZXC?FA&3P2H7_9?$99(?VNSI68R0C/K_A!I$:_F[V&0_0 :*M$CXCR
M3NI>T5YLO132F,_N\0#2%P9RZ*&*8VJSO48,S;+T4.1%675*O8A:5\?=C1N2
M&WED>NU-Y/5EJ>8G3"R \HNO',*ZJ3\2/$6U.>6@,C(1@L(DFPJTHN^$SWIV
M1&H#J(PEXEN6VVZKAORRK0NMOD*6ZQ"/;FY*^<?N)=F6 ;9LZ%YGQA1ID$OC
MNR4/RX3IAY]LS$X#.8ZV.'T4U.L:$6IM _^=)S*QX0X2#HZ1K6]OYW >%-6Q
M2HU0FX>XP.]^1.O[6M__(&@1Q3T9,1OV/<01/QL1:?"P4B"/0O-'Y[DQ*>RR
MJ+U7L$8ACE_JG[4JK%8[%JO-]]KE;KP4W.BMR4-=R-V %(=2<-RTE%5<0S^/
M6],(AC_-7L6-R._Q([S<*\*7B ()7A2Q'7QM5P'"CP@G-!T)!&M!'W^K??_1
MVZ1E([R<LI?KR\7LVG!)+!>4LC1+OR X,QK%+1"2*EU#- Q;<Z%M\OHSX^#_
MBOM1-[*&2"ZTIDP-FU4L5RC];ITV["XO]?-R:B'%*]\4PGTJF-SDT>%?_KEZ
MD'9_<)SU_3_*O@1>DU3!LM[,IYPNF' _M84D0E?AWM<^.D39'T2#/5&H*>\4
MDU36[O\U8NG_#WMF<STX+AZ(B <[@DM>1F++OE\LCV>CO_ZA>'Y6_'H-8F*S
MZY=E3^ 3O\#ZMI&4?3T#@V&[[ATYF2E)'7,UT12KA:K(X*RV*/4H]02\5/ND
M*QCJ3=_C7OTJ";RQGX!H9K>9#'TLSL-H8T:^ )KQLA9M#?!#!\U&5:FI$5>]
M?#A+$@93&?GGLT<MIM7$U C<!GO;N,'.^13;1$]WJT;5 3Z&%]5?V=I&OAX&
M3-.\0;._L<CY!;"4>\S)?K0SMRG*:[J4/<F8B^'G6ST#D.%7WH4_]&M_?,#7
M2#G+T*L1,_[DW4FW5@EX>+AB> #FK1:H469"[8[=:9_J@MK=XKUEI8,/8I7C
M)I-*DUBROR ^5?E $&-*:ZNK%8-S!9^ 7;:4,<:)'4\\WA2!VP+$'Z5G3Q4L
MMNAU8^UXQ[UI1A3* ZUKRLH'G)-THYY;SF&+9HHGD0KWT-=_/'_X<?\#6[0>
M1$&S<3!1-77T-#72\Y!WJ*[E-?T@2EWH^ZN8V16/?H&E3@=;&2THYYTJ(E8_
M<')Y!"Z\-K#64;'%C_1^69Y0;D_U?J1BC( SO[85+Q2.Q.34<&C>1FF.[4SE
M#@^6)1DB"XB[N),(P4NZ<0RXZTJL"8X:R47Q\[A57DYOB:19C;)P-5ZO)$^Y
MSP@^ <ZJIV$>OAZL(X]8WH3*V]8O=:MFW?;G^<VLD\54/"AJ0)UL3F63 :**
MDC1)M'/+@B!JM1:ZU*^%HQ60!N-ZL6_!-EZ>(2GRFNEUY 4V9:MW4ZI05S#*
M^3;#^9[$9+U??FCA>>A2-DU^C4LC-_UZZ*8QK0$B=!9DV$SR1.T_6=OX^G7:
MYOEML"@]9F@M$2ZZ!<7L2C!K-3-\A+'^3GSYBE[CDLK^E;W0=)^+MYY1MG?2
M17DZ)*ZC G-R3ZVJH\!#7,/'(X6)WA&7J+].L8@=BUV@1#@$.\8:(R!F2!2O
M^HM!UY'?#2SLU8,[809230$,W4^IN,3).!HMJI_Z3/RXX#7CZ>)%;KK\RGDT
M,:F^UDX [[8MW54XT#JQN=&DE RAVRI09,<YJIWTN!TX=WM2_SY(5;]YX*L6
M/BS$3QB*9;NI(E]F1O'VEKI ^O7P[.B6:ZG,9D*TR>-\#]J(Y0,RLG.*3"WZ
MKA#_ #KN_OQY.FXHK6WXZA"J)@JT7+LSF/%M4RD#CGD4EM]\$2AI%ZSJ>$QU
M_=D#O'2,)8GI\8(\P5&=2DW;F.WF3!\D,;:P%U>-6O#L>\($EK9P7&FY$Y.G
MG'@[>[9]#^MC-5:#=>YW49N_,NEUJOZRO ]1^GMU1H5#&#Q_CXAS2R/FT3()
MS)EUBC-=]#SZ^ED3S?,X?R8Y-JL=!AEQ71_ Z[/RQ^LVFZ+-EB>F01K^AWE>
MRKQ#3N]XGAKPEHV6&0B<-@^&KMV,AJ)'0FP,%A-,5J^/W#:U,,OS!TT[SI/G
M_U!GJ_4H:FC63:%WPMU)G &M[=FN'F.4^Y%.BWE6.%G4<T:@QL>\X7A<]&P$
MKP.<J\Y#P-)+$8BLO.=_XB"+\SGR_OEA(Z '9LJ3,1+J5V*Z^7'P4N2OCY&O
MD]EMM'1,.W EH8>&>MOAGSP0=EJ,G^-HBG-.![DZHQ)#< 58S9[EVCB,54J_
MR9\5Z#$VW]0ZW_M+YHV^#4V^@^._=@TVNBK_\WCC+3^:/0.XU']-O_873F(F
MLJ:NPXMRIRXA9P"%0CU!DN1._,P[U"W?BO83^Y-.K^:T+:XAWT$IN=/;D-=V
M^VVI.+F=K+:.,\ ,^-,9X";K&0 <7W"BZIW]*-K<[(M$35F KR?K.FV8$OUK
M.-,6"&?-)"-94&M0H!KE> #'C0P5]C.+.EU7HA&_+G!79&99,Z>6!%^]@PN-
MC:M:(("O-0WVVI;85.7;9W<_VG476V&C'&]I^J+S@6R6[3+MU6_80!2#4-,K
M1P<$ 32X5,71[W&44B'=2"T->5G.3.F IMM6TJZL-"CVA9;GN:FK$8RPF\^[
M2/C3L2[.#G4QU]53)<+70\]YU[7?K:(>OH)E R<#KCCLO$]=G-"4('17SBD^
M.E5ZO_XI:9V_=.QD<+%(Y2#N#-#(P"=V#PU_$"5.TVVV+3\R:U$Z>_#S58V2
MTNO([S.P74_WQ*T ,5%K3C$!R&%96'7U^J\YTJ\FRZ\,+@Y"69Q</6%7;KJL
M;4&J:HB:&CU294>V!8I36"UP'SQ?]"N\WZ[,'^9XJ.1XAS?0"G]=H>RQ1%O)
MA4Z[&R"D1'\CR*2ZM@^;9T#4%T@L;&;+E(@3O!&4%= ![0'55D(X>9OQV3&5
M2=6:4"DHMM<Z6R_<.V@JT1M'0(6:!V]-C('8S.=BJ#=^25TAS\[[$/U]&OV=
MX,TT2_\F"753T06Y7AI7WEVR[7EGJ:<SX[JBGH$MS?ZHMHAS]DIF$I!WIQ<;
M8D+]#B_**.X#RTUP'-"HQOQ\_M20DNIZ/4\YY\P;P$S?F[?HOK@O49[:4'V;
M<[>HOU#$+G5;]78@"OM:M("%)BHFGTC,3%U^L;\/^4QB5OFH7:VBCS4==M57
MZ83X6$K5(>3<VK94)P^GHS;QQSP(($AO(!/4I9R3LK^:D:K(E6_\4&0$J3:V
MQH)04]59AZ&J\]WF]G%K'FN16%6XV9&VX)Y+;<J+WN15E;8 WEC\CYDZB=]"
MW>$RMJ4Q>3Q;1IW4[XJ6B.N^6]L[LNK70E)X:+[WQI?H+'%H8FJSKD:5)2YC
MXO=UJJJ]6=,7!H9O9!H,1\3<Z#B=,;MJ=.IU\_V;FU?>!=@68\4DUKM=(1&_
M[=U!KQF$,I[#1ZO:U#WDC%-HNAEI.SW_GXT=^N'4V)L8NG!X6_<W]YG0U2A.
M^L8LIT_T:Y2IH=D.AEIH'K5-7&*)NO:@53WJ]W23:49P<( JZBZ20G&KD\80
M))AE#$65@&\9VN!O?*])U4?,*W(S@F>G..SJ9[,UFCZDO>_4KGQUS][HHV;>
MJ'<R&YUB-8YQ:6#0T=$50KOJ#7?B<5>D#*'6=<)H"CE\1.-M.#<=6Y(?W)G-
MC*DT2@2)S59QI5U[O@=]>[DW!+AOQM1<)MSC@6HWIXY>M[Y ;*&8%F=3SU=-
M%/4P[V+T&MLKT^UW,D3@F<:'?NWI/*[K*2Q*.6UO^#67)C7CTY7FM<@-U*\5
MM"HM</XLL)95$^_@;AYU/XT[+.[5I4#-[%0RI@_XGZ(QMFVWG*=+H..&*.;\
M-=>^AEZ, 5T0L8TZ^8[SK ,:@;#HM4,LNKW$P-)/(]K#>9.0Y1\^A-_87*&L
M'*'WY>VR&10GWQ9KNYC\(;A2=Z[:/E DKKBD=FQM=!1=M\0+4?-T%S3'4[I@
M>+2''5"$F]IQOQQG]@JN6=)K>[*G]!1YJ?8^[#%]NA%G*<B>X$C1$0X)O*!T
M@9/)FAFXK*^=N]2>J*N&A\Y@YUQ,-S8;G@]IP0N@JF,E;LG)J7BH6TZ2&V/N
MHH;M(S&^#0*B.3/QX:46M4OF]A:6+HSZ$&85F2=^3#R2;D!.>EZ0H/4(3*2W
M7Z3W41V#>#A0C$L[9YWB!Y*K' &#@/B!4 XNO&C/GFWH&(MA18>8WCTQ\BV^
M*-Y2>0O*>V]?%C4%/VQ;LPQ]X*BV9_I>5&>4551<@?]1-)!HO!^% &_#+(BK
MW6R)[K2Z BF>_7F*>!!(C0*H-/ QU/1.AHMK9N;,R)QC]Z/R@%7*T8;K(5<6
M;VY\NBCRA=;N*9_ CG<;XR?>"FL[D&R1R"2_1$9F+ YV:(E-+"D;+->0K@K1
M08_9QEH3>*!(\L[%[8;V1.$JS8-*1&&;C+3,W?FX*?T"RZA+"/:8)OJ';]?(
MV8)%VF]'K>2W FY_"%:K!BI1AYHANRR])/@+/<2VP _CKMZ+6>I#:SKF+'*K
M1VU^K.W3?D!.+'?CO,=I46AIIO3KC<W*%/\CD3FED-AVNNFMUH2M[5@)*87M
MWDO!H-+HW)5Z#^?]GK4CV'AMNSL/0MS=6+=1O,(6-QOQ<&[?I=?+<7F?&A4X
MZ*SD%9(44_9%E<FQ] 79!;\BEZ!'WM7AEWY^WZQX>D7,$,BE0.UHA&U6M89A
M),0Q(YG&N@_>Q$XL#6 U1690Y(0?2 Z7N[,,#F@!PVHG,+;0ZYYHBKCM@)9^
M=&F;/Z^ORR=ZQGHE0!K2&N33YH"N324.$+Q;E03\FE^A VLKIRV.@;![6U$O
M":2N),/2<M(OFB&B(:AX[E% "9\MOM:Q.".L/(ZRC<Z>G&X>X?XK^30,1<')
MK!U?->SJV4PT&%1K9?V6^C1,$+O=C04YI$PLUOL(.<SIZ;"U"UCU.(#?#B02
M2[O-R]-6H_#\_2T]&/9F.5<4_>L>D7 1XGM]/SM$P.>IDE@]KF/QW :I\S/@
MN&P$0:1=J686^1:)TEJFY93$P=N0&JW$$%P?&WD#=2W.5KH+ U/H3$ I9X]@
MLSD2;E5>^<F_7:WB^$RC_S.3<XNC1RY:3%?-L1@Q L]4[2HJ8_&WC^FGA%<T
MXU&\)F/1T4,<-2FEOW^> ?P-B/#,TG#]K%M&2=DN0O$T-*LG&L*T5Y^_U_J&
MEY[/6J:9<W((F0MD,Q@>%HA2.W*3/@.L+-G&<"FX/$3WNV2Q3\SDC*8-?PS1
MB^YNQ8U[#50)R\L-S\49HOM!61U:^[:_1]E4HKA^E757^MF]>?PZG)=;!R';
M*13*5JU1AX6[CB &NXW;B_K5*1A<9&J!G=@7B:%YXL=!PTO4_J;DV_I.0.6$
M%6(I+]0U&N_A@(9D!"3SW5("":FP<80(A26XJ;(]H8[2T%&:_HE!<[7<R@(3
M>=O4=3QD^ JB2S55">49X2RQ0#U,:)/B#[Q2BKC8W6G0/3<$?\MV<E)9 ;>B
MB5-&P?.!/_^@T[7A.ZB83I%R":T+P%PDE_:CNDR] ,6**D"!XCCG'>CNRT/E
M)A)K?&-\X=N)PQ=Q <?2%IM=^_%K%2M*GK?41R>7^5[<&3@&NOK.["M/2GRB
M]'#QT(AZ%[Z67)_(+ N#"I# 8IV#^C-_L</JWTV8N]Z?2!Z-I4<+IY48%./9
M7/EJLLW[BBZQ%<_W67>TZ&ES5Z#6\2+QT<23^B>+Q6^O%U5\[H/MBR3&I"D-
M%$5@O,X KB3E7M%-U,KD?XO//GFB-<E;>)N5O_!=DHZER\>5A6.(=L'Z8TF)
MGU83&T]Z/QBGLMZ^_C0O9=XJN7*XN_K<^<V4M19JYYE3CYSRX,K)1A]SM?4
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M=I.8-4@1PW/K[Y4L;TF.+/]V'O&P$S!L]QL6B]/] 2]J01++<OGLTY.YV'<
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M<*!%#V+("A\6Q^[T)J[#70^3NI&2(C.E<VZVQ-6<([LM*=9 WXW(,X U\ Q
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MQ_/G9P%>FM^=_"U>F1^Z.U^\7!!D==M^_\W.AE@S5WT>SNT!V4723,VFO:T
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M]+B--8$U,='YMGV[T-+N7O 0@^,8&RN>&I%*X+!9/R/'4]<^'8'8^(FMO@F
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M#ML'CM9BQ-GK?GZF^KBK))9Z#6@\S><ONSM'&<POQC^:D](777+JH)&<H1-
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M9<P(7BADF"D?(KPBKNVK30WSUVE)179Y!>6O'(HW2VM)EHXAI !Z=>,4+ !
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M:8];V['N%;,_=HT5>?CQN.V);)*HZ#*C#U5[.U&\(:X'C!SP:E$"VW815D@
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MD)A[@K:G#WW>,XF30L,^;Z[V*SWY<P2W__Q">#2D?__\91C/[V?^L8/3T%R
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MMG(2( -V=)IY:N'@]?8?FI%UZ?SV*A5QG@2([2 !6GY>^)_>)  )\#KPVWE
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M52*+&M77*1DGC6M4#]>/7K]8]IC^@[L,SR\#?S\!UE__P?YO-"/^?S-&R">
M_FNZ/8?_*O0_0P2HS*:^4COEUQUG5V+D24_Q<R<:21^RTK?9S\[E&!Z0&]9O
M6^.P5"Q<\IFZ4T]H\T!0P;%95<T.A;,"I@W=.\L])#B\A>_-!7KS\SB36MX:
M,MX5U;S/^!&8(+'P.V(>3T(Q "EYU,B'D/+P]**\ JV<;.QZQ"X<?9_U'.>_
M&#>4"&&T.@@>ZR<9MA(#O@;DM>*O9QOA&5=X'F@^GYE><U[[?)LG&U8IJ<1"
M(=?F7I2=QMD0IYL<4_>.8[#Q+LM=EK9PJX6^38=3IT>8,7[TL9SJ)/<%Y^#/
M21TPLC3:+;-53>%Z*2A+\O>$<4 %":L(]HA+IHYW$#7BI_FGM))P*=1U$S+C
M6:?HBZ]>D7O?B6;R ;\>MLHH#KK+BG(J=2.6BW]_[J?:9L%JQ^0A/!<BDQ)J
M*&#>L/36:/.K2\T<+@;! F"V]>;2V!BCPW0(9F_<BHJ@W0)O6_,U(XG:,,Q/
M(B7;TLKX*IUV\RVYC18^'5V;"9GMS>D+O>Q3%3_G/M;%V8X=])L,=^WJ@-J<
MCF$[H\O>!>60BU%BPIY%>)]+36;@]NYA;;X2^7(-[PLE.VH,$M<<%>%/:1)F
ME^Y=PQS>6N=BE=.]1F$LNGKZC$*1G\HO3NNSLY,[5LV/IUDJ[0L=WN5=]\<9
M97E3Z._Z8QJR?KM>+:6=/YC)0X;D+C[0?$SNG_I3[+=Y^MZPZCY3UU)"*$@@
MM6N^ 6?-X<<U?_4GA0^Y\I1#FCIF9ZM!! #4CF&I2K@7"_OZ0)8.R+R-9>8A
M4,LQ@>J%,GKM[W3QNI3,.+]5HIMLGX^_P9T=)'&Q@::7NK->QJ<VE_'-WTJM
MF,5<?;7%CVE C NU!BSB7BEKMYZF3!NU&Y)2U-(L&)R28E*%>]!,W4?#)A=H
M1Y4R;9M'D4.K)ZF_(;B>(9K<AM[$;6K')HTZT15E6XJHDMVS?(!2S-RRL>M,
M%4&4RT(54VEQ0IQ"Q^[MWL[3NJAIU-  U7.>-9CS'+>28GZT;5.+NJF,6A#6
MBV1\)7H81KT?0L68!!XH5O4RH(P'"7D>I38='_S)]5*7IB,,18C@:$RGBIGT
MCP]+62]8Z&J8+J\YNIM267Z%EID;3S1NK<LSLL6;#<</4N6]\GU&KFL21?%K
MNWBB4-=SIW#DY)?FW95_X&!+K#Z+$8[R2]#DLJ*BD @)U9+%=/V[Y3]%B%)E
MKRW_B)FJD_NKALS-'+"3G%%@G';Z-J.S.QK!6&$VVI21>J7:DES :HU11^I*
M?6.LR] %Y#O;(-G?'-Z+;5;'\7(GS@\.WX,O++0::AQX\X3?*P9ZE'7F^4XR
M^-G.%X?#=LF795G#XG@EW=UYNZ_0"TS=RPXFCDT/SW6"W''?/P_G%'0S]B(?
MS4HMT_=Z<Z,YDYHS:YYFX%S821U4UOH$J'D"W+&6AOZV?WQEG]=7^ 2P> +H
M3?^<E5;YET.JV?B9]K#P:/4_2E%]Z:*\AKRN$%L@U?1O3-6-BW<M&+O> ^-C
MHFC>[^)<!2[G*RH6D_TEE,2/YSO3;O-*WWQ)[F[6#>,NRJXT:/>IWPTSN*W*
M;6K:.SXTQ?EV^$>C.<DZ5\*W4)DHGQVN3!2QI3B@3R2"SZN)+V#1P/(\I=!?
MB#BY=5JP8>-2FH>\<I//RXRZ?*1HG_5"=4([>\42I[/QMT53P_2@[_L1&G^3
M0#DL. X'/[H:)3NFVPTV3L*[(2U@0(QO#;N.@6-K$DB.RH3)9]:EZT2Y*[Y2
M$A]?U#0YY>>\Q5U*=F;L;[CS'QC)QCI4#_]FHG&!1XCJO>G 6PX>]8+ !"E7
M'T#0$I?91;OC1)%/V.>+CHP?,SOEH07AE0V.SMC7\(^"EINE.2'3)2T+QSPG
MHM EA8JNM8_^#"_RL0?O1#^)I#KHIZWX6*@>\PQY$;.]@6Y"8$K4\3=I["EY
M&UP!)_X=@2BW^?]36]H2X](X9Y7BR;N-OVSME)5HYJ=3Y[9#(RAH')DP)-BX
M&DR1BX6&#C^*33VI/'-:4HLRXSXMVE.PD%TJ/IL1_*E2! *HG- *O((;W:Z9
M>!.=W#61XMR;>/]L3LY^R!$MR8UN\&^J/*CTWS@5-V0AU'5UA8UDV^078MW5
M0BY-^>*KD@.Y2!K@3,GRR-2E-;-3UY-<ITX]WJ^C\ETC3JGH(6%$_+*":ZQ-
MWKDUQ^9+7:+K&Q\(^Q="=&+5$)(59HG[:N8DFA9>;:HSTTY<"]$0WV-@F9H*
ML0HIB- &^R:@3UD_F4;:RR5M]P?@D_XVBW=3PQ5$ N:9J;7'[ELQ9U6@"6)=
M&S@/RQ9KVDGYM(MS>M)0TW9H!A;5=4%6;%ER*B:JT!I;?97;=_@*W*<XSG8S
M&DG>4P.#=SO:R,7K7:\U[K(GO&>W',<W M/\B;D]<3A*DHJ4'IX ?^9-;!4\
MXFP+E?7M#B(XF@GPW5&JUEA5;\ G-3/ORR4L)P;5^5(/6,M _GEHKF'%)/[+
M_"EF\ O-!9CI6&X@\[*WD:VM[^RH40*((3";)GS+T\XL+MQ*1G(;F%FJR3VI
M/],P"UEIF-4<<.W3+\G6T^1/$X@KP![,NDVQIP >%\]H+CO)PVS?H@]32P3<
MZ;^IW"/U!*G8<1;'TAR'MGP%_I*<T0F!**U.:X[\*;KI[/"OVS=LWV33?)PH
M2G9)8FV1-0'.Z9I5:AHO@?,/D&IJD?9)QK=Q-+/C*0I'PA=GD83"WC7?A^2M
M]S C5;D:9Q<-:XX>K/VEVJ!SVOT&)2EO9G8UE,P2/6)\?CN*7@[Z0$&F?XQA
MC=G#@5+W;6HJY<3&P)1HI;UG]  +.>,/2<'X[BH%<K.IRO/ =O@30%AL43-<
M4I [Q:Q4BDC316&AYKX69+[B4])_<+35XK!NL#HE_7M"9?D;1R[6LQ E?&4I
M 5/1<I/.A)]S^^$FL[IQ-"G;HURD%0<K!B7E,#M#<<6"#\?/W^\9<?]LN;4+
MW-GWWDS;!WQ8(=\J7!I,[5D6\:ZY<7X"9%3TS1LPFJMMQ.E;'=,0?60W;.BD
M$3+ZV9QF*E2]C:SC>.;U;4_,-O;=9?"C7LD9"KWS! J]FT+Y@.:Q1(.]W?QB
M3F;7F.>YD$._')Y[_Z6B*D$>QRFM[RCBP0_F4U9=N"P^2J7T?+6BJI K JO@
M)?5]L3Y>L7"BC-,)Q=]Y&,"8H/>I:<7M8;5"R6$IRYXKKMZF8M(0SX7CMG)S
MP>/&4-@OJ!I$_;!JII5\:0<.,BZ@3V4V"HC[$/S.'1-%C$2T_Y*INMI[9;:Q
M.L&WHH&AO(4)@PE8B"7+!IR?";.V_SQ9,Q1#]V))9KJ5T0ZME7YF;)3BZS,K
M9+@^@9\!BB:F\@@?>PJC7?(LS.;X1U:=((*_?:Z0C4/#U#M<<'=QW9&MJ>1X
M(]#+YXM@EL' RY.)1<8]9V;82MZIS_H&S]I^^'>KCFPCK8;QMM\Y5_?>WT9_
MDGC=-)642S'>"T&574ZJWW.),'3.;",D0G'=D(LJ%5NZC^ C=/HW1:F ER.
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MO:[O0,<GSH@Q#8SQ^G[JN/!1U4=7?05MW$BF%'&:9J>I9U"8!\D.R,WY0%"
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M4\/P<E-CC<VF+S9^3',Y7E[PN9YJWR87DIGR](W RIN?+JS"AV3\J3E;SX&
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M9LVFS<-2>O]S#1%W5%LV455*@SX C]4?\YECNZ@88%L4(MG6J]BT/U]R!?_
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M=17B3HZ#KO.\D=<ATL-7N29;:PN\@ENHO86A'=7 \ACI4LG\U!@M5;1WEZW
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MR@2%X\9O-XC7&LZ8O\9X\,,'P)MSAIKQ!WO?#B]+=:A16_#,\,YUNU &/:Q
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MXP?8?EVC[?-V\[I$&R3;L_ 4AI1,1?KP1T)FIJP7+OA!6SX1?$E)5B)4YZ(
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ME!XOT5]B7_-TCI5E]IB1(7T$GHU&J>TA9XM;+E0Y[9]ZN)/CZ!L3SR,<K@.
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M._<'LTXKY4F-J ZSC/=+G>Y:]UD1Y25%L=[IHBVBR=-5SBA-;^0W.[*U\[^
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M9=KA\5C%,*>6(\I%.DL6#;+:4*1@6J0C5BC16Z3;7)6W"A<XQQ%4GD Y-T"
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MS%.5*LF1#9JCD.?4:IZVRSKRSNYX7X6ZGOUY6XR;(O,]T-(RVY]4)OE(_E[
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M&)FS>S1A=XNWN-[XO#D<^2%FZ2;:*0?%9-0$?P;CCC*7ZM'=Y1)8XNP.L_C
M6:Q,PRGJTV.XXPHG\,+9/[Q-BO$PIP^<TW>SJ.QF889O[BBE[LR $T #X)-S
MXO"=F]NW0O938',Z0]KM]#^9M^"!^8JHCEHZK9!2N43<8X(42:\D=@XK@VET
MCS4=9YSRE%#;8'HO9/C?</;!5-G?S6@:LO<50(.I3K/]61;+.SV'MX!7EVKF
M!Q3(:*,3.*9J.RF5,8O(")LC+X0A7C'GHGFL0,YTTGZCDGHAC?_X^^X@=*L3
M.L4HD8ZJ% <2$&=*(R4U0Y)RGPMBO1>D*Q3<G>G+YGS:U;,-\.T2=H<?S-[
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M8E>-7-#ZX\]D ;GJ5&.]22'U..":3>!2H6L/6IJ1[>S-V=[M_EGK!^ :@&L
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M+6/[TR(87+Q^OJQ_;O>NS^Y/=J^Y_V*=T-F#^,T/6KQZX3&3(S,!S!BEBJ8
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M0S8SG5ITAO='R>UF0%@,($/#@:U)Z;026@5SF\$WI[ +7LNJ<5=LI?N"L=O
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M?>/0).73N,^;D/$FOJ7EXD6SJ7C2$L L16)7LUB6&7D/:?-GYJ"*T]$HN8(
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M_G7&/R6Y;(A3Y$-(I(*K%(M.Q"S+I08>CW0Y^'WRS\NE9VRI'%H?'I"% '_
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MS@%, =.Q90N8S@1?.67M3:F4:FSXXMF2JU%2*L'P:GU2^=K:8R.:+)Y;XF(
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M( ^ 6J'6B>-*.A%<'-#C7"05BR4?C"!;0TS.,FN$N>NVD]^EU9'VXK@%K^
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M_0L:;263\F> #S[1:00G: , 'P0-KX77SDV:\%IX[:P$/7H,X;60)KP67OL
M!#UZ#.&UD":\]L:'\<7[YS"/*JS*5<B*&Q*Z)E*B6O*J6)*2<29E%:KPJU58
M*8N@@M>4BI6D5(KM>TS[HT@Z!V]D%M<ZCP^5(4\^+ PY7:?->?EVL]L]*_OG
M]57X^=.+KG9-%^VS&ZJOK,'IOQ\?+W>CL"]!3] 3] 0],5.9LZ!'CR&\%M*$
MUSZTF8KFJI;H/45K,BGO) 41_-  8KQQEJET;:9RFWX1S%0>Z$P%=YCTX%IM
MB-VR960VL>\MOSE._]F[DL?W0?A(S>/H@9]"C&\0[\U11H[4T8D!?_"X+G\!
MDQ@6\'1X^D,6+SP=GCZ_88$6F$EQ (#MS$L 6  6@ 5@X>G]!1:>/KIXX>GP
M= P+>/KH\H6GP]/AZ?!T>'I_@86GCRY>>#H\'<,"GCZZ?.'I\'04:A^A4#N5
MS+,V@7*1:3C8/U#4FE.JVHJ0#"O&72W4#J%$GH(DKXLAY6HD)XPCGY414<6J
M<[U:J/VL['^MS#YV1;;T2\94-X?W3P*[G?:8 LECXP)(!I*!Y!&1+'C4J23>
MH*ITPVN(%$Q*)#V3PJ3,G C'Z)T"DH%DW,?SN386-V?Y& _FZW 6UJDLPG[Q
MLKS9E_-8M@O)E@O!A$#_>#=YU'$:-W_K1^*1& PI;R[B64$F=43Y?DJ<>\RE
MIIN]^.BRL4Q2C<62XJ52D"41LY7Q:'UDZ=J"0C%6^-1>:;AK&0]SE1PSBK*)
MSE:EO9;JVDV!K\.V[)Y?['?[L,ZK]0^_R6!VAZ]^F+J</OOFII1EZ1E?2G6,
M6P#OP27ZR5MFX!.CQQ"8ZR3ANQNO_!<@\.$@L%2ILF.1M-"!E)&:O R:6&WX
M,UI''=,Q$/BJG+_9;,/V[<E_7ZSV;Y^$[?9M ^'C\R:C_>/]?KN*%_O0GO.K
MS8N&P_7^2!?EVJ6SQYC: Y+WZN7HX9L46)&Q=.<FO60L4X@RLI+.LA+G;'#&
M1"HN*U*Z1(K968H\L1BT4RZHJUF)EE([UI(8FV-MWQ/=L.>O*,2J2G6A)3+B
M[B?FSBR=XDLM))*.!V<4H\<0G,/,' R<!P.#TUD)SHF9ZDC)J"F$9,@J[[,;
M9MKYVK&DMV+@?I/^^7ISUA[O[G)R?J2IMV-B:;P%!\%!<! <! ?!P5O-!6OQ
MQIM*MOI,2CA/SA9+QC*E:LHY5WV5@\H99J565%3EI'C[+%@MB;N0;/%,6!_O
MC8.<FZ66&AP$!\%!<! <1.'W]*G,-.-2&T:1&4&JT;815FER,:7@1'(F7]LW
MKC)'*:LEIW(C>6*>8C;M&Z,PR4K%G37'I/*G57]S+-7VZ&VX\P_8GJFT@6U@
M>ZR[KH+EEJ=*PZR:5&&6O,F-R,9(FR0K=KAA]TJ_5LE<^6$*K;TAY57[GI :
MP&T*53,631T!VU[(I1&H?^[0WX!NH'NFT@:Z@>ZQ6JVM];&$2(6Y0DH)3:%8
M13RJR*M*NOWAVGYP#2D5%RB$T'#O:Z7 4R%=L\O51V?4".A62\T]P-V?N_UA
MPW7[[U"??_CT_D+QJXV-0MD>_K%W[D.7+QU^V5>K?7LGZ7?C\^IU631'V9RW
MMS>T;RS6FWW[46';_KKY5'O9#]MPMG@3MOO%IB[V[>47ZW"1VUO.@S4=:OC#
M\(>Z6H=U6K47[_;M+\[;S]\]ZBSP#TIE,_W'CIJCW^J?RL5-O[X[ _F]@-@K
ML7C]RXD=;\(/Y9+9%&I[RU^%LY_"V]V__67Q5PBD:[P<ZPR1_WS\CY/%MZ??
MG"Q>/CD]>?;DY.7BVU=/>T/ 2,'Y_MGC[Y^>OCIYNGCR_-G+Y]^>/GT\_.'E
MJ_:?OY\\>_5R\?R;Q<N3[TY;U!XO7GQW\LW)=]\-+_B/Q]\-?_7LW:?_\?S;
MIR??O;P\V]?_V^+D_WQ_^NK_+KYX>O+-Z9/35U\./_[5Z;/O3Y["H"<BL;M,
M[[XX7;><;7.Q"^N\6R[*SZD,C9>O#_G=H5-W]^7#%<IA^O/^-[][H\.;^BI<
M[#?OIY'#>VF)\?#6AY?367B[N=BW'_]S:7/2PZ_BC#UB__K^&]KC/PMO=N6K
M76EI<TN%W\?@LO?U\+/_<O7 JQ]7NU5<G;6Y^5?OO__?KA]\=?GK!'O$K?W7
M(70?FU:_>T^/&%,WO>:&K]OV>_1G_@S^2(C/_1GZD=<W_IYCQ&-&,3./C)1X
M'W@?1WL??W!.G_O$8_J.=43I1R!R([;L<.; >-/MRU]_GQM%]WF8\?&">XND
MX,Y"VP(Y?.5__<7\Y>[#_*>.W?UDU;N>,MTKDREWRZ?VLFQ7[86/_Q:WB[_^
M[Q?;4LMV6_+BLO>[RX.3?]EUZ.\9WC"X;ON0IG3E.Y[$V/PX5F!O08\["BO8
MT24[GF_S:AVV;P$+6!0LZIU%B7NPJ/ZT/(X!/<YY-53'A+-WZ6M893I=TWCB
M[^_)P&7@,G/1\D@ND]+%^<794)AS:3//]Z_+]O+3)YOS]JM?E_5N]6.![8P]
M/F [L)TYV@Z,!<8"8YF=EL<QEE>;_?L)TV'AYETWP_LR*)C-B*,"^\+8%WZ@
M^\+W@0"L[7_ROC"6]*? BW[<"<DIG.E^YL6'4FLXTQR<"94IO3P), *,F \C
MD+W"F>!,<*;^G G9*YP)S@1GZL^9GH0W0P,TK G6!&N"-?5D3:?KM#DOBR^^
MW>QVMS@^%08%@X)!P:#NSJ">EKI**TSK8$VP)EA35]9T>4CQXHMW%H7TJ7>/
M^H,2P,.)7?=9 _@IX;_'<YWO[83!K\-96*>R"/O%TY+*>2S;A>3+A6!"],V5
M>1PH=^S _N$1YZ.'=0H1_/0RBVZN5O@38>WL,@//!7<E>=*&*5*J5'+*52HA
M5,,*3\%<NSY0\%IBY)JTX(64T)%\S8R"*T4RSQS3[.IE!J_*^9O--FS?7B8)
ME[OFSR_VNWU8Y]7ZA]]<;7 XZ'+WX9T&I\^^N>$N [GTC"^E.L9%1!CLO0SV
MT6,(#MU#LG4WAG>+*X+ J!X9I;@UQ6E&QN?&&RT:;UCD5/UPU8[F3')^!XQZ
M$K;;X6Z-RSJ*Q_O]=A4O#H<)O]J\:(!:[X]T+[U=.JN K7ZP=:^UPMT8Q&11
MAQP"/M%I!"=H ]/-$[(,PHJ<6F*0+*EB*P7!A@ONDTZ!<Q:8N9HGA*P=RTZ0
M+[5]C_&>HBR>>/7"BZ2SX?':Q7Q'G[PZL_1"+8V22 -F-+Q'CR'(@]DKJ#0N
ME8JKN=@<R0BA24EA*00;J-0<E2_&E6R/0J7/N"[VC^'$Q-))D ED IEZER;(
M!#)],IEL\,8%':FZR$CQX,DQZ<BD6@VW*4BKKY))9F&SDI;:Q"J28L&2"Y*3
M]3GI:+TTLMP;F3CW2Z4$R 0R@4R=2Q-DNG<RC8:;+]X_AWEPDC%>>*Z,:LZN
MS<9")L=M(6YK+4JTV5SQ5SEI>7N)CH)8E(V3WJ@VZRMMZI>=UVW65T,4Q^3D
MKJF@?78#,(4'*^_3D$8L@1X]ON#H9&4+CH*C=\!1'G3Q+"FJMDT;E6A,=&T&
M23RIE&S6C(MP;24T\9JD5,3:)+5Q5$OR0A5J4U2660D^:'?_'/7&+J6T@"E@
M"IA"MH I8'K?,-61RQJ+I%A-(E7$L!"K*]5B3 XY6<NO;2O:ZIG)65-,UI-2
M)K?Y:$UD>=,@,]:I>JTH]NYAJO22>0Z6CL[28[2##GE933,@[FC#_72WNSAT
MA&[J8O/^VMO=+4\9G<WCZ"T!^N3 ?MQKSE<YGY7QPSJ%"/Z>--_%$$G.;Q[&
M<+.2@J G+.C18PBOA33AM?#:_@5]AXUZ'2M^LOX,\,$G.HW@!&U@NFN7UID2
MHRX48K&D@G$4>9#$F<ZQ!B=,C5?7+EG6)6E=*<D<ALW#2"'X3,8D&9A1T9OP
MT;7+83VEY*<7V]7ZAQ=EN]KDR_Z]]N8/7]I]=O<>9TOCY-*:8RQB8LQCS,\0
M_5#K U3K= E5HFYT"9E448U0T3,*K#HJLCJEN>?.7"OY/"*A_A'.+LK' 77[
M;@FIED8<HXT/@[Z703]Z#,$C2',Z/,)2(00-KX77SDV:\%IX[:P$/7H,X;60
M)KP67OL !#UZ#.&UD.9TO':Z:]I&::ZS9V239:2*D11R' XTT$;Q]C47KEWU
M85.*P]&I5$*2I'BNY&WA9*25M>08.5-8TWX@@Q[7A?60<QVJ%RB&71DN0CQ_
M4]:[,(@>W;'=9! S:42;0@31 7L?LS4(NA=!CQY#>"VD":^%U_8O:-SB-"E_
M!OC@$YU&<((V /!!T+,2-.P7:IV.6F&_$/2L! W[A5JGH];I;M+'I%.2P9)7
MW)"2T9-+19#U6D0KI!&Y7-VDY]658&LFR90BE:0AWSXE+7S.E16GTL?/2/Z=
M3?K##N/7PP;CDP_V%_]]N]D=:]M>+*UF./%Q1BXP>@P!*$AS.H#"_ ""AM?"
M:^<F37@MO'96@AX]AO!:2',Z7CO=A9<4HZZ."\I,>5(^1?+59&)22Y=8-2[F
MN^Z.P,++G%P UVGTD(3]H^SV;90-MVE\]_)[7*'13R;QF2U7O81U"A&<8"8Q
MP5D;!-V+H$>/(;P6TH37PFO[%S2Z)";ESP ??*+3"$[0!J:[7!F=C2QH2S:&
M0DH$3TXH03*R&#*O0FC].0>4__1C^>/K,[XKN_UVE?8E'U[V^*>PS<-:2\F?
M?9^&-'+)>[A, Z-_UJ,?K():IZ-63-(@Z%D)&O8+M4Y'K;!?"'I6@H;]0JW3
M42OL%X*>E:!AOU#K=-0*^X6@L2D)KYV;-.&U\-H)M0/,IJMM-(T_?W/81"\_
MEVU:[<HM^@%F\PQZHR)ZBM!9."LJ0M"]"'KT&,)K(4UX+;RV?T&C'V!2_@SP
MP2<ZC> $;>!/A+6S?H!<0_'1%0K6,U+"<?*J.#+:AJA4S$74S^D'N.'XDLN>
M@,,7+U=8=B?O5E@^OQV NV.T F#@8^#/D/]0ZP-4ZW0QQ6JL=8!3K+PA)Y9
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MMC,9/YOZ&+KY8BI5U.8[C@,<S!H,C17#D:)PL/"@6#$(]% $>N=S&+ VB&;
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MX5C)7N%S(+Z $P.=P3V$@4!\0: #U@:L/331#%@;L/:@!'KG<QBP-HAFP-J
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MW(:'F!E!#$N)RC(4XUPAFE.*!,\UP@(G\-]$"&J>QK!KD>Z;<R(>6F.8A=,
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M/RB2MPK;U%J!C!4849-3Q!.%D;*QR9,L3@G=2D;#7I)\$M- \GM!\B'%8N?
MZ%(LBHF"*:M-]"/L*/_33_"W)_72',:J#4V!"^>AAA)B&J+RM;_J#K><*R4$
M2E,L$654(JYCCK(TR6EJI!7)6JG=[_%I/$JQ^6"JHM1O6RQ]W2+I0MWIJU"-
M6K6]UBPTV\;QAX >.T>/P&I!+H<HEP-FM>!2V [')B*.<\TEW"U/@6,SBYA*
M*3*$T51S;J6)M^%2&"K'=NZ#>\@V&65Q*%UP&*Z#PX@B[ Q'3A[L'QA%TL K
M3=RA#=="S>_B$/49AGH5HCX#FN.#C/KLKU+$,QDG J=(DB1'5/,8,4)B%%LM
M!=4Q-F:M_D%N>9QI#=]1.4>49AH);17*,<A%G.6,VGBK2M&3152^J@EQ,L+I
M<.H4[T6@99\1*'!GX,YASW'@SD%QI^":93'AR+JR_51C@J01&N$\%YQE(J5D
M+4<ACM/$<)PC3+1%E!&)!)88464S2;EV]1H.@#MQ2D<$#Z>=>B#/D(FP5^X$
M W]\A"/A,%9J:,K04QQB(T?$@9$NYW)LAJ,./8?;\[^&<D!V\QH$96FK1V09
M3RFW%B5YQD#QL0)QDS*4N ^T(E3EZXV.",_CE%F$DR1%-,T(8CF-D8Y3G>%4
M*>&<$_NO+-%DE)%M*$O/ % O1%T*]#K@60WT&N@UT.L*O:8VIQEF*;)26$2)
MS1!35"*98TDD82JW;(U>K5#*,(&$$!QY<A98&91:S;3EDF4T.P1ZC>-1%@\G
M?S#0:TAN^&YOA"S'>ALH<CZ?3L?F"GX1XTC#]AN7];SR'0F]@\*.R\]1,6DV
M%NR6$(]Y5AT)YM!]\C\_D!^>/FXP1"8>FFX:YGJ/YCH@1T".PY'F,-<AC#6D
M,%:7G.Y.T):-L3:YB,;^3UY*4&G1''X1=6V:^-9_RRKZ<[NJ_7^;+XT+(8NQ
M+UL8568L7!1L5K9WA$DPD_J[--##6.>AX5GPT@4OW0L]$/5__K\O),9TF)OF
MA7B. N0/>%8#Y ?(#X&9E<",%A(X(^-(Q$PA&L<$24$TBJEE-$D,CQ.\C5.G
M']W;G-G?:W/LU.XS.1/%Q!4'[XZ,OBFKLTY;?^=4ZW>MVGVSK3@+&<5Q%L(L
M R++SEJ&_PIX;__C\[WN$CUV0FY#>-DG!Z/F4O>P5\4,1J+NG)]/EV"1*U5>
MP?!NG,4^*5VQ<E'!GP&LX+*+2HRCJ:A\;7/7Q'L^$7-=^*34<N+3I;UMWO8G
M@XOK&?S!!9'JHTVU @;T]M' !&/8NP"3^QX_N(UPUX3P6W-QN7 ;3L6%:?@%
M"0M#?B7&G\5-_?,/T9^?641V:@,,83?L* C^3W%MHG>%-=&Y*LQ$P9?>S?31
M8R<G>_SF\<JC!^A_S<I_+7#X7S!V>'S=_-0A\C F\[VGDUD9_;Y@C9.EUW8
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M[L3:BL+E42]C)0^PP:9EO<P*[I2.5<AY)*0T"_SU6W?3UZ;0+;+LNG=T^?=
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MJT;4VJ>W@W4#>R7FL[([K>;& T+FAN\N1V-Q [('C_AB],_-XW <'\5_ZKX
M2SD6T]J\JLU45&)FNGGPAR:;>_^PJ4;,=5$7_A#@S:ON'G?4BFD>F]*C-/N3
MF\6[#O*UPSOBY"&7/>0:=L2V=:L!C"KTY!YJL]R!5!((/;F?M]K=0$3^<2?9
MOG?E-G@9AE2(8'-)M^$MWA";>P<F"4QRT$Q" I,,B$GZONE '0&@ D %@!H:
M0)$ 4'L"4*%9T6 <Y&?+')/IO%*7PA]O7(EXA>X,SQ&<"NV_!SJ+H07B,Z9H
M9(KDB5:N5);($*6)1)RG%.6QBAE6FC"Y5MWD>\H+/S8M\6P9+&R2-AZ?V45'
M)&&CE&^KDV^ B4' 1*"Q()]#F,5 8\](8Y1(Q5B:(QQSBZA.!!*YUBZ-V4BK
M<(PE7J,Q*Y0R#*X4@B/*K44"*X-2JYFV7+*,;CV[?OLTQEUZX2AW548#BX4V
M02_1I';99 -WS;XX92.T$1]$Z" H&T]1$31.C9)"(ZVE1)1D,6(\$XAFJ2'2
MV(S)1W7D??I#4N_+B3M;:_26E) L24:$)8-J51"P(W!;X+8#EL_ ;4_ ;6EN
M,<E)C+)8)XB"W8R$(<*=LB%,I03LY?5V<\]I2#\[MW$.)G:^+?,Z8,?6&^R\
M%()ZH=;]UYM?8!Z==H49/&!$'[JH^M=;.YR>?_BP**0:B?'8G5.S\_$8N</T
M_JC7HG",J&;-7Y=5(?KA^XU]-=8Z*\PB$>FB]H55W=>M**H(%N$/,XNNQ7AN
MCJ+3]9JMKM^#F53E>.RJ.8NH+KX@7UTE*JTUONI*6S]+&EC.B?N# ="XB?XF
M)G/W?)S"Q>YU_C8?-[\=16>W!P?SUKV.;H8ZA1T& W'U;0^O8+[")I/ 42A+
M%%AP)G&U4!5!EB;<,&9L+LP:R^4QC6,;(\P5!:M/YDB*W*(4TS3F-A6<DWX_
M>2^-G3!^<+-Y/#MUT_FI? -+_YM?^7^XA?]@*J>YB NS0E:P(&;1.0Z1/FN1
M'_["!EZ3XD]=@6'86$TQ<??+FM#?*D-\]_YI:SO9HJIGD9S7Q<34=:1A>Y3-
MP>^Q6/O NII"M_;)XWNA+,^:.PPY[.8G2KDNBBI%J8@5HDPJQ*BDR"@5$T*3
M7*BUN(J,<9QHH9!KD.)B,09)GC.$8YF:V"8D970/BOR[^OY[4./_I?4Z >&1
MS#5SRT$ 786B&/%$842P!H'$5.5XK3Z@(WD;@Q03ZZ*#.7R;Y31#F!B*,Y+E
ME,KA2V2R)Q*YTG4B.8IZQ>$&-="'5*H;U( /K3Q0B@TP!,^0ZQ;C.FO%2,:9
M0!J+#"?6*/LX+6RQE6>E^N,MT+?1C2PVM<&:#=I9#_ZBA;H&IL/CR]X1DHXX
MOMLK/@BA6E-[0%LS7ME9:6/G5)VCZ'@?RG0,:GB^U"5,J)_5P]J^";9,$YHB
MQC*&:*P2Q(RV"&>I,+&1)H[7:@5^CVX(_ LH[??GB9@6,S%N=NY'XSM!ZC=E
M]<;7@GK;:NB/W[@CRN-1.GBF7;-85@IDW6&P#+AXS9VMLK=:2 H#1V@.BJ D
M>0K&/VB04A&*M,4VEHDT9%UNOZ>0U(FK "-+5Z3^VO04QV77X- )^+8XI$?1
MR=F[=\>_G'WT[7^CXU\_GI[^=OK^T_FC7*&/Z2>^@^EI+G6/>N7PKE!W3MBO
MYW^/>H(&X.P,PK;-[?%%9;S(U5O8\T_W#H\K8'4H%4K/)M%KHQI5!B=-Y^11
MX_G^_?S8+VOSR]\C'^8$]<QW:18;UO]=H<!B-4L!6/5]KPO-XL*E2]QUT8M^
M'8LOY?D5_/CWL3.7WL*3QV/3=)'Y4)534X&<_?B^/(J2GY9=RN !O?;-H%4[
M)IIU'9J_\OCVA=T[N*LN_2_N0^_)4(LOF<X?"+1G!"CM(R#X:S,NI\U=O/L>
M] ;7/Q#6^G^;QS@G'RQ\.9FKL2EGA?:^>UA2,Y\5JAZUO=F:]H:1^0*_U*Y)
M],6XE+YK3C.K,))__N,4Q7'6.!.]5]_[W-7*6\$ IN7$S?ZEBT* W@1J"0PG
M<K7XD:O%OQB^;X+8C5HZ%Z:?B*4[= IS715FYMA^^3S?T:V:7_1?/IJ.Q<RI
M-Z/HP\>WY[^-VI7LEL3=#?2C_\Q!RY_43HCKIM7'Y1S$T_?H<)/A[^T:OK4O
MWW_"ZNQ&P%S"5STK7#E]D.,N]$#R?KWWKRQ[)(T2+K[2]1$?+41@*@K="44T
MG\)(W2LV_A:WH/]U6$IURH@%NQ$TB]@Y7&/0-@3F HDT9DP(D2JVGEMF#2>Q
M:\+*-=C$)G5]342"<BFYBBU/.:;]R,3*(BS6X/=F;EM7UHH._?OYZT4@(NNK
MTBB]SXM*XJ.A:]%P]1A&-6"]^,5RXGEQ-1_/Q,0TK3T]D#DH,5^,FG>0_C!*
MN<69MV+%=Q#E^8?C)2&6&PEZ29/1KU4YGP+W7OG6(4LR_/7=2L?.2%@+:-EV
MN8"1CUSL=<&039?0?ZXR7PVL>V#N YG%L18X0WD,_U PHA!7J0;,2S*FP"#C
MF-U&.DJ5P-19;205\ _/P0)CPC60DR++A5),?)/W#P;O/WJ\LP_'HXPEHSR[
M.U-H$%O*R9RC]=N^ Q R$-0V]M]MBR8)X/!8-N8XI9AJE-O,!80$1\SWN6,8
MVU20A),UEK4J234&4HXU98@J;I"0$B.M.+9&IIR*]0QNX>M(>]>RFTH0/2]W
MJ^PZ<7AQ/@- J,_LL7=5B-<.S*JZO?I;!)$>96S@(@A60]O=>,TL:2W7MSZ'
M;\4@:73MC==$SI_BNM#U5,^L4SUMZ7)[N@B4T\G'IJ,.-:^! -WU[@[N&ABE
M+GP>8?.\V]MDF24C;YH- V]1S^6_06]U>\AY<Q"P@%-?_4F_>@;JQ:*M\Z("
MMA*5>VJ;8529BP(N:)C+9Y2",;(<G//FP:>36K1W\*Q7U-$?H NL=F[6A>M6
M,W.6S+SR'=%!4D"BG)I>UK#O"V>73":FV0X+1ETX"UM"W=CYW7\"G!A:BG2)
M:5^S:9S1-[N$WY:&8/UJ6!OQCF+]_4+:]"@E[$\_KRXN6*!@9=Z\LF/SY?;2
M_AO$MK WW6/\-0BV0C7[V2\B@M>[JE^Y;C7.I;"VW,O!PJ.3_$\#7?_-$U),
MW#LA/R_?\(BOS%E_.O*4X)QEE),DISE)735LO-B,O05<%#7_TZV1#63R?OC+
M\5?\*P[NW,9:^EE&FW/$8(P*WLKE1X^:S#!8$:3&HJZC8Q!(]/;'7W^*/KX_
MCHP#=0?O[NRUZV3J'R+&TTN!,,#DK)A5-U-@ *!:6_@<TYM6M[_;\=&YE0 ?
M87NWE=\+ITLYK+:F:O(>2O\RBZWF<Y:;?X&D_21H\\PN[:T4DMN>,.!^);DF
MZ?N_+Q<GJJ?BPC2Y\DA8&/8K,?XL;NJ??XC^O.NDZ&<\G=27E0#5WS2?O:X,
M32_@P8#W7D*WWX0K'3Q;I=K4RQ1=!\13@$>'FO5LKF]65?WCXT^O5Q6G6WI^
M=^O/3GN69HFQ;7![!?I!?9Z/Q:RL +-AY'/KVMP[\&T# >V%D6A:]SB(=O=H
MR<4I:>7\HM6#6Q?]!V__XC^39O0C9QAOY*"Z'!NO6OMQ TJYV1EYR+]K[$)?
M@ZKMN.'V"*;%=3F#I[MGPBA'*X9!\S(M5ZZS$ QPQ<>_&-C/ ]4Y>T08 &TO
M=4^RI[IG+X*V","MANX:)ZR9N&2:NE-&FWUK(C#O78---RH7E[NHQ%4=C=VI
M&W'A=K4/N_G-NOEDPZT0I/GBHJA%W80]>\'$7EAM%3U?+Z[YV U_,Y;^O-*B
M-NRXO=]QR?[ON*]MM+Y2L;;A&E_*I@T'4W=AO&_+>49;WUR?"R?PZ/$RW+T(
MS:S&V%<=.1_:!_44DTT;Z<6ZOWY?> 2_&GPS M;7G:!L&[W7719(Z5(OVD\Z
M/VCK 5A<LRHKL/1ZKIH[-!*S=B-W+--43@J:((>$>1-+KZOYXG0F0%KW8>-G
M[7DVO_H>R]20SDVQ?)UV,+U7]<DJ$S?:S1DJ=W@2>@KJ]%;2C$L0J1\0[FS4
M9S<*N$LGVPM?B_.;]R?%#=Z-NIE#Y\L>M^%+-YIV8R%Y@YJ?(L#QHF[\(N[\
M7.6#D\OMM[YH1WZL[A2K>X%BXEPO]R6#.!U9N5/\$W_6U\V]7S#XK*C,S)_X
M^\KPCJ+SI3^^DRR8 -/4!U@1R<9':QI9\._RX%%^;8(*>ULR1V[0 B8-[!28
MW?9OZE*,QV9RT4(?&$SN'&ACJ\(X'9PIT_[N;G -HJ+]S];[]ILO- O2SGXK
MG; P1EU. !PN8.HOP3CP\-M\J]E'S9^+NA^^N%>XWC9/ 4ENTF]6(@S.2>.$
MZ5XA=0 MNDGH/5ZYCKY=_./VWOXV(;HM,^V2M$-LUL'+/ZS 0H*_+EA?N4=4
M3XTJ;*':K]Z:*#_3;K1=4M4B!: &"766YDKVVHH->S]4M-O1#:&911=N %CS
M[[, S8>O<JN'@H4]:[(/FJ4J%!C95?N"*Q[9;UR:V^.MYRX!KIVWT^*[E]RV
M)X%[0K,D=R#_<GSM_+I^;3I<Z.[N\_6*2LVO7-1.F7KU!3^7\[&&,2OC_-5B
MZ:IVB7.M>>"HL9C,ESF)W@'1+FRWD*M+NZ@PT"Y2R$$:GIYS3YAO! K$V)TX
M7\@IJ!FB&A?."^0]0 NYF,-_QUZL=)O!ZK7?5]&/Q4]KFT(T8-\\K;_G5K[;
M[)VU*QVJNRAPJT OLI[6]"FGX?[L8.+'8N,85K_0'T95WHCQK-F>GD;!C"VJ
M]JR\\*^]47?KXXJ[CYA.83-Y_6G3PY91_[N!WGO%ZT6#::?3?('%TRL)PLU
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M(=FKXC'*]H=7B>QB"<=[KIQ:ZF#0UR?[U(G\.NQL%*BZQ:1'P .IZDM5S#^
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M:(CQN1(]4ASM$D:WBK_XGJ3?[DC7+?+O5A#IW<,V>T[O 8@-9'I4RGZ#7GE
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MT:E&IQJ=:GC7Z%2C4Y]V\H,=1KXH! L%>*=^$ "KN%',W(3[06%'89%LZ=0
M6"WQBYAE050PGX-O"YZIRVPG\460"\?WM@:!/JA.=9QXYCC&49V.4C6%%I,1
M6%)']__[;Z)I7O1;L8][L/]+6EM_W?'#[?_>-X[#E'!,R]BZ,V5OE&FW%XX_
M.?$/A<[W6:)OC+(C,\HBD7IYG/DL]S!HP87#. ]M)OP"_B7E(@V=^TBU?^A+
M[[-6>+\N&ZD/1'ZZS/^^S+N_ZTDJ:,71%)7[-N7N+S;RX"*O[;_PY$)OPO$3
MH]*?7-48E6Y4^N&I=#E%RI_JY9B.\#_TZV$$O!'PAT%G(^"-@#?7PPAX(^!_
M, XV MX(^$.^'J:\<S*78JN\<_\ Y'U9N/Y@Y-GVC&6#<YJ6EK\?.,%0D+DG
M+DJRO-H@TTQ&S_\ 6*B[G,,4K8##38:)S.&!L%-6^';(?%ZX+ W3@&6V$WEA
MD19YDGY/,NSJ4@S12:>7O)RC-/Y4O:H6BVIYMJZRSTK@WE-!:CA+DF!2>*4;
M&?L'LI6,FIPX98V:-&KR^)SE(T.PN%Z2Y:$0+(VP602/?<9M.V:!F^:I;V=.
M%/K?4_[Z4$K[8.MB#T1]3QBI8E2[4>T'P=]&M1O5_I2J/0K"A <%XVF:,]_'
MSA8)!_<\]).D$$*$[A8X]6NJ<)]6M4^P/->H=J/:C6I_<O(;U6Y4^Y&K]M#.
MTCSV44W;!?/CV&$I=SP61GE11)F7>SM"[5]1#/RTJGV*5<)&M]^NV\?H!8-;
M.W0\U8].63-5X!BYVM#;2!$C10Q7&WH?$KV-%#%2Y/BXVM#;2!$C10Q7&WJ;
M0IK#+J217\67O2C7L(YL[]&]%LL*/N/KJC9IPNEJ@6/N2CM%+6#H?6#T-E+$
M2)'CXVI#;R-%C!0Q7&WH?4CT-E+$2)'CXVI#;S.NX:GC6OL.ZA_T0)$S#F3A
MYZ+K!T-]7QIKTXC<*I=[V\-DU6*UH7$,RZU>,RM1R\?L_?7>;C3]KC.ZLQ/U
MGC$9EVE)Q_MIG/7DI#T4*AZ@COD*TDX,H.XDGI.F1<K"-.;,CYV,Q6X6,CLO
M["2+W303V].JOF$P@A;"IU(&O]LL4E&_+\Y( K_?K)LU7X)</-\>@2"%=!^@
M;M\&2[?#F>T&,SOT)C7YP$@ HZ&,ACIB_C0:ZB$T5%#X;N[8+/("T%!1YK D
M]2*6>[E;I%'NQ2+^GL8G3Z&A$F^6V/;,C^^K=LH(@$D( *.@#'].@8I&03VB
M@O*BS$T*&S22ZV [S1 \H0C\*-M.L,^FYP?"_9[V'4_C0OFSP$UF;A@:#75,
M$L!H*,.?4Z"BT5"/J*'\+(V\+'?!'4I#[$+!6>IG'LMX(OPP=.(L$/<QDOXQ
M-53DS:+ G_G.M*:;'K\ ,(C]R60VWQ2%R-9655ABL9I7UT*H7.1JSI??.#'^
M.(YDBA;&0_2W,<.I'JMWUZ$,ISI<*R5)\R(1=LP<UW.8[WL^XWYA,^':A<>#
M,+;SZ#Y2D6^762T6L!(^5RVRR/@X[>$T/E7T;V"GB/P#O\8OG]8U7Y[3[YKO
MC?X&]LP)XPFWS?I1QWH9U3AQRAK5:%3CX36U_+ZYC4; '\SU, +>"/C#H+,1
M\$; F^MA!+P1\#\8!QL!;P3\(5\/4U@WF4MQ2(5UWS7*_3CX9(IFP_TDW0]B
MVLVA4/I()]H<<%ZLB)/$3CR6!%[,_#")&+=YR H_#=W,"3)/V ]8HO=:2LXM
M$,\]%.DE43!S/6=2 )X#F1]SZ-+$:$2C$0^%TD8C3DPC.HDCG#SWF%MD'O.#
MT&9Q$;C,YH[GIFGA^D'Q@"6!#Z01)UH4:!2B48@'05FC$)^:AXU"?"*%*/+(
MC3P>,Y'D@OF1<!CG :BY/,?F+JEGAP]9@OA@+N(TBQ"-1C0:\2 H:S3B4_.P
MT8A/I!%=X7A>8L.Q!3%HQ #\1 [>(N-^&*2QR&.;!P]8\OA &G&B18]&(>[.
M31M4TJ&C97YTRIINW<?(U8;>1HH8*6*XVM#[D.AMI(B1(L?'U8;>1HH8*6*X
MVM#;E$D<9YG$NQMJ&\8U#-NU#C=6-9AQ01,49C]0>FYXIQ[F^OS%I.Y^K-2=
M%\=Y%-DV$UGA,S^+$Y:*V&4.#_S<]9,@M[? +-]2[_"&U\MR>=Y\$+7N]C7J
M2OIW^*/(S]9\+9KWQ>E"U, ?KZOYG-<-_01,2& 808F[+HOGWI+%LT]LD[^;
M8O[.:,R)4]9H3*,QCZ^YP#-]7L>AOT58%"+R!"OR(F&^&X:,Q[[/O)#[?LQ%
ME#OW4IWQD/J[ 2[YUY_8K8K<=XTBGZ80?&Z4O%'R1\S?1LD;)?^$2CZ.8IX$
M2<Y"4/7,+X1@21QR\-E!5:?<3;GP[Z/B9 I*WDN,DI^F$#1*WBCY8^9OH^2-
MDG]")9_S@O/ SUC@AS[S'>ZS-"@\%CNV&Q=^EGO%UNCE;RFB>7HE[YR$ME'R
MTQ2">Y6\F40V&<'W?1B'.R =OJM_XW$<[A3MO8?H;&OLO6DTA3X<>^]P+:PD
M*8(T"0L61HAU"!+!$I&$+.:I$Z1N5&3>]F36>\ ZJ/KD T,[/(*TF8YI=2B2
MW>C,Z7&QT9E&9YH8R>-H\"#+[<CWF1VG$?.=U&-IF&2,%W%2\#R+;.$\!-KA
M?C7XH^,=?BA5/N%4B%'S1LT?!'\;-6_4_!.J^<+A$?CB@H5Y!$ZW4\386<QF
M/';=*( /06T_!-[A:=3\O2$>C)HW:MZH>:/FC9HW:OX0U+R;Q;Y(<L[B)"^8
MG]N<)7:6LLS)"VRPG?!@N_;P'A /3Z'F[Q'S8-3\4V >X,^84_\W?8CO-L0C
M\/>\O'QJ*CV>KH;-?H/@:26 HIH>+1,"CT51RER7@\V.%G\<QCY+G#"(>!"'
MW(GNP\X_RRY$OID+N-C+=4GHAO)2G(EL4Y?K4C1OOF3S32[R7^MJ\8K&9'*\
MG^^+L>3X!.OX95YEGW^R!(B#%9YWO1$3NR6/*-@_70A+8DU2,:^NK&:S@*7#
M(QN+7_$Z;ZSU!5];5Z(6EE!4M@H@,_R[L+*.UE956 IV8@E%=8OCST59(]IE
MOFGP:U?59IY;%_P2WRB6%H<#9?I$3_J<^H/<2"V>Y"FHMZO%XL)>\,VZTM(>
MUP.4Q>7CU]F<7U>;-;SBBP#50:]S;/O$_EG_($,-N&K$BT:L> W*4=.!#"/Y
M[)]VP<(NRZ9,RWFYOGZAG[$''B9?ZT4G0?PS4G&?(E3+.W'N]+6[?,<]\</[
M>I99UE<MR_:??%FW !KCQ\0S;G?4TC+E5BD6WY,0Z[RKKQ!C\91C -\;7;DO
MRGZ#>GA NK8M^<)':,DW=#+L$_0QFFI>YKO\^XFP_%?:4FDUS^_AY#Y=U$)8
M?\#?+QKKS1+-I#.Q6@N<<&%Y]FQ*D9K!.;:NXO1.T@@O([R,\'H$X?6N7!K9
M=02RRYC$4ST9HU4>0ZL\1I=JHU7N>G*N[7I&=1@!9024$5!3%5"N$5!&0!D!
M90345 64L:",@#("R@BHR0HH8T$=BH R'8 F [MZOT+,5(,-?E:;.KO@C;"&
M'7V:B:N9XP!?/3IJ]\E)>RA4/,#9=8<+Y ]B)^=!05#\@OFVR!F/\I )3_@N
M=\+0L8-M(+_O^R)VF!_&@OG<C1DO>,Z<((V3(/'MC =C'.]WHG=/%\!*ZP'L
M7\K*/J+_[;M?;X'R)S,_LF>PJTGA^8UD,)K+:*XCYD^CN1ZB!"T7PDEMG]E!
M%##?]3E+7<]E69[949BG3I'SL>:*<R=*\R1E1>:EV%"F8#QQ/)9EL>]Z?I@7
M<3I-S17//,^=)=&T6L09R6 TE]%<1\R?1G,]@.8"+\MW'2]F:>BZS"_LG,5!
MZ+&<>WY:.'98N%L]4N+8LWTW]9GK!S&#KX&V2[C+XM1WH\Q)@SBPIZFY''OF
MV=XLC*951&U$@U%=1G4=,7\:U?4 JDMXPO53)V <.VG[D0U*+ U<E@<%%R(+
MLS!(QJHK@\]XFJ4L%0'VX<;?9*[/(KL0=IK8GA_YTU1=T2RQHYF;&,WUN)+A
M/M.5QS'#[,G$P,>SOW]C/O(X"#]% ^-^)B<].6D/A8K&P'A, R/FPLN*E 5Y
M(ICOB((E.!G=*YPX=(2(8]_;ZBL$3 !V1 [?+'+PIUV;Q7&2L#0/DXQ[A><Z
M^30-C-"=P4(G-5#-B 6CMHS:.F+^-&KK(=I>A[&?9EG!7!$XS,^]D,4B\QE/
MPYRG29PE;CY66SR),M!VH*=LWV=^#&HK"06XUI&3^Y'@/"^VIEM,0VT%KC-S
M_/L"T1BY, FY8/26X<\I4-'HK4?56RZ/"C]G05IDS/>BC'%/^"Q($N[Y/$N*
MQ-]*1?(\\Y( OAG[,?PFPT'7><2BM(A2AQ=V7$P4_AD'L]"/C=HZ)K%@U);A
MSRE0T:BM1U1;GIV#( \#T#XYJJ#(96D4Y"PO$L$3&SX36]A/CZ=IGF8Y2RBR
M:(/&2G,_8)E3P)-<D8?N1!$TL>W.O" P>NO)DI!F@H DSZ[= XE^% +@5N]W
MBH(=Y:&3^"QR<(J"XX!T$C:.44%H19XBU.(^IBB\76;50GSB7UZ733:OFLV]
MSD-P;BU:?M!D]ZB@_9N/.SJQWKY[]?Z/-]:GT__OS=FN@3U/M#+KNX8CA$]Z
M.O=G"KP&];L\I^D3:VJYS)>YM<3^I8N*^I>*[?ZE%O91F5GW<);WMP_< )H-
M?'EMU2+#+@8Y[ 4G9< EM=;\BY6*I8 ?X62-O^Q:^P%;;DG$76[;+ URL,("
M-V0\C@I6Q$&8N+%(TF#+<K-%+.S(39GK^Q%8;G& 4C)@ 4*B[=!)(T?LE7AO
MOJS$LA&_2(H.!T>=O6Y'0X5]DXP%=YT-M7N3D>=G 4\CEM@)9WZ2.2P."@=^
M9GL>MWD<%^%XDT7.;0]E?^CE'HCU&$B4@*'J)E'FNO !D.>)-FF?[*HZVF.,
M3N**6?#M.9Y'OA'8:8%;J[K"N2;P3_#76JPW]=+B^9^;9KV G\#=P^-8"GF*
M5^7Z@N0,7$_\].\G9R=T+\\W9<Z7&7XP!YL?I5$EQ^'P5;D&F?G/=B(.6/F"
MU]D%2:E<7(IYM:)7"3RKO(05B.;$^@:A-BE*DX1U)[:DG1+VN.0H>*V%5Z0^
M U$3,A\%8VK;@HFL"(5M1TZ1;\W?<ETG21,O95[L>5C]&+&8.SZ+_33THJAP
M8F\KX?A=(F;LVK)&9"A>T-5LQ'+?WFR0=IXC?,:=Q(9U.AY+'#MD41#;/L^X
MX*FXC^&"#[NW975H0G.7 5)WDO/[1G0=BQ7ZJ2=;%KQ<KN'_T7ZSBLU\;EWR
M^4:J #Z?5U>D*X!)OL%HI2].3K:BHH2=67^"VFKR,I.]C)26W<!N:Z3'&L7N
M.<>N1N= %U1UR%4TYDPRV<FT=O4P00['_7:>OY=6;_='(2<>A4$N6E#^BI\+
M&4ADO( UO^#S*W[=O/S)^JN)#7U';"@( N%G=LYR[%  3H3-$I^[++!!-SI!
M7N3>=\6&KB[%B]]$=0X$N2BSUWS-37!H_WG')]9O;][_]O'TP^]O7UFO3S^=
M&FT(JSC;I,T:!WF"4K@FS0"N3\_\_C__SQ<73+"7C36OEN=L7EZBKFP:L6[D
M9%%@,HZ#0T&OX,_D+&=+#G/&(:+PN#VZ\37X9O)?G0DZ(2=W4BGW*C#2Q(^\
M-$@9" BX_$ 1EGBVQP+/B],P#SW;WJK-^Y9@\D?T?47^@=?KZT\U7S;2F&V,
M^-C/#LF)]?'-WTX_O7EM?3C]^.G_6I\^GKX[.WWUZ>W[=V=&DHSLZ@N>DS0H
M*C2BT8BL)<]9*V0Z:]WCNA=[1ERK?=,<7?\D<..?7PY)FI?-:LZO7Q1S\65,
M4(P+E<6U7AY]AX&@J]<OB70,R+)H7J2\$7.PY;>(W&T27NU%/T^4ZKL)4BYQ
M3XSH\A6ON(%F?7)$@>M$<>@GKA?YD1O\3,;4%Q3@K3G5.\9VLO'/H_5-A(0_
M_=O;)6@?QQU&G<AZ)[5&T4?X=K.94\"0GX,72(% ] N;K(0_E@4(<9Z#FUUA
M$UA17Y89O)O"D*]KL#S F\)/_G9B_9= KTK,K I<R'VZML!\OZ@;TI/<6D@]
MN>_;:06>FASB78ML7=7-B?6)1GSO6'1>P<*6U5K.\>96LQ(9+1_VNZ#W+?BU
ME0KZ>[FD2YL"/6 KL 1Y?3<K\(^_,QRW1P=Z893'19PSAX<A\_.@8$GB.RP*
M1%AD69S$\9;1G @>1QZHOR0 &]LO',Z2B'O@S22@.G-?P&_[1O.I)L8GM440
M0^^J-1S9!UA)E6^'A?)-G?/KJ3"LX[<B<VR73,B LH!BC692:P6$K:VKNES#
MQ\A_0.T3Z\.F;C9@?;91^!T<.[R7*W@H72EUCRR^6M75EQ*.2X !>V3)M@",
MOM"G%GF.#YQ=V(QGB<TBU_$]$=FYP[>**;_F-FB+\$-=%:+!&"&?GR[S5_!
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MOAAQA:DV,=4FCWXA_^L->Q=XCO5,VY'/979#? 'G(?!:&[9KA*:3)WA-7V_
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M</:IP!9W<K\Z@D3.B(%C3%9"]1%AUC/J:)IMUJPJBA?=AZ$<JO!\"S*VJC
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M=1JDI>T.O:.*X^C'G=#2CZ&GZ%]W!1!\+M1 A9R\SSO(*2,9QGWK6V'_1ND
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ML!JZ"FA3N_?0"I_2/'2M]CH+/G=$TK>!*XB!]T\NB8'WB8&=9F4GPU<NZ=O
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M&DV;9/T%97UA;+F)D&<W#LRM/N3)HASX_QL1/SO(><UDV%Z9U\T<RUHYK-N
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MSI*'%\P>F'_"(?_P6F'V)N)9<NX[?':G0.A5V^V_[>;_XO>G_P%02P,$%
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M2+H=63U]9SJ\/27-8OM7#6Q>D ;D\=,% 4WW1S@BAI $G EA3P)3PHEH(W3
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MIM>A;N [,;MOID\VTN:=S,TNNLDIV/9;ZI4IDB^DU]VTJ'69=NIXTGSA!6N
M$8CK-0W^2N*#19 G+/LBWZ\"NBC)J:KX02=HO]\A?W@F7KTEY8ER)5TC5JCR
M*QD*QA^K=*VN]ODJMC)ML]SASA.F[@H98B"Y7W/;>C]Q5Z4HAWC\&LOTK:2I
MKX](T2=7DVIVB=_4_;H;EC\+SL#I+3% F\*G:/Z$BSM)%C"NJ ZBD(7$YW4O
M&>J"*7*TZ2MU&RD54V\=-E1S1)[ BU;$2Z0KJ-*68E?P3LI?/=Y3FD+Z%*[R
M@:GO%S2;>EO4@0J7@5%WEN8 +3*H=6 6S/']NFW9==L:ZD4O-(;%):2735P:
ME2:?\W^><(+W_P=02P,$%     @ ZCYI5XFXWOJ#&P  ;,L! !0   !W=F4M
M,C R,S Y,S!?9&5F+GAM;.U=6W?C-I)^GU^A];[,G%VW+YW,IOND,T>^]?BL
MV_*QY<G,4PY,0A:W*4(#D+:57[\ +Q(I B!(@0+ ^&$RB06 51\*A:I"H?#S
MW]X6X>@%8A*@Z,O!R8?C@Q&,/.0'T?.7@\>'P_'#^?7UP=]^^=//_W%X.+JX
MNKX=W<+7T=B+@Q=X$1 O1"3!</3GAV]_&?WS[/YF=!-$WY\ @:,+Y"4+&,6C
MP]$\CI>?CXY>7U\_^+,@(BA,8OI!\L%#BZ/1X6$^_#F&@/U]= %B./I\>GSZ
M\?#DY/#XI^GI\>?3D\\??_CPU],?CO_K^/CS\7&I&UJN</ \CT=_]OXR8KWH
MMZ,(AN%J=!5$(/("$(X>BH_^]^@Z\CZ,QF$XNF>]R.@>$HA?H/\A&S.D''P.
M"S;>2/"9>'.X #?(2\G[<E#BY^T)AQ\0?CXZ/3[^>+3N)6S!_NNP:';(_G1X
M<GKX\>3#&_$/1G0V(I)^6^$C17/VJQ^O.Y0;_WB4_;AN6AOZ]6/:]N33IT]'
MZ:_KIB3@-:2#GAS]\]O-0PK)(9W,F (,#W[YTVB4(0>PAU$([^%LE/_KX_UU
MG;H@BH_\8'&4MSD"84@_G8XPQW FY+]@B6'W(T/M/TL]X]42?CD@P6(9PH.C
MG6FB_PXCMC0.?3@#21AWI% X3G_TH@4(HMW)K0RCF]IT\,,%7#Q!W)54WAB:
MZ9S3X;"7/,'#-3 =J96,)**Y('B;VG1)@A<8!C-(O( J;9BI4Z;_CC]]/#Z*
MP1N*T&)UE#+Q$%.=RM3Q8P02/XBA?XZ8(@Y\^G=__2N9S!X@#B 9WU'6(,;T
MMSG ]+^C[%_F*/3I=G'Y[R2(5Q=P%GC!UJIX?6%Z+2,BY7H?G^X;OGOZC]_4
M&3D'9'X5HE?2 ,VNP^Z%[<TVGT[#&=UZ*(6+)17@=#\<^Y1H^O\@O(YF""_2
M/U[ & 2A"OL:AN\;A@V)YR@,P1/"&67/&&93TQT"'4/OC_U;&%/C"2W@#2+D
M#N()II8BP*MTYB24:@&HSX_; F$4!W[ #-67;#60RS<O3'SH7V&T. >AEX0I
M]9/9!6L&_4N (VJL$ZU8:J)BS]HI8V@*WN .XK;3F/N3HGL8LLWA#N!X-<6
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MZB([F@.T=F*W?]$2QF#T K3'IU':QMA:!, [YA_F?V;_> ($_O+_4$L#!!0
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M A.GZ<4K;/$X 1732]ZXTHS['X,C8@93>[I"^9&F39_)YH@N! E_28,-PS<
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M?WJ'/[_+:)+2:QSRFS^5(IB)-C !W:GTW_SQ)MG2BTBIT[^_*U@XJ&5@IE:
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MO8JD,>L6*P+&40%I-PS0,!\35V6E1L6D&X$0BW6ZI!5M+4:V"GXXYD*P[36
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MQ*)DI0-/HD&>2LY$K6SEN%QM!6[=)F@@SMYN@2*&Q:"KB&.@#;$-U<7?J8%
M=,&ACOA=F(]FO_*4><9;P]9X7=FU'(/S2M4 !\5D=V!E^X=U4P4)='+JP8?
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MBRM5;W.;=Z:.\#(Z66BI$SLY,1P]1&W>$;&/"\?WSY,(!B!B UIMU1%I5PN
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MS_"R/)V*G,U6.5T)S2/+(>,:59LK>9;!8U_",%ESB9Z.4MH^L1>XQL9:]:T
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M_\HAO 1T#8T>9FY^6&6H^Z 3<048]A=!I8\P\ZU#E@!7$=O^_-/-3G_@C1X
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M.024-?_1:*R:_S8]%B,G&9A"I97366+]=,@' ;VDVG;$AR<VM08COXD))KI
M!%PICF4^,@4V&V!4_/*635@D4A,X4"VG*C9IXP[#DDT_#JN-)>[:'@L),L\T
MCC>'0'?Q:1<DK<A ?O,;YH]LS4>#'HAA5QX6,**I8D/%,*&<9C9>""HO HLF
M7/$QC[B>#?/2KA"4\N<E_#[4O8=JX/B5]I>4V=GK'7Q%F=V=N3+P02[V++14
M-1BDNJ9';H1FH7'BB1(1]_.!FS"EN0=3>& #J(8VC I_J*=I5X>!*]4JYE*N
M]WO]PWV>C( #-;!0Y&@'^I._GY-630UY]VP5-5+P;F*WU+:&^?(+AU#I_P&K
M?"[C,'!(+74](DVT:_\4:^^@V(E)WV$">T]#RF6[[ANW[N]-"N"ZA;^WJE@I
MG?#$]- P]/TMTKYE[T=B[X=<T'\?FKWW=DG7:$GW^LN6M!71ZR^B%[P7+6>O
M$6</7K?">LV6]*B5U9LKJ^L=RRU_KQ%_#UI\O6Y+>MC9;T7VIHKL;]KS:]E^
MC=B^E>1KMZ2M)-]@27YW*$;30B]:V;-&LJ=5)VNWI'>J$_B+X4'+PZ:Z@_W>
M[NO]E_-K-G ALI5>MH<)VGCD1L<CKV'&RDLZ,_C@RIR:PV (O-BF#4]NTD&H
M9[U3X*ONP2YCE5,ZH^[06TV$\EP@<YFZ":_OEJ#PI:I<F1U1A<<]S?E/DP4@
MX IT>_X:YE*,W379+N(YHKH\A[UPFX$]^;;\%+4]DUVD.2OO3,BO&2]"JCMX
MF;8TPS?7"]<W9@ZD+F]N64/V[/=\L#0Y#VI/&OJ<J0[>&@YTH\PMAPJ^Q6+"
MBE/?>#K8S5<'%LMT+*Q<[8"9!W3D+H4N5M%FUBI&:1-K52ZNYG)N<6P,I3M\
MOG()J?NK*2<>"RC><S9VVER2+2;<O .F9^MVP/3L!O=NOPWW=7<6;;N=_J/8
M=2T6?,:HZ1\:YCC\'7.E0"L*OMI8 Y.7P<L01P%J88Z2$2%1)1* 4C."40DJ
MH B?9CFH*ZY]KD\U56 E0+KQ.),*<9_-"<%E63>@MDKC(M-=$713X6'JE'&F
M@$&5*OJ$-UME 'AKLV-3#2-$7LK3!A6(N#S15WAS35H3R43006RWD&_(O%C)
MO*4Z]B[L+YJTB5.*;DH649?1W(ZR'N$UA!"^ZNC>ALFH%FJL'=3X==V@Q@G(
M2A_EY9U@8W,3PK98HQ$JYFIYMC"7'<IYAJSC1HI4<IO$SX 'R28<VC 7>5R*
MB'LSYSF"YHV2=7^I4JA^IR$S^AB=-Y[)_:;RM&XV;91T5XZC>O>JW<K3Y947
MD(LL\DW2*'/9N 4<9D<,VPNR*.#0/ZQ9F&R#?,(<VBBZVFFS!7YGMU9H!D,Q
M99/R)&1C)M#D6\QY(;\3Q[&238\F\<Y8R>H3S=JDJY6<B!&=%KSIWLMLCK4O
M7X;FQL@?F&<0O:$,T#]P(OV,$-W>6;M2>=..'EU!/<6&[T&JOW?+M_7\/H3G
M=_=>GM_C5V/AS][\>/PJU''TYO]02P,$%     @ ZCYI5RR5S<8#"   [$(
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MVG]__ U02P$"% ,4    " #J/FE7E/:V+Q>5   VNP  $0
M@ $     :6UG-38T,C,T-CA?,"YJ<&=02P$"% ,4    " #J/FE72+]^1?9"
M @ Q30, $0              @ %&E0  :6UG-38T,C,T-CA?,2YJ<&=02P$"
M% ,4    " #J/FE7+ZV; ^BE 0!,+Q\ $               @ %KV ( =W9E
M+3(P,C,P.3,P+FAT;5!+ 0(4 Q0    ( .H^:5=2DCLQUPT  *J"   0
M          "  8%^! !W=F4M,C R,S Y,S N>'-D4$L! A0#%     @ ZCYI
M5_=7?Z[4"P  :I@  !0              ( !AHP$ '=V92TR,#(S,#DS,%]C
M86PN>&UL4$L! A0#%     @ ZCYI5XFXWOJ#&P  ;,L! !0
M ( !C)@$ '=V92TR,#(S,#DS,%]D968N>&UL4$L! A0#%     @ ZCYI5[')
M-D#Y8@  $IP$ !0              ( !0;0$ '=V92TR,#(S,#DS,%]L86(N
M>&UL4$L! A0#%     @ ZCYI5[YA'^<)+   7",# !0              ( !
M;!<% '=V92TR,#(S,#DS,%]P<F4N>&UL4$L! A0#%     @ ZCYI5U)3$NR\
M#@  ^Z@   X              ( !IT,% '=V92UE>#$P7S$N:'1M4$L! A0#
M%     @ ZCYI5RR5S<8#"   [$(   X              ( !CU(% '=V92UE
M>#,Q7S$N:'1M4$L! A0#%     @ ZCYI5PB%9K;M!P  +T0   X
M     ( !OEH% '=V92UE>#,Q7S(N:'1M4$L! A0#%     @ ZCYI5QM!O5V7
M!   !#(   P              ( !UV(% '=V92UE>#,R+FAT;5!+!08
..#  , / "  "89P4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
